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Abstract 
Agonists of hormone receptors possess affinity (the ability to bind) & efficacy (the 
ability to stimulate effect).  In this thesis, alternative expressions of efficacy by 
recombinant prostanoid Chemoattractant Receptor Homologous molecule of TH2 cell 
(hCRTH2) receptors have been studied using a variety of assays and pharmacological 
techniques.   
When expressed in CHO cells, either with or without co-expression of chimeric GD16z49 
G-proteins, CRTH2 receptor-mediated calcium mobilisation pharmacology was found to 
be as published.  Coupling of receptor activation to calcium elevation involved GEJi/o 
mediated PLCE-dependent mobilisation of both intra- & extra- calcium.  In chimera-
expressing cells, an additional coupling mechanism was observed which was 
presumably GD16z49-mediated. The relative expression of receptor and G-protein 
molecules in both cell types was investigated but because of deficiencies in the methods 
employed the relative expression is essentially unknown.  Because GD16z49 & GEJi/o 
represent different classes of PLCE-activating G-proteins, simultaneous activation of 
them may have produced a synergistic response in chimera-expressing cells which may 
have affected the observed receptor pharmacology. 
When the GD16z49 component was isolated in PTX-treated chimera-expressing CHO 
GD16z49 cells, reversals of potency order were observed with respect to responses in 
untreated cells.  These were most striking for 17 phenyl PGD2, 15 R 15 methyl 
PGF2D15 deoxy '12,14 PGJ2 and 15 R 15methyl PGF2D.  Alterations of potency order 
were also observed in non-chimeric cells (GEJi/o coupling) compared with PTX treated 
chimera-expressing cells.  These were most striking for indomethacin, 16,16 dimethyl 
PGD2, '12 PGJ2 and 9,10 dihydro 15 deoxy '12,14 PGJ2.  
In [35S]-GTPJS accumulation assays using membranes prepared from non-chimeric 
cells and presumably reporting GDi/o coupling, agonist pharmacology was similar to 
GD16z49 mediated calcium mobilisation data.  However, the data were markedly 
different from GEJi/o-mediated calcium mobilisation data generated in non-chimeric 
cells.  These differences were most apparent for 13,14 dihydro 15 keto PGD2, 15 deoxy 
'12,14 PGJ2 and indomethacin. 
Desensitisation of agonist-stimulated calcium mobilisation was also studied.  PGD2 
produced rapid & long-lasting desensitisation of hCRTH2 receptors in a biphasic 
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manner suggesting that two desensitisation mechanisms may operate.  At low 
concentrations of PGD2 desensitisation was PTX-insensitive suggesting that a non-Gi/o-
protein mediated mechanism may be responsible.  Other CRTH2 receptor agonists 
inhibited responses to subsequent PGD2 EC80 exposure in calcium mobilisation assays.  
Interestingly, a group of molecules devoid of agonism in the calcium assay also 
inhibited PGD2 responses.  This group of molecules included 19 hydroxy prostaglandins 
A2, E2 & F2D, and PGE2 and appeared to mediate their effects through a mechanism that 
did not involve a competitive interaction with PGD2. 
The data generated here show that CRTH2 receptor agonist pharmacology is critically 
dependent on G-protein coupling partner and assay methodology, and are strongly 
indicative of agonist-directed stimulus trafficking.  The data are consistent with the 
notion that GEJ subunit activation is not a passive ‘on-off’ event but is rather an active 
event triggered by agonist- and GTP-dependent conformation changes in both receptor 
and GD subunit molecules.   
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Abbreviations: 
AKT Related to A and C kinase-D serine/threonine-protein kinase (also known 
as EC 2.7.11.1; RAC-PK-D; Protein kinase B; PKB; c-Akt; Akt refers to 
the virus from which the oncogene was first isolated). 
ATP  Adenosine 5ƍ trisphosphate 
BCA  Bicinchoninic acid 
BRET  Bioluminescence resonance energy transfer 
BW245C ((4S)-(3-[(3R,S)-3-cyclohexyl-3-hydropropyl]-2,5-dioxo)-4-
imidazolidine- heptanoic acid) 
BWA868C (3-benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexyl-2-hydroxyethylamino)-
hydantoin) 
[Ca2+]i  Concentration of intracellular calcium 
cAMP  3-5-cyclic adenosine monophosphate 
CET  Conformation Ensemble Theory 
CHOK1 Chinese Hamster Ovary K1 cells (wild type) 
COX  Cyclo-oxygenase  
CPM  Counts per minute 
CCPM  Corrected counts per minute 
CRTH2 Chemottractant receptor homologous molecule of Th2 cells  
DAG  Diacylglycerol 
DKPGD2 13,14-dihydro-15-keto-prostaglandin D2  
DMSO  Dimethyl sulphoxide 
DMEM-F12 Dulbeccos modified Eagles medium  Ham F12 mix 
DP2  Prostanoid DP2 receptor (aka. CRTH2) 
DTT  Dithiothreitol 
E/[A]  Concentration-effect curve 
EC  Extracellular loop 
ECx  Concentration of agonist required to elicit x% of a maximal effect 
EDTA  Ethylenediaminetetra-acetic acid 
ER  Endoplasmic reticulum 
ERK  Extracellular signal-regulated kinase 
FCS  Ftal calf serum 
FLIPR  Fluorescence Imaging Plate Reader 
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GAP  GTPase activating protein 
GDP  Guanosine 5'-diphosphate 
GFP  Green fluorescent protein 
GPCR  G-protein coupled receptor 
GRK  G-protein coupled receptor kinase 
GTPase Guanosine-5' trisphosphate hydrolase 
GTPJS  [35S]-guanosine-5'-O-(3-thio) trisphosphate  
HEK293 Human embryonic kidney 293 cells 
HEPES N-[2-hydroxyethyl]piperazine-N-[2-ethanesulphonic acid] 
HMTB  HEPES modified Tyrodes buffer 
HRP  Horseradish peroxidase 
INB  Inhibitor of nuclear factor kappa-B 
IP3  Inositol 1,4,5 trisphosphate 
IP3R  Inositol 1,4,5 trisphosphate receptor 
JNK  c-Jun amino terminal kinase 
L-888,607 ({9-[(4-chlorophenyl)thio]-6-fluoro-2,3-dihydro-1H-pyrrolo[1,2-a]indol-
1-yl}acetic acid 
MAPK  Mitogen activated protein kinase 
NFIU Normalised FLIPR intensity units 
NSAID Non-steroidal anti-inflammatory drug 
NSCC  Non specific cation channel 
NSE  No significant effect 
NS  Non significant (statistically) 
NSB  Non-specific binding 
OT  Occupancy Theory 
PAB  Probenecid assay buffer 
PBS  Phosphate buffered saline 
PDL  Poly-D-lysine coated 
PG  Prostaglandin 
PGD2  Prostaglandin D2 
PIP2  Phosphatidyl inositol 4,5 diphosphate 
PKA/B/C Protein kinase A, B or C 
PLCEJ Phospholipase C E or J 
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PMCA  Plasma membrane Ca-ATPase 
PMSF  Phenylmethylsulphonylfluoride 
PTX  Pertussis toxin 
QSAR  Quantitative structure-activity relationship 
RA  Relative activity (cf. PGD2 = 1.0) 
R:G  Receptor : G-protein 
RGS  Regulator of G-protein signalling 
RP  Relative potency (cf. PGD2 = 1.0) 
SAB  Sulphinpyrazone assay buffer 
SAR  Structure-activity relationship 
SERCA Sarcoplasmic / endoplasmic reticulum Ca2+-ATPase 
SPA  Scintillation Proximity Assay 
SR  Sarcoplasmic reticulum 
7TMR  Seven trans-membrane sequence receptor 
TC  Tissue culture 
TM  Trans-membrane sequence 
Tris-HCl 2-amino-2-(hydroxymethyl)-1,3-propanediol, hydrochloride 
TRP1  Transient receptor potential channel 1 of Drosophila 
Tx  Thromboxane 
USP  United States Pharmacopia 
UTP  Uridine 5ƍ trisphosphate 
WGA  Wheatgerm agglutinin 
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Chapter 1:  Introduction 
 
 
Efficacy and agonist-directed stimulus trafficking. 
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Drug efficacy is the key difference between enzyme and receptor pharmacology: the 
ability of certain molecules (agonists) to communicate chemical information resulting in 
activation of receptors and the transduction of that information to intracellular effectors.  
This thesis examines the relationship between alternative expressions of efficacy using 
recombinant human prostanoid Chemoattractant Receptor Homologous molecule of 
TH2 cell (hCRTH2) receptors expressed in Chinese Hamster Ovary (CHO) cells as a 
case study.  In the following paragraphs of the introduction I describe our current 
understanding of the concept of efficacy in relation to agonist stimulus trafficking  the 
ability of certain agonists to preferentially activate selected response pathways. 
 
1.1  Efficacy 
The origin of the concept of efficacy can be traced back to Langley (1905) who 
described agonism in terms of a receptive substance (later referred to as a receptor 
by Ehrlich (1913)) which transferred stimuli to effector organs.  Thus began the 
evolution of Occupancy Theory (OT) which has now become generally, if not 
universally, accepted as describing accurately ligand-receptor behaviour.  However, the 
classical occupancy theory-based treatment of efficacy suffers from one major flaw 
which Kenakin (2002b) has termed the ligand paradox and which has been vigorously 
propounded by Colquhoun (1987, and subsequent publications: 1993, 1998, 2006a): in 
theoretical terms, the thermodynamic molecular forces that control affinity are also the 
same as those that control efficacy (ie., affinity and efficacy are intrinsically linked) but 
in practical terms it has been demonstrated in numerous medicinal chemistry campaigns 
that affinity can be enhanced while efficacy is diminished and vice versa.  In order to 
explain this and several other phenomena, the Conformation Ensemble Theory (CET) of 
receptor behaviour has been developed (Onaran et al., 2000; Kenakin, 1996; 2002b; 
2004e & b; 2005) in which the paradox is resolved by considering efficacy in terms of 
receptor microstates characterised by individual receptor conformations, each with its 
own ability to activate the myriad intracellular components with which the receptor 
interacts. 
The evolution of receptor theory through the last century is essentially the story of the 
development of the concept of efficacy.  Occupancy theory has risen to be king but 
other models such as Rate Theory (Paton, 1961), Macromolecular Perturbation Theory 
(Belleau, 1964), and the Dynamic Receptor Hypothesis (Jacobs & Cautrecases, 1976), 
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which explain receptor behaviour under particular circumstances, are now enjoying 
something of a renaissance as they reflect certain aspects of CET.   
The contributions of the early pioneers of receptor theory have been excellently 
reviewed in several recent papers (Colquhoun, 2006a, 2006b; Hill, 2006; Kenakin 
2004d).  The first quantitative treatment of OT was developed by Hill (1909) who 
independently derived the equations describing the Langmuir adsorption isotherm nine 
years before Langmuir himself did (Langmuir, 1918) as a result of analyzing the 
interaction between nicotine and curare in frog rectus abdominus muscle.  Hill put 
forward the Hill equation (now the Hill-Langmuir equation), describing drug-receptor 
binding in terms of a hyperbolic function, much as we do today.  Clark (1926), 
apparently in ignorance of this, regarded drug-receptor interaction as analogous to the 
combination of gases with metal surfaces described by Langmuir and to follow similar 
monophasic chemical interaction processes.  Clark assumed that the magnitude of 
agonist effect was proportional to the number of receptors occupied; maximum effect 
(Em) occurred when 100% occupancy was achieved.  In his 1937 paper, Clark further 
developed his concept to resolve two properties of drugs: 1. fixation (binding); and 2. 
the ability to produce an effect after fixation.  Clark did not treat the latter property 
quantitatively, the first attempt to do so was made by Ariëns (1954) who noted that not 
all members of a homologous series of p-aminobenzoic acids were active even though 
all apparently retained affinity.  Ariëns proposed that drugs possessed two independent 
parameters: 1. affinity (binding described by the Law of Mass Action); and 2. intrinsic 
activity, a.  Agonists possess both properties while antagonists possess only affinity.  By 
incorporating a into the Michaelis-Menten (1913) equation which described the 
combination of enzymes and substrates, Ariëns produced a mathematical framework in 
which the concept of efficacy could be further developed: EC50 was considered to 
represent agonist affinity, Ka while Em gave a measure of a.  Since the two properties 
were independent, compounds of high affinity / low efficacy and vice versa could be 
accommodated.  Intrinsic activity ranged on a scale from zero for antagonists to 1.0 for 
full agonists, with partial agonists (a term coined by Stephenson, 1956) taking values in 
between.  In common with Clark, though, Ariëns assumed that for a full agonist, 
response was proportional to occupancy, that Em occurred at 100% occupancy, and that 
EC50 = Ka (ie., when 50% of the receptors were occupied).  Incidentally, parallel to 
these developments in the concept of efficacy, Clark and Gaddum made advances in the 
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treatment of competitive antagonism and drew on work published by Michaelis & 
Menten (1913), Haldane (1930), and others.  These latter authors developed concepts 
describing the competition of substrate and product for an enzymes active site as early 
as 1913, but were not recognized by pharmacologists until Gaddums 1937 paper. 
The next significant step forward is widely credited to Stephenson (1956) but should 
perhaps be more correctly attributed also to Furchgott (1955) and Nickerson (1956).  
Noting that receptor inactivation with irreversible antagonists was capable of producing 
parallel dextral shift of concentration-effect (E/[A]) curves before depression of 
maximal agonist effects, Nickerson proposed that a receptor reserve existed in some 
tissues such that Em could be achieved when only a small proportion of receptors was 
occupied.  In other words, tissues possessed spare receptors, full occupancy was not 
required for a maximal agonist effect, and therefore response was not linearly 
proportional to occupancy.  Stephenson described it thus: 1. response was some 
unknown positive function of occupancy, g; 2. Em could be produced when agonist 
occupied only a small proportion of receptors; 3. Different drugs needed to occupy 
different proportions of the receptor pool to produce Em, and therefore possessed 
different efficacies, e.  It therefore followed that EC50 (the concentration of agonist 
required to produce a half-maximal effect) was not equal to the Ka (the concentration of 
agonist required to occupy 50% of receptors).  It is important to note that efficacy is not 
synonymous with intrinsic activity: in theory it is possible for two agonists with equal 
intrinsic activities to occupy different proportions of the receptor pool at Em and 
therefore to have different efficacies.  In a further development, Furchgott (1966) 
resolved Stephensons efficacy, e, into the product of intrinsic efficacy, H, and the 
concentration of active receptors, [RT], thus demonstrating that efficacy is a product of 
drug-related (H) and tissue-related ([RT]) properties.  The mathematical evolution of 
efficacy reached its current status with the proposal by Black & Leff (1983) of the 
Operational Model of Agonism.  Black & Leff took the Stephenson / Furchgott concept 
of efficacy and brought greater definition to the unknown function, g, and therefore to 
efficacy, e.  By recognizing that the relationship between receptor occupancy and 
ultimate effect was saturable, g was logically deduced to be a saturable hyperbolic 
function of occupancy.  Having defined g thus, it was then possible to formulate an 
equation which derived a value representing efficacy, W, from experimental data, rather 
than the previously used device of assuming an appropriate value.  The transducer ratio, 
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W, is defined as [RO] / KE which can be re-written [RO] x (1 / KE)  where [RO] is the 
concentration of receptors in the tissue and KE is the concentration of drug-receptor 
complex required to produce a half-maximal stimulation of the system.  By comparison 
with Furchgotts definition it can be seen that intrinsic efficacy, H, is mathematically 
analogous to 1/KE but conceptually different: H is wholly drug dependent, whereas 1/KE 
contains both drug- and tissue- dependent elements.  The true benefit of the operational 
model is that within a system, the tissue-dependent factors associated with the responses 
evolved by two agonists cancel out and the transducer ratio becomes the ratio of agonist 
intrinsic efficacies.  However, because Stephenson created a conceptual framework in 
which affinity and efficacy were distinct and separate, more latterly considered as 
thermodynamically impossible (Colquhoun, 1987; 1998), his treatment and models 
based on it (Ariëns, Furchgott, Black & Leff) have been described as simply wrong 
though valuableat an empirical level. 
With the advent of radioligand binding techniques in the 1970s and the molecular 
biological revolution in the late 80s and 90s came the ability to probe the molecular / 
biochemical events surrounding receptor-ligand interactions and with it a revolution of 
the conceptual (molecular?) understanding of efficacy, reviewed by Hill (2006), 
Colquhoun (2006a & b) and Milligan and Kostenis (2006).  However, as with many 
developments in the eclectic world of pharmacology, the first step in this part of the 
story owes its discovery to another branch of science: physiology.  Studying the binding 
of oxygen and carbon monoxide to haemoglobin (Hb), Wyman (1951) proposed that the 
observed co-operativity of oxygen binding could be explained if the two already 
identified conformations of Hb had different affinities for oxygen and that the effect of 
oxygen binding was to shift the conformational equilibrium towards the high affinity 
form.  The concept of induced conformation changes and differential affinity states for 
ligand was to prove influential and far-reaching and led directly to the concepts put 
forward by del Castillo and Katz (1957) and termed the two-state model of ion 
channel activation, which was later applied to receptors.  Efficacy in the two-state 
model, E, was defined as (ion channel opening rate constant / ion channel closing rate 
constant) and was shown mathematically to be inseparably linked to affinity.  
Nonetheless, these ideas were combined with those of Wyman to evolve the reversible 
two-state model in which ion channels could spontaneously open without receptor 
activation (Monod, et al., 1965) paving the way for development of the concept of 
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constitutive receptor activation.  An agonist was conceptually defined as a molecule that 
could enrich the population of activated receptors, in other words, a molecule with 
preferential affinity for active receptors: the greater that affinity, the more activated 
receptors were present.  Efficacy was therefore defined as the ratio of agonist affinities 
for the active and inactive receptor states: E = KA / KA* where E is efficacy, and KA & 
KA* represent the affinity of the agonist for the inactive and active receptor states, 
respectively.  The ability of an agonist to have differential affinity for two states has 
been termed species bias (Kenakin, 2004c).  Colquhoun has advocated the use of this 
model for interpreting the behaviour of ion channels and in later treatments has invoked 
the presence of multiple states linking receptor binding, through various stages of 
conformation change to channel opening (Colquhoun, 2006b), efficacy being an 
unspecified function of the rate constants describing these processes.   
Application of the two-state model to 7TM receptors necessitated further refinement 
with the demonstration in the late 1970s and early 1980s of the existence of G-
proteins and the delineation of their roles as key messenger proteins linking receptors 
with intracellular effectors (Gilman, 1995; Rodbell, 1995).  Thus G-protein coupled 
receptors (GPCRs) became an entity and the ternary complex model of receptor 
behaviour was born in order to account for biphasic agonist binding but only 
monophasic antagonist binding in the same system (de Lean, et al., 1980): in parallel 
with the Wyman treatment of haemoglobin binding, agonists bound to receptors, 
recruiting G-proteins and inducing the formation of high agonist affinity, G-protein 
coupled ternary complexes.  Molecular manipulation of receptors and expression in 
recombinant systems allowed the study of GPCRs under conditions not previously 
attainable by the use of tissues and primary cells.  Costa & Herz (1989) noted the ability 
of highly expressed recombinant receptors to be spontaneously (or constitutively) active 
and of certain antagonist molecules to inhibit this basal activation.  Thus efficacy took 
on a vectorial quality (reviewed in Kenakin, 2004b) determined by the relative 
stoichiometry of receptors and G-proteins, the affinity of activated receptors for G-
proteins and the natural tendency of the receptor to form an activated state.  In order to 
take these observations into account Samama, et al., (1993) proposed the extended 
ternary complex model (ETC)  the natural consequence of combining the ternary 
complex model with the reversible two-state model described above.  Under the ETC, 
receptors ([Ri]) can spontaneously isomerise into an active state ([Ra]) in a manner 
determined by an allosteric constant, L (L = [Ra] / [Ri]).  The activated receptor can 
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couple to G-protein with or without the presence of bound agonist.  The agonist ligand 
has a higher affinity for the activated receptor than for the inactive receptor, the ratio of 
affinities being given by D, while G-protein has a higher affinity for the ligand-bound 
receptor, the ratio of these affinities being given by J.  Thus, in the ETC, and the 
thermodynamically complete Cubic Ternary Complex (CTC; Weiss, et al., 1996a, b, c) 
efficacy is determined by D and J, and may be positive or negative.  Compounds with 
negative efficacy are termed inverse agonists. 
 
1.2  Receptor-response pleiotropy 
The models described above essentially view receptors in terms of two macroscopic 
states: active and inactive (Colquhoun, 1987), though as Kenakin (2004c) has pointed 
out, by virtue of the infinitely numerically variable nature of the parameters describing 
efficacy, the two-state models can be considered to be infinite state models.  
Furthermore, in all treatments the receptor is considered to be the pharmacology-
defining unit with all intracellular sequelae of agonism related to it in a linear fashion, 
in other words, pharmacology is genotypically determined (Kenakin, 2002d).  Recent 
findings have questioned this assumption: we now know that receptors exhibit a broad 
range of activities including G-protein coupled transduction, non-G-protein coupled 
transduction, desensitisation, internalisation, homo- and hetero- dimerisation, and that 
observed pharmacology is determined by phenomena such as constitutive activation, 
stimulus trafficking, protean agonism and phantom gene behaviour (reviewed in Hall, et 
al., 1999; Kenakin, 2002a; Pierce, et al., 2002).  Receptors are thus capable of weaving 
a rich tapestry of intracellular events, the integrated sum of which determines the overall 
physiological response.  Pharmacology is what we observe, and what we observe a 
receptor doing in response to drug challenge we can appreciate to be dominated by the 
environment in which the receptor resides when we study it.  As such, pharmacology 
can be phenotypically determined (Kenakin, 2002d).  In contrast to the simplistic 
definition of efficacy given by Colquhoun (1998), the combination of phenotypic 
determination and simultaneous effects on multiple pathways (activation or inhibition 
depending on the system set-point) gives efficacy a pleiotropic aspect which 
complicates both its definition and quantification. 
Pleiotropy in receptor coupling was first conceived of in terms of promiscuous receptor 
coupling to G-proteins (reviewed in Kenakin, 1996) with the observed pharmacology 
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being the resultant effect of two (or, presumably, more) G-protein transduced pathways.  
Considerations such as these led to Scaramellini & Leff (1998) proposing the three-state 
model of receptor behaviour in which the receptor had specific activated states relating 
to each of two different G-proteins.  However, while their model could account for 
stimulus trafficking at the empirical level (the phenomenon by which certain agonists 
appear to specifically direct receptor signalling traffic toward specific intracellular 
effector pathways) it shed no light on molecular events associated with it, nor did it 
provide a framework for either the complexity of trafficking we now observe, or for 
protean agonism.  (The latter phenomenon is a behaviour exhibited by certain molecules 
in which the agonist activity of the molecule may appear positive, negative or neutral 
relative to the basal activity of the system in which it is being studied; protean agonism 
is believed to be an expression of the ability of receptor ligands to stabilise a discrete 
subset of receptor conformations which may or may not intersect with the subset found 
under basal system activation conditions (Kenakin, 1997)).  The body of evidence in 
support of stimulus trafficking is now huge, and applies to the myriad of activation 
sequelae mentioned above (reviewed in Kenakin, 2003).  Conformation Ensemble 
Theory provides a heuristic framework by which these concepts, including inverse 
agonism, protean agonism and pathway-selective antagonism, can be explained 
(Onaran, 2000; Kenakin, 2002c).  Unfortunately, the Probabilistic Model of receptor 
behaviour that arises from it has too many parameters to be useful for quantitative 
purposes but is nonetheless useful as a concept and will be described below. 
 
1.3  Conformation Ensemble Theory 
The concept of protein molecules such as enzymes unfolding and refolding to adopt a 
multitude of tertiary structure conformations is not new (James & Tawfik, 2003) and 
was used as the basis for the work of Burgen (1966) who advanced the complementary 
ideas of conformation induction and conformation selection to explain how the 
interaction between a ligand and a receptor might affect the structure of the latter.  
Direct evidence in support of the fluid nature of protein structure has now been obtained 
from a variety of molecular approaches such as nuclear magnetic resonance (e.g. 
Woodward, et al., 1982; Choy & Forman-Kay, 2001), fluorescence lifetime 
spectroscopy (e.g. Ghanouni, et al., 2001), fluorescence correlation spectroscopy 
(Vukojeviü, et al., 2005, for review) & fluorescence-resonance energy transfer (e.g. 
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Buskiewicz, et al., 2005)  studies.  We can now view a receptor as a protein undergoing 
constant spontaneous structural re-organisation and therefore adopting a spectrum of 
conformations or states quite independently of the presence of ligand (Peleg, et al, 
2001).  The presence of a ligand can be envisaged to stabilise a certain subset of these 
conformations and thus enrich the population of these states at the expense of 
conformations not stabilised by the ligand.  Although direct evidence for this seems to 
be lacking, analogous data for the stabilisation of oestrogen receptor conformations by 
the p160 coactivator have been generated (Tamrazi, et al., 2005).  Some of these 
conformations are predicted to be compatible with the structural requirements for G-
protein activation, others with the requirements for desensitisation, and yet others to 
have no resultant effect.  So by stabilising a subset of conformations, agonists are 
predicted to enrich a specific subset of activation states resulting in activation of a 
specific spectrum of linked intracellular effector processes.  In this view of receptor 
behaviour inverse agonists are predicted to have the opposite effect: enriching states that 
do not signal through the pathway under study resulting in depletion of activating 
conformations and producing an observed reduction in response.  Neutral antagonists 
stabilise all conformations equally and are thus predicted to be a truly rare species (in a 
study of 380 antagonist-receptor pairings at 73 different GPCRs, 85% of antagonists 
were shown to be inverse agonists [Kenakin, 2004e]).  Several behaviours can be 
expected to naturally arise from this treatment of receptors:  
1. Ligands stabilise their own set of conformations which may overlap with 
those stabilised by other ligands but will not be identical.  This has been 
described by Kenakin (2002) in terms of the conformational cafeteria in which 
certain receptor states are taken by the ligand binding to it but these states are 
replenished to allow further selections to take place.  However, the analogy can 
be extended to describe the ligand dependent selection of conformations to 
create a meal of observable effects.  These ideas represent a convergence 
between thinking applied to receptors and ion channels (the multiple activation 
state model for ion channels described above; Kenakin, 1995).  Therefore, it 
follows that stimulus trafficking can be expected to be the norm, not the 
exception, even amongst agonists from the same series.  Taken to its ultimate 
conclusion, this means that structure-activity relationships are highly dependent 
on the assay-readout selected (Kenakin, 2005) and that for a given receptor 
separate SAR may exist for all readouts studied.   
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2. Stimulus trafficking conceived of in these terms predicts two previously 
unrecognized drug behaviours: collateral efficacy (simultaneous and differential 
activation of multiple intracellular pathways by a single agonist-receptor pair) 
and permissive antagonism (differential inhibition of multiple activation 
pathways by an antagonist; Kenakin, 2005).  Provided that assay systems 
suitable for exploitation of these behaviours can be configured for high 
throughput, these behaviours may provide the conceptual basis for creating 
therapeutic agents with greater selectivity.   
3. The conformations on offer in the cafeteria for a given receptor must be by 
definition always the same (i.e. infinitely variable between limits determined by 
the receptor structure).  However, the subset of these that result in activation of 
an observable process are predicted to be limited and determined by the 
environment in which the receptor finds itself (phenotypic determination; 
Kenakin, 2002d).  The principle of reciprocity may be applied here: that which 
induces a change is itself changed in the process.  In other words, although all 
receptor conformations are available, they are not all equally available because 
some are selectively stabilised by the presence of other molecules in the cellular 
micro-environment with which the activated receptor interacts.  To pursue the 
analogy, although the cafeteria kitchen has all the ingredients, and the cook 
(nature) can make all the dishes, the menu on offer changes to fit with the 
availability of the cooks utensils.  Therefore, when a ligand enters the 
conformational cafeteria, it must select from what is available to create its own 
meal.   
4. Under this model, efficacy may be defined in terms of the ability of a ligand 
to stabilise or enrich certain conformations at the expense of others (Onaran, et 
al., 2000).  Low efficacy agonists are those capable of producing a partial 
enrichment (relative to full agonists) of particular conformations needed to 
produce a response, or may enrich conformations leading to partial activation of 
cellular effectors.  The same response pathway in a different cell may not have 
the same stochastic requirements for transduction resulting in either greater or 
lower relative activity but the probability of finding activating receptor 
conformations remains constant.   
The latter consideration forms the basis of the Probabilistic Model first developed by 
Onaran, et al. (2000) and re-presented by Kenakin (2002b).  In this model, the 
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probability, p, of an activating conformation is related to ratios of receptor microstate 
energies, *b, and the energy transitions between states, j.  Different ligands (hormones 
or receptors) have different *b values and alter the distribution of states differently.  If 
two species simultaneously interact then the resulting conformations are given by the *b 
values of both.  Affinity and efficacy are therefore defined in terms of state 
redistributions governed by p, b, and j and, as before, are linked thermodynamically and 
mathematically.   
 
1.4  Some predictions of CET 
The formulation of the model does not allow for fitting of expectations to experimental 
data since concentration and effect terms are lacking.  However, some predictions of 
agonist behaviour can be made if we make some assumptions about system properties.  
Firstly, I propose to assume that a receptor system is defined by a resting state in which 
the receptor can adopt any of a series of conformations with equal probability.  
Secondly, that an agonist will enrich a defined subset of conformations, i.e. that the 
agonist has a dynamic range of conformations that it can stabilise which is a subset of 
all possible conformations.  This subset comprises activating and non-activating 
species.  Thirdly, that response generation requires the number of activating 
conformations to exceed a limiting value (i.e., a threshold must be crossed).  As 
predicted by CET, increasing concentrations of agonist will enrich both the activating 
conformation states and agonist-stabilised non-activating states at the expense of the 
other conformations available to the receptor.  Under these conditions we can predict 
the following:  
1. The probability and therefore the maximum number of receptor molecules in 
an activating conformation will depend on: a) agonist concentration; b) the 
dynamic range of the agonist since a wider range will necessitate a lower 
probability of any individual conformation occurring; c) the propensity of the 
receptor to remain in its resting state ie., the thermodynamic energy barrier to be 
crossed in the process of activation; d) the propensity of the receptor to 
spontaneously adopt non-activating conformations.   
2.  The response observed will depend on: a) the probability and therefore the 
number of active conformations required to cross the threshold; b) the dynamic 
range of the agonist with respect to enrichment of activating and non-activating 
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conformations; c) the dynamic range of the agonist with respect to activation of 
multiple pathways.   
Item 2b deserves further consideration since this is the unique feature of this treatment.  
If the dynamic range is wide then even where the agonist response progresses along 
linear uni-molecular lines, shallow curve slopes could result as the effect of increasing 
agonist is diluted out by non-activating conformations.  Furthermore, as agonist 
concentration rises, the probability of less favoured agonist-stabilised conformations 
appearing in appreciable numbers increases.  Since the system can be predicted to 
possess a system maximum probability (PSmax) for the most favoured states which 
cannot be exceeded, the effect of enriching the less-favoured states will be to deplete the 
most favoured.  Depending on the relationship between these various conformations and 
the activating conformations relevant to the effect being measured, a bell-shaped 
response curve might be observed.  More interestingly, this treatment predicts that a 
given receptor-agonist pairing could recruit one response pathway which then declines 
as a second (or more) pathway is recruited.  Each pathway may therefore possess its 
own stabilisation / destabilization properties.  This is a significant departure from 
classical treatments of receptor behaviour in which stabilisation of a pathway-activating 
receptor conformation may be considered to be uni-directional.  Finally, partial 
enrichment of activating species (partial agonism) could arise from either a wide 
dynamic range or a dynamic range shifted along the conformation axis relative to a 
full agonist.  Therefore, study of what we term partial agonists as a group may be a 
rich hunting ground for the detection of further examples of stimulus trafficking.  We 
should bear in mind, though, that terms such as full and partial really describe 
environment-specific behaviours of agonists: for example, the apparently full 
endogenous hormone ligand 5-HT can be observed to behave as an agonist in a GDi3 
antibody capture [35S]-GTPJS binding assay in CHO cell membranes expressing 
h5HT1B receptors in assay medium containing 100mM NaCl but as an inverse agonist in 
the same assay at 10mM NaCl: in other words as a protean agonist (Newman-Tancredi, 
et al., 2003b). 
 
1.5  Agonist-directed stimulus trafficking 
Theoretical models are useful conceptual frameworks for stimulating thought and 
guiding the design of new experimental strategies but are only as good as the data that 
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support or refute them.  In a debate recorded by Newman-Tancredi (2003a) in the 
International Congress Series, Brann and others have re-asserted the usefulness of the 
concept of receptor-reserve in explaining many findings initially attributed to stimulus 
trafficking, particularly where restricted sets of compounds have been used.  However, 
potency order reversals, or of greater significance, efficacy (relative activity) order 
reversals, where adequate control of potential confounding factors exists, cannot be 
explained on a strength of signal basis (Kenakin, 1995b; Clarke & Bond, 1997; 
Kenakin, 2003).  Kenakin (2003) has summarised some of the original papers 
describing trafficked agonist responses.  In Table 1 I have reviewed key findings of the 
literature published since 2000 which have been generated at serotonergic 5-HT1A/B/D, 
adrenergic D2A, dopaminergic D2 short, neurotensin NTS1, cannabinoid CB2, oxytocin 
OT and virally-encoded U51 chemokine receptors.  Clarke, speaking in the same debate 
(Newman-Tancredi, 2003), has suggested that one might expect the degree of 
pharmacological divergence (and therefore the probability of observing stimulus 
trafficking) would increase with increasing molecular distinction between coupling 
pathways.  Thus, comparisons of two GD coupled pathways might be expected to yield 
strength of stimulus based differences, while comparison of G-protein and non-G-
protein coupled responses at the same receptor (such as regulation of guaninie 
nucleotide exchange factors [GEFs] for small G-proteins like Ras [Pak, et al., 2002], 
regulation of Na+/H+ exchangers [Hall, et al., 1998], and E-arrestin mediated 
recruitment of a wide range molecules including Src family non-receptor tyrosine 
kinases [Luttrell, et al., 1999], ERK1/2 MAP kinases [DeFea, et al., 2000] and 
phosphodiesterase 4 isoforms [Perry, et al., 2002]; Maudsley, et al., 2005, for review) 
might yield clearly trafficked responses.  However, the data presented in Table 1 clearly 
shows that stimulus trafficking can be observed between responses mediated by 
endogenous, recombinant and mutant G-proteins, when comparing GD with GD, GD 
with GEJ, and G-protein coupled with non-G-protein coupled responses.  Trafficking 
may almost be considered to be the norm but care must be exercised in the 
interpretation of data before stimulus trafficking can be assumed.  In addition to the 
strength of stimulus consideration other possible confounding factors include: 
1.  Multiple ligand binding / interaction pockets including allosteric modulation.  
Allosteric compounds may enhance or reduce the effect of ligands interacting at the 
primary (or orthosteric) ligand binding site by interacting with a distinct (or allosteric) 
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binding site.  The allosteric enhancers increase primary ligand affinity or efficacy while 
allosteric antagonists produce the opposite effect (see Neubig, et al., 2003 for further 
detail).  Competitive antagonists have been used to demonstrate the common receptor 
binding site origin of trafficked responses but the existence of pathway-dependent 
permissive antagonism (see above, Kenakin, 2005) invalidates this approach since it is 
possible for a given receptor-ligand pair to inhibit one response pathway while having 
no effect on an other (eg. Akin, et al., 2002; Pauwels, et al., 2003b; Shoemaker, et al., 
2005). 
2.  Methodological considerations including steady state vs. kinetic (especially FLIPR-
based [Ca2+]i) readouts (eg. Shoemaker, et al., 2005), sodium or GDP concentration 
related pre-coupling in [35S]-GTPJS binding assays (Pauwels, et al., 1997; Newman-
Tancredi, et al., 2003), time- or agonist concentration-related readout destabilisation 
(chemical and biochemical; Newman-Tancredi, et al., 2002), and altered expression of 
receptor or G-protein. 
3.  Recruitment of multiple activation pathways in systems believed to be stimulus 
biased to single molecular species (eg. Newman-Tancredi, 2003). 
4.  Host cell to host cell differences.  For example, studies comparing data generated in 
C6-glial cells and African Green Monkey COS-7 (SV40 transformed kidney epithelial 
CV1) cells (Wurch, et al., 1999; Pauwels, et al., 2003b). 
 
1.6  Concluding remarks 
A large body of evidence exists to support the existence of stimulus trafficking.  Indeed 
some features of data already in the literature may indicate that the phenomena I have 
predicted in theoretical terms above, exist in reality.  For example, the selective but 
transient recruitment of GDi2 at low concentrations of 5-HT by the 5-HT1A receptor 
followed by the stable recruitment of GDi3 at high concentrations (Newman-Tancredi, et 
al., 2002): thus, the GDi2 activation curve appears bell-shaped.  These intriguing 3-
dimensional locks we refer to as 7-transmembrane receptors are sure to present us with 
further complexities the more we study them.  The challenge is for us to make sense of 
them and generate quantitative frameworks within which we can exploit their properties 
through drug discovery.  In the following chapters of this thesis, I describe 
investigations into agonist stimulus trafficking at recombinant prostanoid hCRTH2 
receptors expressed in CHO cells.  The findings are novel and may point the way to the 
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discovery of the first molecules to selectively trigger the desensitisation of a prostanoid 
receptor without classical second messenger activation. 
 
 20
Table 1.  Summary of key stimulus trafficking literature since 2000.  (Selected earlier references have been included where appropriate). 
Receptor Assay 1 Assay 2 Assay 3 Findings Reference 
5HT1A Xenopus laevis oocytes; 
Ismoth; non G-protein 
mediated? 
Xenopus laevis oocytes; 
ICl(Ca); Ca
2+-dependent 
marker of GPCR 
activation 
Xenopus laevis oocytes; 
GIRK; GEJ mediated. 
Same recombinant receptor in each 
assay; Ismooth has unique profile; 
F13714 is agonist in assays 2 & 3 but 
is antagonist in assay 1. 
Heusler, et al., (2003)  
5HT1A CHO cells; FLIPR-based 
Ca2+ assay; GEJi 
mediated. 
CHO cells; [35S]-GTPJS; 
GDi2 measured. 
- Full agonists were agonists in both 
assays.  GTPJS assay partial agonists 
were inactive in FLIPR assay. Small 
relative activity changes in the GTPJS 
assay became large changes in FLIPR 
assay.  Agonist rank order changes. 
Pauwels & Colpaert, 
2003. 
5HT1A CHO cells; FLIPR-based 
Ca2+ assay; wild type 
receptor: GD15 fusion 
protein. 
CHO cells; FLIPR-based 
Ca2+ assay; mutant 
Thr149Ala receptor: GD15 
fusion protein. 
- Mutation of conserved Thr in IC2 of 
receptor inhibits calcium responses but 
not cAMP inhibition responses, ie. 
differential pathway coupling. 
Wurch, et al., 2003 
5HT1A CHO cells; [35S]-GTPJS; 
GDi3 antibody capture 
assay. 
CHO cells; [35S]-GTPJS; 
GDi3 antibody capture 
assay; unlabelled GTPJS 
included. 
- Low [5HT] selectively activates GDi3. 
High [5HT] induces switch to other G-
protein and destabilisation or 
suppression of GDi3.  Trafficking at G-
protein sub unit level revealed. 
Newman-Tancredi, 
2002 
5HT1B CHO cells; [35S]-GTPJS; 
GDi3 antibody capture 
assay. Same assay & 
conditions as Newman-
Tancredi, 2002.   
CHO cells; [35S]-GTPJS; 
GDi3 antibody capture 
assay; unlabelled GTPJS 
included. 
- GDi3 accumulation signal stable ipo 
high [5HT].  Loss of signal is specific 
to 5HT1A receptor.  Protean behaviour 
of 5HT revealed by manipulation of 
[Na+] (alteration of pre-coupling). 
Newman-Tancredi, 
2003 
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5HT1B Rabbit common carotid 
artery contraction; GEJi/o 
mediated L-type Ca2+ 
channel assay. 
Inhibition of forskolin 
stimulated cAMP in 
rabbit common carotid 
artery; GDi/o assay. 
- All agonists tested active in assay 2; 
only some active in assay 1. 
Akin, et al., 2002 
5HT2C Standard [35S]-GTPJS 
accumulation assay. 
[35S]-GTPJS GDi3 & 
GDq/11 antibody capture 
assay. 
- Receptor highly coupled to GDq/11, less 
so to  GDi3. Agonists are NOT 
trafficked between the two readouts.  
Strength of stimulus changes observed.  
Differences in coupling could underpin 
apparently trafficked responses at the 
effector level. 
Cussac, et al., 2002 
D2A COS7 cells; WT receptor; 
± co-exprsn GD15; IP3 
accumulation 
COS7 cells;  mutantD2A 
Thr373Lys receptor; ± co-
exprsn GD15; IP3 
accumulation 
C6 glial cells; 
endogenous WT 
receptor; GDi/o coupled. 
Mutant & WT receptor agonist profiles 
equivalent in COS7. Co-exprsn. GD15 
reveals agonism in antagonist 
molecules, ie. RG pair dependent.  
COS7 GD15 & C6 glial WT receptor 
agonist profiles different: trafficking? 
Wurch, et al., 1999 
D2A CHO cells; WT receptor; 
co-exprsn. GD15; FLIPR 
assay 
CHO cells; Asp79Asn 
receptor; co-exprsn GD15; 
FLIPR assay 
CHO cells; Thr373Lys 
receptor; co-exprsn GD15; 
FLIPR assay 
Host, G-protein, assay same, agonist 
rank orders different: trafficking?   
Assay 1 here produces agonist profile 
not equivalent to profile of assay 1 in 
Wurch, et al., 1999. 
Pauwels & Colpaert, 
2000 



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D2A CHO cells; WT receptor; 
co-exprsn. GD15 or GD15 
fusion protein; FLIPR 
assay 
CHO cells; Ser200Ala 
receptor; co-exprsn. GD15 
or GD15 fusion protein; 
FLIPR assay 
CHO cells; Ser204Ala 
receptor; co-exprsn. GD15 
or GD15 fusion protein; 
FLIPR assay 
Extends observations in 2000a paper.  
Mutations alter binding affinity and 
agonist rank order of potency.  Relate 
to R conformations.  Differences 
observed even for closely related 
molecules. Suggests agonism or 
antagonism not a property of molecule; 
rather, is a property of R, G, L, E 
combination, ie. of the assay system 
environment. 
Pauwels & Colpaert, 
2000b 
D2A COS7 cell membranes; 
WT receptor; ± mutant 
GDo; [35S]-GTPJS 
accumulation assay.  
COS7 cell membranes; 
WT receptor; ± mutant 
GDo; receptor binding 
assay.  
- Mutant G-proteins altered agonist rank 
orders of potency & max. effects, and 
changes in R binding affinity.  
Therefore, reciprocal changes in R & 
G behaviour occur demonstrating the 
transmission of information in a G ĺR 
direction. 
Wurch, et al., 2001 
D2A CHO cell membranes; 
WT receptor; ± mutant 
GDo or GDi2; [35S]-
GTPJS accumulation 
assay.  
C6 glial cells; WT 
receptor; ± mutant GDo 
or GDi2; inhibition of 
forskolin stimulated 
cAMP.  
- Efficacy is mutant G-protein 
dependent: no efficacy (+ve or ve 
through GDi2; spectrum observed 
through GDo.  Efficacy is assay 
dependent: none observed in cAMP 
assay.  Antagonist activity suggested to 
be pathway dependent since lack of 
correlation observed.  However, some 
antagonist effects not clearly 
demonstrated to be so. 
Pauwels, et al., 2003 
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viral u51  COS7 cells; constitutive 
activation; IP3 
accumulation and GDq-
dependent CRE 
activation. 
COS7 cells; cytokine 
stimulated activation; IP3 
accumulation, Ca2+ 
mobilisation, and GDi/o-
dependent CRE 
activation assays 
COS7 cells; cytokine 
stimulated activation; ± 
recombinant G-proteins; 
IP3 accumulation, Ca
2+ 
mobilisation, and GDi/o-
dependent CRE 
activation assays 
Cytokines tested have distinct rank 
orders at each readout. R coupled to all 
GDi, GDo, GDq & GD11 proteins co-
exprsd.  Stimulus biased systems 
provided further evidence of 
trafficking: different G-proteins 
produced different effects on 
constitutive activity but not on 
cytokine rank orders. 
Fitzsimmons, et al., 
2006 
CB2 CHO cells; inhibition of 
[3H] cAMP 
accumulation; GDi/o 
mediated. 
CHO cells; pERK-MAP 
accumulation; GEJi/o 
mediated. 
CHO cells; calcium 
mobilisation; GEJi/o 
mediated. 
Assays 2 & 3 produce equivalent 
agonist data but potencies vary on a 
strength of stimulus basis relative to 
fractional receptor occupancy. Assay 1 
vs. assay 2 produces different agonist 
rank order of potency but not assay 1 
vs. assay 3.  Same coupling?  Kinetics 
and degree of response integration 
with Ca2+ readout will confound 
comparisons.  Also fractional receptor 
occupancy is based on displacement of 
agonist radiolabel by agonist compds. 
Shoemaker, et al., 
2005 
rat NTS1 CHO cells; IP3 
accumulation; GDq/11 
mediated. 
CHO cell membranes; 
stimulation of cAMP; 
GDs mediated. 
CHO cells; arachidonic 
acid production; GDi/o 
mediated. 
Assay4: CHO cell 
membranes; [35S]-GTPJS 
accumulation; GDi/o 
mediated. 
Reversal of agonist rank order potency 
between assays 1 & 2.  Preferential 
coupling of R to GDi/o and GDs. 
Skrzydelski, et al., 
2003 
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D2S CHO cells; WT & 
Thr343Arg mutant 
receptors; ± GDo, GDqo & 
GD15 G-proteins; FLIPR 
Ca2+ assay. 
CHO cell membranes; 
WT & Thr343Arg mutant 
receptors; ± GDo, GDqo & 
GD15 G-proteins; [35S]-
GTPJS accumulation. 
- Pharmacology G-protein dependent.  
Paper refers to multiple activation 
binding sites but data fit better with 
stimulus trafficking.  Distinct binding 
site hypothesis requires antagonists to 
be simple binding blockers, ie. with no 
efficacy. 
Pauwels et al., 2001 
OTR Human prostate 
carcinoma DU145 cell 
membranes; endogenous 
receptor; [35S]-GTPJS 
accumulation; GDi/o 
mediated. 
Recombinant expressing 
HEK293 & Madin-Darby  
canine kidney cell & 
endogenous expressing 
DU145 cell proliferation; 
GDi/o mediated 
DU145 cells; pERK1/2 
detection; GDi/o 
mediated. 
Assay 4: HEK293 cells; 
recombinant receptor; IP3 
accumulation; GDq 
mediated. 
Atosiban is antagonist at GDq coupled 
OTR and agonist via GDi/o coupled 
OTR. Investigation in range of GDq 
based systems at varying R:G 
expression levels needed. 
Reversi, et al., 2005 
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Chapter 2:  Methods. 
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 Procedures conducted by named individuals are indicated by the bar in the margin.  
Unmarked text indicates procedures conducted by author. 
 
Although the assay methods described below have been developed such that they may 
be used for high throughput screening (HTS), none of the data described in this thesis 
was obtained as part of an HTS campaign.  Indeed, with the exception of GW853481X, 
the molecules assayed for activity at hCRTH2 receptors here were specifically excluded 
from high- and low- throughput screening campaigns because their structures were 
considered unsuitable for medicinal chemistry efforts. 
 
2.1  Cell preparation and cell culture 
 
2.1.1  Preparation of CHO GD16z49 cell line 
(BIOCAT 80890; Prepared by Tanja Alnadaf & Bob Ames, GSK; used  with 
permission)  
A construct for the GD16 G-protein in which the last 49 amino acid residues were 
substituted for the last 49 residues of the GDz G-protein was made by the method of 
Mody, et al. (2000) and cloned into the pCIH vector.  CHO cells transfected with the 
plasmid were dilution cloned in the presence of 400 Pg ml-1 hygromycin B. 
 
2.1.2  Preparation of CHO hCRTH2 cell lines  
(BIOCATs 94875 (CHO K1 hCRTH2) and 80870 (CHO GD16z49 hCRTH2; prepared by 
Ashley Barnes & Emma Koppe, GSK; used with permission) 
The coding region of the hCRTH2 gene (GenBank AB008535) was cloned into 
pcDNA3 (Invitrogen) at the BamHI-NotI site.  The clone was cut out at the XbaI and 
EcoRI sites, and a Klenow sequence filled in. The clone was then ligated into pCIN3 at 
the EcoRI & EcoRV sites. The EcoRV site was destroyed in the process but the XbaI 
site is present at the 3'end of the hCRTH2 gene.  The resulting construct was linearised 
with SspI before transfection. 
Transfection of  CHOK1 Wild Type or CHO GD16z49 cells was achieved as follows: 10 
Pg of linearised DNA was mixed with 0.8 ml Lipofectamine® reagent and allowed to 
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stand for 20 min at room temp.  The DNA mixture was combined with 9 ml of 
Optimem® and introduced to a culture flask containing cells from which medium had 
been aspirated.  Flasks were returned to the incubator for 6 hr at the end of which spent 
transfection reagent was discarded, cells rinsed with PBS, and 50 ml tissue culture 
medium A added (DMEM-F12, 10% FCS, 2 mM L-glutamine, 400 Pg ml-1 hygromycin 
B, 100 PM flurbiprofen).  After 24 hr the medium was replaced by medium additionally 
containing 1mg ml-1 neomycin (culture medium B). 
Routinely, cells were cultured in the presence of the non-selective COX1/2 inhibitor 
flurbiprofen to prevent autocrine stimulation and down-regulation of prostanoid 
hCRTH2 receptors by endogenously synthesised prostaglandins.  It was found necessary 
to adjust the concentrations of the antibiotics used in order to achieve suitable growth 
rates.  In all subsequent studies cell culture medium of the following composition was 
used: DMEM-F12, 10% FCS, 2mM L-glutamine, 62.5 Pg ml-1 hygromycin B, 0.25 mg 
ml-1 neomycin, 100 PM flurbiprofen (culture medium C). 
Cells were separated using flow cytometry in order to isolate individual clones in the 
wells of 96-well tissue culture plates.  Each clone was expanded and pharmacologically 
characterised.  Single clones displaying the largest responses to PGD2 were selected for 
further study. 
 
2.1.3  Transient transfection of CHO hCRTH2 cell lines with E-ARK 495-689 
A construct encoding the C-terminal (residues 495-689) of E-adrenergic receptor kinase 
(E-ARK) was cloned into pcDNA3 (Invitrogen) at the BamHI-NotI site (Dickenson & 
Hill, 1998; kindly prepared by Ms. Nicola Hawley).  CHO GD16z49 host cells, CHO 
GD16z49 hCRTH2 cells or CHO K1 hCRTH2 cells were grown to 80 % confluence,  
medium aspirated, and then washed with PBS.  Cloned pcDNA was transfected into 
cells using Lipofectamine® according to manufacturers instructions.  For a single 75 
cm2 tissue culture flask 0.25 ml of diluted Lipofectamine® and 40 Pg of diluted pcDNA 
were mixed and allowed to stand for 30 min at room temperature.  The DNA mixture 
was combined with 9 ml of Optimem® and introduced to the flask which was incubated 
for 6 hr (CHO K1 CRTH2 cells) or 3 hr (CHO GD16z49 CRTH2 cells).  At the end of this 
period the transfection mixture was removed and 50 ml of normal culture medium re-
introduced.  Cells were allowed to grow for a further 24 hr (CHO GD16z49 CRTH2 cells) 
or 48 hr (CHO K1 CRTH2 cells) before being plated out for assay. 
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2.1.4  Cell culture regime 
CHO cells expressing hCRTH2 receptors had a doubling time of approximately 18 hrs 
(determined by subjective assessment of confluency and split ratios) and were used for 
assays when 80 % confluent (judged microscopically).  Split ratios at passage of 1:3-
1:40 in culture medium C were used in order to bring flasks to the required level of 
confluency on the intended days.  The impact of different split ratios on receptor 
expression was not assessed. Typically, a 1:3 split was used for 80 % confluency on the 
next day from an 80-90 % confluent flask.  For maintenance culture, cells were 
passaged twice weekly at split ratios of 1:30 or 1:40.  Cells were used at passages 6-28 
and were plated at 2 x 104 cells well-1 in 384 well plates. 
 
2.1.5  Passage technique 
Quantities specified are for one 175 cm2 tissue culture flask.  Cell culture medium was 
removed and the cell layer washed with 10 ml sterile phosphate buffered saline (PBS).  
After removal of the PBS, 5 ml Versene® was added and the flask incubated at 37 °C 
for 2-4 min until the cells detached from the plastic.  Cells were dislodged from the 
plastic with a sharp knock and the resulting cell suspension titurated twice to ensure 
clumps of cells were disaggregated.  Following centrifugation (100 x g, 5 mins) 
Versene® was removed and the cell pellet dispersed by manual shaking of the tube.  
Fresh culture medium C was added (10 ml) to provide a suspension for introduction to 
further tissue culture flasks containing 50ml medium C.  The volume of suspension 
added was adjusted to achieve the intended split ratio. 
 
2.2  Calcium mobilisation assay 
 
2.2.1  Plating of cells for assay 
Cell suspensions in fresh culture medium C were prepared as described above.  For use 
in assays, the concentration of cells present in each suspension and the distribution of 
cell sizes, where relevant, was determined by automated cell counting using a Sysmex® 
cell counter according to the manufacturers instructions.  The volume of culture 
medium C added to cells was adjusted to give 4 x 105 cells ml-1 and 50 Pl of the final 
suspension added to each well of a sterile, black-walled, clear bottomed poly-D-lysine 
coated 384 well plate [Greiner, Cat No 781946] using a Multidrop® microlitre 
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dispenser (384 well setting, 50 Pl, 24 col).  Plates were incubated for 18-24 hrs at 37 °C, 
5 % CO2 in air, 95 % humidity.  For assays investigating the role of GDi-class G-
proteins, cells were plated out in media additionally containing 50 ng ml-1 of pertussis 
toxin (PTX).  Deviations from this method during assay development are noted in the 
text. 
 
2.2.2  Assay procedure 
Immediately prior to assay, culture medium was replaced with 30 Pl well-1 of assay 
buffer (sodium chloride 145 mM, potassium chloride 5 mM, calcium chloride 0.8 mM, 
magnesium chloride 0.1 mM, glucose 10 mM, HEPES 20 mM, 3 mM probenecid, and 
brilliant black 1 mM, pH 7.4) containing Fluo-3 AM (4 PM) & Pluronic F127 (0.044 %) 
using a Multidrop® (384 well setting, 30 Pl, 24 col).  Following incubation (37 °C, 90 
min, air, ambient humidity) plates were transferred to a Fluorescence Imaging Plate 
Reader (FLIPR®; Molecular Devices) to monitor changes in Fluo-3 fluorescence after 
addition of compounds. Compounds eliciting an increase in fluorescence were taken to 
be agonists.  In order to assess antagonist and/or inhibitory activity, the same plates 
were placed back into incubation (37 °C, 11 min, air, ambient humidity) before being 
returned to the FLIPR instrument for addition to all wells of an EC80 concentration of 
PGD2.   Compounds resulting in inhibition of PGD2 EC80 responses were taken to be 
receptor antagonists, signal transduction inhibitors or assay specific inhibitors (e.g. 
fluorescent dye quenchers).  The following FLIPR protocol settings were used: pipettor 
speed 5 Pl sec-1, tip height 30 Pl, 2 x 10 Pl mixes at 5 Pl sec-1, add sample after 5 s.  
Data were generated in triplicate from three separate experiments often performed on 
the same day using separately prepared compound dilutions and cell preparations; 
reagents were shared. 
Compound dilutions were prepared in clear polypropylene 384 well plates keeping 
DMSO constant at 1 %, final assay concentration.  This was achieved by making 
compound dilution series in 100 % DMSO (highest starting concentration typically 1 
mM; ten 1 / 3 v v-1 dilution steps; Biomek 2000®), plating out 1 Pl of each 
concentration per well (Biomek FX®), followed by the addition of 25 Pl per well of 
assay buffer (Multidrop®) to generate dilutions in 4 % DMSO.  Addition of buffer was 
carried out immediately prior to use of the compound plate.  The final dilution to 1 % 
was achieved when compounds were added to the cell plate on the FLIPR instrument 
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(10 Pl compound dilution + 30 Pl assay buffer; highest final assay concentration of 
compound typically 10 or 1 PM).  The final dilution factor for PGD2 EC80 added in 
antagonist mode assays was 1 in 5; PGD2 EC80 was determined experimentally on each 
day prior to assay.  FLIPR tips were re-used where the same compounds were handled.  
In assays where multiple additions of compounds were made to the same wells of the 
assay plate concentrations and volumes were adjusted such that 1% DMSO final assay 
concentration was not exceeded.  Deviations from this method during assay 
development are noted in the text. 
 
2.2.3  Calcium assay-based investigations into desensitisation of hCRTH2 receptors. 
Desensitisation & synergism assays involved the addition of an agonist to hCRTH2 
expressing cells followed by subsequent application of the same or a different agonist 
after a suitable incubation period.  The first application of agonist is referred to as 1st 
treatment; the second as 2nd treatment; the style of 1st and 2nd treatments varied 
according to the type of data being generated.  In some experiments these assays were 
performed following application of protein kinase inhibitors and activators; this is 
referred to as pre-treatment.  In initial time course studies transient Ca2+ fluxes 
recovered to baseline by 10 min post-challenge; PGD2-induced desensitisation was also 
essentially complete by 10 min post-challenge.  Therefore the incubation periods 
between pre-treatment & 1st treatment, and between 1st & 2nd treatments was routinely 
set at 11 min. 
The following protocols were used: 
1.  Time course & effect of different PGD2 concentrations on subsequent PGD2 E/[A] 
curve generation.  In these assays, 1st treatment involved the application of PGD2 
dilution series (as eleven 1 / 3 v v-1 dilution steps) in a column-wise arrangement to the 
first 11 columns of a 384 well plate.  Following incubation for times ranging from 1 min 
to 120 min, 2nd application of agonist took place.  For 2nd treatment, PGD2 dilution 
series were added again as eleven 1 in 3 steps in a row-wise arrangement to wells 
already exposed to agonist on first treatment.  In this way 2nd treatment agonist curves 
(positive-going resulting in calcium elevation) were constructed in wells all treated with 
the same 1st treatment PGD2 concentration, referred to as an ECx (concentration of 
agonist producing an effect equal to x % of the maximum effect produced by that 
agonist). 
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2. Generation of PGD2 and 15 keto PGF2D pIC50 data.  Compound IC50s were generated 
against PGD2 EC70. First treatment comprised addition of a compound dilution series; 
2nd treatment comprised addition of PGD2 EC70 to all wells exposed to 1
st treatment. 
3.  Effect of protein kinase inhibitors on receptor desensitisation.  These studies can be 
considered the mirror-image of those described at 1., above.  Pre-treatment involved the 
application of the PKA inhibitor H89, the PKA activator dibutyryl cAMP, the PKC 
inhibitor GF109203X, vehicle (0.25 % DMSO), or combinations of either H89 or 
dibutyryl cAMP with GF109203X; 1st treatment comprised application of PGD2 E/A] 
curves in a row-wise fashion; 2nd treatment was application of PGD2 dilution series in a 
column-wise fashion such that an inhibition curve was produced at each PGD2 ECx 
(negative-going resulting in inhibition of calcium mobilisation). 
4.  Effect of agonist E/[A] curve generation on subsequent E/[A] curve generation.  
Both desensitisation and synergism were studied with this protocol.  First treatment 
comprised addition of agonist (PGD2 or UTP) dilution series row-wise to the wells of a 
384 well plate.  For desensitisation assays 2nd treatment comprised re-application of a 
dilution series of the same agonist (PGD2/PGD2 or UTP/UTP) to the same wells of the 
plate such that a given concentration of agonist was added twice to each well.  For 
synergism assays, the approach was similar but 2nd treatment involved application of the 
other agonist (PGD2/UTP or UTP/PGD2).   
 
2.3  [35S]-guanosine-5'-O-(3-thio) triphosphate binding assays 
 
2.3.1  Adaptation of cell line to suspension culture & cell culture regime; performed by 
Emma Koppe & Olutu Oganah; used with permission. 
To facilitate large scale cell culture and membrane preparation, adherent CHO K1 
hCRTH2 clones were adapted to suspension culture.  Adaptation was carried out once 
the clone had been expanded to yield a confluent 75 cm2 TC flask and was achieved by 
culture of cells in serum-free medium in 2 l plastic Erlenmeyer flasks (Fisher Scientific, 
Loughborough, UK) with plug caps in an Innova shaking incubator (37 °C, 145 rpm, 
normal air [i.e., no CO2]; New Brunswick Scientific, Edison, N. J.).  Cells were grown 
to approximately 1 x 109 cells flask-1 in 500 ml medium (approximately 2 x 106 cells ml-
1 determined by light absorbance; pre-calibrated by haemocytometer counting).  Culture 
medium (medium D) was of the following composition:  DMEM-F12, pluronic F-68 0.1 
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% v v-1, flurbiprofen 50 PM, neomycin 0.5 mg ml-1.  For storage cells were frozen down 
in Complete® medium containing 10 % DMSO at passage 12. On resuscitation, cells 
were centrifuged at 100 x g and resuspended in 10 ml medium D for culture in a 75 cm2 
flask. After 24 hr culture, cells were split 1:2 and resuspended in 2 x 15 ml medium D.  
After a further 24 hr culture the cells were suspended in 50 ml medium and introduced 
to 175 cm2 flasks.  Finally, after 3 days culture the contents of each 175 cm2 flask were 
introduced into Ehrlenmeyer flasks, as described above.  Maintenance culture was 
performed by splitting cells every 5 days with a 1 in 3 split at each passage.   
 
2.3.2  Membrane preparation; performed by Bob Middleton & Jim Coote; used with 
permission.  
For membrane preparation, cells were harvested by centrifugation of culture medium 
containing cells at 500 x g for 10mins.  Pellets from multiple flasks were combined to 
produce a single cell pellet which was resuspended in 50 ml ice-cold HE buffer (50 mM 
HEPES, 1 mM EDTA, 100 PM leupeptin, 25 mg ml-1 bacitracin, pH 7.4 with potassium 
hydroxide).  From 5 x 2 l flasks, approx. 8 ml of cell pellet were obtained, resulting in 
approx. 500 mg of membrane pellet.  All subsequent steps were performed at 4 °C. 
Cells were homogenised for three 5 s periods using an Ultra-Turrax blender on blue-
black setting (c.20,000 rpm) with 1 min between each period.  The resulting 
homogenate was plunged into ice for 30 min to allow foam to settle following which it 
was passed through a 25 gauge syringe needle five times.  To remove large fragments of 
debris the homogenate was centrifuged at 450 x g for 10 min, following which the 
supernatant was taken and centrifuged for a further 30 min at 22,000 x g.  The final 
supernatant was discarded and the resulting pellet resuspended in ice-cold HE buffer (2 
ml per three 175 cm2 tissue culture flasks).  Aliquots (100 Pl) were stored frozen at -80 
°C. 
 
2.3.3  Protein determination 
Membrane preparation protein concentration was determined using the bicinchoninic 
acid (BCA) method using a proprietary kit and according to the manufacturers 
instructions (Sigma, Poole, UK).  Proteins reduce alkaline Cu(II) to Cu(I) in a 
concentration-dependent manner.  BCA is a highly specific chromogenic reagent for 
Cu(I) forming a purple complex with an Absmax at O = 562 nM.  Absorbance is directly 
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proportional to protein concentration and was measured at O = 550 nM on a 
ThermoMax microplate reader (Molecular Devices, Sunnyvale, CA).  Linear regression 
and interpolation was performed using SoftMaxPro software.   Samples did not contain 
more than the permitted amount of interfering substances. The kit reagents did not 
contain detergent. 
 
2.3.4  Assay procedure 
[35S]-guanosine-5'-O-(3-thio) triphosphate (GTPJS) binding assays were performed 
using a 384-well plate-based LEADseeker® scintillation proximity assay (SPA; 
Amersham Biosciences, Amersham, U.K.).  The assay utilises the agonist-stimulated 
replacement of GDP by GTP at activated GD G-proteins (described by McKenzie, 
1992).  Under resting conditions GDP occupies the nucleotide binding site of GD G-
protein subunits which associate with GEJ subunits to form a complete G-protein 
heterotrimer.  The molecule binds to receptors via the C-terminal tail of the GD subunit.  
Agonist binding produces a conformation change in the intracellular C-terminal of the 
receptor which facilitates G-protein interaction with the receptor and which conveys the 
activation signal to the G-protein.  A conformation change results in the nucleotide 
binding site having preferential affinity for GTP which now replaces GDP triggering 
GD-GTP dissociation from GEJ subunits which go on to activate their respective 
effectors.  The activation is terminated by the inherent GD subunit GTP hydrolase 
activity which converts the bound GTP to GDP followed by re-association of the G-
protein subunits into the non-activated heterotrimer.  Agonist activation of receptors 
induces GD-GTP formation in a concentration-related manner.  When GTP is replaced 
by non-hydrolysable [35S]-GTPJS, GD-[35S]-GTPJS cannot be inactivated by the 
hydrolase activity and thus accumulates in a manner dependent upon the degree of 
receptor activation. SPA is a method by which the radiolabelled G-proteins may be 
quantified.  The technique utilises scintillant-containing polymer beads (often poly-
vinyl toluene) coated with wheatgerm agglutinin (WGA) to immobilise membrane 
fragments expressing the receptor and G-proteins of interest by binding to N-
acetylglucosamine present in many membrane-associated glycoproteins.  By so doing, 
receptor and scintillant are brought into close proximity.  Binding of [35S] radioligand to 
the receptor results in the production of E-particles close enough to the beads to produce 
scintillation.  Particles produced by non-bound radioligand are absorbed by the assay 
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medium (aqueous buffer) and do not produce a signal.  Scintillation is detected using a 
suitable scintillation counter.  LEADseeker is a development of the technology designed 
for 384 well-plate format assays in which scintillation can be detected using a Perkin 
Elmer Viewlux imaging plate reader; beads used in these studies were WGA coated 
polystyrene. 
Membranes were rapidly thawed, titurated three times with a Gilson pipette and diluted 
to 1 mg ml-1 in assay buffer (HEPES 20 mM; magnesium chloride 10 mM; sodium 
chloride 100 mM; pH 7.4 with 1 M potassium hydroxide (aq)) also containing saponin 
to facilitate passage of compounds and radioligand into membrane vesicles (150 Pg ml-1 
diluted from a 10 mg ml-1 saponin solution in assay buffer at room temperature) and 
stored on ice.  LEADseeker beads were suspended at 25 mg ml-1 in assay buffer 
supplemented with saponin 150 Pg ml-1 immediately prior to mixing with membranes.  
Thirty minutes prior to assay, bead and membrane solutions were mixed 1 : 2 v v-1 in 
order to immobilise membrane fragments onto the beads, guanosine 5ƍ-diphosphate 
added in order to reduce pre-coupling and hence basal radioligand accumulation (GDP, 
30 PM diluted from a 10 mM solution in assay buffer kept on ice), and the suspension 
kept on ice with occasional agitation.  [35S]-GTPJS solution was diluted to 1.2 nM in 
assay buffer; immediately prior to adding radiolabel to the assay plate, GDP was added 
to yield 30 PM, final assay concentration. 
Assays were performed in solid white non-sterile polystyrene 384-well micro titre plates 
(Nalge Nunc, Nerijse, Belgium) and proceeded for 1 hr at room temperature in a total 
assay volume of 42 Pl comprising: 1 Pl antagonist or vehicle, 1 Pl agonist or vehicle, 25 
Pl radioligand and 15 Pl bead / membrane mixture (added last to start the reaction).  
Scintillation counting was performed using a Viewlux® imaging plate reader (Perkin 
Elmer, Wellesley, MA) with a 5 min E-particle counting protocol.  Binding signal 
(generated as described above from the accumulation of GD-[35S]-GTPJS on receptor-
activated G-proteins with subsequent disintegration of the radionuclide to produce E-
particles in close proximity to scintillant containing polystyrene beads) was stable 
between 60 and 120 min.  Agonists and antagonists were prepared as 40 x concentrates 
in DMSO in clear polystyrene V-bottom 96-well micro titre plates (Nalge Nunc).  
Dilution series were prepared as eleven 1 / 3 v v-1 steps and transferred to assay plates 
using a Biomek FX® liquid handling robot.  For antagonist mode assays 1 Pl of 40 x 
PGD2 EC80 in DMSO was added to all wells (0.8 PM to achieve 20 nM final assay 
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concentration).  In order to eliminate carry-over of test compounds, reactants were 
added in the following order: radioligand, agonist (added column-wise), compounds 
(added row-wise working from lowest to highest [PGD2]), bead/membrane mixture 
(added row-wise working from lowest to highest [PGD2] with tip changes to prevent 
carry-over). 
 
2.3.5  Pertussis toxin treatment of membranes 
CHO K1 hCRTH2 cell membranes were treated with pertussis toxin (PTX) as follows 
(quantities given are sufficient for approximately 100 wells of a 384-well plate): 250 Pl 
of 100 mM dithiothreitol (DTT) in GTPJS assay buffer was mixed with an equal 
volume of 50 Pg ml-1 PTX solution (as described in Reagents and Compounds; 250 Pl 
PBS for sham-treated samples) and left to incubate at room temperature for 1 hr (i.e. 
final concentrations of 50 mM DTT + 25 Pg ml-1 PTX in a 500 Pl volume).  Membrane 
suspension (200 Pl, 5.9 Pg ml-1) was centrifuged (10,000 x g, 10 min, room 
temperature), the supernatant discarded, the pellet resuspended in 240 Pl PTX assay 
buffer (HEPES 15 mM; magnesium chloride 10 mM; EDTA 2 mM; DTT 2 mM; 
thymidine 20 mM; nicotinamide adenine dinucleotide 10 PM; pH 8.0 with 1 M sodium 
hydroxide (aq)) and mixed with 260 Pl DTT / PTX mixture (i.e. final concentrations of 
26 mM DTT and 13 Pg ml-1 PTX in a 500 Pl volume).  The resulting mixture was 
incubated for 30 min at room temperature prior to centrifugation (conditions as above) 
and resuspension of the pellet in 500 Pl GTPJS assay buffer. 
 
2.4  Radioligand binding assay 
 
2.4.1  Membrane preparation 
For membrane preparation, cells were harvested as described under Passage technique 
to produce a single cell pellet which was resuspended in 50 ml ice-cold HE buffer (50 
mM HEPES, 1 mM EDTA, 100 PM leupeptin, 25 Pg ml-1 bacitracin, 1 mM PMSF, 2 
PM pepstatin A, pH 7.4 with potassium hydroxide).  All subsequent steps were 
performed at 4 °C. Cells were homogenised for three 5 s periods using an Ultra-Turrax 
blender on blue-black setting (approx. 20,000 rpm) with 1 min between each period.  
The resulting homogenate was plunged into ice for 40 min to allow foam to settle 
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following which it was passed through a 25 gauge syringe needle five times.  To 
remove large fragments of debris the homogenate was centrifuged at 450 x g for 10 min, 
following which the supernatant was taken and centrifuged for a further 30 min at 
48,000 x g.  The final supernatant was discarded and the resulting pellet resuspended 10 
x volume in ice-cold HE buffer without PMSF and pepstatin A (2 ml per three 175 cm2 
tissue culture flasks).  Aliquots (100 Pl) were stored frozen at -80 °C. 
 
2.4.2  Protein determination 
Membrane protein concentration was determined as described in section 2.3.3. 
 
2.4.3  [3H]-PGD2 competition binding, and assay development  
Reactions were performed in a buffer of composition: 20 mM HEPES, 10 mM 
magnesium chloride, 1 mM potassium EDTA, adjusted to pH 8.0 with 1 M potassium 
hydroxide (aq).  Cold PGD2 (10 PM) was used for determination of non-specific 
binding (nsb).  U-bottom deep-well 96-well blocks (Costar) were prepared containing 
25 Pl [3H]-PGD2 with 25 Pl PGD2 (nsb), 25 Pl buffer (total binding) or 25 Pl test 
compound or vehicle.  The reaction was initiated by the addition of 50 Pl of membranes 
and proceeded for 60 min at room temperature, or 30 min for competition binding 
assays.  For protein linearity assays, membrane protein was diluted in the range 0.4  
102 Pg well-1 for CHO K1 hCRTH2, and 0.08  19 Pg well-1 for CHO GD16z49 hCRTH2.  
For all other assays, 6.4 Pg well-1 CHO K1 hCRTH2 and 12.8 Pg well-1 CHO GD16z49 
hCRTH2 membranes were used. The reaction was terminated by rapid filtration through 
a 96-well GF/A glass fibre filtermat pre-soaked in assay buffer, which was subsequently 
dried and treated with Meltilex solid scintillant (Wallac, Turku, Finland). Results were 
obtained by scintillation counting (1450 Microbeta Trilux liquid scintillation counter, 
Wallac) using a suitable 1 min [3H] counting protocol.  Microbeta counter efficiency is 
generally around 20 % (i.e. 80 % of radionuclide disintegrations are not detected) 
resulting in data expressed as counts per minute, rather than disintegrations per minute.  
Count per minute (cpm) data were corrected by the counter software for quench and 
inter-detector variability.  Data used were therefore corrected counts per minute (ccpm).  
Assays were performed in triplicate in three separate experiments. 
 
2.4.4  [3H]-PGD2 saturation binding  
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Conditions used in this experiment were as follows: buffer composition as described 
above; [3H]-PGD2 dilution series  1 / 2 v v
-1, 0.03 nM  13 nM; membrane 
concentrations - CHO K1 hCRTH2  12.8 Pg well-1;  CHO GD16z49 hCRTH2 6 Pg well-1; 
CHO GD16z49 host 5.8 Pg well-1; cold [PGD2], plate preparation and other conditions as 
described above.  The binding reaction proceeded for 60 min at room temperature and 
was terminated by filtration, as before.  For saturation analysis, ccpm data were further 
corrected for counter efficiency by reference to standard samples diluted in Optiphase 
Gold liquid scintillant and counted on a Wallac 140905A liquid scintillation counter 
using a 1 min tritium counting protocol.  Assays were performed in triplicate in three 
separate experiments.   
 
2.5  Western blot analysis  
Sodium  dodecyl  sulphate  –  polyacrylamide  gel  electrophoresis  (SDS - PAGE)  was  
performed using the NuPAGE ® electrophoresis system (Invitrogen, Paisley, UK) 
according to the manufacturers instructions.  Briefly, samples were prepared in a total 
volume of 100 Pl comprising 50 Pl sample, 25 Pl LDS sample buffer and 10 Pl 
NuPAGE sample reducing agent (dithiothreitol) in order to load 5 Pg protein 10 Pl-1 
well-1.  The resulting mixture was incubated at 65-70 °C for 10 min, and 10 Pl loaded 
into the wells of a 10 % Bis-tris gel with 4 Pl Multi Mark molecular weight markers in 
lanes 1 & 12.  The gel was electrophoresed for 60 min at 200 V constant in NuPAGE 
MOPS running buffer until the blue dye track reached the gel base.  For Coomassie 
Blue staining and visualization the gel was immersed in Simply Blue Safestain for 24 
hrs with shaking following which it was removed and rinsed with water.  Stained and 
rinsed gels were dried overnight between two cellophane sheets previously soaked in 
Gel-Dry drying solution. 
Western Blot was performed on electrophoresed but not stained gels using the NuPAGE 
XCell Mini-Cell and Blot Module according to the manufacturers instructions.  Gels 
were placed on a nitrocellulose membrane previously soaked in Transfer Buffer, and 
two 0.45 PM filter papers, also pre-soaked, before being arranged in a Western blot tank 
with the gel nearest the cathode.  The blot was run for 60 min at 30 V, constant, in 
Transfer Buffer.  Equivalence of protein loading was demonstrated by immersing blots 
in a staining solution of 0.2 % w v-1 Ponceau S in 3 % w v-1 trichloroacetic acid (aq) for 
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5-10 min, followed by a water rinse.  Following photographic recording, dye was 
completely removed by washing in water for 1 hr. 
Western blot antibody treatment -  Nitrocellulose membranes containing proteins were 
blocked by soaking in Block Buffer (BB; 5 % w v-1 Marvel ®, 20 mM Tris-HCL, 30 
mM sodium chloride, 0.1 % w v-1 T20) for 1hr at room temperature, with shaking.  BB 
was then replaced by 10 ml of a 1/500 v v-1 dilution of primary antibody (except for 
DGDq: 1/1500 v v-1)  in BB and incubated for 18 hrs at 4 °C, with rocking.  Membranes 
were immersed for 10 mins in fresh wash buffer (WB; 20 mM Tris-HCL, 30 mM 
sodium chloride, 0.1 % w v-1 T20) three times before being incubated for 1 hr at room 
temperature in 10 ml of a 1/1000 v v-1 dilution of horseradish peroxidase (HRP) 
conjugated secondary antibody in BB.  Finally, membranes were again washed by 
immersion for 10 mins in three changes of fresh WB.   
Detection  HRP was detected using the Super Signal West Pico (SSWP) 
Chemiluminescent Substrate kit (Pierce, Rockford, IL).  Briefly, 5 ml SSWP stable 
peroxide solution was added to 5 ml SSWP luminal / enhancer solution.  The resulting 
solution was added to the antibody-treated Western blot and incubated for 5 min at 
room temperature, with shaking.  Following this the solution was discarded and the blot 
wrapped in cling film before placing in a film cassette containing a Hyperfilm ECL 
sheet (Amersham Ltd., Amersham, UK).  After exposure at room temperature (1-20 s) 
the film was developed. 
 
2.6  Data Analysis 
 
2.6.1  Data normalisation: 
Data was not normalised with respect to a reference response (for example, ionomycin).  
Instead, data from each well in calcium mobilisation assays were normalised with 
respect to the basal fluorescence in that well according to the equation: 
 
basal
FIUNormalised minmax100 u   Eqtn. 1 
Where basal is the average of five fluorescence readings taken at 1s intervals prior to 
addition of compounds or vehicle, max-min is the result of maximum fluorescence 
reading minus minimum fluorescence reading in the 55 s following compound addition, 
and normalised FIU are normalised FLIPR Intensity Units.  By so doing, and 
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controlling the number of cells seeded into each well, variations in data due to 
differential cell multiplication or confluency, and differential dye loading were 
removed.  Addition of any liquid, even buffer, to wells resulted in a transient decrease 
in fluorescence followed by partial recovery to a new lower steady state, therefore basal 
fluorescence is not synonymous with minimum fluorescence. 
  
2.6.2  Curve fitting:  
A four-parameter logistic equation of the form: 
> @
> @nHnH
nH
m
AEC
AE
E  50
     Eqtn. 2 
was fitted to data.  Thus, estimates of maximum effect (Em), curve mid-point (EC50), 
and Hill slope (nH) were obtained; other terms in the equation are effect (E) and 
concentration ([A]).   
 
2.6.3  Calculation of affinity estimates – antagonism.   Constancy of agonist E/[A] curve 
shape in the presence of increasing antagonist concentrations was assessed by 
computerised curve-fitting followed by students t-test on asymptotes and slopes.  At 
concentrations of antagonist producing small amounts of curve shift, agonist curve 
shape was often unaffected.  These data were used to determine empirical estimates of 
apparent antagonist affinity based on the method of pA2 determination (apparent pA2) as 
follows:  
Computed EC50 values were used to calculate affinity estimates (pA2) according to the 
equation:   
)1log(]log[
2
 CRBpA             Eqtn. 3 
Where [B] is the antagonist concentration and CR is the ratio of agonist E/[A] curve 
EC50 values in the presence and absence of antagonist calculated as: 
CONTROLTREATED ECECCR 5050 /    Eqtn. 4 
Where constancy of agonist E/[A] curve shape in the presence of increasing antagonist 
concentrations was shown (assessed by computerised curve-fitting followed by students 
t-test on asymptotes and slopes) computed EC50 values were fitted to a modification of 
the Schild equation (Arunlakshana & Schild, 1959) suitable for non-linear regression 
(Lew & Angus, 1995).   
cBEC pKb log)10]log([log 50               Eqtn. 5 
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Where the constant logc is the difference between the agonist control curve EC50 and 
the antagonist affinity (pKb).  The curve fitting process also provides estimates of Schild 
slope and a value representing the linearity of the plot.  Where these values were 
consistent with unit slope and linearity, the data was taken to be commensurate with the 
expectations of simple competitive interaction and a pKb value was quoted. 
Individual estimates of curve parameters and affinity values were obtained at each 
antagonist concentration in each experiment and then averaged to provide mean data.  
Quoted values are therefore the mean ± standard error (sem) of n separate experiments, 
each derived from a separate set of compound dilutions and cell preparations.   
 
2.6.4  Calculation of affinity estimates – Saturation binding:  The amount of specific 
radioligand binding to each receptor type was calculated as the difference between total 
and non-specific binding at each concentration.  Three equations were fitted to data: 
1. A hyperbolic plus linear equation fitted to total binding data.  
][
][
].[max Bm
BK
BB
ccpm
nHnH
d
nH
      Eqtn. 6 
Where ccpm are corrected counts per minute as defined above, Bmax is the maximum 
amount of radioligand binding under saturating conditions, [B] is the concentration of 
radioligand, Kd is the radioligand binding dissociation constant, nH is the Hill slope, and 
m is the slope of the linear nsb relationship. 
2.   A linear equation fitted to non-specific binding data and using the value of m to 
constrain fitting to equation 1. 
   cBmnsb  ][      Eqtn. 7 
Where nsb is non-specific binding, m is the slope of the relationship, [B] is the 
concentration of radioligand and c is the intercept of the line on the ccpm axis which 
should equal background radiation. 
3.  A hyperbolic equation fitted to specific binding data. 
nHnH
d
nH
BK
BB
ccpm
][
].[max
      Eqtn. 8 
Where terms are as previously defined. 
For each data set, the fitting method giving rise to parameter estimates with the smallest 
fitting errors was used.  Where parameter estimates did not bear a close relationship to 
observed data, the estimates were not used regardless of the fitting error size. 
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2.6.5  Calculation of Z’:  
Z is a statistical parameter that expresses in a single numerical value the relationship 
between signal window and statistical variation in the maximum and minimum response 
values for an assay (Zhang, et al., 1999).  The parameter may adopt values from 1.0 (for 
a perfect assay with no statistical variation around the maximum and minimum values) 
to -f (for an assay with no signal window relative to the variability).  In practice, values 
between 0 and 0.8 are obtained; values above 0.2 are acceptable for assays determining 
compound activity from complete concentration-effect curves.  Z is calculated as 
follows: 
minmax
minmax )3()3(1'
xx
SDSDZ 
     Eqtn. 9 
 
Where SD is standard deviation, x is arithmetic mean, and max / min denote maximum 
and minimum responses. 
 
2.6.6 Statistical analysis 
For all assays, individual estimates of curve parameters and affinity values were 
obtained in each experiment and then averaged to provide mean data.  Quoted values 
are therefore the mean ± standard error of the mean (s.e.m.) of n separate experiments, 
each derived from a separate set of compound dilutions and cell preparations.  Unless 
otherwise stated n = 3 throughout. 
Where quoted relative potency (RP) = EC50 (test agonist) / EC50 (reference agonist) and 
relative activity (RA) = Emax (test agonist) / Emax (reference agonist). 
Statistical analysis was performed using an unpaired, two-sided Students t-test in 
GenStat 8.1 (Lawes Agricultural Trust, through VSN International) software.  P < 0.05 
was taken to indicate statistical significance.  
Comparison of agonist fingerprint data was performed using ANOVA in SAS System 
v.9.0 software (SAS, Marlow, U.K.); each compound was then compared to PGD2 data 
using a Dunnett's post hoc comparison.  Slope data were analysed as log10 of the slope 
values. 
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2.7  Reagents and compounds 
 
Heat-inactivated foetal calf serum (Cat. No. 01000-147), Versene, L-Glutamine, 
neomycin (Geneticin; G418), & phosphate buffered saline were obtained from Gibco-
BRL, Ltd., Paisley, U.K..  Dulbeccos Modified Eagle Medium HAM F12 mix, 
hygromycin B, flurbiprofen, probenecid, prostaglandin D2 (PGD2), N 6,2ƍ-O-
dibutyryladenosine 3ƍ,5ƍ-cyclic monophosphate sodium salt (dibutyryl cAMP),  uridine 
5ƍ triphosphate (UTP), pertussis toxin, non-steroidal anti-inflammatory drugs (NSAIDs), 
magnesium chloride hexahydrate, sodium chloride, guanosine diphosphate and saponin 
were obtained from Sigma Ltd., Poole, Dorset, U.K..  Thapsigargin, ryanodine, H-89, 
SC-51322 and U73122 were obtained from Biomol International L.P., Plymouth 
Meeting, Pennsylvania, USA.  Pluronic F127 & fluo-3 acetoxy-methyl ester were 
obtained from Molecular Probes Inc.  Brilliant Black BN was obtained from ICN 
Biomedicals Inc., Irvine, California, USA..  GW671021X (L-798106; 5 - Bromo - 2 - 
methoxy - N - [3 - (2 - naphthalene - 2 - yl - methylphenyl) - acryloyl] - benzene 
sulphonamide), GF109203X (2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-
indol-3-yl)maleimide), GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-
benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide), GW853481X (compound 
10c in European Patent Application EP1170594 A2; (1-benzothiazol-2-ylmethyl-5-
fluoro-2-methyl-1h-indol-3-yl)-acetic acid), AH23848B (([1D(z), 2E5D]-(±)-7-[5[[(1,1'-
biphenyl)-4-yl]methoxy]-2-(4-morpholinyl)-3-oxocyclopentyl] -5-heptenoic acid), 
BWA868C90 (3-benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexyl-2-hydroxyethylamino)-
hydantoin) and BW245C ((4S)-(3-[(3R,S)-3-cyclohexyl-3-hydropropyl]-2,5-dioxo)-4-
imidazolidineheptanoic acid) were obtained from GlaxoSmithKline Pharmaceuticals 
Ltd, Stevenage, Herts., UK.  Prostanoid agonists, SC-19220 and other antagonists were 
obtained from Cayman Chemical Company, Ann Arbor, Michigan, U.S.A..  Rabbit 
polyclonal (DGDi [SC-262], DGDs [SC-823], DGDz [SC-388], DGDq [SC-393], DGD11 
[SC-394], DGDq/11 [SC-392]) & goat polyclonal (DGD16 [SC-7416]) primary antibodies, 
and horseradish peroxidase-conjugated bovine anti-rabbit [SC-2379] and donkey anti-
goat [SC-2033] secondary antibodies were obtained from Santa Cruz Biotechnology 
Inc., Santa Cruz, CA).  
Pertussis toxin, supplied as 200 Pg ml-1 in 50 % glycerol, was diluted to 50 Pg ml-1 in 
PBS and stored at 4 °C. 
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Flurbiprofen (10 mM) was made up as follows: approximately 15 mg flurbiprofen was 
dissolved in DMSO to produce a 100 mM solution and 12 Pl of 2 M sodium hydroxide 
(aq) added.  The resulting solution was diluted 1:10 with PBS and sterile filtered 
through a 0.22 PM Acrodisc® syringe filter unit or similar into a sterile container.  If 
the solution failed to go clear following addition of the PBS then more sodium 
hydroxide was titrated in prior to filtration. 
Fluo-3 AM was dissolved in DMSO to give a 2.27 mg ml-1 (2 mM) solution and was 
stored at 4 °C.  Prior to addition to assay buffer, the Fluo-3 solution was mixed with the 
appropriate volume of pre-warmed pluronic F127 solution.  Brilliant black was prepared 
as a 100 mM concentrate in MilliQ water and sterile filtered before storage at 4 °C.  
PGD2 and other prostanoid agonists were dissolved at 1 or 10 mM in absolute ethanol 
and stored at -20 °C.  Where compounds were supplied in methyl acetate, the solvent 
was evaporated to dryness with gentle heating, and the prostanoid re-dissolved in 
ethanol.  
[3H]-PGD2 (approximately 640 nM solution in 3:2:1 v v
-1 mixture of methanol : water : 
acetonitrile; specific activity 5.77 TBq mmol-1 / 3.7 MBq ml-1; stored at -20 °C), [35S]-
GTPJS (900 nM, 37 MBq ml-1; Amersham, U.K.) and LEADseeker® scintillation 
proximity assay beads were obtained from Amersham Biosciences, Amersham, UK.   
pcDNA containing a sequence encoding E-ARK 495-689 was the kind gift of Ms. 
Nicola Hawley, Institute of Cell Signalling, Queens Medical Centre, Nottingham, UK.  
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Chapter 3:   
 
Structure-activity relationship of prostanoid receptor 
ligands at human prostanoid CRTH2 (DP2) receptors: 
critical dependence upon G-protein coupling partner. 
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3.1  Summary: 
The cloned human prostanoid CRTH2 receptor was expressed in CHO cells with the 
chimeric GD16z49 G-protein.  Prostaglandin D2 (PGD2; 0.5 nM  10 PM) produced 
concentration-related elevation of intracellular calcium (pEC50 7.8 ± 0.2; nH 1.1 ± 0.08) 
in a fluorescence-based calcium mobilisation assay.  Culture of cells in the presence of 
the COX1/2 inhibitor flurbiprofen (100 PM) was essential for high agonist potency 
suggesting that endogenous prostanoid synthesis by the host cells reduces CRTH2 
agonist potency. 
The observed rank order of agonist potency was as described in the literature for this 
receptor: 15 R 15 methyl PGD2 > PGD2 > PGJ2 > 15 deoxy '12,14 PGJ2 > 15 S 15 
methyl PGD2 > 13,14 dihydro 15 keto PGD2 >> PGF2D.  BW245C, PGE2, PGI2 & 
U46619 were without significant effect.  The antagonists BWA868C (DP1), SC19220 
(EP1), GW627368X (EP4), and SQ29548 (TP) were without effect demonstrating that 
these receptors were not mediators of responses to PGD2.  Extracellular calcium was not 
required for the production of calcium transients in these experiments.  However, PGD2 
responses were markedly inhibited by pertussis toxin (PTX) indicating transduction 
through GDi/o class G-proteins.  
When the GD16z49 component was isolated in PTX-treated chimera-expressing cells, 
reversals of potency order were observed compared to responses in untreated cells.  
These were most striking for (relative potency CHO GD16z49, CHO GD16z49 + PTX; 
PGD2 = 1.0) 17 phenyl PGD2 (85, c. 30), 15 R 15 methyl PGF2D(11, NSE) & 15 deoxy 
'12,14 PGJ2 (31, 2).  The rank order of agonist potency following PTX treatment was: 15 
(R) 15 methyl PGD2 > PGD2 > PGJ2 = 15 deoxy '12,14 PGJ2 > 13,14 dihydro 15 keto 
PGD2 > 15 (S) 15 methyl PGD2. PGF2D & BW245C were without effect. The potencies 
of J series prostanoids were largely unaltered, while F & D series prostanoid potency 
decreased after PTX treatment. 
15 R 15methyl PGF2Dwas active in non PTX-treated cells (pEC50 6.4 ± 0.08; relative 
activity cf. PGD2 0.6) but inactive in PTX treated cells.  In contrast,  13,14 dihydro 15 
keto PGF2D was inactive here but has been reported as a low potency agonist in a cAMP 
lowering assay reported elsewhere and a high potency binding ligand (pKi 8.5).  These 
molecules may therefore represent receptor-G-protein-effector selective agonists or 
antagonists.  Two molecules produced dextral shifts of PGD2 E/[A] curves and were 
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identified as CRTH2 receptor antagonists: AH23848B (pA2 5.3 ± 0.1) and GW853481X 
pA2 (6.5 ± 0.07).  
These data have been used to produce an agonist pharmacophore at human prostanoid 
CRTH2 receptors (see below) and demonstrate the critical importance of the receptor-G-
protein-effector grouping as the SAR-determining unit in biochemical assays.   
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C=O > COH 
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3.2  Introduction: 
Heterotrimeric (DEJ) G-proteins are a family of membrane-associated proteins.  They 
are central to the expression of cellular responses to a range of extracellular stimuli 
which elicit their effects through cell-surface receptors (Downes & Gautum, 1999; 
Kostenis, et al., 2005, for reviews).  There are 16 D-subunit, 5 E-subunit and 14 J-
subunit genes, each encoding a separate protein product, with splice variants existing 
for at least two D-subunit genes.  Whilst it is clear that not all possible combinations of 
gene products are allowed, definitive information mapping the existence of heterotrimer 
combinations in all settings is limited but growing.  However, it is possible to state that 
a restricted set of non-dissociating EJ complexes exist but their relationship to the D-
subunits is not clearly understood. Thus, there exists the potential for a large number of 
distinct protein complexes. 
G-protein D-subunits are classified according to their sequence homology and the 
intracellular effectors with which they interact (Milligan & Kostenis, 2006): GDs to 
stimulation of adenylate cyclase, GDi/o to the opposite effect  inhibition of adenylate 
cyclase (though this ability is not shared by GDt and GDgust; GDi/o may also be coupled 
to regulation of certain Ca2+ and K+ ion channels), GDq/11 to stimulation of 
phospholipase CE and elevation of intracellular calcium, and GD12/13 to stimulation of 
the low molecular mass G-protein Rho.  This list is of effectors is by no means 
comprehensive and the reader is directed to the review by Milligan & Kostenis (2006) 
for a more thorough description.  G-protein coupled receptors (GPCRs) are often 
classified according to the G-protein with which they classically couple but this 
relationship is by no means definitive: a given receptor can couple with multiple G-
proteins (for example, splice variants of the prostanoid EP3 receptor exist which can 
couple to GDs, GDi, & GDq G-proteins; Namba, et al., 1993) and G-proteins exist with 
the property of coupling to receptors of multiple transduction classes.  This latter group 
of G-proteins, know as  promiscuous or universal coupling G-proteins, are members 
of the GDq/11 family, and comprise GD14, GD16 and its murine equivalent, GD15 (Ho, et 
al., 2001; Offermanns & Simon, 1995).  Universal coupling is a misnomer since many 
examples of GPCRs that do not couple through them are known but none-the-less they 
have found wide application in the arenas of orphan receptor ligand fishing (Wise, et 
al., 2004) and drug discovery assay development where the creation of cell lines 
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containing widely-coupling G-proteins gives the greatest probability of establishing 
useful screening systems for any given GPCR (Kostenis, et al., 2005). 
In a search to identify a truly universal G-protein, much attention has focused on 
establishing the structural determinants of G-protein / receptor coupling specificity in 
order to create modified G-proteins with greater promiscuity: the so-called chimeric G-
proteins.  Chimeric G-proteins consist of a G-protein backbone suitable for the effector 
readout one wishes to exploit, with key amino residues substituted to provide coupling 
specificity for a desired receptor class.  Building on earlier work establishing the key 
role of the C-terminal penta-peptide of GDi and GDs as a GPCR interaction site, 
Conklin, et al. (1993) demonstrated that an effective chimera could be produced 
allowing coupling of the normally GDi-coupled adenosine A1 and dopamine D2 
receptors to inositol phosphate production by substitution of only three C-terminal 
amino acid residues of GDq for those of GDi2 (Gq-Gi23; Gq-i3).  Maximally effective 
chimeras substituted between four and nine residues; this and other groups have 
established Gq-Gs, Gi-Gq, Gi-Gs, Gs-Gi and Gs-Gq chimeras displaying varying 
degrees of coupling promiscuity (Milligan & Rees, 1999, for review).  This work has 
been greatly expanded and refined such that we now understand that there are at least 
four other regions of the G-protein molecule important to determination of receptor 
coupling specificity: the extreme N- and C- termini, the DN-E1 loop, the D4-E6 region 
and the D5 helix (Kostenis, et al., 2005, for review). 
The promiscuous G-protein, GD16, is unable to couple to several receptors normally 
associated with GDi class G-proteins (Mody, et al., 2000; Kostenis, et al., 2005).  In 
order to circumvent this limitation, chimeras built on a GD16 backbone with coupling 
determination sequences taken from GDi/o G-proteins have been created (Mody, et al., 
2000).  This group chose to use sequences taken from the pertussis insensitive GDz G-
protein because of its ability to couple a wide range of Gi coupled GPCRs to inhibition 
of adenylate cyclase.  Two of the resulting chimeras, G16-Gz25 (substitution of the D5 
helix) and G16-Gz44 (substitution of approximately half of the D4-E6 region and the D5 
helix) were found to substantially increase the coupling promiscuity of GD16 toward Gi 
coupled receptors.  Because of this, and the observation that GD16 is a suitable coupling 
partner for other chemoattractant receptors (Yang, et al., 2001), we decided to use a 
G16-Gz49 chimeric G-protein to generate a calcium coupled cell line for the 
chemoattractant receptor, CRTH2 (chemoattractant receptor homologous molecule of 
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Th2 cells; Nagata, et al., 1999) which is activated by the prostanoid prostaglandin D2 
(PGD2). 
Prostanoids are a group of lipid hormone mediators that are derived from C-20 fatty 
acids (Smith, 1992) by the action of cyclo-oxygenases (COX) 1, 2 (Smith, 2000, for 
review) and 3 (Chandrasekharan, et al., 2002; Chandrasekharan & Simmons, 2004).  
They consist of the prostaglandins (PG) and the thromboxanes (Tx) and they elicit a 
wide variety of biological responses through activation of G-protein coupled receptors 
(Coleman, et al., 1994; Narumiya, et al., 1999; Breyer, et al., 2001).  The prostanoid 
receptor family consists of eight distinct rhodopsin-like receptor proteins each being the 
product of an individual gene.  These have been termed the DP, EP1, EP2, EP3, EP4, FP, 
IP and TP receptors.  In most cases, the myriad biological functions stimulated by 
prostaglandins are transduced by activation of G-proteins (Bos, et al., 2004; Hata & 
Breyer, 2004).  Thus prostanoid DP, EP2, EP4 and IP receptors are classically associated 
with elevation of intracellular cyclic adenosine monophosphate (cAMP) levels through 
activation of Gs G-proteins; EP1, FP and TP receptors with elevation of intracellular 
calcium through Gq (though not clearly established for EP1; Bos, et al., 2004); and EP3 
with reduction of intracellular cAMP levels through Gi.  However, these classical 
associations arent always applicable depending upon the test system under scrutiny and 
in the cases of EP1, EP3 and TP, upon the splice variant being studied (Pierce & Regan, 
1998). 
Recently, the ninth prostanoid receptor named CRTH2 or DP2, was identified through 
differential gene expression studies using human T-helper lymphocytes (Nagata, et al., 
1999).  Prostaglandin D2 (PGD2; Figure 1) was later shown to be the natural ligand for 
this receptor (Hirai, et al., 2001).  CRTH2 is a 7-trans-membrane sequence receptor 
(7TMR) belonging to G-protein coupled receptor (GPCR) family A and is most closely 
related structurally to other leukocyte chemoattractant receptors (Abe, et al., 1999; 
Nagata & Hirai, 2003).  CRTH2 is coupled via pertussis-toxin sensitive GDi/o to 
reduction in intracellular cAMP (Sawyer, et al., 2002) and calcium mobilisation (Hirai, 
et al., 2001; Powell, 2003) presumably via G-EJ subunits, and through a pertussis toxin 
(PTX) insensitive mechanism to E-arrestin translocation (detected by a GFP-tagged E-
arrestin / luciferase-tagged receptor BRET interaction and interpreted by the authors to 
indicate non-G-protein dependence; Mathiesen, et al., 2005).  Evidence indicating 
possible GDq coupling of the receptor to eosinophil shape change (species undefined;  
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Stubbs, et al., 2002; Böhm, et al., 2003) relies on a lack of PTX sensitivity but has not 
excluded the possibility of coupling via GDz nor of E-arrestin mediated activation of 
intracellular effectors ( Hall, et al., 1999; Lefkowitz, et al., 2006).  The receptor gene is 
located on human chromosome 11q and on murine chromosome 19 but does not share 
linkage with other chemoattractant molecules.  CRTH2 is expressed on basophils, 
eosinophils and Th2 cells but not on neutrophils or Th1 cells.  Nagata and colleagues 
(1999) also showed that CRTH2 is expressed on activated Th2 cells including allergen-
responsive cells which suggests a role for this receptor in ongoing Th2-mediated 
immune reactions.  Receptor activation results in Ca2+ mobilisation in Th2 cells and 
chemotaxis in eosinophils, basophils and Th2 cells.  Parallel responses occur in 
eosinophils involving chemotaxis, CD11b expression and L-selectin shedding 
(Monneret, et al., 2001), and also shape change and degranulation (Gervais, et al., 
2001).  
There are some interesting structural features of the CRTH2 receptor molecule.  It shares 
only 10 % sequence homology with the most similar prostanoid receptor (the prostanoid 
FP receptor) and rather more homology (35 %) with chemoattractant receptors such as 
fMLP-1, C3a, C5a and GPCR1 (DEZ; Methner, et al., 1997).  Unlike other prostanoid 
receptors, the charged arginine residue in the seventh transmembrane sequence (TM7), 
believed to be essential for high affinity prostanoid agonist binding (Narumiya, et al., 
1999, for review), is absent (Nagata & Hirai, 2003).  Predictably, with such low 
sequence homology, there are corresponding dissimilarities in other regions of the 
molecule important to binding of ligands to prostanoid receptors.  These include 
sequences in extracellular loop 2 (EC2), TM2 and TM4, the significances of which are 
poorly understood. 
Despite the structural differences, CRTH2 appears to demonstrate pharmacology 
commensurate with a member of the classically-defined prostanoid receptor family (for 
example Nagata & Hirai, 2003; Powell, 2003; Sawyer, et al., 2002).  Its pharmacology 
is, however, unique and distinct from that of the prostanoid DP receptor: PGD2, 13,14-
dihydro-15-keto-PGD2 (DK-PGD2), prostaglandin J2 (PGJ2) and indomethacin are 
agonists but the selective DP agonist BW245C is without effect  (Hirai, et al., 2002).  A 
recently discovered synthetic CRTH2 agonist, L-888,607 has sub-nanomolar affinity for 
CRTH2 but only micromolar affinity for DP (Gervais, et al., 2005).  Furthermore, the 
selective DP antagonist BWA868C appears to have low affinity for (Hirai, et al., 2003) 
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and be devoid of antagonist activity at (Monneret, et al., 2001) CRTH2 receptors.  In a 
poster communication, I have confirmed and extended our knowledge of agonist 
activity at recombinant hCRTH2 receptors transiently expressed in HEK293 cells 
(Wilson & Volppe, 2002) while Sawyer, et al. (2002) have published a competition 
binding fingerprint for prostanoid receptor ligands and COX-inhibitors at the receptor.   
The aims of the present study were two-fold: firstly, to validate the commonly used 
approach of coupling G-protein coupled receptors (GPCRs) to a more convenient assay 
readout by means of a chimeric G-protein (in this case a normally GDi-coupled receptor 
to calcium influx through GD16z49); and secondly, to more fully characterise the agonist 
pharmacology of human prostanoid CRTH2 receptors in order to generate a functional 
structure-activity relationship (SAR) and pharmacophore hypothesis which may assist 
future efforts to find selective ligands for this receptor.  A number of compounds 
important to these studies are illustrated in Figure 1. 
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3.3  Results: 
Results obtained by other individuals are indicated by a bar in the margin.  Unmarked 
text indicates results obtained by the author. 
 
3.3.1  Selection of CHO GD16z49 hCRTH2 clone. 
Two clones of CHO GD16z49 hCRTH2 cells were selected for further study based on 
PGD2 EC50  on initial test at passage 6.   
Analysis of cell size distribution revealed that clone 8 cell populations contained a 
higher proportion of large volume forms than populations of clone 17.  Cell plating 
conditions were therefore adjusted to achieve generation of confluent monolayers of 
cells in assay plates. 
Prostaglandin D2 (0.5 nM  10 PM) produced concentration-related increases in [Ca2+]i 
in cells of both clones (Figure 2; cells plated out at 5000 and 10,000 cells well-1, clones 
8 and 17, respectively).  The potency (pEC50) of PGD2 was similar in both cell lines 
(clone 8: 7.0 ± 0.03; clone 17: 6.9  ± 0.05) but marked differences in maximum 
response (clone 8: 143 ± 2; clone 17: 70  ± 2; P < 0.05) and Z (clone 8: 0.38 ± 0.02; 
clone 17: -0.47  ± 0.2; P < 0.05) were observed (data are mean of >120 individual E/[A] 
curves, or in the case of Z, of 6 determinations, produced on three separate assay 
occasions, at the same passage number).  All subsequent data were generated in clone 8 
cells. 
 
3.3.2  Effect of indomethacin. 
Blockade  of  endogenous  prostaglandin  synthesis  by  inclusion  of  the  non-selective  
COX inhibitor indomethacin (3 PM) in the cell culture medium at passage 10 was found 
to increase the proportion of large swollen cells in both clones at P11 in a manner 
which could not be quantified by the Sysmex counter I used.  Clone 8 cells cultured 
with and without 3 PM indomethacin produced identical PGD2 E/[A] curve parameters 
(Figure 3A); the only significant change produced by indomethacin was to improve 
assay reproducibility.  When tested for agonism, indomethacin  (10 PM  0.5 nM) 
produced concentration related [Ca2+]i elevations (Figure 3B & Table 1; cells at 1 x 10
4 
cells well-1) but was approximately 8-fold less potent than PGD2 with a relative activity 
of 0.63 cf. PGD2 (= 1.0; P = 0.02).  When the same cells exposed to the indomethacin 
dilution series were challenged 11 mins later with a fixed concentration of PGD2 (1 PM) 
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in the continued presence of indomethacin, an inhibitory E/[A] curve was produced (see 
Chapter 6 for investigation of mechanism).  The inhibitory pIC50 of indomethacin was 
identical to its calcium mobilization pEC50 (Table 1); relative activity cf. PGD2 = 1.0.  
 
3.3.3  Effect of other NSAIDs: selection of flurbiprofen as cell culture medium 
supplement. 
The NSAIDs acetyl salicylic acid (aspirin), 4-acetamidophenol (acetaminophen), 
diclofenac, sulindac, diflunisal, acemetacin, indole-3-acetic acid (heteroauxin), [+]-
naproxen, ibuprofen, S-flurbiprofen and piroxicam did not display any agonism or 
desensitisation effects at concentrations up to 10 PM (Table 1).  In the same experiment 
PGD2 pEC50 was 6.3 ± 0.2 and pIC50 (desensitisation or inhibition vs. PGD2 EC80) was 
6.6  ± 0.2 (P > 0.05). 
Because of its high in vitro potency vs. COX1 and 2, flurbiprofen was selected for 
further study.  Culture of cells in the presence of 10 PM flurbiprofen resulted in an 
increase in PGD2 potency (pEC50) from 6.9 ± 0.1 to 7.4  ± 0.1 and in Z from 0.25 ± 0.1 
to 0.5 ± 0.09 (P < 0.05).  Investigation of the literature suggested that flurbiprofen is 
99.95 % plasma protein bound in humans (Knadler et al., 1989; Szpunar et al., 1989) 
and that increasing the concentration used in the culture medium to 100 PM might yield 
a more effective free drug concentration.  Culture of cells in the presence of 100 PM 
flurbiprofen resulted in a further increase of PGD2 potency to 7.8 ± 0.06 and of Z to 
0.64 ± 0.02 (P < 0.01).  Changes in E/[A] curve asymptote were not observed.   
 
3.3.4  Development of assay protocol and requirement for extracellular calcium.. 
Using cells cultured in the presence of 10 PM flurbiprofen, a range of assay 
conditions were investigated (Table 2).  The optimum set of conditions were found to 
be: FLIPR experiments performed at room temperature, pipettor speed 5 Pl s-1, pipettor 
height 30 Pl, 2 x 10 Pl mixes at 5 Pl s-1, camera exposure time 0.4 s, plate type Greiner 
poly-D-lysine coated, cell seeding density 20,000 cells well-1, anion exchange inhibited 
with probenecid, dye quench with brilliant black required, pluronic acid included, 
flurbiprofen omitted from the assay buffer, and 0.8 mM Ca2+ included in the assay 
buffer.  Replacement of cell culture medium with serum-free medium 24 hours prior to 
assay worsened responses to PGD2.  Where there was little to distinguish between 
conditions the option most similar to other assays running in our labs was chosen.  All 
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subsequent data were generated in cells cultured in the presence of 100 PM 
flurbiprofen.  The impact of alternative methods of data analysis on agonist (PGD2 & 
UTP) curve parameters was investigated under optimal assay conditions.  Analyses 
based on calculations as described in Methods (((max-min)/basal)x100) yielded pEC50 
and slope data that were not different from analyses based on the area under the 
fluorescence / time curve (AUC; Table 3). PGD2 maximum effect values expressed as a 
percentage of the UTP maximum effect were 40 % smaller using AUC-based analysis.  
Analyses based on maximum rate of fluorescence change during the increasing phase of 
calcium responses gave markedly lower agonist potencies and flatter PGD2 curve 
slopes.  All analyses were therefore performed as described in Methods. 
 
3.3.5  Assessment of host cell response to prostaglandins. 
CHO GD16z49 cells without the prostanoid hCRTH2 receptor were grown and plated for 
assay as described in Methods.  A non-statistically significant trend towards small 
decreases in basal fluorescence was produced by PGD2 (0.17 nM-10 PM) which was 
insensitive to challenge with the prostanoid DP receptor antagonist BWA868C (1 PM), 
the putative prostanoid hCRTH2 receptor antagonist GW853481X (10 PM; compound 
1c in Bauer, et al., 2002), and the prostanoid EP4/TP receptor antagonist AH23848B (30 
PM; Figure 4). PGE2 produced small concentration-related elevations of [Ca2+]i over the 
same concentration range which were significant at 0.33 PM (P = 0.05) but were non-
significant at 10 PM (Figure 4, panel B).  The data was not of sufficient quality to 
obtain a robust curve fit however the following parameters were estimated: pEC50 7.6 ± 
0.3, Emax 16 ± 2.  Although the mean data plot is suggestive of a biphasic E/[A] curve, 
examination of individual curves were clearly monophasic.  PGE2 responses were also 
insensitive to challenge with antagonists including the potent and selective prostanoid 
EP4 receptor antagonist GW627368X.  Exposure of cells to antagonists at the 
concentrations used did not result in basal fluorescence changes. 
 
3.3.6  Effect of  standard prostanoid receptor agonists and antagonists. 
In contrast to findings in host cells, in CHO GD16z49 hCRTH2 cells prostaglandins E2 
(PGE2), I2 (PGI2, prostacyclin), and U-46619 were devoid of agonist effects up to 10 
PM; prostaglandin PGF2Dproduced small elevations of [Ca2+]i at 10 PM resulting in a 
maximum response of 14 ± 2 % cf. PGD2 controls (Figure 5).   
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BWA868C, SC19220 (prostanoid EP1 receptor antagonist), SQ29548 (prostanoid TP 
receptor antagonist) and GW627368X (prostanoid EP4 receptor antagonist) were devoid 
of antagonist activity up to 10 PM vs. 0.3 PM PGD2.  GW853481X antagonised PGD2 
responses to give a pIC50 of 6.1 ± 0.2 (P < 0.05 cf. control) and a slope of 2.5 ± 0.3 (P > 
0.05; Figure 6, Panel A).  Complete blockade of PGD2 responses was not achieved, 
maximum inhibition being 72 ± 5 %.  Further assay demonstrated that GW853481X (10 
PM) produced rightward displacement of PGD2 E/[A] curves with simultaneous upper 
asymptote depression (1 PM antagonist Emax = 81 ± 6 % of control; P = 0.05) to yield an 
apparent pA2 estimate of 6.5 ± 0.06 (Figure 6, Panel B).  However, higher 
concentrations of antagonist did not elicit any further depression of Emax.  GW853481X 
did not antagonise responses to UTP (1 PM) in the same cell line.  (In later experiments 
(Chapter 7), this molecule produced agonist-like effects in these cells at high 
concentrations (pEC50 4.5 ± 0.1, Emax 5 ± 3 %)).  AH23848B also antagonised PGD2 
responses but with lower potency: the maximum inhibition achieved being 24 ± 9 % at 
10 PM vs. 0.3 PM PGD2.  However, AH23848B produced parallel rightward 
displacement of PGD2 E/[A] curves resulting in an apparent pA2 estimate of 5.3 ± 0.1 
(Figure 7) and was devoid of agonist effects. 
 
3.3.7  Effect of pertussis toxin treatment. 
Pertussis toxin (PTX; 50 ng ml-1) produced marked inhibition of responses to PGD2 in 
CHO GD16z49 hCRTH2 cells (Figure 8, Panel A).  In the absence of PTX, PGD2 pEC50 
was 7.5 ± 0.06, slope 1.1 ± 0.03; in the presence of PTX PGD2 pEC50 was 6.4 ± 0.06 
(P=0.01), slope 1.9 ± 0.2 (P < 0.05), and curve maximum 15 ± 1 % cf. PGD2 no PTX 
control (P < 0.01).  The effect was reproducible over 6 rounds of passage spanning four 
weeks of cell culture (Figure 8, Panel B).  A small passage-related change in PGD2 
pEC50 was observed through the course of this study (for example, PGD2 pEC50 at P10 
7.5 ± 0.05; at P16 6.9 ± 0.02; P < 0.01) which was statistically significant at all time 
points tested (P12, 14 & 16) in both PTX treated and untreated groups.  
 
3.3.8  Agonist ‘fingerprinting’ of hCRTH2 receptor in CHO GD16z49 cells ± PTX 
treatment. 
A panel of 76 prostanoid molecules was screened for agonist activity in CHO GD16z49
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hCRTH2 cells with and without PTX pre-treatment at concentrations up to 10 PM 
(Table 4).  Without PTX treatment, 65 % of the compounds tested were found to be 
without agonist effect.  Curve slopes for active compounds were generally in the range 
1.2-2.0; slopes greater than this were observed for some partial agonist compounds.  
The following rank order of agonist potency was obtained for the most active 
compounds (relative potency [RP cf. PGD2 = 1.0], relative activity [RA cf. PGD2 = 1.0]; 
full agonists shown in bold type, partial agonists in normal type): 15 (R) 15 methyl 
PGD2 (0.5, 0.9) > PGD2 > 15 (R) 15 methyl PGF2D (11, 0.6) > 15 deoxy PGD2 (20, 
0.9) > PGJ2 (27, 0.9) = 15 deoxy '12,14 PGJ2 (31, 0.9) > 15 (S) 15 methyl PGD2 (38, 
0.8) > 13,14 dihydro 15 keto PGD2 (39, 1.0) > '12 PGJ2 (47, 0.9) > 9,10 dihydro 15 
deoxy '12,14 PGJ2 (54, 0.9) > 17 phenyl PGD2 (85, 1.2) > PGD3 (100, 0.8) > 15 keto 
PGF2D (131, 0.7) > PGD1 (224, 0.9) > 15 (R) PGF2D (379, 0.6) > 16,16 dimethyl PGD2 
(402, 0.8) > 15 keto PGF1D (408, 0.3) > PGF2D (>400, 0.2) > butaprost methyl ester 
(497, 0.7) > latanoprost (794, 0.3) > cloprostenol (1585, 0.3).  BW245C was without 
significant effect.   
Following PTX treatment, the profile of agonist activity was markedly altered.  Under 
these conditions, PGD2 produced a maximum effect equal to 37 ± 0.9 % of the 
maximum response produced in non-PTX treated cells during the same experiment (P < 
0.05; PGD2 pEC50 in non-PTX treated cells 7.9 ± 0.09).  A similar proportion (62 %) of 
compounds were without agonist effect.  A group of 5 compounds (7 %) consistently 
produced very low level agonism, statistically not distinguishable from baseline noise, 
but with high potency (RP  0.23  0.02).  For the group of compounds described above, 
the rank order of agonist potency was: 15 (R) 15 methyl PGD2 (0.7, 0.9) > PGD2 = 15 
deoxy PGD2 (1.0, 1.1) > PGJ2 (2, 1.0) = 15 deoxy '12,14 PGJ2 (2, 1.0) > '12 PGJ2 
(3, 1.0) = 13,14 dihydro 15 keto PGD2 (3, 0.7) > 9,10 dihydro 15 deoxy '12,14 PGJ2 
(4, 0.8) > 15 (S) 15 methyl PGD2 (6, 0.6) > 16,16 dimethyl PGD2 (11, 0.4) >> 17 
phenyl PGD2 (max effect 0.6) = PGD3 (max effect 0.4) = 15 keto PGF2D (max effect 
0.2) = PGD1  (max effect 0.2).  Cloprostenol, PGF2D, 15 keto PGF1D, butaprost methyl 
ester, 15 (R) 15 methyl PGF2D, latanoprost & BW245C were without significant effect. 
 
3.3.9  Data Tables. 
Follow on next page. 
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 Table 1.  Effects of several non-steroidal anti-inflammatory drugs (NSAIDs) in CHO GD16z49 hCRTH2 cells.  Cells were cultured in the presence 
of  3 PM indomethacin prior to assay; other conditions as defined in Methods.  RP is relative potency cf. PGD2 (= 1.0); RA is relative activity cf. 
PGD2 (= 1.0). Min & max values are expressed in normalised FLIPR intensity units as described in Methods.  Data are mean ± sem; n = 9.  
 Agonism Inhibitory or antagonist effects (vs. 0.3 PM PGD2) 
  min max pEC50 slope RP RA min max pIC50 slope RP RA 
4-acetamidophenol 55 ± 3 47 ± 4    0 114 ± 4 115 ± 3    0 
Acetyl salicylic acid 50 ± 4 47 ± 6    0 114 ± 6 117 ± 8    0 
Diclofenac 63 ± 7 45 ± 3    0 122 ± 4 128 ± 4    0 
Naproxen 58 ± 2 52 ± 9    0 122 ± 3 126 ± 2    0 
Sulindac 60 ± 6 50 ± 5    0 119 ± 4 123 ± 9    0 
Diflunisal 55 ± 8 43 ± 3    0 117 ± 3 127 ± 5    0 
Acemetacin 57 ± 5 50 ± 9    0 115 ± 2 126 ± 6    0 
Indomethacin 56 ± 4 104 ± 24 5.6 ± 0.2 1.3 ± 0.4 7.8 0.63 23 ± 6 132 ± 4 5.6 ± 0.06 2.0 ± 0.7 2.3 1.0 
Ibuprofen 56 ± 6 53 ± 9    0 118 ± 5 121 ± 6    0 
Flurbiprofen 60 ± 5 54 ± 9    0 121 ± 5 129 ± 4    0 
Indole 3 acetic acid 58 ± 1 53 ± 5    0 121 ± 6 125 ± 8    0 
Piroxicam 57 ± 3 57 ± 6    0 120 ± 13 130 ± 3    0 
PGD2 58 ± 5 133 ± 6 6.3 ± 0.2 1.0 ± 0.2 1.0 1.0 17 ± 6 128 ± 6 6.0 ± 0.1 1.2 ± 0.3 1 1.0 
Vehicle 58 ± 4 54 ± 7    0 119 ± 6 128 ± 5    0 
PGD2 (agonist time-matched control for antagonist read) 39 ± 5 142 ± 6 6.6 ± 0.2 1.0 ± 0.06   
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Table 2.  Determination of assay conditions & parameters.  Cells cultured in the 
presence of  10 PM flurbiprofen.  PDL: poly-D-lysine coated; SAB  assay buffer plus 
sulphinpyrazone (120 PM); PAB  assay buffer plus probenecid (2.5 mM); BB  assay 
buffer plus brilliant black (1 mM).  Data are mean ± sem of 32 E/[A] curves determined 
on 2 assay plates in a single assay (plate type & seeding density n=3). 
 
Condition Options min max pEC50 slope Z´ 
Assay temperature Room temp. 27 ± 1 152 ± 2 7.3 ± 0.04 1.3 ± 0.05 0.6 
 37 °C 28 ± 1 141 ± 2 7.4 ± 0.04 1.4 ± 0.07 0.6 
Liquid dispense speed 5 Pl s-1 28 ± 1 141 ± 2 7.4 ± 0.04 1.4 ± 0.07 0.6 
 10 Pl s-1 27 ± 1 132 ± 2 7.6 ± 0.04 1.4 ± 0.09 0.7 
 20 Pl s-1 59 ± 2 145 ± 2 7.3 ± 0.04 1.4 ± 0.09 0.3 
Pipettor height 30 Pl 59 ± 2 145 ± 2 7.3 ± 0.04 1.4 ± 0.09 0.3 
 40 Pl 57 ± 1 150 ± 2 7.3 ± 0.04 1.3 ± 0.09 0.4 
Camera exposure time 0.4 s 28 ± 1 141 ± 2 7.4 ± 0.04 1.4 ± 0.07 0.6 
 0.5 s 36 ± 2 144 ± 9 7.4 ± 0.04 1.1 ± 0.05 0.5 
Plate type Nunc 27 ± 1 141 ± 2 7.5 ± 0.04 1.3 ± 0.07 0.4 
 Greiner PDL 36 ± 2 132 ± 2 7.5 ± 0.02 1.4 ± 0.07 0.4 
Cell seeding density 5,000 well-1 28 ± 1 114 ± 1 7.5 ± 0.04 1.3 ± 0.07 0.3 
 10,000 well-1 30 ± 1 134 ± 2 7.5 ± 0.04 1.4 ± 0.09 0.4 
 20,000 well-1 24 ± 1 170 ± 2 7.6 ± 0.04 1.1 ± 0.04 0.6 
 40,000 well-1 16 ± 1 196 ± 2 7.4 ± 0.02 0.8 ± 0.02 0.7 
None - - - - 9.9 Anion exchange inhibitor 
SAB - - - - -1.7
 PAB 18 ± 1 199 ± 3 7.9 ± 0.05 1.0 ± 0.05 0.8 
Quench None 24 ± 1 118 ± 3 8.0 ± 0.05 1.3 ± 0.1 0.1 
 BB 18 ± 1 199 ± 3 7.9 ± 0.05 1.0 ± 0.05 0.8 
Detergent None 10 ± 0.2 131 ± 3 6.6 ± 0.04 1.0 ± 0.02 0.8 
 Pluronic acid 9 ± 0.2 139 ± 3 6.5 ± 0.02 1.0 ± 0.02 0.8 
None 10 ± 0.2 131 ± 3 6.6 ± 0.04 1.0 ± 0.02 0.8 COX inhibition during 
assay Flurbiprofen 15 ± 0.4 116 ± 3 6.4 ± 0.05 0.9 ± 0.02 0.7 
Extracellular calcium None added 24 ± 0.5 145 ± 1 6.7 ± 0.04 1.3 ± 0.07 0.7 
(EGTA not used) 0.2 mM 20 ± 0.4 114 ± 1 6.7 ± 0.04 1.2 ± 0.04 0.6 
 0.4 mM 20 ± 0.2 118 ± 2 6.5 ± 0.04 1.1 ± 0.05 0.7 
 0.8 mM 10 ± 0.2 131 ± 3 6.6 ± 0.04 1.0 ± 0.02 0.8 
 1.6 mM 24 ± 0.5 108 ± 2 6.5 ± 0.04 1.0 ± 0.04 0.6 
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Table 3. Impact of alternative data analysis techniques on PGD2 and UTP E/[A] curve 
parameters.  Data were analysed either as described in Methods (((max-
min)/basal)x100), or by analogous processes using measurements of area under the 
fluorescence / time curve (AUC), or of the maximum rate of fluorescence change during 
the increasing phase of a calcium response (Max. Rate).  Data are mean ± sem of 
duplicate determinations from three independent experiments. 
 PGD2 UTP 
 pEC50 slope max as % UTP 
max 
pEC50 slope 
Max-min 7.9 ± 0.09 1.8 ± 0.3 61 ± 6 7.0 ± 0.1 1.2 ± 0.3 
AUC 8.0 ± 0.09 1.4 ± 0.2 37 ± 4 6.9 ± 0.1 1.2 ± 0.2 
Max rate 7.1 ± 0.2 0.9 ± 0.1 28 ± 0.3 6.0 ± 0.09 1.2 ± 0.2 
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Table 4.  Pharmacology of prostanoid molecules in CHO GD16z49 hCRTH2 cells with and without pertussis toxin (PTX) treatment.  RP: relative 
potency cf. PGD2 (= 1.0); RA: relative activity cf. PGD2 (= 1.0).  Data are mean ± sem; without PTX n = 4 - 10; with PTX n = 3. 11 dehydro 
TxB2, 15 (R) 19 (R) hydroxy PGF2D13,14 dihydroxy 15 keto PGA2, 6 keto PGF1D6 keto PGE1, '17 6 keto PGF1DPGA2, 15 (R) PGE2, 
PGF1DPGA1, 13,14 dihydro 15 keto PGF1D15 keto PGE1, 19 (R) hydroxy PGF1D11 dehydro 2,3 dinor TxB2, PGI2, 15 (R) 19 (R) hydroxy 
PGF1D13,14 dihydro 15 keto PGE1, TxB2, 15 (R) 19 (R) hydroxy PGE2, PGK1, 15 keto PGE2, 20 hydroxy PGE2, 11E 13,14 dihydro 15 keto 
PGF2D19 (R) hydroxy PGF2DPGK2, PGI3, PGE2, 19 (R) hydroxy PGE1, PGB2, Cicaprost, Sulprostone, BW245C, Butaprost free acid, 17 
phenyl PGE2, 16,16 dimethyl PGE2 & Iloprost were without significant effect under either set of conditions.   denotes data from single curve fit.  
Statistical comparison by ANOVA followed by Dunnetts comparison to PGD data; * denotes P < 0.05. 
 Without PTX With PTX 
Compound pEC50 slope max RP RA pEC50 slope max RP RA 
15 (R) 15 methyl PGD2 7.7 ± 0.04 1.6 ± 0.2 89 ± 7 0.5 0.9 6.6 ± 0.04 1.1 ± 0.04 93 ± 4 0.7 0.9 
PGD2 7.8 ± 0.1 1.3 ± 0.1 100.0 1.0 1.0 6.5 ± 0.07 1.4 ± 0.1 100.0 1.0 1.0 
15 (R) 15 methyl PGF2D 6.4 ± 0.04* 1.6 ± 0.2 63 ± 5* 11 0.6   NSE   
15 deoxy PGD2 6.8 ± 0.2* 1.7 ± 0.09 90 ± 2 20 0.9 6.5 ± 0.09 1 ± 0.1 110 ± 4 1.0 1.1 
PGJ2 6.4 ± 0.07* 1.5 ± 0.1 87 ± 3 27 0.9 6.2 ± 0.03 1.2 ± 0.03 98 ± 3 1.8 1.0 
15 deoxy '12,14 PGJ2 6.6 ± 0.0* 1.4 ± 0.04 86 ± 3 31 0.9 6.2 ± 0.0 1.6 ± 0.09 99 ± 4 1.8 1.0 
15 (S) 15 methyl PGD2 6.0 ± 0.09* 1.6 ± 0.4 82 ± 4 38 0.8 5.7 ± 0.09* 1.9 ± 0.4 61 ± 4* 5.8 0.6 
13,14 dihydro 15 keto PGD2 6.5 ± 0.04* 1.2 ± 0.07 97 ± 4 39 1.0 6.0 ± 0.04 1.4 ± 0.07 73 ± 2* 2.8 0.7 
'12 PGJ2 6.4 ± 0.09* 1.8 ± 0.2 91 ± 3 47 0.9 6.1 ± 0.04 2.1 ± 0.5 102 ± 2 2.5 1.0 
9,10 dihydro 15 deoxy '12,14 PGJ2 6.3 ± 0.04* 1.6 ± 0.2 89 ± 4 54 0.9 5.9 ± 0.04* 1.5 ± 0.04 83 ± 4* 3.5 0.8 
17 phenyl PGD2 6.2 ± 0.09* 1.4 ± 0.1 122 ± 4 85 1.2   61 ± 2*  0.6 
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PGD3 6.0 ± 0.06* 3.7 ± 0.1* 82 ± 1* 100 0.8   38 ± 2*  0.4 
15 keto PGF2D 6.0 ± 0.1* 2.0 ± 0.6 73 ± 3* 131 0.7   18 ± 5*  0.2 
PGD1 5.8 ± 0.1* 1.2 ± 0.1 89 ± 3 224 0.9   17 ± 14*  0.2 
15 (R) PGF2D 5.5 ± 0.2* 1.8 ± 0.3 55 ± 2* 379 0.6   15 ± 5*  0.2 
16,16 dimethyl PGD2 5.5 ± 0.2* 3.2 ± 0.5* 78 ± 6* 402 0.8 5.4* 3.9 41 ± 3* 10.5 0.4 
15 keto PGF1D 5.6 ± 0.06* 1.6 ± 0.3 28 ± 3* 409 0.3   NSE   
PGF2D < 5.2  17 ± 3* > 400 0.2   NSE   
Butaprost methyl ester 4.8 ± 0.1* 3.1 ± 1.0* 58 ± 4* 497 0.7   NSE   
Latanoprost 4.7 ± 0.2* 2.6 ± 0.7 30 ± 6* 794 0.3   NSE   
Cloprostenol 4.4 ± 0.06* 1.4 ± 0.2 31 ± 1* 1585 0.3   NSE   
Misoprostol   20 ± 1*  0.2   NSE   
15 (S) 15 methyl PGF2D   16 ± 3*  0.2   NSE   
13,14 dihydro 15 keto PGF2D   12 ± 4*  0.1   NSE   
11 deoxy 11 methylene PGD2   10 ± 3*  0.1   NSE   
PGF3D   9 ± 4*  0.1   NSE   
13,14 dihydro PGE1   NSE     17 ± 11*  0.2 
PGE3   NSE     19 ± 19*  0.2 
20 hydroxy PGF2D   NSE     23 ± 16*  0.2 
13,14 dihydro PGF1D   NSE   7.8 ± 0.1* 1 ± 0.06 5 ± 1*  0.05 
13,14 dihydro 15 keto PGE2   NSE     10 ± 5*  0.1 
PGE1   NSE   8.1 ± 0.06* 1.1 ± 0.06 13 ± 4*  0.1 
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PGD1 alcohol   NSE   7.1 ± 0.3 1.9 ± 0.5 4 ± 0.6*  0.04 
15 (R) 15 methyl PGE2   NSE     16 ± 12*  0.2 
13,14 dihydro 15 (R) PGE1   NSE     9 ± 7*  0.1 
19 (R) hydroxy PGA2   NSE     14 ± 12*  0.1 
15 (R) PGE1   NSE     10 ± 1*  0.1 
19 (R) hydroxy PGE2   NSE     14 ± 6*  0.1 
2,3 dinor 11E PGF2D   NSE   7.7 ± 0.2* 1.9 ± 0.6 6 ± 1*  0.1 
11deoxy PGE1   NSE   8.2 ± 0.07* 1.1 ± 0.3 8 ± 4*  0.1 
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Table 5.  Potency and activity of indomethacin reported in literature.  Data are mean (nM) ± s.e.m.  Terms in table are:  pcAMP - inhibition of 
forskolin stimulated cAMP accumulation; Ca2+ - calcium mobilisation; CTX  chemotaxis; GTPJS  GTPJS binding assay. * Denotes max 
effect at 10 PM. 
Species Cell line Read out PGD2 EC50 Indomethacin EC50 RP RA Binding Ki / IC50 Reference 
Human HEK293(EBNA) pcAMP 1.8±0.4 14.9±4.9 8 1.0  Sawyer, et al., 2005 
 HEK293 GD15 Ca2+ 22.1±4.4 ND   25±4 Sawyer, et al., 2002 
Human L1.2 pcAMP 0.24 4.5 19 1.0 1000 Sugimoto, et al., 2005 
  Ca2+ 1.2 49 41 1.0   
  CTX 0.5 40 80 1.0   
Human K562 Ca2+ 1-5 50 10-50 1.0 8100±1900 Hirai, et al., 2002 
 Jurkat CTX < 1 c.40 > 40 2.0   
 TH2 CTX c. 4 50-250 12-60 1.0   
 Basophil CTX 5-25 c.250 10-50 1.0   
 Eosinophil CTX 5-25 c.250 10-50 1.0   
Human CHO GD16z49 Ca2+ 500±100 2,500±400 8 0.63  Present chapter 
 CHO GD16z49 + PTX 
+  flurbi 
Ca2+ 15.8±8 c. 10,000 c. 40 0.58*  Present chapter 
 CHO K1 + flurbi Ca2+ 13 ± 6 126 ± 10 10 0.85  See Chapter 4 
 CHO K1 membranes GTPJS 8 ± 2 400 ± 0 50 1.1 See Chapter 7 See Chapter 5 
Human Unspecified      3000±1000 Hata, et al., 2005a 
Murine ER293 pcAMP 0.9 7 8 1.0 1500 Hata, et al., 2005a 
Murine HEK293 pcAMP 0.7±0.3 2.0±0.7 3 1.0 1900±300 Hata, et al., 2005b 
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3.4  Discussion: 
Definition of appropriate methodology is a key step in the preparation of any assay 
system for data generation and must take into account technological aspects of the 
instrumentation, physicochemical aspects of the reagents, biological characteristics of 
the assay system, as well as good laboratory practice.  In this chapter, I have 
demonstrated the definition of suitable experimental procedures for generating 
quantitative SAR data at human prostanoid CRTH2 receptors expressed in CHO cells 
also expressing the GD16z49 chimeric G-protein, the use of those data to generate 
alternative pharmacophore hypotheses describing agonist interaction with the receptor, 
and the importance of viewing the receptor / G-protein pairing as being a key 
determinant of pharmacological selectivity. 
Clone selection was primarily based on examination of prostaglandin D2 (PGD2) 
concentration-effect (E/[A]) curve data which clearly demonstrated the superior 
magnitude of responses generated by clone 8.  However, these data were produced by a 
single agonist in an un-optimised assay system, without supplementation of cell culture 
medium with a COX inhibitor.  The absence of assay optimisation data at this stage is 
not likely to have impacted significantly on the choice of clone since alteration of 
technology- and assay methodology- related parameters made little or no impact on 
PGD2 pEC50 or maximum effect. However, of greater potential significance is the 
absence of COX inhibition during this part of the study.  Endogenous production of 
prostaglandins by cells in culture has been demonstrated for many cell lines, including 
CHO K1 cells (Kargman, et al., 1996).  Foetal calf serum has been shown to 
concentration-dependently stimulate production of up to 0.2 ng PGE2 per 10
6 cells per 
30 mins of incubation under resting conditions (Murakami, et al., 1996) though figures 
for PGD2 are lacking.  The mechanism by which this occurs is unclear but presumably 
relates to the presence of various growth factors, cytokines, hormones and other 
proteins in the serum, some of which may activate cell surface receptors on CHO cells.  
Over 36 hrs of cell culture in a 175 cm2 tissue culture flask as much as 16 nmol of PGE2 
could be produced (calculation based on Murakami, et al., 1996, assuming c. 3 x 108 
cells flask-1 at confluency).  Much will be spontaneously hydrolysed or metabolized, as 
discussed below, but it seems likely that local concentrations near to the cells will be 
sufficient to result in autocrine stimulation of prostanoid receptors with the potential to 
cause desensitisation or down-regulation.  The data I present here shows a significant 
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increase in PGD2 pEC50 when cells are cultured in the presence of an effective 
concentration of COX inhibitor, implying (but not proving) that inhibition of 
prostaglandin synthesis has resulted in response pathway up-regulation.  It is unknown 
whether cells of clones 8 and 17 produce equal amounts of prostaglandin, whether 
receptor desensitisation is indeed occurring (see Chapter 6 for further investigation), if it 
does whether it progresses along identical pathways in both clones, and therefore 
whether the clones would respond identically to effective COX inhibition.  It is also 
unknown whether CHO K1 cells express significant amounts of prostaglandin 15 
dehydrogenase (PG15dH) and thus whether metabolism of PGD2 to 15 keto PGD2 can 
occur to any appreciable extent over the time course of the assay.  For this reason, it 
would have been desirable to simultaneously assay another metabolically resistant 
agonist such as 15 (R) 15 methyl PGD2.  Thus, it is conceivable that the true 
performance of these clones was masked by poorly controlled assay conditions. 
The non-selective COX 1/2 inhibitor indomethacin (3 PM; Figure 1) was without effect 
on PGD2 pEC50 and maximum responses but increased the variability of responses to a 
fixed concentration of PGD2.   As  described  above, the inclusion of a COX inhibitor 
was expected to improve assay performance by preventing autocrine receptor activation 
and desensitisation.  In addition to COX inhibition, indomethacin possesses a range of 
other activities including inhibition of a PGD2 11-ketoreductase (Lovering, et al., 2004) 
and is also an agonist at prostanoid CRTH2 receptors (Hirai, et al., 2001; Sawyer, et al., 
2002; Stubbs, et al., 2002; Sugimoto, et al., 2005).  The data presented here shows that 
indomethacin, like PGD2, produces a profound and rapid inhibition of the ability of cells 
to respond to subsequent PGD2 EC80 challenge.  The net effect of cell culture with 
indomethacin on PGD2 responses will therefore be the sum of simultaneous 
prostaglandin synthesis inhibition (and therefore agonist response potentiation), 
inhibition of a PGD2 metabolic pathway, plus direct receptor activation possibly leading 
to subsequent desensitisation, and occupancy of the receptor leading to a partial agonist 
/ full agonist interaction.  It seems surprising, then, that indomethacin did not produce 
more marked effects on PGD2 responses: culture medium contained 3 PM indomethacin 
which would be expected to produce c. 30 % inhibition of PGD2 responses. The 
difference may reflect possible recovery from the inhibitory effect during the 90 min 
dye-loading phase of the experiment since cell culture medium was replaced by 
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indomethacin-free assay buffer at the start of the assay.  This will be investigated further 
in Chapter 6.   
Indomethacin is reported to be a potent and full agonist at prostanoid CRTH2 receptors 
in human native, human recombinant and animal native receptor assays with potencies 
relative to PGD2 (RP) of 15-50 (Table 5).   In these studies PGD2 potency in the order 
of 1-20 nM was described.  In my hands the relative potency (RP) of indomethacin was 
8 with a relative activity (RA) of 0.63 against a PGD2 potency (EC50) of 0.2 PM.  This 
is the first demonstration that indomethacin is a low efficacy (partial) agonist at human 
prostanoid CRTH2 receptors and suggests that receptor-response coupling efficiency in 
these cells is relatively poor.  (PGD2 potency is also low compared to that reported 
elsewhere (Table 5)).  The pharmacophore giving rise to prostanoid CRTH2 receptor 
binding and agonism is likely to be unrelated to the COX 1/2 inhibitor pharmacophore 
since other NSAIDs were devoid of agonist and antagonist activity at the receptor.  
Indeed, in common with Hirai, et al., (2002), I found the structurally related plant auxin 
indole-3-acetic acid was without effect suggesting that the agonism shown by 
indomethacin has specific structural requirements.  It is conceivable that indomethacin 
is producing an effect through activation of endogenous 5-hydroxytryptamine 1B 
receptors (Dickenson & Hill, 1998) but three lines of evidence argue against this: firstly, 
in CHO K1 hCRTH2 cells, indomethacin is a partial agonist (pEC50 6.9 ± 0.1) and shifts 
PGD2 E/[A] curves with an apparent pA2 of 6.1 ± 0.1 (Chapter 7); secondly, 
indomethacin displaces [3H]-PGD2 from CHO K1 hCRTH2 cell membranes (pIC50 7.5 ± 
0.2; Chapter 7); thirdly, a large body of evidence has been reported (e.g. Armer, et al., 
2005; Hata, et al., 2005) that indomethacin and other, but not all, indole-based 
molecules have high affinity for prostanoid CRTH2 receptors.  Sawyer, et al., (2002) 
found that sulindac possessed some affinity for the receptor (pKi 5.4) and so some 
inhibition would be expected here.  However, the sulphone form of the molecule has 
much lower affinity (pKi 4.7) which would be below the detection limit of this assay.  
Interestingly, the desensitisation potency of indomethacin was identical to its potency as 
an agonist but with a maximum effect equal to that of PGD2, i.e. complete inhibition of 
responses to 0.3 PM PGD2, suggesting that agonist exposure leads to an inhibition that 
is amplified with respect to the calcium mobilisation response.  Since indomethacin is a 
partial agonist, the expectation is that its E/[A] curve is superimposable on its receptor 
occupancy curve.  As described in Table 5, most affinity estimates for indomethacin at 
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prostanoid CRTH2 receptors range between 1 and 8 PM; the EC50 of 2.5 PM obtained 
here is entirely consistent with the previous data.  Prostanoid CRTH2 receptors are 
described as being coupled to both calcium mobilisation and inhibition of adenylate 
cyclase through GDi/o (Sawyer, et al., 2002, 2005; Sugimoto, et al., 2005), to E-arrestin 
recruitment via a non-PTX sensitive mechanism (Mathiesen, et al., 2005), and possibly 
via GDq/11 or GDz to eosinophil shape change (Stubbs, et al., 2002; Böhm, et al., 2003).  
In studies using inhibition of forskolin-stimulated cAMP production as the assay 
readout, agonist potencies are consistently around 10-fold higher than in corresponding 
calcium mobilisation assays in the same cell line (Sawyer, et al., 2002, 2005; Sugimoto, 
et al., 2005).  Therefore, it seems reasonable to assume that calcium mobilisation and 
cAMP reduction occur in parallel in the cells used here.  Therefore, the observed 
inhibition of agonist responses subsequent to an initial exposure of cells to agonists may 
be occurring as a result of other, better-coupled, response pathways that have not been 
measured in these studies, e.g. inhibition of adenylate cyclase, activation of MAP 
kinases or regulation of K+ channels.   
The 2-arylpropionic acid, S-flurbiprofen (Figure 1), is a potent, non-selective, COX1/2 
inhibitor which was without effect at human prostanoid CRTH2 receptors.  R-
flurbiprofen is much less active as a COX inhibitor but the enantioselectivity associated 
with other actions of flurbiprofen such as J-secretase inhibition (Gasparini, et al., 2005; 
Peretto, et al., 2005) inhibition of apoptosis involving p53 (Grosch, et al., 2005) 
activation of c-Jun-terminal-N-kinase (Grosch, et al., 2003), inhibition of hepatic 
mitochondrial ȕ-oxidation and oxidative phosphorylation (Browne, et al., 1999) and 
antimicrobial activity against certain fungal infections (Chowdhury, et al., 2003), varies.  
None of the non-COX activities are predicted to have a direct effect on prostaglandin 
synthesis, action, and metabolism, however, flurbiprofen is also a substrate for human 
cytochrome P450 2C9 (Wester, et al., 2004), a cytochrome with preference for 
lipophilic acids such as prostaglandins.  Cytochrome dependent Z- or 20- hydroxylation 
of prostaglandins followed by E-oxidation to a carboxylic acid is a major metabolic 
route for prostaglandins, while cP450s of the 2B, 2C and 2J families, particularly cP450 
2C9, metabolise arachidonic acid to epoxyeicosatrienoic acids (EETs; Michaelis, et al., 
2005).  Although information specifically relating to cP450 2C9 in CHO cells is not 
available, it is widely reported in the literature that CHO cells possess a fully 
functioning mitochondrial cP450 system even though endogenous expression of specific 
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cytochromes including 1B1 (Luch, et al., 1998) and 2D6 (Ding, et al., 2001) may be 
low or absent.  Therefore, it is conceivable that in addition to suppressing the synthesis 
of prostaglandins in CHO cells, flurbiprofen simultaneously acts to inhibit the shunting 
of arachidonic acid into the EET synthetic pathway and, of greater potential 
significance, the metabolic inactivation of prostaglandins.  This latter effect would serve 
to both increase autocrine receptor desensitisation and inhibit metabolism of 
exogenously applied prostaglandin.  However, given the wide distribution of 
prostaglandin 15 dehydrogenase (PG15dH) in hamsters (Terada, et al., 2001) and the 
presence of the enzyme in rat ovarian tissues (Inazu & Fujii, 1996), it seems reasonable 
to assume that CHO cells express PG15dH and that increased persistence of 
prostaglandins in the cells or the culture milieu is unlikely to occur.  An effect on the 
metabolism of exogenously applied prostaglandins is not suspected because assays 
performed using non-NSAID treated cells revealed that application of flurbiprofen 
solely during the assay period did not alter PGD2 E/[A] curve parameters. 
Estimates of the potency of flurbiprofen as a COX inhibitor, and of the rank order of 
activities shown by a range of NSAIDs vary according to the methodology used.  
However, flurbiprofen is consistently shown to be of high potency at both COX-1 and -
2.  Recently, a third COX isoform has been identified, COX-3, at which  ibuprofen has 
been shown to have higher potency than at the other COX isoforms (Chandrasekharan, 
et al., 2002; reviewed in Chandrasekharan & Simmons, 2004).  The expression of COX-
3 in CHO cells is as yet undetermined but it seems likely that flurbiprofen will also be 
active at this enzyme.   
Of great importance to the application of flurbiprofen in this setting is its high plasma 
protein binding.  This has been estimated at over 99.9 % (Knadler, et al., 1986; Evrard, 
et al., 1996) in human plasma, and has been shown to be similarly high in the plasma of 
other species.  Cell culture medium contains 10 % foetal calf serum which is sufficient 
to bind approximately 99 % of the flurbiprofen added, leaving free concentrations of 0.1 
and 1 PM (30 and 300 x COX-1 Ki, respectively) at nominal concentrations of 10 and 
100 PM.  Thirty-fold Ki is insufficient to achieve adequate enzyme inhibition but 300-
fold Ki can be considered to achieve near total inhibition of prostaglandin synthesis.  
This is borne out by the PGD2 potency data which shows incremental increases as 
[flurbiprofen] rises from zero, to 10 PM, and finally to 100 PM.  As discussed above, 
based on our current knowledge of flurbiprofen this is likely to be via COX inhibition 
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rather than some other aspect of the molecules pharmacology.  Concentrations above 
this were not tested because of the technical difficulties associated with the sterile 
preparation of high concentration flurbiprofen solutions but if these can be overcome it 
may be possible to achieve further increases in PGD2 potency.  
It is not my intention to discuss every detail of the assay development data since it is 
largely self-explanatory.  Where a particular reagent or technique did not lead to an 
increase in assay performance, the selection of methodology was based on the cheapest, 
simplest or most standardised technique with respect to other assays running in the lab 
at that time.  Certain features of the method do deserve particular mention.  Since 
running the assay at 37 ºC made no difference to PGD2 E/[A] curve parameters, assays 
were run at room temperature.  The FLIPR® instrument possesses a built-in 384 tip 
pipettor which has settings for dispense speed, dispense height, number of reagent 
mixes and so on.  Details such as these are rarely defined in the scientific literature but 
make a critical difference on the quality of the data that can be obtained.  Artefacts 
caused by addition of liquids to assay wells generate responses which arise from dye 
concentration changes or mechanical stimulation of the cells as added liquid flows over 
them.  The latter effect increases as flow increases and the data presented in Table 2 
shows larger basal responses with reduced Z at relatively modest pipettor speeds.  
Similarly, little data is published comparing alternative organic anion transport 
inhibition strategies as mechanisms for ensuring Fluo 3 retention by cells.  Here, 
sulphinpyrazone was without effect, giving rise to results identical to those obtained in 
the complete absence of inhibitor, and confirming the use of probenecid as a standard 
intervention.  The development of a homogenous assay format using the sulphonamide 
quenching dye brilliant black BN was found to be necessary since a more conventional 
wash protocol led to detachment of cells from the plasticware.  Brilliant black may 
interfere with certain agonists, typically peptide molecule agonists such as prokineticin 
(ligand for AXOR8) and TARC (ligand for CCR4; Coma, I. & de los Frailles, M., 
personal communication), and others such as angiotensin, bradykinin & neurokinin 
(Molecular Devices; http://www.moleculardevices.com/pdfs/MultispanPoster.pdf).  
This is likely to arise from a charged interaction with  multiple centres of negative 
charge in the brilliant black molecule but in the case of prostanoids, this will result in a 
repulsion of the negatively charged carboxylate group.  The data indicate that there is no 
effect of brilliant black on PGD2 potency.  Lastly, the vehicle concentration used (1 % 
DMSO) is at the limit of acceptability to the CHO cells used here.  Addition of vehicle 
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was observed to produce low magnitude transient calcium fluxes which did not alter 
responses to subsequent addition of PGD2.  Concentrations of DMSO above this 
increased the variability around responses to a fixed concentration of PGD2 (1 PM) and 
resulted in wells failing to respond to agonist on an apparently random basis.  It is 
possible that during the transfection and clone expansion process, cells were selected 
with greater resistance to solvent exposure, allowing the use of a high solvent 
concentration such as this. 
Calcium fluxes in response to PGD2 in CHO GD16z49 hCRTH2 cells do not require the 
presence of extracellular calcium thus indicating the endoplasmic reticulum (ER) as the 
likely source of the calcium and implicating the phospholipase C E  inositol 1,4,5 
triphosphate (PLCE  IP3) pathway as the coupling mechanism.  Furthermore, the 
ability of pertussis toxin (PTX) to abolish responses in CHO K1 hCRTH2 cells and to 
reduce responses in CHO GD16z49 hCRTH2 cells by 85 % suggests the involvement of 
GDi/o G-proteins, presumably coupling to PLCE through the GEJ subunits (see Chapter 
4).  Because responses in CHO K1 hCRTH2 cells were abolished, all GDi/o coupling in 
CHO GD16z49 hCRTH2 cells should also have been abolished.  Therefore, the small 
signal remaining after PTX treatment in the chimeric cell lines is assumed to be due to 
coupling through the chimeric G-protein since the expression of this molecule is taken 
to be the only difference between the two receptor-expressing cell lines.  Although 
incubation with higher concentrations of PTX was not attempted, incubation of double 
the number of cells with the same concentration of PTX produced identical results.  The 
weakness of this signal is not typical of calcium coupling through the alpha subunits of 
GDq class G-proteins which raises the possibility that this signal is actually mediated via 
GEJ subunits.  In this regard, it is interesting to note that curve slopes in non PTX-
treated cells are generally lower and indicative of coupling through two response 
pathways.  In experiments comparing PGD2 E/[A] curves in cells ± PTX treatment 
conducted in parallel, PGD2 curve slope was found to increase (data in text at section 
3.3.7) however this effect was lost when mean data sets from non-parallel experiments 
were compared (Table 4).   The increase in slope presumably reflects removal of the 
GDi/o coupling pathway and is contrary to the expected result of interruption of 
synergising interactions (see below).  Further delineation of this response pathway is 
clearly needed perhaps using the GDq inhibitor YM254890 (Takasaki, et al., 2004), the 
phosphatidyl choline specific PLC (E) inhibitor U73122 (Walker, et al., 1998), and the 
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non-IP3 receptor inhibitor ryanodine.  In addition, over-expression of a EJ-subunit 
scavenger such as the C-terminal of E adrenoreceptor kinase 1 (EARK1 495-689; 
Dickinson & Hill, 1998) would provide confirmation of the molecular identity of the 
coupling partners in the chimeric cell line. 
CHO GD16z49 host cells were essentially devoid of responses to PGD2.  The small 
decreases in basal fluorescence observed were most likely due to addition artefacts in 
this experiment.  CHO cells are reported to endogenously express prostanoid EP4 
receptors (Crider, et al., 2000) which classically do not couple to calcium mobilisation.  
However, we have generated data in separate studies (not shown) that indicates PTX-
sensitive coupling of EP4 receptors  in highly expressing recombinant systems, raising 
this as a possibility.  Indeed, the bell-shaped E/[A] curve produced by PGE2 here is 
indicative of a dual mechanism of action but insensitivity to challenge with the EP4/TP 
receptor antagonist GW627368X (Wilson, et al., 2006) effectively rules prostanoid EP4 
receptors out.   Similarly, the inactivity of DP & CRTH2 antagonists rules out these 
receptors.  Taken together prostanoid EP1 (GDq-like coupling) and EP3 (splice-
dependent GDi/o, Ds, & Dq coupling) receptors remain as likely candidates.  Given that 
the maximum response to PGE2 in the host cells was c.10 % of the PGD2 maximum 
response in receptor expressing cells, and that PGE2 was without effect in receptor 
expressing cells, if an endogenous EP receptor is present, its impact on the overall study 
will be minimal.  The lack of effect of PGE2 in receptor-expressing cells could arise 
from dual opposing effects on intracellular calcium.  Indeed, the activity of other E 
series prostaglandins in PTX-treated cells (see below) support the notion that an 
endogenous receptor is present.   
Agonist pharmacology in CHO GD16z49 hCRTH2 cells bore the hallmark features of 
prostanoid CRTH2 receptors: lack of activity of PGE2, PGF2D, PGI2 & U-46619; high 
potency responses to PGD2 but not the prostanoid DP1 receptor agonist BW245C; 
agonist rank order of potency 15 R 15 methyl PGD2 > PGD2 > PGJ2 > 15 deoxy '12,14 
PGJ2 > 15 S 15 methyl PGD2 > 13,14 dihydro 15 keto PGD2; insensitivity of PGD2 
responses to the prostanoid DP1 receptor antagonist BW868C; and sensitivity to the 
putative prostanoid CRTH2 receptor antagonist GW853481X (Bauer, et al., 2002; see 
references cited in Table 5 for agonist pharmacology).  Furthermore, PGD2 responses 
were insensitive to prostanoid TP, EP4 & EP1 receptor antagonists, discharging the risks 
associated with endogenous expression of prostanoid EP4 and EP1 receptors, and the 
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established pharmacophoric overlap with prostanoid TP receptors indicated by the 
activity of ramatroban reported in Ishizuka, et al., 2004.  
Interestingly, the prostanoid TP / EP4 receptor antagonist AH23848B (Figure 1; 
Brittain, et al., 1985) was an antagonist at prostanoid CRTH2 receptors.  The low 
potency of AH23848B necessitated the use of a high concentration of the compound in 
order to observe displacement of PGD2 E/[A] curves. This also prevented a clear 
demonstration of the compounds mechanism of action since higher antagonist 
concentrations could not be achieved.  In the presence of 30 PM antagonist, the PGD2 
E/[A] curve was shifted to the right with no depression of the upper asymptote.  There 
was, however, a non statistically-significant increase in curve slope.  Increased curve 
slopes can indicate complexities in the behaviour of the antagonist or of the biological 
system, for example multiple PGD2-sensitive receptors or  the presence of a 
physicochemically protected sub-population of receptors that the antagonist cannot 
access.  Given that the trend is non-significant and that increased curve slopes have not 
been observed with the use of this compound elsewhere in this thesis (chapter 4., figure 
8) it seems likely that this is an isolated observation.  The apparent pA2 value of 
AH23848B vs. prostanoid CRTH2 receptors is similar to its established affinity at 
prostanoid EP4 receptors and to its previously reported binding pKi of 5.5 at human 
prostanoid CRTH2 receptors (Sawyer, et al., 2002).  I therefore propose that AH23848B 
should be reclassified as a prostanoid CRTH2 / EP4 / TP receptor antagonist. 
These data also confirm that compound 1c (GW853481X; Figure 1) in Bauer, et al., 
2002, is indeed a prostanoid CRTH2 receptor antagonist, and establish an apparent pA2 
estimate of 6.5 for the molecule.  The compound did not elicit any agonist effects over 
the concentration range tested here but in later experiments (see Chapter 7) did produce 
agonist like effects at higher concentrations (pEC50 4.5) which may explain the non-
total inhibition of PGD2 EC70 by this compound (Fig. 6, Panel A) and which may 
contribute to the observed depression of PGD2 Emax noted below.  The selectivity of the 
compound was confirmed by its lack of activity against UTP acting at the endogenous 
P2Y2 receptor in these cells.  Although agonist Emax was decreased by treatment with 1 
PM antagonist, higher concentrations did not elicit any further decreases.  This suggests 
that curve depression was neither a systematic effect of the compound nor an expression 
of hemi-equilibrium phenomena (a common observation in calcium mobilisation assays 
where the response takes place in a time frame (seconds) too fast for agonist and 
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antagonist to establish a new equilibrium at the receptor).  Notwithstanding the Emax 
effect, PGD2 curves were shifted to the right in a parallel fashion suggesting 
GW853481X is competitive.  Indeed, the constancy of the apparent pA2 estimate across 
the antagonist concentrations tested is also indicative of a reversible competitive 
interaction.  The trend (non significant) in apparent pA2 estimates towards lower values 
at higher antagonist concentrations is likely to be a reflection of the impact of upper 
asymptote depression on curve midpoint location.  Analysis based on mid-points is only 
valid where no depression of agonist Emax occurs.  If depression does occur, analysis in 
this way is likely to result in pA2 under-estimation while hemi-equilibrium will distort 
affinity estimates in the opposite manner, leading to over-estimation.  Therefore, the 
affinity reported here is a reasonable estimate and GW853481X may be described as a 
competitive prostanoid CRTH2 receptor antagonist.  (In Chapter 7, data will be 
presented showing no Emax depression by GW853481X and resulting in a pKb 
determination by Schild analysis of 6.3 ± 0.16). 
The panel of 76 prostanoid molecules produced a range of activities at human 
prostanoid CRTH2 receptors and have established for the first time a comprehensive 
agonist fingerprint for the receptor.  Although there is no a priori reason to expect 
binding and functional assay data to correlate, comparison of binding pKi values taken 
from Sawyer, et al., 2002, with functional pEC50 values generated in non-PTX treated 
cells yielded a correlation coefficient (r2) of 0.88 (Figure 9).  However, this is 
misleading since the slope of the regression is significantly less than 1.0, and functional 
pEC50 data are >1.0 log unit lower than binding pKi data for all molecules except PGD2.  
The rank order and pEC50 values for agonists obtained here is consistent with data 
presented for calcium mobilisation elsewhere and lends further weight to the widely 
acknowledged principle that binding is not a good indicator of function.  However, the 
binding data do appear to correlate with potencies determined using cAMP lowering as 
the functional assay readout (r2 = 0.90, slope = 1.0; Figure 9; Sawyer, et al., 2002).  The 
latter data indicate high efficiency receptor-effector coupling and under these 
circumstances the impact of efficacy on potency is reduced (affinity driven potency; 
Kenakin, 1999).  The converse is true in poorly coupled systems where efficacy is a 
more important determinant of potency.  In the present studies, calcium mobilisation 
data are indicative of poor coupling (low PGD2 and indomethacin potencies c.f. 
literature values) and would be expected to demonstrate efficacy-driven agonist 
potencies.  A number of functionally inactive compounds have been reported to possess 
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binding affinity; pKis for these compounds are close to or beyond the detection limit of 
the functional assay and so are not expected to be active.  One notable exception is 
13,14 dihydro 15 keto PGF2D (Figure 1; pKi 8.5) which produced small responses at 10 
PM (12 % of PGD2 max), was of low potency in the cAMP assay, and was excluded 
from the correlation described above.  Binding pKi was estimated by competitive 
displacement of [3H]-PGD2, consistent with an orthosteric competitive interaction. Thus 
13,14 dihydro 15 keto PGF2D could be an antagonist at human prostanoid CRTH2 
receptors with respect to calcium mobilisation, but an agonist with respect to cAMP 
reduction.  Whether this is an example of a permissive antagonist (Kenakin, 2005) will 
depend on the nature of the hypothesized antagonism and will be investigated in 
Chapter 7.  In this respect it would be interesting to determine whether this molecule 
could activate or inhibit the PTX-insensitive E-arrestin recruitment of prostanoid 
CRTH2 receptors reported by Mathiesen, et al. (2005).   
Before discussing the impact of PTX treatment on agonist activity, I wish to make some 
observations relating to agonist SAR at human prostanoid CRTH2 receptors in non 
PTX-treated CHO GD16z49 hCRTH2 cells.  Only prostaglandin D (9 hydroxy 11 keto), J 
('9,10 11 keto) and F2D (9,11 dihydroxy) cyclopentane ring groups gave rise to 
molecules with agonist activity with the rank order D > J > F2D  Although hydroxyl 
group hydrogen atoms are weakly acidic (pKa ~ 16) the main functionalities of these 
and carbonyl groups in this setting are as hydrogen bond (H-bond) donors (hydroxyl) 
and acceptors (hydroxyl and carbonyl).  H-bond acceptor functionality at C11 is shared 
by all three ring systems and it would appear that that conferred by carbonyl groups is 
more effective at stimulating agonism, possibly by adoption of alternative resonance 
structures. The rigid conformation accorded by the C=O double bond may access a 
binding / activation motif that the more flexible and less electronegative OH group 
cannot.  It is therefore surprising that prostaglandin E (9 keto 11 hydroxy), I (11 keto 
6,9 fused tetrahydrofuran), and K (9,11 diketo) structures are inactive.  These findings 
can be reconciled if the binding pocket accessed by the head group is sterically 
restricted such that a small flexible H-bond donor is needed at C9 with specific spatial 
relationship to a conformationally rigid H-bond acceptor at C11.  The importance of the 
C11 carbonyl is re-iterated by the complete lack of activity shown by 11 deoxy 11 
methylene PGD2.  Alternatively, the fatty side chains of prostaglandins have a high 
degree of conformational freedom which is critically affected by substitutions onto the 
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cyclopentane ring.  Thus the relationship of H-bond donors and acceptors may exert 
their effect through alteration of side chain conformation. 
Stereoselectivity around the C15 position has been demonstrated by Monneret, et al. 
(2003), for D series prostaglandins.  These data confirm the finding that 15R 
stereochemistry gives rise to higher potency than 15S for D series prostaglandins and 
extends it to include F series prostaglandins.  All naturally occurring prostaglandins, 
have 15S hydroxy stereochemistry but 15 R PGF2D is more potent than PGF2D.  15 R 
PGD2 is not available but is predicted to have higher potency than PGD2 but not 15 R 
15 methyl PGD2 since 15 R PGF2D has lower potency than 15 R 15 methyl PGF2D.  
Interestingly, the effect of C15 methyl substitution depends on the stereochemical 
arrangement: 15 S 15 methyl reduces potency / activity, while 15 R 15 methyl increases 
potency for both D and F series prostaglandins.  These data may suggest that in the R 
conformation, the 15 hydroxy group is exposed and interaction with the receptor is 
facilitated.  The role of the CH3 group may be to sterically hinder 15 hydroxy group 
interactions in the S configuration but to enhance it in the R form.  However, the 
obligate importance of the 15 hydroxy group is called into question by data for 15 
deoxy variants of D and J series prostaglandins.  Thus 15 deoxy PGD2 is less potent 
than PGD2 but 15 deoxy variants of PGJ2 are equipotent.  This may reflect the precise 
conformation of the E side chain which in the case of the J series molecules is affected 
by C=C double bond rearrangement from C13 to C12 and 14.  Thus, the presence of a 
C15 hydroxy may be required to stabilise a conformation through H-bond interactions 
which is also stabilised by the presence of '12,14 double bonds.  Circumstantial evidence 
in support of the importance of the C=C double bonds is given by the reduction in 
potency shown by PGD1 and PGD3. Other authors have suggested that PGD3 and PGD2 
are equipotent (Monneret, et al., 2003) so taken together these data may indicate the 
presence of a '17 reductase enzyme in the eosinophil assay used by Monneret. 
The direction of the H-bond interaction is difficult to assess: 15 keto PGD2 is less potent 
suggesting H-bond donation is required but 15 keto PGF1D and 15 keto PGF2Dare more 
potent than their respective natural prostaglandins suggesting H-bond acceptance is 
required.  The common functionality in these groups is H-bond acceptance; the 
differences may arise from the positioning of oxygenated groups on the cyclopentane 
ring with the rigidity of the carbonyl at C15 being required to overcome the lack of 
spatial restriction in the C11 hydroxy group of F series molecules.  Forcing the C11 
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group into its binding pocket may also be demonstrated by the PGF2D analogues 
cloprostenol and latanoprost which both carry bulky aromatic hydrocarbon groups at the 
C18 position.  Indeed 17 phenyl Z 18,19,20 trinor PGD2 also retains activity but 
presumably the reduction in potency relative to PGD2 is now due to hindrance of C15 
hydroxy interactions since 16,16 dimethyl PGD2 is only weakly active. 
Lastly, although substitution of an isopropyl group into the C1 carboxylic acid group in 
latanoprost retains activity, complete loss of the carboxylate functionality abolishes 
activity, as in PGD1 alcohol.  Thus a picture emerges of an agonist pharmacophore for 
human prostanoid CRTH2 receptors in non-PTX treated cells, illustrated in Figure 10.  
The coupling partner in this setting is assumed to be EJ subunits of GDi/o G-proteins but 
this requires greater definition since coupling through GD16z49 also occurs 
simultaneously. 
SAR data at the same receptor in PTX-treated cells (i.e. assumed to be coupled through 
the GD16z49 G-protein) were more complicated.  The rank order of agonist potencies, 
and the stereochemistry within the D and J series were preserved but relative to each 
other there was a marked drop in the potency of D series agonists.  There was an even 
greater drop in the potency of F series agonists suggesting that although an H-bond 
acceptor is still required at C11, there is increased spatial stringency around the C9 
position for activation of GD16z49.  One molecule, 15 R 15 methyl PGF2D, displayed a 
dramatic change in activity, becoming inactive in the PTX treated cells: possibly an 
example of a G-protein specific agonist at human prostanoid CRTH2 receptors.  PGD2 
Emax under these conditions was insufficient for quantitative analysis of competition but 
did permit GW853481X pIC50 determination (6.4 ± 0.3), which was consistent with non 
PTX-treated values. 
These pharmacophoric requirements are apparently contravened by an A series 
molecule (9 keto '10,11) and several E series (9 keto 11 hydroxy) molecules that showed 
very weak activity.  Features of the SAR (lack of C11 H-bond functionality, opposite 
stereochemistry at C15) are strongly indicative of a second pharmacophore at a different 
protein.  Indeed, C15 S > R is the typical stereoselectivity demonstrated by other 
prostanoid receptors.  As discussed above, there is evidence from studies in CHO 
GD16z49 host cells that may indicate the presence of an endogenous prostanoid EP1 or 
EP3 receptor in these cells.  Alternatively,  if one flips these molecules such that the 
functional group at C9 occupies the space formerly occupied by the group at C11 it is 
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possible to envisage a possible mechanism for E and A series prostaglandins to dock 
with the pharmacophore.  It is also interesting to note that PGE1 and 3 are both active 
while PGE2 is inactive, suggesting that the fully flexible E chain in PGE1 and the 
conformationally restricted chain in PGE3 both position the C15 group favourably while 
this is not possible in PGE2 itself.  However, given the molecular contortions needed to 
bring the C15 hydroxyl group into position, this alternative binding modality seems 
unlikely.  A further possibility is that these agonists are acting at a second agonist 
binding site on the receptor.  If this were so then complexities in agonist and antagonist 
pharmacology might be expected, for example agonist-specific antagonist affinities and 
complex radioligand binding (see chapter 7 for further comments) but the detection of 
small responses in chimera-expressing host cells suggests that another receptor type 
may be present. 
These data highlight some of the difficulties inherent to pharmacophore generation.  All 
compound potencies, affinities and activities, irrespective of their origin in binding or 
functional assays, are the combined product of affinity and efficacy (Colquhoun, 1987, 
1998; references cited in Rang, 2006).  In many functional settings, this will involve 
activity at multiple, sometimes opposing, transduction and regulation pathways 
producing a composite snapshot of compound SAR specific to that pharmacological 
environment: bad news for receptor classification studies!  These data  demonstrate 
large changes in agonist rank order of potency generated in the same cell line under two 
different G-protein coupling conditions and highlight the critical importance of the 
coupling partner as a determinant of compound activity.   
The choice of coupling partner in recombinant cell based assays is usually based on 
pragmatism and is often decided simply on the basis of the one that works first.  
Greater rationality can be applied by tailoring the biological reagent to provide an assay 
reporting the biochemical changes relevant to the physiological process under 
investigation.  Thus native G-proteins are always first choice but where multiple 
transduction pathways exist, perhaps mediated by different second messengers, then 
care must be taken to select the pathway of most relevance to the ultimate application.  
However, the concept of selecting the right one may be considered redundant since the 
simple answer is that they are all right.  Assay systems that provide for greater 
integration of biochemical processes in whole single cells, groups of cells, and whole 
tissues may provide integrative SAR more predictive of eventual in vivo activity.   
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The data presented in this chapter have raised some important questions which will be 
addressed in subsequent chapters:  
1. Definition of prostanoid SAR at human CRTH2 receptors coupled through GDi/o 
alone using GD and GEJ readouts. 
2. Relationship between this pharmacophore (activity based) and the receptor 
structure (structure based pharmacophore). 
3. Screening for prostanoids with affinity but no efficacy (antagonists). 
4. Greater definition of calcium mobilisation signal transduction. 
5. Exploration of the significance and SAR of agonist induced desensitisation. 
6. Examination of 13,14 dihydro 15 keto PGF2D and 15 R 15methyl PGF2D as 
putative  R-G pair selective agonists. 
and finally, 
7. The antagonist properties of AH23848B at human prostanoid CRTH2 receptors. 
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3.5  Figure caption list: 
Figure 1. Structures of some molecules relevant to these studies. 
 
Figure 2.  Prostaglandin D2 (PGD2) concentration effect curves in CHO GD16z49 
hCRTH2 cells of clonal cell lines 8 and 17, plated out at 5,000 and 10,000 cells well
-1, 
respectively (taking into account their different growth characteristics, this represented 
the same degree of confluency for the two clones).  Cells were grown in the absence of 
COX inhibition.  Data are mean ± sem of twelve E/[A] curves from three separate 
assays.  Terms are as defined in Methods. 
 
Figure 3.  Panel A: Prostaglandin D2 (PGD2) concentration effect curves in CHO 
GD16z49 hCRTH2 cells of clonal cell line 8.  Cells grown ± indomethacin (3 PM).  Data 
are mean ± sem of twelve E/[A] curves from three separate assays.  Panel B: PGD2 and 
indomethacin E/[A] curves in clone 8 cells grown in the absence of COX inhibitors.  
Data are mean ± sem of sixteen E/[A] curves from three separate assays. 
 
Figure 4.  Panel A: Prostaglandin D2 (PGD2) and PGE2 concentration effect curves in 
CHO GD16z49 (host) and CHO GD16z49 hCRTH2 (CRTH2) cells.  Cells grown in the 
presence of flurbiprofen (100 PM).  Data are mean ± sem of six E/[A] curves from three 
separate assays.  Panel B:  Effect of prostaglandins or vehicle on CHO GD16z49 (host) 
cells.  * denotes P = 0.05.  Panel C: Effect of vehicle, 30 PM AH23848B, 10 PM 
GW853481X or 1 PM BWA868C on responses to 10 PM PGD2 or PGE2 in CHO 
GD16z49 (host) cells. 
 
Figure 5.  Representative data showing the effect of the prostaglandins PGD2, PGE2, 
PGF2D, PGI2 and the prostanoid U-46619 in CHO GD16z49 hCRTH2 cells.  Data are 
mean ± sem of four E/[A] curves generated in a single experiment.  Data in text and 
tables for these compounds were generated over four experimental occasions. 
 
Figure 6.  Panel A: Inhibition of responses to 0.3 PM PGD2 by GW853481X in CHO 
GD16z49 hCRTH2 cells.  Data are mean ± sem of seven E/[A] curves generated 
separately in the same experimental occasion.  Panel B:  PGD2 E/[A] curves generated 
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in the presence of vehicle or increasing concentrations of GW853481X (Schild analysis) 
and, inset, Clarke plot of antagonist pA2 estimated at each concentration of antagonist 
vs. log[antagonist concentration].  Data are mean ± sem of four E/[A] curves generated 
separately in the same experimental occasion. 
 
Figure 7.  Panel A: Inhibition of responses to 0.3 PM PGD2 by AH23848B in CHO 
GD16z49 hCRTH2 cells.  Data are mean ± sem of seven E/[A] curves generated 
separately in the same experimental occasion.  Panel B:  PGD2 E/[A] curves generated 
in the presence of vehicle or 30 PM AH23848B.  Data are mean ± sem of six E/[A] 
curves generated in three separate assays. 
 
Figure 8.  Effect of pertussis toxin treatment on responses to PGD2 in CHO GD16z49 
hCRTH2 cells. Panel A:  PGD2 E/[A] curves in PTX-treated or -untreated cells at 
passage 10 (P10).  Data shown are for 2 x 104 cells well-1; treatment of 4 x 104 cells 
well-1 produced identical results.    Panel B:  Left chart:  Maximum responses to PGD2 
in PTX-treated cells at passages 10-16 (P10-16) compared with responses in untreated 
control (C) cells; Right chart: PGD2 pEC50 in PTX-treated and -untreated cells at P10-
16.  Data are mean ± sem of twelve E/[A] curves generated in three separate 
experiments. * denotes P < 0.01 cf. PGD2 pEC50 in PTX-untreated or ** PTX-treated 
cells at P10. 
 
Figure 9.  Correlation plots of functional assay pEC50 data with binding assay pKi 
values (Sawyer, et al., 2002).  Panel A: Calcium assay pEC50 (this study) vs. pKi; Panel 
B: cAMP assay pEC50 (Sawyer) vs. pKi.   
 
Figure 10.  Summary of agonist pharmacophore at human prostanoid CRTH2 receptors 
expressed in CHO GD16z49 cells deduced from agonist potency data in non-pertussis 
toxin treated cells.  Activity is therefore assumed to represent coupling through the EJ 
subunits of GDi/o. 
 
 
3.6  Figures 
Follow on next page 
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Chapter 4: 
 
Agonist stimulus trafficking by human prostanoid CRTH2 
(DP2) receptors coupled to calcium mobilisation through 
chimeric GD16z49 and endogenous GEJi/o G-protein 
subunits. 
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4.1  Summary: 
In chapter 3 it was shown that human prostanoid CRTH2 receptors expressed in 
CHO cells with chimeric GD16z49 G-proteins couple to calcium mobilisation through 
pertussis toxin-sensitive & -insensitive mechanisms with different agonist rank 
orders of potency.  To further investigate this phenomenon a cell line expressing the 
receptor without the chimeric G-protein was made and again studied using a calcium 
mobilisation assay.  CHO K1 host cells were devoid of responses to prostaglandins 
while non chimera-expressing CHO K1 hCRTH2 cells responded to PGD2 with 
concentration-related elevation of calcium (pEC50 7.9 ± 0.06; nH 3.4 ± 0.4; n=12).   
As found previously in chimera-expressing cells, prostanoid CRTH2 receptor 
pharmacology was confirmed in non-chimeric cells by the agonist rank order of 
potency: 15 R 15 methyl PGD2 > PGD2 > PGJ2 > 15 deoxy '12,14 PGJ2 >>> PGF2D.  
BW245C, PGE2, PGI2 & U46619 produced no significant effect.  PGD2 responses 
were insensitive to the DP receptor antagonist BWA868C (1PM) but were sensitive 
to the putative CRTH2 receptor antagonists AH23848B & GW853481X (pA2 5.5 ± 
0.06 & 6.6 ± 0.3, respectively; n=3). 
Saturation radioligand binding was conducted in membranes from both chimeric 
and non-chimeric receptor-expressing cells using [3H]-PGD2 as radiolabel.  Analysis 
revealed the presence of a single population of binding sites.  Affinity (pKd) and 
receptor expression (Bmax) estimates were:  CHO K1 hCRTH2 pKd = 8.6 ± 0.2, Bmax 
= 3.6 ± 1.1 pmol mg-1;  CHO GD16z49 hCRTH2 pKd = 8.7 ± 0.06, Bmax = 9.9 ± 2.9 
pmol mg-1 (n=3).  Western blot analysis revealed the presence of GDi-2, GDi-3, GDz, 
GDs and GDq G-proteins in both cell types.   Expression appeared greatest in CHO 
GD16z49 hCRTH2 cells suggesting that the relative expression of receptor and G-
proteins in the two cell lines is equivalent.  However, deficiencies in the methods 
employed mean the true R:G ratio is unknown. 
Pertussis toxin (PTX; 50 ng ml-1) abolished responses to PGD2 in CHO K1 hCRTH2 
cells suggesting that calcium mobilisation is entirely mediated by Gi/o class G-
proteins in this cell line.  (Partial (85 %) inhibition in chimera-expressing cells has 
been shown previously in Chapter 3).  Transient expression of the C-terminal of E-
adrenergic receptor kinase (E-ARK 495-689) resulted in a 43 ± 12 % inhibition of 
PGD2 Emax in CHO K1 hCRTH2 cells but not in CHO GD16z49 hCRTH2 cells (n=3).  
This suggests that PTX-sensitive PLCE stimulation in both cell types is GEJ 
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subunit-dependent.  Calcium mobilisation in both cell types ± PTX (where 
applicable) was independent of extracellular Ca2+ and was fully inhibited by 
thapsigargin (3 PM), U71322 (3 PM) and heparin (1 USP unit well-1).  These results 
suggest that prostanoid hCRTH2 receptors couple to calcium mobilisation in both 
CHO cell lines via GEJi/o and / or GD16z49 subunit-mediated PLCEactivation IP3 
generation and release of ER-stored calcium via IP3 receptor operated Ca
2+ 
channels. 
Using a panel of 65 prostanoid molecules, prostaglandins of the D, F & J series were 
found to be agonists at CRTH2 receptors in non-chimera-expressing cells (n=3).  D 
series molecules had potencies ranging from 8.0 ± 0.07 (15 R 15 methyl PGD2) to 
5.0 ± 0.03 (PGD3); J series molecules ranging from 6.7 ± 0.03 (PGJ2) to 6.3 ± 0.02 
(9,10 dihydro 15 deoxy '12,14 PGJ2); and F series molecules ranging from 5.5 ± 0.02 
(15 R PGF2D) to 54 ± 16 % at 10PM (PGF2D).  Several other F series molecules were 
inactive.  Compared to the GD16z49-mediated responses in PTX treated chimera-
expressing cells reversals of potency order were observed.  These were most striking 
for (relative potency (RP) CHO K1, CHO GD16z49; c.f. PGD2 = 1.0) indomethacin 
(10, c.40) 16,16 dimethyl PGD2 (158, 11), '12 PGJ2 (32, 2.5) and 9,10 dihydro 15 
deoxy '12,14 PGJ2 (40, 3.5).  In terms of absolute potency J series agonists were little 
affected e.g. 15 deoxy '12,14 PGJ2 (pEC50 CHO K1, CHO GD16z49: 6.5 ± 0.02, 6.2 ± 
0.03) while F series agonists were most affected (e.g. 15 R PGF2D 5.5 ± 0.02, 15 ± 8 
% stimulation at 10 PM). 
These data demonstrate marked reversals of agonist rank orders of potency in well 
characterised prostanoid CRTH2 receptor assay systems and cannot be explained by 
a simple strength of stimulus model of agonist behaviour.  The potential effects of 
a synergising interaction between GD16z49 and GEJi/o mediated signals has not been 
excluded and could affect the interpretation of the potency changes observed.  The 
data could be consistent with the expectations of agonist stimulus trafficking and 
provide the first demonstration of chimeric G-protein-specific agonist 
pharmacology. 
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4.2  Introduction: 
In chapter 3, I presented data confirming published agonist rank orders of potency and 
extended it to provide a comprehensive agonist fingerprint of human prostanoid CRTH2 
receptors expressed in CHO cells with the chimeric GD16z49 G-protein.  Surprisingly, calcium 
mobilisation in these cells was found to be pertussis toxin (PTX) sensitive even though both 
wild-type GD16 and GDz subunits from which the chimera is constructed are PTX-insensitive.  
Following PTX treatment, residual responses to prostanoid agonists could still be observed 
but the rank order of agonist potency was markedly altered.  Thus, in these cells, 85 % of the 
calcium mobilisation response to PGD2 was assumed to be mediated by PTX sensitive GEJi/o  
subunits, and 15 % by PTX insensitive GD16z49 subunits.  Agonist pharmacology was critically 
dependent upon the cell line and conditions employed: in non PTX-treated cells agonist 
responses arose from activation of both pathways.  The present study was therefore 
undertaken to produce SAR in CHO cells expressing human prostanoid CRTH2 receptors 
without the chimera in order to provide data generated solely by GEJi/osubunit coupling.  By 
comparison with data generated through GD16z49 coupling, I present evidence which strongly 
suggests that prostanoid hCRTH2 receptors traffic agonist stimuli to their coupling G-protein 
partners. 
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4.3  Results: 
4.3.1  Selection of CHO K1 hCRTH2 clone 
Prostaglandin D2 (0.5 nM  10 PM) produced concentration-related increases in [Ca2+]i in 
cells of both clones (Figure 1).  The potency (pEC50) of PGD2 was similar in both cell lines 
(clone 10: 8.3 ± 0.04; clone 15: 8.1 ± 0.04; P < 0.05) as was Zƍ (clone 10: 0.54; clone 15: 
0.60) but marked differences in maximum response were observed (clone 10: 77 ± 4 NFIU; 
clone 15: 158  ± 6 NFIU; P < 0.01; mean of 8 individual E/[A] curves, or in the case of Zƍ, of 
1 determination from eight duplicate data points, produced on a single assay occasion).  
Similar trends were observed with the prostanoids (pEC50, upper asymptote[NFIU]; clone 10; 
clone 15; n = 24) 13,14 dihydro 15 keto PGD2 (7.5 ± 0.06, 71 ± 2; 7.4 ± 0.04, 149 ± 2), 15 R 
15 methyl PGD2 (8.6 ± 0.02, 69 ± 1; 8.6 ± 0.02, 138 ± 5) and PGF2DND, 62 ± 2; ND, 88 ± 
5).  Statistical comparisons: potencies NS; max P < 0.05.  Clone 15 cells used subsequently. 
 
4.3.2  Determination of protein concentration 
A single batch of membranes from each cell line specified below was prepared for the 
experiments described in this chapter.  The following estimates of protein concentration in  
CHO cell membranes were generated: CHO GD16z49 host 0.08 ± 0.03 mg ml-1; CHO K1 
hCRTH2 5.9 ± 0.3 mg ml
-1; CHO GD16z49 hCRTH2 1.2  ± 0.06 mg ml-1 (n = 3). 
 
4.3.3  Saturation radioligand binding 
Data describing the development of the assay method will be presented in chapter 7.   CHO 
GD16z49 host cells (5.8 Pg well-1 membrane protein) did not bind [3H]-PGD2 (0.05 - 16 nM).  
Cells transfected with human prostanoid CRTH2 receptors bound [
3H]-PGD2 in a 
concentration related manner (Figures 2 & 3).   Non-linear regression of data resulted in the 
following estimates of affinity (Kd) and number of binding sites (Bmax):  CHO K1 hCRTH2 
pKd = 8.6 ± 0.2, Bmax = 3.6 ± 0.8 pmol mg
-1, nH = 1.3 ± 0.3;  CHO GD16z49 hCRTH2 pKd = 8.7 
± 0.06, Bmax = 9.9 ± 2.0 pmol mg
-1, nH = 1.5 ± 0.5 (all n = 3).  Linear Scatchard 
transformation of the data indicated the presence of a single population of saturable binding 
sites.  However, given the methodological deficiencies pointed out in Chapter 7, these Bmax 
estimates could be as little as 50 % of the true Bmax. 
 
4.3.4  Western blot analysis 
Ponceau S staining showed that protein loading was equivalent across all wells (Figure 4). 
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Western blot analysis revealed the presence of GDi-2, GDi-3, GDz, GDs and GDq G-proteins in 
all three cell types (Figure 5).  The amount of staining for all proteins varied in the order: 
CHO GD16z49 hCRTH2 > CHO GD16z49 > CHO K1 hCRTH2.  Blots for GDq and GDq/11 
revealed multiple immunoreactive bands of molecular weight 39-45 kDa in all samples. The 
GDq antibody labelled a 45 kDa band in the GD16z49 expressing cell lines but not CHO K1 
hCRTH2 cells; this band was also detected in all samples by the GDq/11 antibody.  In contrast, 
the GDq/11 antibody detected a weakly staining band at 38 kDa only in the chimeric cell lines, 
with no correlate detected by the GDq antibody.  Two bands of approximately 80 kDa were 
detected by the GDz antibody in all samples.  The GDi antibody failed to label GDi-1 and GDi-2 
positive controls while the GD16 antibody failed to develop.  Staining with the GD11 antibody 
was largely unsuccessful, with clear evidence of negative staining, but may have detected an 
immunoreactive protein of 40 kDa.  Bands of high (c. 100 kDa) and low (c. 25 kDa) 
molecular weight were also detected in all blots.        
 
4.3.5  Assessment of CHO K1 host cell response to prostaglandins. 
Uridine triphosphate (UTP; 1.7 nM  100 PM) produced concentration-related increases in 
fluorescence and yielded a pEC50 of 7.3 ± 0.1 and Emax of 235 ± 35 (n = 3) normalised FLIPR 
intensity units (NFIU).  Vehicle (1 % DMSO) produced large calcium fluxes in this cell line 
which were observed to increase in magnitude with increasing dye-loading time (64 ± 5 NFIU 
at 60 min loading time).  Prostaglandins D2, E2, F2D & U-46619 (0.17 nM  10 PM), and 
iloprost (17 pM  1 PM) did not produce any significant effect over that of vehicle (Figure 6).  
A vehicle concentration-effect relationship was not established in this cell line.  The 
prostanoid receptor antagonists AH23848B & GW853481X (both 10 PM), and BWA868C, 
GW627368X, GW671021X, SC-51322 & SQ-29548 (all 1 PM) also produced no effect on 
basal fluorescence, or on fluorescence in the presence of  PGD2 and PGE2 (both 0.17 nM - 10 
PM; data at 10 PM presented in Figure 7; result of statistical comparison = NS). 
 
4.3.6  Effect of  standard prostanoid receptor agonists and antagonists in CHO K1 hCRTH2 
cells.  
Prostaglandins E2 (PGE2), iloprost and U-46619 were devoid of agonist effects up to 10 PM; 
prostaglandin PGF2Dproduced small elevations of [Ca2+]i at 10 PM resulting in a maximum 
response of 54 ± 11 % cf. PGD2 controls (P < 0.05).  The non-selective COX 1 / 2 inhibitor 
indomethacin was an agonist (pEC50 6.9 ± 0.07, RP = 10; max effect 84 ± 4 %, RA = 0.85).  
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The putative prostanoid CRTH2 receptor antagonists AH23848B and GW853481X 
antagonised PGD2 responses giving rise to apparent pA2 estimates of 5.5 ± 0.07 (Figure 8, 
Panel A) and 6.6 ± 0.4, respectively (Panel B).  AH23848B inhibited PGD2 Emax in a 
concentration-related manner producing  22 ± 12 %  inhibition at 30 PM, while GW853481X 
elicited 18 ± 10 % inhibition at 3 PM (both P < 0.05). 
 
4.3.7  Effect of pertussis toxin treatment. 
CHO K1 hCRTH2 cells.  In the absence of Pertussis toxin (PTX) PGD2 pEC50 was 7.6 ± 0.1, 
slope 1.5 ± 0.1.  PTX (50 ng ml-1) reproducibly produced complete inhibition of responses to 
PGD2 over 6 rounds of passage spanning four weeks of cell culture (Figure 9, Panels A & B).   
Passage-related changes in PGD2 pEC50 were not observed but the potency at P16 was 
significantly lower than at P10, though not when compared to P14 (PGD2 pEC50 at P10 7.5 ± 
0.05; at P16 6.9 ± 0.02; P < 0.05; at P14 7.2 ± 0.05; NS).    
CHO GD16z49 hCRTH2 cells.  Under the same conditions of PTX treatment the 85 % 
inhibition of PGD2 Emax described in Chapter 3 was reproducible over 6 rounds of passage 
spanning four weeks of cell culture.  
 
4.3.8  Experiments with inhibitors of the calcium mobilisation pathway 
All data reported in this section are from n=3 independent experiments.  Vehicle (0.25 % 
DMSO) produced small, transient changes in basal fluorescence in both CHO K1 hCRTH2 
(28 ± 9 NFIU) and CHO GD16z49 hCRTH2 (42 ± 9 NFIU) cells but the effect was greatly 
diminished in CHO GD16z49 hCRTH2 cells incubated with PTX (19 ± 4; Panel A of Figures 
10, 11 and 12; P < 0.05).  Addition of H-89, ryanodine and U71322 (all 3 PM) produced 
effects equivalent to that of vehicle addition.  Thapsigargin (3 PM) produced a large increase 
in fluorescence (178 ± 18 NFIU) which reached a maximum after 20 s and subsequently 
decayed by 30 % over the next 30 s.  Fluorescence returned to basal levels over the following 
15 mins (equilibration period before addition of PGD2).  Heparin (1 USP unit per well; 125 
Pg ml-1) produced variable changes in basal fluorescence in each assay ranging from no effect 
to 29 ± 12 NFIU (calculated across the 11 treated wells in each assay) while the lipofectamine 
vehicle for heparin (0.31-2.5 % v v-1) produced no significant effect (Panel A, Figure 13).  
Transient transfection of cells with the C-terminal of E-adrenergic receptor kinase (E-ARK 
495-689) resulted in 43 ± 12 % inhibition of PGD2 Emax in CHO K1 hCRTH2 cells (P < 0.05; 
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Figure 14) and no inhibition in CHO GD16z49 hCRTH2 cells (calculated from matched PGD2 
control and treated data).     
PGD2 E/[A] curves (0.17 nM  10 PM) were unaffected by pre-treatment with either vehicle, 
lipofectamine, H-89 or ryanodine (Panel B of Figures 10, 11 and 12).  U71322 treatment 
totally abolished responses to PGD2 in  CHO GD16z49 hCRTH2 cells ± PTX and reduced the 
Emax in CHO K1 hCRTH2 cells by 84 % (control 152 ± 11; U71322 treated 25 ± 9 NFIU; P < 
0.01).  Thapsigargin totally abolished increases in fluorescence in response to PGD2 in both 
cell lines ± PTX (where applicable).  However, in the presence of thapsigargin, PGD2 
produced small but reproducible concentration-related reductions in fluorescence in both cell 
types which were abolished by PTX treatment (not statistically significant).  Heparin 
treatment without the incorporation of lipofectamine vehicle reduced responses to 10 PM 
PGD2 by 82 % (control 166 ± 3; heparin treated 30 ± 28 NFIU; P < 0.01; Panel B, Figure 13).  
Responses were totally abolished when lipofectamine was included. 
 
4.3.9  Agonist ‘fingerprinting’ of hCRTH2 receptor 
4.3.9.1  CHO K1 cells without PTX treatment.  A panel of 76 prostanoid molecules was 
screened for agonist activity in CHO K1 hCRTH2 cells without PTX treatment at 
concentrations up to 10 PM (Table 1).  A large proportion (72 %) of compounds were without 
agonist effect.  Amongst the active compounds, curve slopes were generally steep (1.8-3.7).  
Slope parameters in excess of this were shown by 15 R 15 methyl PGF2D (5.1 ± 2), 15 S 15 
methyl PGD2 (5.2 ± 1.8), 15 keto PGF2D (8 ± 1.1) and 15 R PGF2D (8.2 ± 1.4).  The 
following rank order of agonist potency was obtained for the most active compounds (relative 
potency [RP cf. PGD2 = 1.0], relative activity [RA cf. PGD2 = 1.0]; full agonists shown in 
bold type, partial agonists in normal type): 15 R 15 methyl PGD2 (0.8, 0.9) > PGD2 = 15 
deoxy PGD2 (10, 1) > PGJ2 (16, 0.9) > 15 deoxy '12,14 PGJ2 (25, 0.9) = 13,14 dihydro 15 
keto PGD2 (32, 0.9) = '12 PGJ2 (32, 1) = 9,10 dihydro 15 deoxy '12,14 PGJ2 (40, 0.7) > 
PGD1 (79, 0.8) = 15 S 15 methyl PGD2 (78, 0.9) > 17 phenyl PGD2 (100, 0.9) > 16,16 
dimethyl PGD2 (158, 0.9) > 15 R 15 methyl PGF2D (251, 0.4) = PGD3 (254, 0.9) = 15 R 
PGF2D (251, 0.7) > 15 keto PGF2D (316, 0.6) >> 15 keto PGF1D (max effect 0.2) = PGF2D 
(max effect 0.5) = latanoprost (max effect 0.1) = cloprostenol (max effect 0.1).  Butaprost 
methyl ester, 15 S 15 methyl PGF2D, BW245C & 13,14 dihydro 15 keto PGF2D were all 
without significant effect.  These data correlated well with data previously obtained in CHO 
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GD16z49 hCRTH2 cells without PTX treatment and presented in chapter 3 (Figure 15): 
maximum effect correlation coefficient (r2) = 0.9; agonist pEC50 r
2 = 0.83. 
 
4.3.9.2  CHO GD16z49 cells + PTX treatment.  The same panel of prostanoid molecules was 
screened for agonism in CHO GD16z49 hCRTH2 cells with PTX pre-treatment (reported in 
Chapter 3 and represented in Table 1 for comparison).  These data correlated poorly with the 
data from CHO K1 hCRTH2 cells without PTX treatment (Figure 16): maximum effect 
correlation coefficient (r2) = 0.56; agonist pEC50 r
2 = 0.65.  (For regression analysis, where 
compounds were inactive in the +PTX pEC50 data set, a value of 4.5 was assigned.  Therefore, 
the true r2 value is lower than 0.65). 
 
4.3.10  Data Tables. 
Follow on next page.
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Table 1.  Pharmacology of prostanoid molecules in CHO K1 hCRTH2 cells without PTX treatment.  RP: relative potency cf. PGD2 (=1.0); RA: 
relative activity cf. PGD2 (=1.0).  Data are mean ± sem of four - ten separate E/[A] curves generated over two - four assay occasions.  Butaprost 
methyl ester, Misoprostol, 15 S 15 methyl PGF2D13,14 dihydro 15 keto PGF2D11 deoxy 11 methylene PGD2, PGF3D11 dehydro TxB2, 15 R 
19 R hydroxy PGF2D13,14 dihydro PGE1, PGE3, 20 hydroxy PGF2D13,14 dihydroxy 15 keto PGA2, 6 keto PGF1D6 keto PGE1, '17 6 keto 
PGF1DPGA2, 15 R PGE2, PGF1DPGA1, 13,14 dihydro PGF1D13,14 dihydro 15 keto PGE2, 13,14 dihydro 15 keto PGF1DPGE1, 15 keto PGE1, 
19 R hydroxy PGF1DPGD1 alcohol, 15 R 15 methyl PGE2, 15 R 19 R hydroxy PGF1D13,14 dihydro 15 keto PGE1, 13,14 dihydro 15 R PGE1, 
11 dehydro 2,3 dinor TxB2, 19 R hydroxy PGA2, TxB2, 15 R 19 R hydroxy PGE2, PGK1, 15 keto PGE2, 20 hydroxy PGE2, 15 R PGE1, 11E 
13,14 dihydro 15 keto PGF2D19 R hydroxy PGF2D19 R hydroxy PGE2, 2,3 dinor 11E PGF2DPGK2, PGI3, PGE2, 19 R hydroxy PGE1, PGB2, 
11deoxyPGE1, Cicaprost, Sulprostone, BW245C, Butaprost free acid, 17 phenyl PGE2, 16,16 dimethyl PGE2 & Iloprost were without significant 
effect.  PGI2 was not tested. Statistical comparison by ANOVA followed by Dunnetts comparison to PGD2 data; * denotes P < 0.05. 
 
Compound pEC50 slope max RP RA 
15 R 15 methyl PGD2 8.0 ± 0.07 2 ± 0.3 93 ± 2 0.8 0.9 
PGD2 7.9 ± 0.06 3.4 ± 0.4 100 ± 4 1.0 1.0 
15 deoxy PGD2 6.9 ± 0.03* 2.6 ± 0.4 95 ± 2 10 1.0 
Indomethacin 6.9 ± 0.07* 5.5 ± 3.2 84 ± 4* 10 0.8 
PGJ2 6.7 ± 0.03* 2.6 ± 0.7 88 ± 1 16 0.9 
15 deoxy '12,14 PGJ2 6.5 ± 0.03* 2.7 ± 0.2 91 ± 4 25 0.9 
13,14 dihydro 15 keto PGD2 6.4 ± 0.1* 3.7 ± 0.9 94 ± 2 32 0.9 
'12 PGJ2 6.4 ± 0.07* 3.2 ± 1.0 103 ± 3 32 1.0 
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9,10 dihydro 15 deoxy '12,14 PGJ2 6.3 ± 0.03* 3.3 ± 0.5 69 ± 22* 40 0.7 
15 S 15 methyl PGD2 6.0 ± 0.03* 5.2 ± 1.8 90 ± 1 79 0.9 
PGD1 6.0 ± 0.07* 1.8 ± 0.2 83 ± 1* 79 0.8 
17 phenyl PGD2 5.9 ± 0.03* 2.7 ± 0.7 86 ± 6* 100 0.9 
16,16 dimethyl PGD2 5.7 ± 0.07* 2.2 ± 0.6 86 ± 6* 158 0.9 
15 R 15 methyl PGF2D 5.5 ± 0.03* 5.1 ± 2.1 43 ± 2* 251 0.4 
PGD3 5.5 ± 0.03* 3.5 ± 0.4 92 ± 7 251 0.9 
15 keto PGF2D 5.4 ± 0.03* 8 ± 1.1 58 ± 8* 316 0.6 
15 R PGF2D 5.5 ± 0.03* 8.2 ± 1.4 73 ± 9* 251 0.7 
15 keto PGF1D   16 ± 3*   
PGF2D   54 ± 11*   
Latanoprost   14 ± 3*   
Cloprostenol   12 ± 3*   
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Table 2.  Summary of G-proteins detected in Chinese Hamster Ovary cells by Western 
Blot, and reported in literature. 
 
Citation GDs GDi1 GDi2 GDi3 GDo GDz GDq GD11 GD12 GD13
This study X Q X X  X X X   
Xu, et al., 2005   X X X    X  
De Lapp, et al., 
1999 
   X   X(or 11)    
Newman-Tancredi, 
et al., 1999 
X    X (or i)  X(or 11)    
van der Westerlo, et 
al., 1995 
X      X(or 11)   X 
Chambers, et al., 
1994 
X Q X    X(or 11)    
McKenzie & 
Milligan, 1990 
 Q X        
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Table 3.  Binding affinity of prostaglandin D2 (PGD2) at human prostanoid CRTH2 
receptors reported in literature.  Data are mean ± s.e.m.   
Cell line Type Radioligand Affinity 
(nM) 
BBmax (pmol mg ) -1 Comment Reference 
L1.2 Ki [
3H] ramatroban 23   Sugimoto, et 
al., 2005 
COS-7 Kd [
3H]-PGD2 12.9 ± 2.1 57.5 fmol / 30k cells  Mathiesen, 
et al., 2005 
CHO K1 Kd [
3H]-PGD2 12.1 10.2 ex-Euroscreen  
HEK293 Ki [
3H]-PGD2 1.7 ± 0.8   Gervais, et 
al., 2005 
CHO Ki [
3H]-PGD2 12.9   Gazi, et al., 
2005 
K562 Ki [
3H]-PGD2 61 ± 23   Nagata, et 
al., 2003 
HEK293 Kd [
3H]-PGD2 2.5 ± 1.1 7.8 ± 2.9 low affinity 
site Kd 109 ± 
68; Bmax 29.5 ± 
9.5 
Sawyer, et 
al., 2002 
 Ki [
3H]-PGD2 2.4 ± 0.2    
CHOK1 Kd [
3H]-PGD2 2.7 ± 2 3.6 ± 1.1  Present 
study 
CHO GD16z49 Kd [3H]-PGD2 2.3 ± 0.5 9.9 ± 2.9   
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4.4  Discussion: 
In Chapter 3, I presented data defining suitable assay conditions for the determination of 
quantitative SAR data in CHO cells expressing the human prostanoid CRTH2 receptor with 
the chimeric GD16z49 G-protein.  Data obtained following treatment of CHO GD16z49 hCRTH2 
cells with pertussis toxin (PTX) established an agonist fingerprint for prostanoid CRTH2 
receptors which differed markedly from that obtained in non PTX-treated cells.  These data I 
took to represent coupling through  GD16z49 subunits (PTX-treated) or a mixture of GD16z49 
and GEJi/o subunits (non PTX-treated) but coupling via GDq and / or GDz was not ruled out.  
The data were insufficient to firmly establish the impact of the chimeric G-protein on 
prostanoid CRTH2 receptors and the chapter closed posing a number of questions.  In this 
chapter I have delineated the molecular pathway coupling prostanoid CRTH2 receptor 
activation to calcium mobilisation in CHO cells, demonstrated the equivalence of CRTH2 : 
GDi/o stoichiometry in CHO GD16z49 hCRTH2 and CHO K1 hCRTH2 cells, and established 
new SAR data at prostanoid CRTH2 receptors coupled through GEJi/o subunits free from the 
influence of the chimera.  The impact of the chimeric GD16z49 G-protein on CRTH2 receptor 
pharmacology is significant and I present alternative pharmacophores deduced from these 
data. 
Comparison of agonist E/[A] curves clearly demonstrated the suitability of CHO K1 hCRTH2 
clone 15 for use in these studies.  Clone selection data presented in Chapter 3 was affected by 
two deficiencies: 1. Use of un-optimised assay methodology; 2. Failure to employ 
metabolically resistant prostanoid agonists.  Neither of these factors have affected the data 
presented in this chapter.  In addition to using the methodology developed in Chapter 3, a 
range of agonists of different chemical series, and of differing susceptibility to metabolism 
produced identical rank orders of potency and activity in the clones examined.  The selection 
of clone 15 is therefore based on a more reliable data set. 
A comprehensive analysis of the G-proteins expressed by CHO K1 cells is not available.  
However, using Western blot techniques analogous to those used here, other authors have 
shown the presence of GDs, GDi2, GDi3, GDo, GDq, GD11, GD12 & GD13 (Table 2 & references 
cited therein).  Quantification of protein expression is not possible from the data presented 
here since the level of protein saturation by antibody has not been assessed, neither has a 
positive control been run for most of the G-proteins studied.  Because of these deficiencies it 
has not been possible to make definitive identifications of stained protein bands.  However, 
assuming that the antibodies have detected the proteins against which they have been raised, it 
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has been possible to make qualitative comparisons of expression between membrane samples 
since Ponceau S staining demonstrated equivalent protein loading in each lane.  The anti GDi 
primary antibody used here was raised against the conserved C-terminal amino acid sequence 
of rat GDi3 and was expected to be active at all three GDi proteins.  Certainly, the antibody is 
functional, so it seems surprising that it failed to detect any of the recombinant GDi positive 
control proteins.  Nonetheless, two bands of the correct approximate molecular weight (c. 40 
kDa) were detected in each membrane sample which presumably correspond to GDi2 and GDi3 
since an absence of GDi1 has been demonstrated previously in CHO cells (Table 2 and 
references cited therein).  The lack of control staining may therefore reflect insufficient 
loading, incorrect handling, or may suggest that the control proteins are not authentic.  A 
further band of high molecular weight (c. 100 kDa) was detected, presumably representing a 
G-protein dimer which may have arisen as an artefact of sample preparation.  Similar high 
MW bands were also visible in blots for GDs, GDq and GDq/11.  Expression of GDi proteins 
was highest in the two cell lines also expressing the GD16z49 chimera and was highest of all in 
CHO GD16z49 hCRTH2 cells.  Since the manufacturers literature states that this antibody does 
not cross react with non-GDi proteins this could arise either as a result of expression of the 
chimera (and subsequent to the generation of a new intracellular signal: the chimera can 
couple to any available receptor, not just hCRTH2) or of cell culture in the presence of the 
selection antibiotic, hygromycin B.  Hygromycin B is a bactericidal aminoglycoside produced 
by Streptomyces hygroscopicus which inhibits protein synthesis in many species including 
higher eukaryotes (references in Pfister, et al., 2003).  In contrast to the typical 2-
deoxystreptamines, hygromycin B inhibits protein synthesis by blocking ribosomal 
translocation without causing significant misreading in vivo.  Thus, the potential for 
hygromycin B to alter the expression of proteins is obvious.  A net  increase in expression 
probably results here because the low concentration used stimulates a compensatory up-
regulation of the synthetic apparatus in cells also expressing the hygromycin resistance gene.  
The altered synthesis appears to apply generally to all proteins since increased expression of 
GDs and GDq G-proteins may also be observed, and saturation radioligand binding of [3H]-
PGD2 to prostanoid hCRTH2 receptors estimates a Bmax in chimera-expressing cells 
approximately three-fold higher than that in CHO K1 cells (see below).  Interestingly, the 
highest expression levels were observed in cells cultured in the presence of both hygromycin 
B and geneticin (G418), a semi-synthetic aminoglycoside antibiotic.  Geneticin is also 
reported to bind to membrane phospholipids and to interact with phospholipase C subtypes 
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(references in Kung, et al., 1997).  Since both cell lines expressing prostanoid CRTH2 
receptors are cultured in the presence of geneticin this will not impact on comparisons of 
pharmacology between the cell types but may invalidate CHO GD16z49 cell pharmacology 
since these cells were cultured only with hygromycin. 
Blots for GDq and GDq/11 revealed multiple immunoreactive bands of molecular weight 49-52 
kDa in all samples.  It is tempting to speculate that the 52 kDa band detected by the GDq 
antibody only in GD16z49 expressing cells represents the chimera but given the high MW, and 
the detection of this band by the GDq/11 antibody in all three samples, doubt exists over the 
identity of this protein.  In contrast, the faint band at 45 kDa detected by the GDq/11 antibody 
in the chimeric cell lines may represent GD11 up-regulated by culture in the presence of 
hygromycin since no correlate was detected by the GDq antibody.  The couplet of 
approximately 75 kDa detected by the GDz antibody does not correspond to monomeric GDz 
(40 kDa; Casey, et al., 1990) but could represent dimers of both complete and C-terminal 
truncated forms of the protein.  If this were so, then it raises the possibility that the PTX 
insensitive component of signalling in CHO GD16z49 hCRTH2 cells is due to GDz coupling.  
However, no such resistant coupling is observed in CHO K1 hCRTH2 cells which also stain 
for this G-protein making GDz coupling unlikely.    
Both non-linear regression and linear Scatchard transformation of radioligand saturation data 
indicated the presence of a single population of saturable binding sites with Kd estimates 
commensurate with published data (Table 3 and references cited therein).  In their 2002 study, 
Sawyer et al. detected the presence of two binding sites using similar binding conditions but 
with final radioligand concentrations of up to 80 nM.  Apart from the obvious cost 
disadvantage, such high radioligand concentrations also suffer from high vehicle levels (7 % 
ethanol in their case) and were not employed in this study.  Sawyers HEK 293 (EBNA) cells 
transfected with human prostanoid CRTH2 receptors were cultured in the presence of high 
concentrations of four antibiotics (penicillin, streptomycin, G418, and hygromycin B) and as 
discussed above, culture with these agents has the potential to alter protein expression.  
Therefore, while the detection of the low affinity site must be treated with some caution, the 
data presented here do not rule its existence out.  Indeed, data presented in Chapter 7 will 
suggest that a pool of receptor protein not observed in these saturations does, in fact, exist. 
Saturation binding was undertaken in order to estimate the concentration of prostanoid 
CRTH2 receptors expressed in the two cell lines used here. Receptor concentration is 
routinely expressed as pmol of receptor per mg of protein and is therefore critically dependent 
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on accurate [protein] determination.  The bicinchoninic acid (BCA) technique employed here 
is widely used and regarded as sufficiently accurate for these purposes.  However, accurate 
construction of standard protein samples and the ability of the standard to represent the 
properties of the test protein is paramount.  Bovine serum albumin is a typical standard 
protein and is assumed to be suitable: the impact of other standards on the final estimate was 
not tested.  However, the obvious difference here is that BSA is a soluble protein, while the 
sample under test was a preparation of membranes, most of which are likely to exist as a 
suspension of vesicles.  The samples were not treated with detergent making detection of 
intravesicular protein not possible.  Even though the statistical errors around the [protein] 
determination are relatively small (amounting to c. 5 % error) and can be taken to be 
reasonably reliable for comparative purposes, failure to detect the intravesicular protein will 
have resulted in an underestimate of protein concentration.  Nonetheless, the data indicate 
three-fold greater expression of receptor on CHO GD16z49 hCRTH2 cells relative to CHO K1 
hCRTH2 cells, and no binding to host cell membranes (despite the low protein concentration 
in the membrane preparation, similar amounts of protein per well for all three membrane 
samples were achieved in the binding assay).  The estimates generated by non-linear 
regression agreed very closely with those obtained by linear transformation of the data and 
can therefore be considered reasonably reliable.  However, according to the ternary complex 
model of receptor behaviour (DeLean, et al., 1980) agonist radioligands such as [3H]-PGD2 
preferentially label the high affinity G-protein coupled state of the receptor and thus estimates 
of the number of binding sites obtained in this way are critically dependent on the amount of 
G-protein coupled to the receptor.  Many factors can affect the degree of pre-coupling, such as 
the presence of divalent cations, sodium, GDP / GTP ratio and G-protein expression (Graeser 
& Neubig, 1992).  The sodium concentration in the assay mixture was virtually zero: sodium 
was omitted from the buffer, pH adjustment was performed with KOH, and EDTA was 
included to chelate any remaining sodium.  However, as with the protein determination, 
membrane vesicles may have created micro-environments with locally higher [Na+].  As 
discussed above, the Western blot data indicate increased expression of G-proteins in CHO 
GD16z49 hCRTH2 cells relative to CHO K1 hCRTH2 cells and cast doubt on the estimates of 
receptor expression since more G-protein could increase the conversion of receptor molecules 
to the high affinity binding state.  It is not possible to deduce whether this is the case but the 
Western Blot data is strongly suggestive of increased protein synthesis which is expected to  
apply equally to all proteins if regulation is at the level of the synthetic machinery and not at 
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the level of mRNA transcription.  Overall, the receptor : G-protein stoichiometry relevant to 
calcium signal transduction appears to be similar in the two cell lines since the potency of 
PGD2 is similar (CHO K1 hCRTH2: 7.9 ± 0.06; CHO GD16z49 hCRTH2 [no PTX]: 7.8 ± 0.1).  
Thus, although changes in protein expression have been detected they appear to be of 
insufficient magnitude to produce alteration of agonist behaviour, however it is important to 
realise that given the deficiencies in both binding and blot data, the R:G stoichiometry in the 
two cell lines tested is essentially not known.  Finally, PGD2 responses appear to be shifted to 
the right with respect to the binding pKd.  The reason for this is unclear, even allowing for the 
use of an agonist radioligand, but may relate to the inhibition of PLC by geneticin. 
As shown in Chapter 3, calcium fluxes in response to PGD2 in CHO GD16z49 hCRTH2 cells do 
not require the presence of extracellular calcium (indicating calcium release from the 
endoplasmic reticulum; ER) while pertussis toxin (PTX) abolishes responses in CHO K1 
hCRTH2 cells and reduces responses in CHO GD16z49 hCRTH2 cells by 85 % (suggesting 
coupling through Gi/o class G-proteins).  Because calcium is mobilised from intracellular 
stores, the likely PTX-sensitive coupling partners are GEJi/o subunits.  The residual signal in 
the chimeric cell lines is assumed to be due to coupling through the GD16z49 G-protein but the 
low agonist potency and activity via this mechanism is not typical of GD coupling to PLCE.  
The CHO cells used here have been shown to express GDz and GDq/11 which could couple in a 
PTX-insensitive manner.  However, non-chimera expressing cells also express these G-
proteins but do not exhibit PTX-insensitive responses to PGD2 making coupling via GDz or 
GDq/11 unlikely.  While the effect of PTX treatment was constant over the time course of these 
experiments, small but significant changes in agonist potency were seen.  However, since 
comparative data sets were generated at the same passage using independently generated 
reagents, this is of little consequence.  
To further delineate the mechanism of signal transduction, PGD2 E/[A] curves in the presence 
of various calcium signalling pathway inhibitors were assessed.  Transient transfection of 
cells with the C-terminal of E-adrenergic receptor kinase (E-ARK 495-689) using conditions 
similar to those used here has been shown to result in a 41 % inhibition of adenosine A1 
receptor mediated [3H]-IP3 responses in CHO cells via sequestration of G-protein EJ subunits 
(Dickenson & Hill, 1998, and references cited therein).  The 43 % reduction in PGD2 Emax in 
CHO K1 hCRTH2 cells observed here is of a similar magnitude.  Taken with the observed 
total ablation of signalling in these cells by PTX, this indicates that prostanoid CRTH 
receptors in these cells couple via GEJi/o subunits to calcium mobilisation.  While studies have 
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not been conducted to demonstrate the specificity of the inhibition for PGD2 mediated 
responses, because the conditions used here are so similar to those in the literature, one can 
reasonably assume that it is mediated by the transfected protein.  The lack of inhibition 
observed in the CHO GD16z49 hCRTH2 cells, either with or without PTX treatment suggests 
firstly, that the chimeric G-protein can compensate for small reductions in GEJi/o functionality 
in these cells, and secondly, that GD16z49 (and not its cognate GEJ subunits) mediates signal 
transduction in PTX treated chimeric cells.  Larger degrees of inhibition have been 
demonstrated by other groups (e.g. 80 % inhibition of adrenergic D2A mediated spinophilin 
recruitment in HEK293 cells; Brady, et al., 2005) which may indicate differences in 
transfection efficiency, protein expression levels or differential ability of E-ARK 495-689 to 
sequester different GEJ subunit types. 
The PLCEJ inhibitor U71322 totally abolished PGD2 induced increases in [Ca2+]i in both cell 
lines, with and without PTX treatment (where applicable) confirming that calcium 
mobilisation is wholly PLC-dependent and that both GEJi/o and GD16z49 activate PLC 
isoforms.  Other activities of U71322 such as inhibition of Ca2+-ATPase, phosphatidyl 
inositol 4 phosphate kinase inhibition and non-PLC/non-PKC mediated inhibition of integrin 
expression on platelets (Lockhart & McNicol, 1999) are probably of little consequence in this 
context. 
The ability of the sarco-endoplasmic reticulum Ca2+ ATPase (SERCA, calcium pump) 
inhibitor thapsigargin (Treiman, et al., 1998), but not of ryanodine (which displays 
concentration-dependent agonist and antagonist properties), to produce elevation of 
intracellular calcium and inhibit responses to PGD2 suggests the involvement of IP3R- 
mediated calcium release from internal endoplasmic reticulum calcium stores.  In the presence 
of thapsigargin, PGD2 elicited reductions in basal fluorescence in both cell types but not 
following PTX treatment suggesting that prostanoid CRTH2 receptors couple via Gi/o G-
proteins to a calcium-sequestering or -removing mechanism, perhaps involving GDi mediated 
Ca2+ channel regulation.  Care must be exercised in interpreting this result: thapsigargin 
inhibits the calcium response and any calcium-dependent transduction / desensitisation 
processes but does not inhibit IP3 / DAG formation, DAG-dependent MAPK activation, 
adenylate cyclase inhibition and E-arrestin translocation.  Therefore, thapsigargin treatment 
may have simply revealed the presence of a normally activated calcium homeostasis 
mechanism.  However, although the magnitude of the fluorescence observed at very low 
PGD2 concentrations is similar to that of vehicle in untreated cells, the time-course profile of 
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fluorescence changes and the lower basal fluorescence level are very different suggesting that 
the vehicle effect is not the same (Figure 10, Panel C).  The effect of thapsigargin is 
therefore to reduce the magnitude of a fluorescence change of uncertain physiological 
relevance under conditions of a large calcium gradient between the cytoplasm and the internal 
calcium stores (i.e. favouring calcium sequestration).  As mentioned above, PTX blunts the 
vehicle effect and so the absence of the calcium sequestration effect from PTX-treated cells 
probably reflects the absence of the vehicle effect.  Taken together, it seems unlikely that the 
CHO K1 hCRTH2 dataset has been contaminated by the presence of an unobserved calcium 
sequestration mechanism absent from the PTX-treated CHO GD16z49 hCRTH2 cells but further 
investigation is obviously warranted.  Taking all these data together, it is now possible to 
describe the mechanism of calcium mobilisation in both CHO K1 hCRTH2 and CHO GD16z49 
hCRTH2 cells as shown in Figure 17. 
CHO K1 host cells appeared to be sensitive to 1 % DMSO vehicle in a manner related to the 
duration of the dye-loading period.  This concentration of vehicle was considered to be 
desirable since many prostanoid molecules have limited solubility in water; GW853481X was 
particularly insoluble.  DMSO (1 %) produced smaller effects in the other CHO cell lines 
studied in this thesis which may reflect selection of vehicle-resistant cells as a by-product of 
the clone selection process.  Effects such as these have been traditionally interpreted as an 
indication of generalised solvent-induced membrane or protein disruption but it is becoming 
recognised that DMSO can also have some fairly specific effects at the molecular level, for 
example, as an agonist for the pregnane X receptor (PXR; NR1I2; Su & Waxman, 2004).  
DMSO vehicle effects in CHO GD16z49 hCRTH2 cells appeared to be PTX-sensitive implying 
the activation of a receptor-G-protein mediated mechanism possibly via a specific DMSO-
sensing receptor or through generalised perturbation of GDi/o coupled receptors, or indeed of 
the G-proteins themselves.  However, in the presence of 1 % DMSO, CHO K1 host cells were 
devoid of responses to prostanoid receptor agonists, while a panel of prostanoid receptor 
antagonists failed to produce any significant effects in the presence of PGD2 and PGE2 
indicating that these host cells do not possess a calcium-linked prostanoid receptor.  The 
finding of small PGE2-induced calcium changes in CHO GD16z49 cells described in Chapter 3 
reflects chimera-specific coupling to a prostanoid receptor of the GDi/o or GDq-coupling 
classes and therefore most probably a prostanoid EP1 or EP3 receptor. 
As with CHO GD16z49 hCRTH2 cells, agonist pharmacology in CHO K1 hCRTH2 cells also 
bore the hallmark features of prostanoid CRTH2 receptors: lack of activity of PGE2, PGF2D, 
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PGI2 & U-46619; high potency responses to PGD2 but not the prostanoid DP1 receptor agonist 
BW245C; agonist rank order of potency 15 R 15 methyl PGD2 > PGD2 > PGJ2 > 15 deoxy 
'12,14 PGJ2 > 15 S 15 methyl PGD2 > 13,14 dihydro 15 keto PGD2; insensitivity of PGD2 
responses to the prostanoid DP1 receptor antagonist BW868C; and sensitivity to the putative 
prostanoid CRTH2 receptor antagonists AH23848B & GW853481X.  It is therefore, perhaps, 
not surprising that a high degree of correlation was observed in agonist potency and activity 
data generated in the two cell lines.  Figure 18 displays agonist potency data for the two cell 
lines in a Shuffle Diagram, so named because it allows one to see relative changes in SAR 
amongst compound series rather like shuffling cards in a pack.  It is obvious from this 
diagram, how similar the data sets are.  Indeed, the concordance extends further such that the 
pharmacophore model developed in Chapter 3 applies equally well to data generated using 
CHO K1 hCRTH2 cells (Figure 19).  This finding is interesting given the postulated 
synergising interaction between GD16z49 and GEJi/o discussed in chapter 6: the 
pharmacophoric equivalence observed suggests that the synergising interaction is dominated 
by the GEJ signal and that the effect of the D16z49 signal is merely to amplify it.  However, the 
non-equivalence of pharmacophores resulting from the sole activation of GD16z49 with those 
involving GEJ signals reveals subtleties in the amplification factor generated which are likely 
to be important in certain settings. 
Data generated in CHO K1 hCRTH2 cells with the antagonist AH23848B differed from that 
obtained in chimera-expressing cells.  In CHO K1 cells, AH23848B produced concentration-
related PGD2 Emax depression which, as described in Chapter 3 for GW853481X data, could 
indicate the emergence of hemi-equilibrium due to the inability of the antagonist to establish a 
new equilibrium with the receptor in the presence of agonist during the time frame of the 
calcium mobilisation response.  In recombinant cell-based systems, this is often driven by 
slow antagonist off-rate kinetics (i.e. low koff) which are frequently associated with high 
antagonist affinity.  The apparent pA2 of AH23848B for hCRTH2 receptors is 5.5, while 
literature reports are consistent with the molecule being a competitive antagonist of 
prostanoid EP4 (most recently Davis, et al., 2004) and TP (Brittain, et al., 1985) receptors 
with no suggestion of non-receptor mediated actions.  If, as noted above, the lower G-protein 
expression in CHO K1 hCRTH2 cells results in poorer receptor-effector coupling (which may 
be the case since the agonist radioligand detects a smaller number of high affinity sites in 
these cells), then the smaller control PGD2 Emax values observed in these cells relative to 
chimera-expressing cells may indicate that maximum effect requires near 100 % receptor 
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occupancy.  Therefore, since hemi-equilibrium effects are occupancy-dependent (Kenakin, 
2004b) these cells may be more sensitive to the phenomenon.  Kenakin (2004c) also notes 
that unstirred liquid layers may exist close to the cell monolayer in 384 well plate-based 
experiments which may also give rise to hemi-equilibrium effects.  However, these are not 
suspected in the present experiments because the FLIPR pipettor head conducts two 10 Pl 
mixes of the well contents during the assay.  DMSO is readily miscible with aqueous buffers 
and would tend to prevent the formation of an unstirred layer.  
An interesting feature of the agonist data obtained using CHO K1 CRTH2 cells are the high 
curve slopes achieved compared with data obtained in non-PTX treated chimera-expressing 
cells.  The synergism between GD16z49 and GEJi/o subunits postulated elsewhere in this thesis 
would be expected to lead to increased curve slopes in the chimeric cell line but the observed 
data is contrary to this.  One possibility might be that the two coupling partners are recruited 
sequentially giving rise to a flatter slope in the chimeric cell line. Alternatively, the 
amplification may be limited to an effect on lower concentrations of agonist, having the effect 
of selectively left-shifting responses up to a threshold mid-way up the agonist E/[A] curve and 
thus flattening slope.  The latter hypothesis may be supported by the observed biphasicity in 
PGD2 E/[A] curves amplified by pre-exposing cells to UTP (GDq signal; chapter 6) where the 
upper part of the agonist response curve appears to be largely unaltered.  If this explanation 
were correct one might expect the slope parameters for different agonists in CHO K1 CRTH2 
cells to be fairly similar and those in chimera-expressing cells to be more variable due to the 
variability in the amplifying factors generated by the various agonists (see above).  The 
opposite trend is apparent from the data raising the possibility that the effect of synergism 
here is to smooth out agonist responses over a wider concentration range.  In endogenously 
constituted systems this may allow greater control of overall response levels and therefore 
fine-tuning of physiological responses.  The reason why agonist responses produce generally 
higher and more variable slope values in non-chimeric cells is unclear and seems to imply the 
presence either of a threshold effect not present or suppressed in chimera-expressing cells, or 
the presence of a threshold-smoothing effect absent from the non-chimeric cells.  The impact 
of this phenomenon on the relative potency values obtained is difficult to assess.  A synergy-
related left shift of agonist responses in chimera-expressing cells is unlikely to affect all 
agonists equally resulting in variable alterations of relative potency with respect to RP in non-
chimeric cells.  The pharmacophoric differences between the non-PTX treated chimeric cell 
line and the other two data sets may therefore relate to the interruption of synergy. However, 
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even if this is the case, the differences reflect another aspect of agonist stimulus trafficking 
since the resultant effect of the synergising signals differ between agonists.  Finally, these 
considerations shed no new light on the discrepancy between PGD2 occupancy (determined 
by radioligand binding) and agonist response curves since the effect of the synergy seems to 
be to amplify responses to low concentrations of agonist and to left-shift agonist pEC50 values 
though this is still far to the right of the binding pKd.  
Thus, it is now possible to determine the impact of the change from GEJi/o mediated coupling 
to GD16z49 mediated coupling on prostanoid CRTH2 receptor pharmacology.  Viewing the data 
sets in their entirety, there is little or no correlation between CHO K1 hCRTH2 and CHO 
GD16z49 hCRTH2 + PTX agonist potency and relative activity data (Figures 16 & 20).  The 
correlations appear to suggest that some full agonists in the non-chimeric system have 
become partial agonists in the chimeric system.  However, this is an artefact of the inclusion 
of data for some compounds that did not elicit full E/[A] curves in the chimera-expressing 
system in order to get a more accurate estimate of the overall correlation.  In other words, 
non-chimeric cell agonist Emax data has been correlated with agonist effect at highest 
concentration tested in the chimeric system.  For those compounds still generating full E/[A] 
curves, the relative activity remained unchanged suggesting that there is no fundamental 
change in coupling efficiency despite the putative three-fold difference in [3H]-PGD2 binding 
sites (but as noted above the R:G ratio is essentially unknown).  The accuracy of the Bmax 
estimates generated here is questionable but the relative amounts in the two CRTH2-
expressing cell lines can be assessed since they are both subject to the same confounding 
factors.  Since the amount of G-protein detected by Western blot appears to follow the 
number of binding sites, R:G stoichiometry seems to be constant leading to the expectation 
that agonist receptor-effector coupling should also be constant.  However, elevated G-protein 
expression will of itself lead to the detection of a higher number of high affinity agonist 
binding sites because of the effect of G-protein pre-coupling to the receptor.  Therefore, 
receptor expression may well be constant between the two cell lines with greater pre-coupling 
in the chimera-expressing cells.  Thus, one would expect agonist responses to be of greater 
magnitude and potency in CHO GD16z49 cells but the rank order of potency and relative 
activity in the two cell lines to be connected by a simple strength of stimulus relationship.  
Agonist profiling in both cell types (+ PTX treatment in chimeric cells) showed that 
indomethacin, D, F & J series but not E series prostaglandins were agonists at CRTH2 
receptors.  When the GD16z49 component was isolated in PTX-treated CHO GD16z49 cells, 
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reversals of potency order were observed (compared to the GEJi/o-mediated response in CHO-
K1 cells).  These were most striking for (relative potency CHO K1, CHO GD16z49; potency of 
PGD2 = 1.0) indomethacin (10, c.40) 16,16 dimethyl PGD2 (158, 11), '12 PGJ2 (32, 2.5) and 
9,10 dihydro 15 deoxy '12,14 PGJ2 (40, 3.5).  In terms of absolute potency J series agonists 
were little affected e.g. 15 deoxy '12,14 PGJ2 (pEC50 CHO K1, CHO GD16z49: 6.5 ± 0.04, 6.2 ± 
0.03) while F series agonists were most affected (e.g. 15 R PGF2D 5.5 ± 0.04, only 15 ± 8 % 
stimulation at 10 PM).  Classically, a gross change in agonist rank order such as this, if 
detected in non-recombinant cells, would be taken as an early indication of a new receptor 
subtype but this clearly is not the case here.   
Prostanoids of the F and D series possessing a 15 hydroxy group were most critically affected 
by the switch in coupling partner having much lower potency at the chimera-coupled receptor 
(Figure 20).  Two alternative views of these data may be conceived:  
1.  The chimera is well-coupled.  In this scenario, D series compounds indicated in Figure 20 
with black arrows are largely unaffected by the switch, while the compounds indicated with 
red arrows now activate the receptor with much lower potency.  Thus J series and many D 
series compounds are unaffected while agonists possessing the 15 hydroxy group are now 
unable to activate the receptor with high potency and F series compounds are almost inactive.  
Some features of the data set support this view: a) The relative activity of agonists producing 
complete E/[A] curves is unchanged; b) F series (partial) agonists would be predicted to elicit 
E/[A] curves of potency similar to that in non-chimeric cells but with reduced maximum 
activity but this has not been observed; c)  The agonist 13,14 dihydro 15 keto PGD2 has 
paradoxically increased in potency and undergone a rank order reversal with respect to PGD3 
(although the absolute changes in potency are small, the relative change is of 0.4 log units).  
From this view of the data, one would deduce that the 15 hydroxy group is critical to high 
potency agonism through native GEJi/o class proteins but that the benefit of this substituent is 
lost when the receptor is chimera-coupled.  Inspite of this alteration in the importance of C15, 
the R > S stereochemical relationship is preserved.  The C11 carbonyl is an obligate 
requirement for chimera-coupled agonism being present in all active agonists; the H-bond 
acceptor at C9 may still confer some benefit to D series molecules but is unable to support 
agonism without the presence of the carbonyl.  The impact of E-chain modification on J series 
molecules cannot be fully described since few compounds are available but seems to be of 
little importance.  On the other hand, E-chain modified D series compounds show a range of 
activities though many of these modifications result in inactivity implying that the combined 
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effect of the C11 carbonyl and C9 hydroxyl is to push the E-chain into a conformationally 
(PGD1 and PGD3) and sterically (16,16 dimethyl PGD2 and 17 phenyl PGD2) restricted 
pocket not accessed by J series molecules. The natural conclusion is, therefore, that the 
requirements for agonism have become more stringent (Figure 21).   
2.  The chimera is poorly coupled.  Under these conditions all compounds now activate the 
receptor with lower absolute potency but the compounds indicated with black arrows activate 
the receptor with higher relative potency to the compounds indicated by red arrows.  The 
observations made above are still pertinent but now a much lower degree of E-chain 
stringency must be invoked.  This would be consistent with the notion that less stringent R-G 
activation requirements underpin the promiscuity of GD16.  There are no indications from the 
data set to support this scenario and so a high degree of coupling has been assumed.  
Therefore simple strength of signal changes appear to be insufficient to account for these 
data. 
Can these findings be related to the structure of the receptor?  It is important to realise that the 
altered SAR represents differential G-protein activation by the same receptor.  In other words, 
the ligands are binding to the same receptor, with the same binding and activation residues 
implicated, and the same alteration of receptor tertiary structure.  Presumably, what differs is 
the impact of these changes on the tertiary structure of the different G-proteins.  However, G-
protein pre-coupling to receptors and high affinity receptor state stabilisation is widely 
acknowledged (described in Kenakin, 2004b).  It follows from consideration of the extended 
ternary complex model (Samama, et al., 1993) that alteration of receptor affinity for ligands  
by G-proteins is expected.  Therefore, one cannot rule out the possibility that the chimera may 
alter receptor  ligand binding interactions.  Although it is tempting to speculate that those 
ligands active (and therefore with affinity) at native coupled receptors but inactive at chimera-
coupled receptors might represent chimera-specific antagonists, an alternative explanation 
might be that the chimera has reduced their binding affinity for the receptor.   
A structure-based ligand docking model of murine CRTH2 has been recently presented by 
Hata, et al. (2005).  Using site-directed mutagenesis and determining the binding affinity of 
PGD2, 13,14 dihydro 15 keto PGD2, indomethacin and ramatroban, these authors have 
suggested that PGD2 occupies a binding pocket situated between the transmembrane helices 
and orientated in an opposite manner to that of other prostanoid receptors: the cyclopentane 
head group occupies the space between TMIII and TMVI with the C9 hydroxyl stabilised by a 
hydrogen bond with Glu-268 of TMVI; the D-chain carboxylate forms a charge interaction 
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with Lys-209 of TMV; Arg-178 in ECII is believed to impose geometric constraints on the 
binding pocket.  There are some attractive features of this model: firstly, the carbonyl at C11 
could interact with His-106 in TMIII to form a hydrogen bond  this would allow J series 
prostanoids to bind; secondly, the importance of Arg-178 could be to form an H-bond with 
the C15 hydroxy group and because ECII is linked by a disulphide bridge to ECI/TM3 this 
might provide a mechanism by which a high agonist potency conformation might be induced; 
thirdly, bulky E-chain substituents might sterically interact with ECII residues to prevent H-
bond formation at C15; and fourthly, it might explain why PGD1 alcohol is inactive since it 
would fail to interact with Lys-209.  Thus a picture emerges of ligand recognition mediated 
by TMIII & TMVI, with recognition of agonist both here and at ECII / TMV.  Simple 
predictions of agonist potency based on strength of H-bond acceptance at C15 cannot be made 
since stereochemical orientation is so important.  However, the data I present here suggests a 
greater importance of the His-106 (donor) / C11-carbonyl (acceptor) interaction relative to the 
Glu-268 (acceptor) / C9-hydroxy (donor  since C9 acceptors are inactive) interaction.  This 
lends further support to the model and explains the observed inactivity of C9 acceptor 
substituted prostanoids. 
An objection to this view of the ligand binding pocket is that with the exception of Glu-268, 
mutation of all the other residues mentioned above to alanine resulted in abolition of PGD2 
binding Hata, et al. (2005), whereas the data I present clearly show that abolition of certain 
interactions by modification of the agonist do not result in complete loss of activity.  This 
could indicate that the mutations have resulted in greater molecular changes than the intended 
interruption of ligand binding, and therefore that our understanding of the binding pocket is 
incomplete.  
To summarise, the switch from GEJi/o to what is assumed to be GD16z49 coupling of prostanoid 
hCRTH2 receptors does significantly alter agonist SAR.  In other words, I have demonstrated 
that for agonists, chimera-specific pharmacology is more than a theoretical hazard in drug 
discovery, and that there is a need to validate each non-native G-protein / receptor pairing 
created.  Chimera-specific antagonists, if they exist, would be a further extension of the 
potential difficulty into the realm of antagonism and would indeed be an exciting discovery. 
The work I have presented in Chapter 4 goes a long way towards addressing several of the 
questions posed at the end of Chapter 3 including a clear demonstration of divergent 
pharmacology where a receptor is coupled through GEJ and GD subunits.  Can the same be 
demonstrated where alternative subunits of the same G-protein couple to the same receptor?  
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For this a [35S]-GTPJS binding assay using membranes generated from CHO K1 hCRTH2 
cells is needed to generate SAR data for the receptor coupled to GDi/o activation, and this is 
presented in Chapter 5. 
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4.5  Figure caption list: 
Figure 1. Prostaglandin D2 (PGD2) and 15 R 15 methyl PGD2 concentration effect 
curves in CHO K1 hCRTH2 cells of clonal cell lines 10 and 15.  Data for 13,14 dihydro 
15 keto PGD2 and PGF2D shown only for clone 15.  Data are mean ± sem of twenty-four 
E/[A] curves from three separate assays. 
 
Figure 2.  Saturation radioligand binding of [3H]-PGD2 to CHO K1 cells expressing  
hCRTH2 receptors alone.  Panel A: Total, specific and non-specific binding.  Kd and 
BBmax estimated by non linear regression.  Panel B: Scatchard transformation of specific 
binding data showing fit to single binding site. 
 
Figure 3.  Saturation radioligand binding of [3H]-PGD2 to CHO cells expressing both 
GD16z49 G-proteins and hCRTH2 receptors.  Panel A: Total, specific and non-specific 
binding.  Kd and Bmax estimated by non linear regression.  Panel B: Scatchard 
transformation of specific binding data showing fit to single binding site.   
 
Figure 4.  Representative Ponceau S stain of nitrocellulose protein blot prepared as 
described in Methods.  Samples and molecular weight markers as indicated (kDa).  
Image shows equivalent staining in all lanes indicating equivalent sample loadings. 
 
Figure 5.  Western blots developed with antibodies for G-proteins as follows: Panel A  
anti GDi & GDz; Panel B  anti GDq, GDq/11, GD11, GD16; Panel C  anti GDs.  Samples 
in all panels are: M - molecular weight markers; 1  CHO K1 hCRTH2 membranes; 2  
CHO GD16z49 hCRTH2 membranes; 3  CHO GD16z49 host membranes.  Additional 
samples in Panel A are: 4  recombinant rat GDi3; 5  recombinant rat GDi2; 6  
recombinant rat GDi1.  Procedures as described in Methods.  Films exposed for 1 s 
except for GDi, GDz and GDq which were exposed for 20 s.  Molecular weight markers 
as indicated (kDa). 
 
Figure 6.  Concentration effect curves in CHO K1 host cells generated in response to 
uridine triphosphate (UTP),  a range of prostanoid receptor agonists, 1 % DMSO 
vehicle and buffer, as detailed in figure legend.  Data are mean ± sem of three 
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independent experiments conducted on the same day.  Vehicle effects observed were 
significantly larger than effects observed in other settings. 
 
Figure 7.  Effect of prostanoid receptor antagonists, 1 % DMSO vehicle and buffer on 
CHO K1 host cells.  Key to abbreviations:- AH: AH23848B 10 PM; BW: BW868C 1 
PM; GW6: GW627368X 1 PM; L: L-798106 a.k.a. GW671021X 1 PM; SC: SC-51322 
a.k.a. GW773521X 1 PM; GW8: GW853481X a.k.a. Compound 1c 10 PM; SQ: SQ-
29548 1 PM; V: 1 % DMSO vehicle; B: buffer.  Panel A: Effect of antagonists and 
vehicle on otherwise untreated CHO K1 cells; Panel B: Effect of antagonists and 
vehicle on responses to PGD2 10 PM; Panel C: Effect of antagonists and vehicle on 
responses to PGE2 10 PM.  Data are mean ± sem of three independent experiments 
conducted on the same day. 
 
Figure 8.  Antagonism of PGD2 by GW853481X and AH23848B in CHO K1 CRTH2 
cells.  Panel A:  PGD2 E/[A] curves generated in the presence of vehicle or increasing 
concentrations of AH23848B (Schild analysis) and, inset, Clarke plot of antagonist pA2 
estimated at each concentration of antagonist vs. log[antagonist concentration].  Data 
are mean ± sem of four E/[A] curves generated separately in the same experimental 
occasion.  Panel B:  PGD2 E/[A] curves generated in the presence of vehicle or 
increasing concentrations of GW853481X (Schild analysis) and, inset, Clarke plot of 
antagonist pA2 estimated at each concentration of antagonist vs. log[antagonist 
concentration].  Data are mean ± sem of three E/[A] curves generated separately in the 
same experimental occasion. 
 
Figure 9.  Effect of pertussis toxin treatment on responses to PGD2 in CHO K1 hCRTH2 
cells. Panel A:  PGD2 E/[A] curves in PTX-treated or -untreated cells at passage 10 
(P10).    Panel B:  Left chart:  Maximum responses to PGD2 in PTX-treated cells at 
passages 10-16 (P10-16) compared with responses in untreated control (C) cells; Right 
chart: PGD2 pEC50 in PTX-untreated cells at P10-16.  Data are mean ± sem of twelve 
E/[A] curves generated in three separate experiments. * denotes P < 0.05 cf. PGD2 
pEC50 in PTX-untreated cells at P10. 
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Figure 10.  Investigations using inhibitors of cell signalling molecules in CHO K1 
hCRTH2 cells.  Panel A: Effect of inhibitors on basal fluorescence.  Panel B: Effect of 
inhibitors on PGD2 E/[A] curves.  Panel C: Representative calcium flux time courses in 
response to exposure of cells to 10 PM PGD2, 0.25 % DMSO vehicle (V), vehicle in the 
presence of 3 PM thapsigargin (V+T) and buffer (B).  All inhibitors were added at 3 PM 
(final assay concentration) in 0.25 % DMSO vehicle.  Data are mean ± sem of three 
independent experiments. 
 
Figure 11.  Investigations using inhibitors of cell signalling molecules in CHO GD16z49 
hCRTH2 cells.  Panel A: Effect of inhibitors on basal fluorescence.  Panel B: Effect of 
inhibitors on PGD2 E/[A] curves.  All inhibitors were added at 3 PM (final assay 
concentration) in 0.25 % DMSO vehicle.  Data are mean ± sem of three independent 
experiments. 
 
Figure 12.  Investigations using inhibitors of cell signalling molecules in CHO GD16z49 
hCRTH2 cells treated with pertussis toxin (50 ng ml
-1).  Panel A: Effect of inhibitors on 
basal fluorescence.  Panel B: Effect of inhibitors on PGD2 E/[A] curves.  All inhibitors 
were added at 3 PM (final assay concentration) in 0.25 % DMSO vehicle.  Data are 
mean ± sem of three independent experiments. 
 
Figure 13.  Investigations with heparin in CHO K1 hCRTH2 cells.  Panel A: Effect of 
vehicle on PGD2 E/[A] curves.  Vehicle was either buffer or buffer + lipofectamine 
(Lipo) 0.3, 1.25 or 2.5 % v v-1.  Panel B: Effect of heparin (1USP unit well-1; 125 Pg ml-
1) on PGD2 E/[A] curves.  Heparin was pre-mixed with lipofectamine for 30 mins prior 
to assay.  Data are mean ± sem of three independent experiments. 
 
Figure 14.  Effect of transient transfection of cells with the C-terminal of E-adrenergic 
receptor kinase (E-ARK 495-689) in: Panel A - CHO K1 hCRTH2 cells; Panel B - CHO 
GD16z49 hCRTH2 cells; Panel C - CHO GD16z49 hCRTH2 cells with pertussis toxin (50 ng 
ml-1) treatment.  Data are mean ± sem of three independent experiments. 
 
Figure 15.  Correlation plots of functional assay potency and activity data obtained in 
CHO K1 CRTH2 cells with that obtained in CHO GD16z49 hCRTH2 cells without PTX 
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treatment.  Panel A: correlation of pEC50 data; Panel B: correlation of maximum effect 
data.  
 
Figure 16.  Correlation plots of functional assay potency and activity data obtained in 
CHO K1 CRTH2 cells with that obtained in CHO GD16z49 hCRTH2 cells with PTX 
treatment.  Panel A: correlation of pEC50 data; Panel B: correlation of maximum effect 
data.  
 
Figure 17.  Schematic representation of calcium mobilisation pathways in CHO K1 
hCRTH2 and CHO GD16z49 hCRTH2 cells based on data described in Results.  
Abbreviations: hCRTH2  human chemoattractant receptor homologous molecule of 
Th2 cells; GD& GEJ alpha subunit and beta/gamma subunit complex of GTP-binding 
protein; PLCEJ  phospholipase C E or J; PIP2  phosphatidyl inositol diphosphate; 
DAG  diacyl glycerol; IP3  inositol triphosphate; IP3R  inositol triphosphate 
receptor; ER  endoplasmic reticulum. 
 
Figure 18.  SAR Shuffle diagram displaying agonist potency SAR in CHO K1 hCRTH2 
and CHO GD16z49 hCRTH2 cells, the latter without PTX treatment. 
 
Figure 19.  Summary of agonist pharmacophore at human prostanoid CRTH2 receptors 
expressed in CHO K1 cells (GEJi/o coupling) deduced from agonist potency data.  
  
Figure 20.  SAR Shuffle diagram displaying agonist potency SAR in CHO K1 hCRTH2 
and CHO GD16z49 hCRTH2 cells with PTX treatment. 
 
Figure 21.  Summary of agonist pharmacophore at human prostanoid CRTH2 receptors 
deduced from agonist potency data in pertussis toxin-treated CHO GD16z49 cells (GD16z49 
coupling). 
 
4.6  Figures 
Follow on next page. 
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Figure 3
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Figure 5 – Panel C
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Figure 9
Panel A
Panel B
Log [PGD2]
N
FI
U
-10 -9 -8 -7 -6 -5 -4
0
20
40
60
80
100
120
- PTX
+ PTX
0
20
40
60
80
100
120
C P10 P12 P14 P16
N
FI
U
-20
PG
D 2
pE
C 5
0
5.0
5.5
6.0
6.5
7.0
7.5
8.0
P10 P12 P14 P16
*
133
Buffer
H-89
Ryanodine
Thapsigargin
U71322
Vehicle
10
30
50
70
90
110
130
150
170
Log [PGD2]
-10 -9 -8 -7 -6 -5
N
FI
U
Figure 10.
H-89 Thap Ryan U71322 Veh Buf
Treatment
0.0
50.0
100.0
150.0
200.0
250.0
N
FI
U
CHO K1 CRTH2Panel A
Panel B
134
Figure 10.
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Figure 11
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Figure 13.
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Figure 15.
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Figure 18. CHO GD16z49 hCRTH2 No PTX
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Chapter 5: 
 
 
Agonist stimulus trafficking by human prostanoid CRTH2 
(DP2) receptors coupled through GDi/o G-protein subunits 
to accumulation of [35S]-GTPJS and through either GD16z49 
or GEJi/o subunits to calcium mobilisation. 
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5.1  Summary: 
In chapter 4, data strongly indicative of agonist stimulus trafficking by human 
prostanoid CRTH2 receptors coupled to calcium mobilisation either through GEJi/o 
or GD16z49 was shown.  The equivalence of receptor : G-protein stoichiometry in the 
cell lines used was not demonstrated.  Here, I extend these observations to study the 
agonist pharmacology of responses mediated by GDi/o using a [35S]-GTPJS 
accumulation assay.  In this way, I aim to study responses mediated by the GD and 
GEJ subunits of the same G-protein. 
Prostaglandin D2 (PGD2) stimulated accumulation of [35S]-GTPJS in CHO K1 
hCRTH2 cell membranes in a monophasic, concentration-dependent and pertussis 
toxin-sensitive manner (pEC50 8.1 ± 0.03, slope 1.3 ± 0.09; n = 12).  CHO K1 host 
cell membranes were devoid of responses.  Prostanoid CRTH2 receptor 
pharmacology was demonstrated by sensitivity to the agonists 15 R 15 methyl PGD2 
(all n = 3; pEC50 8.1 ± 0.1), PGJ2 (7.6 ± 0.1), 13,14 dihydro 15 keto PGD2 (7.5 ± 
0.07), indomethacin (6.4 ± 0.06),  & PGF2D (5.5 ± 0.3) and to the putative CRTH2 
receptor antagonists AH23848B and GW853481X (pKb 6.9 ± 0.1 & 7.5 ± 0.1, 
respectively). 
A panel of 34 other prostanoid molecules were also tested for agonism.  Comparison 
with calcium mobilisation data generated through GEJi/o subunit coupling in the 
same cell line revealed several examples of potency and relative activity rank order 
reversals indicative of stimulus trafficking.  The greatest determinant of prostanoid 
agonist sensitivity to coupling partner was found to be the cyclopentyl head group.  
Agonist sensitivity varied in the order: F series > D series > J series.  Signals 
transduced in response to each series appeared to be trafficked relative to the other 
series.  Three molecules were identified as being most sensitive to changes in the 
coupling partner ([35S]-GTPJS RP, RA; calcium RP, RA): 13,14 dihydro 15 keto 
PGD2 (4.0, 1.0; 32, 0.9), 15 deoxy '12,14 PGJ2 (3.2, 1.1; 25, 0.9) & indomethacin 
(50, 1.1; 10, 0.8).  Indomethacin showed a marked preference for coupling through 
GEJ subunits (based on potency) but higher relative activity at GD subunits. 
In contrast with this, comparison of [35S] accumulation data with calcium 
mobilisation data generated through GD16z49 subunits in PTX-treated CHO GD16z49 
hCRTH2 cells showed equivalence of potency and relative activity rank orders with 
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differences in absolute values commensurate with altered signal amplification.  This 
suggests that chimeric GD16z49 G-proteins are an appropriate surrogate for 
endogenous GD mediated coupling of human prostanoid CRTH2 receptors but not of 
endogenous GEJ mediated coupling.  Validation of chimera-based screening 
strategies should therefore make use of a range of physiologically relevant assay 
readouts for comparative studies. 
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5.2  Introduction: 
Drug efficacy is the ability of certain molecules to communicate chemical information 
resulting in activation of receptors and the transduction of that information to 
intracellular effectors.  It is the sum of multiple and diverse intracellular events 
triggered by receptor activation that determines the overall physiological response to an 
agonist.  What we observe a receptor doing in response to drug challenge we now 
appreciate to be dominated by the environment in which the receptor resides when we 
study it.  As such, receptor pharmacology is phenotypically determined (Kenakin, 
2002d) and dependent upon the coupling partners available to a receptor in any given 
system.  
Pleiotropy in receptor coupling was first conceived of in terms of promiscuity of 
receptor coupling to G-proteins (reviewed in Kenakin, 1996) with the observed 
pharmacology being the resultant effect of two (or, presumably, more) G-protein 
transduced pathways.  Many receptors have now been observed that activate certain 
response pathways in preference to others, though both may be available for coupling. 
This phenomenon, known as stimulus trafficking, is supported by a huge body of 
evidence (reviewed in Kenakin, 2003, Introduction, and Urban, et al., 2007) and 
provides scope for two previously unrecognized drug behaviours: collateral efficacy 
(simultaneous and differential activation of multiple intracellular pathways by a single 
agonist-receptor pair) and permissive antagonism (differential inhibition of multiple 
activation pathways by an antagonist; Kenakin, 2005).  The hallmarks of stimulus 
trafficking behaviour are potency order reversals and / or efficacy (relative activity) 
order reversals, where adequate control of potential confounding factors has been 
achieved (Kenakin, 1995b; Clarke & Bond, 1997; Kenakin, 2003).  In particular, care 
must be taken to exclude the impact of simple changes in the strength of receptor-
effector coupling which can have differential effects on affinity- and efficacy- driven 
agonists (exemplified in Kenakin, 1999). 
In Chapters 3 and 4 I put forward evidence supporting the notion that stimulus 
trafficking of responses through GEJi/o and GD16z49 G-proteins coupled to human 
prostanoid CRTH2 receptors was a real phenomenon.  However, the comparison made 
was between an endogenously coupling system (GEJi/o) and a highly exotic genetically 
engineered recombinant coupling system (GD16z49) under conditions of non-equivalent 
receptor : G-protein (R:G) stoichiometry.  Nonetheless, ‘strength of signal’ based 
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changes in agonist pharmacology could be distinguished from trafficked responses.  In 
order to extend these observations, I have sought to detect agonist stimulus trafficking 
mediated by GD and GEJ subunits of the same G-protein coupled to human prostanoid 
CRTH2 receptors in the same host cell type, thereby establishing a priori the 
equivalence of R:G stoichiometry and the cellular environment in which the biological 
systems under comparison were synthesised.  In this chapter, I have developed a 384-
well format [35S]-GTPJS binding assay for the measurement of GDi/o activation and 
compared agonist and antagonist SAR data with that obtained through calcium 
mobilisation stimulated by GEJi/o and GD16z49 G-proteins.  
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5.3  Results: 
5.3.1  Selection of CHO K1 hCRTH2 suspension culture clone 
Dilution clones of adherent CHO K1 cells transfected with human prostanoid CRTH2 
receptors were selected initially with neomycin (1 mg ml-1) and flurbiprofen (10 PM).  
This was subsequently reduced to 0.5 mg ml-1 neomycin to promote cell growth upon 
conversion to suspension culture at passage 7 (P7).  Under these conditions (and 
flurbiprofen 50 PM) only two clones grew sufficiently quickly to warrant further 
examination: clones 5 and 15.  In an unoptimised 96-well plate-based [35S]-guanosine-
5'-O-(3-thio) triphosphate (GTPJS) binding assay using wheatgerm agglutinin coated 
polystyrene beads in the absence of guanosine diphosphate (GDP), 1 nM  [35S]-GTPJS, 
read after 210 mins and using a small-scale membrane batch produced specifically for 
this assay, both clones produced concentration-related accumulation of GTPJS in 
response to prostaglandin D2 (PGD2; Figure 1).  Concentration / effect (E/[A]) curve 
parameters were equivalent for both clones (clone 5 / clone 15: pEC50 6.3 / 6.2; 
maximum effect 147 / 147 cpm; slope (nH) 1.0 / 2.0; non statistically significant).  
Radioligand binding in membranes from un-transfected CHO K1 cells was unaffected 
by exposure to PGD2.  Clone 15 was chosen for all further work based on its superior 
growth characteristics. 
 
5.3.2  Determination of protein concentration 
Protein concentration of CHO K1 hCRTH2 cell membranes was 5.9 ± 0.3 mg ml-1. 
 
5.3.3  Development of assay protocol. 
A range of assay conditions were investigated (Table 1).  The optimum set of conditions 
were found to be: membranes 10 Pg well-1 (equivalent to 10 Pl of suspension); 
LEADseeker beads 125 mg well-1 (equivalent to 5 Pl of suspension); [35S]-GTPJS 1.2 
nM (delivered in 25 Pl); GDP 30 PM (added to bead membrane mixture and radioligand 
to give 30 PM final assay concentration; Figure 2); saponin 150 Pg ml-1 (to facilitate 
solubilisation of membranes and passage of compounds into membrane vesicles); 
incubation time 60 min; read within 120 min.  [GDP] dependency was constant 
irrespective of radioligand concentration and incubation time.  In some cases, the option 
allowing for the most economical use of reagents was chosen.   
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 5.3.4  Effect of  standard prostanoid receptor agonists and antagonists. 
Under optimised assay conditions PGD2 was an agonist with potency (pEC50; n = 12)  
8.1 ± 0.03, slope 1.3 ± 0.09, and Emax 385 ± 4 cpm (Figure 3).  PGD2 E/[A] curves were 
monophasic under all conditions studied.  PGF2D and indomethacin were also agonists 
(pEC50, Emax (cf. PGD2 = 100 %; n = 3): 5.5 ± 0.3, 48 ± 8 %; 6.4 ± 0.03, 113 ± 8 %, 
respectively) but PGE2 was without significant effect.  The putative prostanoid CRTH2 
receptor antagonists AH23848B and GW853481X produced parallel rightward 
displacement of PGD2 E/[A] curves (Figure 4 Panel A & figure 5, respectively) giving 
rise to pKb estimates of 6.9 ± 0.1 and 7.5 ± 0.1, respectively (n = 3).  In addition, 
AH23848B antagonised PGD2 EC80 (5nM) responses resulting in > 100 % inhibition 
and a pIC50 of 6.2 ± 0.07 (Figure 4, Panel B; n = 3). 
 
5.3.5  Pertussis toxin treatment of CHO K1 hCRTH2 membranes 
PGD2 stimulated accumulation of [35S]-GTPJS in untreated membranes, pEC50 7.6 ± 
0.3, Emax 394 ± 40 cpm.  The potency and Emax of PGD2 in sham- and PTX- treated 
membranes was reduced (pEC50, Emax; sham, PTX treated: 7.2 ± 0.4, 131 ± 40; 6.9 ± 
0.2, 64 ± 28; all P < 0.05 cf. untreated controls; Figure 6).  PTX therefore inhibited 
PGD2 responses by 56 % (P < 0.05 cf. sham-treated).  Data was not corrected for loss of 
either membranes themselves nor for loss of accessory proteins from membranes during 
treatment. 
 
5.3.6  Agonist ‘fingerprinting’ of hCRTH2 receptor 
A panel of 34 prostanoid molecules representing a subset of the compounds examined 
in Chapters 3 and 4, were screened for agonist activity in membranes derived from 
CHO K1 hCRTH2 cells (Table 2).  No agonist effect was shown by 50 % of the 
compounds.  The following rank order of agonist potency was obtained (relative 
potency [RP cf. PGD2 = 1.0], relative activity [RA cf. PGD2 = 1.0]; full agonists shown 
in bold type, partial agonists in normal type): 15 R 15 methyl PGD2 (1.0, 0.9) = PGD2 
> PGJ2 (3, 0.9) = 15 deoxy '12,14 PGJ2 (3, 1.1) > 13,14 dihydro 15 keto PGD2 (4, 1.0) 
> 9,10 dihydro 15 deoxy '12,14 PGJ2 (6, 1.1) > 15 S 15 methyl PGD2 (16, 1.0) > 
indomethacin (50, 1.1) > 15 R PGF2D (79, 0.4) = 17 phenyl PGD2 (79, 1.1) > 15 keto 
PGF2D (100, 0.6) > 13,14 dihydro 15 keto PGF2D (126, 0.4) > PGF2D (398, 0.5) > 11 
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deoxy 11 methylene PGD2 (1995, 0.7) > PGF1D = PGI3 (both max effect = 7 %) >> 15 
keto PGF1D = BW245C (=NSE). 
 
5.3.7  Data Tables 
Follow on next page.
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Table 1.  Determination of assay conditions and parameters.  Data are: E/[A] curves - mean ± sem of four curves; bead / membrane matrix data - 
mean ± sem of nine data points; both data determined on 2 assay plates in a single experimental occasion. 
 
Condition Min Max pEC50 Z´ Other conditions 
[GDP]   0 PM 250 ± 1 321 ± 1 8.1 ± 0.02 0.93 Membranes 5 Pg well-1
           0.1 PM 263 ± 2 329 ± 2 8.6 ± 0.02 0.71 Beads 125 Pg well-1
          0.3 PM 242 ± 1 318 ± 2 8.5 ± 0.06 0.75 [[35S]-GTPJS] 0.3 nM 
             1 PM 234 ± 3 298 ± 5 9.1 ± 0.2 0.36 incubation time 2 hrs 
             3 PM 222 ± 5 288 ± 0.06 8.7 ± 0.06 0.64  
           10 PM 151 ± 5 261 ± 3 8.7 ± 0.06 0.6  
           30 PM 141 ± 3 232 ± 2 8.4 ± 0.2 0.67  
         100 PM 134 ± 1 187 ± 4 8.1 ± 0.3 0.48  
[Membrane] 2.5 Pg well-1 135 ± 2 148 ± 2  -1.5 [[35S]-GTPJS] 0.3 nM
                        5 Pg well-1 137 ± 1 164 ± 2  -0.1 incubation time 2 hrs
                     10 Pg well-1 151 ± 4 195 ± 3  -0.2        Bead 62.5 Pg well-1                    [GDP] 30 PM 
                     20 Pg well-1 165 ± 2 230 ± 5  0.49  
                      2.5 Pg well-1 181 ± 2 192 ± 2  -2.3  
                        5 Pg well-1 184 ± 1 204 ± 3  -0.65  
                     10 Pg well-1 199 ± 3 244 ± 4  -0.4        Bead 125 Pg well
-1
                     20 Pg well-1 209 ± 2 292 ± 12  -0.08  
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                      2.5 Pg well-1 228 ± 2 239 ± 2  -2        Bead 187 Pg well-1
                        5 Pg well-1 235 ± 1 252 ± 4  -1.47         
                     10 Pg well-1 242 ± 3 297 ± 5  -0.15 
        Bead 187 Pg well-1
                     20 Pg well-1 258 ± 4 343 ± 6  0.05        
                      2.5 Pg well-1 267 ± 3 275 ± 2  -3.89  
                        5 Pg well-1 272 ± 2 292 ± 1  -0.8  
                     10 Pg well-1 282 ± 3 335 ± 3  -0.02         Bead 250 Pg well
-1
                     20 Pg well-1 279 ± 3 373 ± 9  -0.12  
[[35S]-GTPJS]  0.3 nM 135 ± 4 191 ± 16 8.1 ± 0.1 -0.3 Membranes 10 Pg well-1
                         0.6 nM 198 ± 12 305 ± 13 8.5 ± 0.2 -0.2 Beads 125 Pg well-1
                        1.2 nM 328 ± 9 541 ± 9 8.3 ± 0.06 0.5 [GDP] 30 PM 
                        2.4 nM 512 ± 15 863 ± 14 8.2 ± 0.1 0.6 incubation time 2 hrs 
Incubation time 1 hr 228 ± 4 525 ± 7 8.1 ± 0.06 0.8 Membranes 10 Pg well-1
                           2 hr 337 ± 7 587 ± 8 8.3 ± 0.06 0.7 Beads 125 Pg well-1
                           3 hr 335 ± 8 496 ± 16 8.3 ± 0.1 0.2 [GDP] 30 PM 
                           4 hr 291 ± 3 392 ± 21 8.2 ± 0.4 -0.3 [[35S]-GTPJS] 1.2 nM 
DMSO tolerance 0 % 147 ± 8 304 ± 14 6.8 ± 0.3 0.25 Membranes 10 Pg well-1
                        0.6 % 161 ± 10 370 ± 18 7.0 ± 0.1 0.3 Beads 125 Pg well-1
                       1.25 % 175 ± 8 361 ± 10 6.8 ± 0.2 0.5 [GDP] 30 PM; incubation time 2 hr 
                        2.5 % 169 ± 14 351 ± 50 6.8 ± 0.06 -0.8 [[35S]-GTPJS] 1.2 nM 
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Table 2.  Pharmacology of prostanoid molecules in CHO K1 hCRTH2 cell membranes without PTX treatment ([35S]-GTPJS accumulation 
through GDi/o).  RP: relative potency cf. PGD2 (=1.0); RA: relative activity cf. PGD2 (=1.0).  Data are mean ± sem of three independent E/[A] 
curves generated in a single assay occasion.  15 S 15 methyl PGF2D11 dehydro TxB2, 13,14 dihydro PGE1, PGE3, PGE3, 20 hydroxy PGF2D13,14 
dihydro PGF1D13,14 dihydro 15 keto PGE2, PGE1, PGD1 alcohol, 15 R 15 methyl PGE2, 13,14 dihydro 15 R PGE1, 19 R hydroxy PGA2, 15 R PGE1, 19 R 
hydroxy PGF2D19 R hydroxy PGE2 & 2,3 dinor 11E PGF2Dwere without significant effect†denotes single curve fit.  Statistical comparison by ANOVA 
followed by Dunnett’s comparison to PGD2 data; * denotes P < 0.05. 
 
Compound pEC50 slope max RP RA 
15 R 15 methyl PGD2 8.1 ± 0.1 1.8 ± 0.4 87 ± 3 1.0 0.9 
PGD2 8.1 ± 0.06 1.3 ± 0.2 100 1.0 1.0 
PGJ2 7.6 ± 0.06 1.3 ± 0.1 92 ± 1 3.2 0.9 
15 deoxy '12,14 PGJ2 7.6 ± 0.1* 1.3 ± 0.06 113 ± 2 3.2 1.1 
13,14 dihydro 15 keto PGD2 7.5 ± 0.06* 0.9 ± 0.1 95 ± 1 4.0 1.0 
9,10 dihydro 15 deoxy '12,14 PGJ2 7.3 ± 0.06* 1.1 ± 0.1 112 ± 4 6.3 1.1 
15 S 15 methyl PGD2 6.9 ± 0.06* 1.1 ± 0.1 96 ± 2 16 1.0 
Indomethacin 6.4 ± 0.02* 0.9 ± 0.1 113 ± 7 50 1.1 
15 R PGF2D 6.3 ± 0.06* 1.0 ± 0.1 54 ± 4* 63 0.6 
15 keto PGF1D 6.2 ± 0.2* 1.1 ± 0.1 37 ± 5* 79 0.4 
17 phenyl PGD2 6.2 ± 0.1* 1.2 ± 0.3 111 ± 8 79 1.1 
15 keto PGF2D 6.1 ± 0.06* 1.5 ± 0.3 62 ± 5* 100 0.6 
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13,14 dihydro 15 keto PGF2D 6.0 ± 0.1* 1.4 ± 0.2 39 ± 4* 126 0.4 
PGF2D 5.5 ± 0.2* 0.8 ± 0.2 48 ± 6* 398 0.5 
11 deoxy 11 methylene PGD2 4.8†* 0.8† 74 ± 13 1995 0.7 
PGF1D   7 ± 8   
PGI3   7 ± 2   
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5.4  Discussion: 
The assay developed here is a traditional, total GD G-protein activation assay and does 
not distinguish between GD subunit types as an antibody capture assay would.  Using 
antibody capture techniques Newman-Tancredi, et al. (2003) have demonstrated that 
human serotonergic 5-HT1B receptors expressed in CHO-K1 cells couple sequentially to 
different GD subunit types as 5-HT concentrations increase: low concentrations recruit 
GDi3 whilst higher concentrations appear to stimulate a switch to a different subunit 
type presumed to be GDi2 since CHO cells do not express GDi1.  The initiating 
observation prompting investigation with antibody capture techniques was one of 
biphasic 5-HT E/[A] curves in a traditional [35S]-GTPJS accumulation assay.  In the 
data reported here, PGD2 E/[A] curves are monophasic with slope (Hill coefficient) 1.3 
though the four-fold agonist dilution series employed would tend to mask any fine detail 
in the curve shape.  Interestingly, the data set includes agonists with slope as high as 1.8 
(15 R 15 methyl PGD2) and as low as 0.9 (13,14 dihydro 15 keto PGD2).  Hill 
coefficients of 1.0 are consistent with, but not proof of, simple uni-molecular 
interactions between ligand, receptor and intracellular effectors; deviations from unity 
suggest differences in recruitment of signalling molecules.  Slopes greater than 1.0 may 
indicate co-operative activation of receptors and intracellular effectors resulting in 
signal amplification, for example recruitment of signalling molecules into signalsomes, 
or co-operative recruitment of multiple agonist binding sites.  Values less than one may 
suggest restricted signal activation by, for example, activation of opposing signalling 
networks, agonist degradation or restricted access of the agonist to the receptor.    
PGD2 stimulated [35S]-GTPJS accumulation and [Ca2+]i mobilisation were both PTX-
sensitive indicating the involvement of Gi/o class G-proteins.  Possible candidate 
subunits for the mediation of radiolabel accumulation are GDi2, Di3, and Do though data 
demonstrating the association of particular subtypes with prostanoid CRTH2 receptors 
has not yet been published.  PTX treatment only achieved a 56 % inhibition of 
radiolabel accumulation but since conditions for this experiment were not investigated 
the PTX sensitivity of the 44 % of signal remaining cannot be surmised.  PTX is a toxin 
derived from the bacterium Bordetella pertussis which catalyses the NAD-dependent 
ADP-ribosylation of a cysteine residue 5 residues from the C-terminal end of GDi & 
GDo G-proteins (but not of GDz; Locht & Antoine, 1995; Offermans & Schulz, 1994).  
The toxin molecule is reduced and activated by glutathione in living cells (Kaslow & 
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Burns, 1992) but this must be achieved biochemically with dithiothreitol (DTT) for 
treatment of a membrane preparation.  The DTT concentration used is a balance 
between the concentration required for enzyme activation and that which results in 
unacceptable damage to membrane proteins (Ribeiro-Neto & Rodbell, 1989; McKenzie, 
1992; Ismailov, et al., 1994; Albrecht, et al., 2000; Kitts, et al., 2000).  Furthermore, 
when added to cells, PTX treatment takes place over 18 - 24 hrs prior to assay whereas 
the membrane-based procedure takes place over 30 - 60 min.  These considerations are 
likely to result in the observed less-than-total inhibition of GDi/o using the membrane-
based procedure and cast doubt on the basis for the signal remaining after PTX 
treatment: incomplete inhibition of GDi / GDo, or non-GDi/o coupling through e.g. GDz 
or GDq/11?  It would therefore have been preferable to treat cells before membrane 
preparation for these studies.  However, given the total abolition of calcium signalling 
by PTX in CHO K1 hCRTH2 cells it is possible to rule out prostanoid CRTH2 receptor 
coupling to the PTX-insensitive GDz and GDq/11 G-proteins.  It therefore seems 
reasonable to assume that all radiolabel accumulation is due to activation of GDi2, GDi3 
and / or GDo.  In this respect it is tempting to speculate that the bell-shaped chemotactic 
response curves generated with Jurkat cells (Hirai, et al., 2002), eosinophils (Monneret, 
et al., 2003; Mimura, et al., 2005) and murine L1.2 pre-B cells (Sugimoto, et al., 2005) 
are due to sequential recruitment of separate coupling partners.  Other investigators 
have used similar reagent concentrations and incubation times to achieve similar 
degrees of inhibition (Ribeiro-Neto & Rodbell, 1989; McKenzie, 1992; Ismailov, et al., 
1994; Albrecht, et al., 2000; Kitts, et al., 2000) but the amount of DTT (26 mM) in the 
final reaction mixture was higher than used elsewhere.  Sham treated membranes 
demonstrated a large inhibition of PGD2 stimulated radiolabel accumulation suggesting 
that conditions were too harsh, possibly as a result of the DTT concentration.  The 
receptor does possess cysteine residues which would be reduced in the presence of DTT 
leading to disruption of protein folding and possible loss of function. 
A further aspect of the data presented by Newman-Tancredi, et al. (2003) may also be 
reflected in the present data set.  The high potency activation of GDi3 gave rise to a bell-
shaped recruitment isotherm; in other words, either the activated receptor-GDi3-
radiolabel complex was destabilised by higher concentrations of 5-HT, or its formation 
was suppressed.  If the former, then candidate mechanisms might involve receptor 
desensitisation by membrane associated enzymes such as GRK’s which may lie behind 
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the observed short duration of stable signal in the present assay.  Other possibilities 
include time-dependent receptor dimerisation and loss of activating conformations, 
receptor digestion by proteases (note no protease inhibitors were included in the assay 
buffer) or simple chemical GTPJS hydrolysis though the speed of signal loss is not 
commensurate with this.  Desensitisation mechanisms will be considered further in 
chapter 6. 
The method developed here was biased towards the detection of low efficacy agonists 
through the use of a high [Na+] (100 mM) and [GDP] (30 PM) which together served to 
prevent constitutive receptor activation, reduce basal [35S]-GTPJS accumulation, and 
maximise the window for observation of agonism.  The result of this is that the system 
was insensitive to inverse agonism and increased agonist relative activities (though 
PGD2 potency was similar to that obtained in the CHO K1 hCRTH2 calcium assay) 
creating the impression that coupling to GDi/o was more sensitive to agonism than 
coupling via GEJi/o.  Weaker coupling of receptors to GEJ mediated pathways has been 
noted in a number of systems including rabbit common carotid artery (Akin, et al., 
2002), human serotonergic 5-HT1A receptors (Pauwels & Colpaert, 2003; Wurch & 
Pauwels, 2003), cannabinoid CB2 receptors (Shoemaker, et al., 2005) and rat 
neurotensin NTS1 receptors (Skrzydelski, et al., 2003), all expressed in CHO cells.  Of 
particular relevance here, it has also been suggested in studies of prostanoid CRTH2 
receptors using cAMP inhibition in HEK cells and calcium mobilisation in CHO cells 
also expressing recombinant GD15 (Sawyer, et al., 2002).  The results presented here are 
consistent with this finding but care should be exercised in drawing this conclusion: the 
relevance of the GTPJS-based coupling to more physiological settings such as inhibition 
of forskolin stimulated cAMP has not been determined here, and while data from such 
assays at 5-HT1A receptors have been found to be in agreement (for example, Pauwels, 
et al., 1993, 1997) stimulus trafficking has also been observed between these readouts, 
at least for adrenergic D2A receptor antagonists (Pauwels, et al., 2003). 
The relationship between [35S]-GTPJS - based and [Ca2+]i - based agonist pharmacology 
is interesting.  Calcium mobilisation data obtained using CHO GD16z49 hCRTH2 cells 
(GD16z49 mediated activation of PLCEJ in whole CHO GD16z49 hCRTH2 cells) produced 
a rank order of potency and relative activity that was identical to that obtained in the 
[35S]-GTPJS accumulation assay (GDi/o activation in membranes of CHO K1 hCRTH2 
cells).  Absolute potency and relative activity values were lower in the calcium assay in 
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a manner consistent with ‘strength of signal’ based changes of transduction.  As noted 
in chapter 4, the low potency of agonists acting through the chimera is unexpected given 
the success of several investigators to couple a diverse range of receptors through this 
G-protein (reviewed in Kostenis, et al., 2005) including chemoattractant receptor family 
members such as CCR1 (Tian, et al., 2004) fMLP and C5a receptors (Mody, et al., 
2000; Liu, et al., 2003) with which prostanoid CRTH2 receptors share greatest amino 
acid sequence homology.  Significantly, the chimera employed here incorporates the 
last 49 residues of GDz, rather than the z44 substitution specified in the literature.  The 
z44 substitution encompasses residues in the D5 helix, E6 strand and parts of the D4/E6 
loop structures which comprise the receptor-contacting interface of the G-protein.  
Mody, et al. (2000), noted that a z66 substitution resulted in a failure of the G-protein to 
couple to calcium mobilisation, while Ho, et al., (2004) have refined our knowledge of 
the crucial residues responsible for coupling specificity in the D5 helix.  However, 
neither author has demonstrated whether the observed changes in coupling efficacy are 
due to loss or enhancement of interaction with the receptor or with PLCEper se.  The 
present results appear to suggest that a relatively small modification of an additional 
five residues in the D4/E6 loop may have a large negative impact on coupling of the 
chimeric G-protein to prostanoid CRTH2 receptors though clearly, further investigation 
is required.  The observation of high potency / low activity agonism by E-series 
prostaglandins at prostanoid hCRTH2 receptors expressed with the chimeric G-protein 
and noted in chapter 3 was not replicated in the [35S]-GTPJS accumulation assay.  This 
lack of activity lends support to the notion that these molecules do not activate GDi/o 
through prostanoid CRTH2 receptors and that their exclusion from the pharmacophores 
presented in earlier chapters was appropriate.  No evidence in support of the presence of 
prostanoid EP1 or EP3 receptors has been generated but their activation remains the 
most likely explanation for these data. 
In contrast, agonist calcium mobilisation pharmacology generated using CHO K1 
hCRTH2 cells (GEJi/o mediated PLCEJ activation in whole CHO K1 hCRTH2 cells) 
showed altered rank orders of potency and relative activity compared with the GTPJS 
assay.  Comparison of these data sets provides the strongest evidence yet of agonist-
directed stimulus trafficking at prostanoid CRTH2 receptors since they are free of the 
confounding factors listed in Introduction.  In particular, by examining assay readouts 
based on the same biological system I have established a priori the equivalence of R:G 
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stoichiometry and the cellular provenance of the systems under comparison.  Whilst the 
precise molecular definition of the G-protein coupling partner has not been made, both 
pathways use PTX-sensitive Gi/o class G-proteins and are initiated by the same R:G 
interaction (or interactions).  Similarly, while the methodologies compare kinetic FLIPR 
assay data with steady-state radiolabel accumulation data (though note comments 
above), the impact of this difference is negligible since the chimera-based FLIPR assay 
data yields an identical rank order to the GTPJS assay and allows a distinction to be 
made from simple ‘strength of signal’ based changes.  Activation of multiple, distinct 
ligand binding sites on the CRTH2 receptor molecule giving rise to distinct 
pharmacology can also be excluded by consideration of two lines of evidence: 1.  Schild 
analysis of two structurally dissimilar prostanoid CRTH2 receptor antagonists, 
AH23848B and GW853481X produced profiles of antagonism in both assay formats 
consistent with an action at a single receptor type, i.e. competitive interaction;  2. 
Analysis of saturation radioligand binding data by both linear (Scatchard) and non-
linear regression revealed the presence of a single class of saturable receptor (chapter 4).  
(However, as noted in Chapter 7, other lines of evidence may suggest the presence of 
multiple ligand interaction sites).  Therefore, the alterations of agonist potency and 
activity rank order can be taken to represent agonist stimulus trafficking of response and 
suggest that the relationship between GEJ activation and GD activation is not simply ‘on 
- off’ in nature.  Rather, these data suggest that a graded activation of GEJ is possible, 
related to the nature of agonist interaction with the receptor and in keeping with the 
notion that, ‘the GEJ-dimer is not merely a passive binding partner with the sole 
purpose of stabilising GD but, rather, GEJ actively participates in receptor-mediated G 
protein activation’ (Cabrera-Vera, et al, 2003). 
The data are strikingly similar to those presented by Pauwels & Colpaert (2003) for 
[35S]-GTPJS accumulation and [Ca2+]i mobilisation by 5-HT1A receptors expressed in 
CHO K1 cells.  Serotonergic receptor agonists produced pathway-specific activity and 
rank orders of potency, with the GTPJS assay appearing to be more sensitive to agonist 
activity.  The key difference here is that agonists demonstrate a graded pattern of 
relative activities in both the calcium and GTPJS assays rather than the all-or-nothing 
profile exhibited by calcium-coupled 5-HT1A receptors.  Indeed, while most compounds 
had lower relative activity (cf. 5-HT) in the 5-HT1A GTPJS assay, the present data show 
a series of relative activity changes, with some increasing while others decrease.  Whilst 
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it is possible with the present data to make some ‘broad-brush’ observations concerning 
classes of agonist, the devil is in the detail and no entirely satisfactory pattern can be 
observed leaving stimulus trafficking the most plausible explanation that accounts for 
all of the data. 
Taking first of all the comparison of chimera-generated calcium data (GD16z49 coupled) 
with the non-chimeric GTPJS data (GDi/o coupled; Figure 7, Table 2).  The data show 
changes strongly suggestive of ‘strength of signal’ based alterations of potency and 
activity, the GTPJS assay clearly amplified agonist responses with respect to the 
calcium data.  Agonists of all three classes (D, F & J series) appear to have been 
affected equally but in particular F series agonists have been interspersed amongst 
agonists of the other series in the SAR Shuffle diagram, creating the false impression of 
trafficked agonist responses.  It is clear that side chain substitutions determine the 
precise relationships between agonists of the same class while the greatest determinant 
of agonist potency is the oxygen functional chemistry of the prostanoid cyclopentyl 
head group.  These data also demonstrate that the chimeric GD subunit is a reasonable 
surrogate for endogenous GD subunit activation and are in keeping with Clarke’s 
prediction of less obvious or no stimulus trafficking where molecular coupling partners 
are similar (Clarke, speaking in Newman-Tancredi, 2003a). 
The picture that emerges from comparison of the non-chimeric calcium mobilisation 
data (GEJi/o coupled) with the non-chimeric GTPJS accumulation data (GDi/o coupled) is 
rather different (Figure 8, Tables 2, Chapter 4).  Although a top-level view of the data 
shows similar agonist-class related changes in potency to those described above, a 
closer examination reveals changes in agonist potency rank orders within and between 
classes.  For example, 13,14 dihydro 15 keto PGD2 which was a sensitive indicator of 
trafficking between chimeric and non-chimeric responses (chapter 4), has again 
displayed the greatest change in absolute and rank potency (pEC50, RP calcium; pEC50, 
RP GTPJS: 6.4, 32; 7.5, 4); 15 keto PGF1D has also undergone potency rank order 
reversal with respect to 15 keto PGF2D(pEC50, RP calcium; pEC50, RP GTPJS: 15 keto 
PGF1D - NA, NA; 6.2, 79; 15 keto PGF2D – 5.4, 316; 6.1, 100).  Perhaps more 
significantly, three compounds display particular changes in activity that are not 
consistent with the expectations of ‘strength of signal based’ amplification: 
indomethacin which becomes less potent in the GTPJS assay but with increased relative 
activity (pEC50, RA calcium; pEC50, RA GTPJS: 6.9, 0.84; 6.4, 1.13); 15 R PGF2D 
 164
which becomes more potent but with reduced relative activity (5.5, 0.73; 6.3, 0.54); and 
17 phenyl PGD2 which undergoes an increase in potency smaller than that of other 
amplified agonists but with an increase in relative activity (5.9, 0.86; 6.2, 1.11).  
Looking between agonist series, the net result of these changes is to ‘shuffle’ agonists 
into a new rank order but care should be exercised here: some of these changes can be 
explained on the basis of agonist-class specific sensitivity to stimulus amplification.  In 
contrast to the chimera / non-chimera calcium data where J series compounds were little 
affected (c. 0.25 log unit change) these same compounds appear to be the most affected 
by the non chimeric GD / GEJ switch (c. 1 log unit change).  However, agonist-class 
specific sensitivity to amplification could still be considered a manifestation of stimulus 
trafficking since the receptor / G-protein pair are responding differently to the agonists. 
The present data are interesting in the light of previously published data.  Sawyer, et al., 
(2002) observed that the potency order of 12 agonists at prostanoid CRTH2 receptors 
was constant irrespective of assay readout (calcium mobilisation in GD15 expressing 
cells or inhibition of cAMP in HEK293(T) cells).  However, comparison with the 
present data further confirms the sensitivity of 13,14 dihydro 15 keto PGD2 to the 
coupling partner employed: pEC50 13,14 dihydro 15 keto PGD2, PGJ2; GD15: 7.3, 6.3; 
GDi/o this study: 7.5, 7.6; GEJi/o this study: 6.4, 6.7.  Indeed, Sugimoto, et al., (2005) 
have also generated data that reveal a potency rank order shift of 13,14 dihydro 15 keto 
PGD2 with respect to the present data: calcium mobilisation in L1.2 cells: PGD2 > 15 R 
15 methyl PGD2 > 13,14 dihydro 15 keto PGD2 > indomethacin > 15 deoxy '12,14 PGJ2; 
calcium mobilisation in non-chimeric CHO cells (this study): PGD2 > 15 R 15 methyl 
PGD2 > indomethacin > 15 deoxy '12,14 PGJ2 > 13,14 dihydro 15 keto PGD2.  The 
sensitivity of 13,14 dihydro 15 keto PGD2 may also be related to the shallow slope it 
presents in the GTPJS assay (noted above).  Clearly, further work is needed to 
understand this behaviour. 
The data reported by Sugimoto present several other noteworthy features. As with 
Sawyer’s data, the agonist potency rank order data for calcium mobilisation and 
inhibition of cAMP in L1.2 cells are identical and indicate only stimulus amplification- 
based changes in absolute potency.  However, when viewed together all three sets of 
data detect readout-related changes in the behaviour of indomethacin: inhibition of 
cAMP in L1.2 cells (Sugimoto, et al., 2005) indomethacin >> 15 deoxy '12,14 PGJ2; 
inhibition of cAMP in HEK293(T) cells (Sawyer, et al., 2002)  indomethacin = 15 
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deoxy '12,14 PGJ2; accumulation of [35S]-GTPJS, (this study) 15 deoxy '12,14 PGJ2 >> 
indomethacin.  In keeping with my data in the GTPJS assay, Sugimoto also notes that in 
both the calcium mobilisation and cell migration assays (both in L1.2 cells) 15 deoxy 
'12,14 PGJ2 is a more efficacious agonist than PGD2 itself.  However, my data also show 
that this relative activity relationship is reversed in calcium assays in CHO cells.  It 
therefore appears that three agonists are particularly sensitive to the molecular identity 
of the coupling partner of human prostanoid CRTH2 receptors: 13,14 dihydro 15 keto 
PGD2, 15 deoxy '12,14 PGJ2 and indomethacin. 
 Outside of the patent literature, a number of reports, including the present study, have 
described antagonists for the prostanoid CRTH2 receptor.  These antagonists fall into 
three classes: compounds believed to be simple competitive antagonists such as the 
indole-3-acetic acids described by Armer, et al. (2005), and the 4-
aminotetrahydroquinolines of Mimura, et al. (2005); pathway specific antagonists such 
as the indoles described by Mathiesen, et al. (2005; though alternative explanations 
have not been excluded); and atypical competitive antagonists such as ramatroban 
(Sugimoto, et al., 2005), as well as  AH23848B and GW853481X reported here which 
appear to show agonist and / or pathway dependent affinity.  By comparison with 
calcium assay data presented in Chapters 3 and 4, the latter two compounds show 
preferential affinity for the [35S]-GTPJS pathway (GDi/o coupling) over the calcium 
mobilisation pathway (GEJi/o coupling) of 25- (AH23848B) and 8-fold (GW853481X).  
Whilst technical deficiencies are always a possibility in any experiment, the magnitude 
of these fold-increases do not lend themselves to simple errors in compound handling.  
Indeed, based on the calcium mobilisation data, one would have to unwittingly use a top 
final assay concentration of AH23848B of 3 mM (compound handling plate 
concentration of 0.3 M) in order mistakenly arrive at this affinity estimate!  Similarly, 
the difference cannot be accounted for by considering the differential kinetics of the two 
assay systems: the faster kinetics of the calcium assay would tend to increase the 
affinity of the antagonists, not decrease it.  Therefore, the true difference in affinity 
could be greater than that quantified here.  It is difficult to conceive of a mechanism by 
which this phenomenon could occur.  There is no evidence of non receptor-mediated 
effects in either assay and as noted above, several lines of evidence support the 
existence of a single orthosteric binding site for agonists and antagonists. Pathway-
dependent effects have been said to require an allosteric mode of interaction (Kenakin, 
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2005) and, in this case, this would involve pseudo-competitive allosteric effects in both 
assay formats.  However, it is also conceivable that differences in antagonist affinity at 
the same orthosteric site might arise when the receptor couples to different G-proteins if 
it is accepted that the effect of the activated receptor on the G-protein has a reciprocal 
effect on the receptor and transmits a conformation change to the latter molecule 
resulting in a change at the orthosteric binding site (Hill, S., personal communication).  
Evidence exists in support of this concept, for example the effect of G-protein coupling 
on agonist binding affinity (Kenakin, 2004c).  Alternatively, the difference may relate to 
the use of whole cells in the calcium assay and membranes in the presence of saponin in 
the GTPJS assay: the former allows access to the receptor only from outside the cell 
while the latter allows access from both sides with the assistance of a solubilising agent.  
Thus, the affinity of these compounds in the GTPJS assay may represent a 
‘methodology assisted affinity’ rather than a coupling pathway dependent affinity. 
At a conceptual level, the molecular determinants of stimulus trafficking between GDi/o 
and GEJi/o are not difficult to understand.  The process begins with a heterotrimeric 
GDEJ-GDP complex coupled to the agonist-free CRTH2 receptor (McKenzie, 1992).  
The coupling is understood to be via the C-terminal of the GD subunit and not to 
involve residues of the GEJ subunits.  Agonist binding confers a conformation change 
which results in an affinity change at the nucleotide binding site of the GD subunit and 
the exchange of GTP for GDP.  The dissociation of the GEJ subunits from the GD 
subunit ensues and during this period of dissociation, the G-protein subunits interact 
with their effectors.  The transduction period ends with the hydrolysis of GTP back to 
GDP and the re-association of the subunits.  The conformation change induced by 
agonist binding we can now interpret as a collection of stabilised conformations of both 
the receptor and the GD subunit (since it is also a protein macromolecule and subject to 
the same conformational considerations).  This information is transmitted to the GEJ 
subunits through their contact points with the GD subunit and presumably result in 
stabilisation of a collection of conformations of this protein giving rise to the observed 
differences in response.  Thus, GEJ activation can be viewed to possess a ‘volume 
control’ and not simply as an ‘on – off’ event’.  Furthermore, as Cabrera-Vera, et al 
(2003) point out, the potential for direct receptor-GEJ interaction resulting in the 
activation of the latter has been recognised at the molecular level, lending further weight 
to this notion. 
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The pharmacophores that describe the assay readout specific interactions of agonists 
with prostanoid CRTH2 receptors therefore describe the differential ability of certain 
molecules to drive transduction through the GD subunit and on to the GEJ subunits.  
Because the GEJ subunits only undergo limited rearrangement on activation (references 
cited in Mirshahi, et al., 2006) there is limited scope for trafficking based on differential 
conformational changes at this point.  Trafficking probably represents differential 
conformational changes in the GD subunit which result in differential transmission of 
data to the GEJ complex.  So we can now interpret the pharmacophores developed in 
chapters 3 and 4 in terms of the ability of compounds to stimulate conformation changes 
in the GD subunit.  In terms of agonist structure the major determinants of signal 
transduction appear to reside in the cyclopentyl head group, C15 and C1 carbon 
substitutions.  In terms of effector output, an additional factor may include the ability of 
activated GD to ‘steal’ GEJ by preferential interaction with its own effectors (adenylate 
cyclase).  
Why are 13,14 dihydro 15 keto PGD2, 15 deoxy '12,14 PGJ2 and indomethacin 
particularly sensitive to the additional ‘push’ required to transmit activation data 
through to GEJ?  In the case of indomethacin, Hata, et al. (2005), have commented that 
it appears to possess greater intrinsic efficacy than PGD2 itself towards inhibition of 
cAMP at murine receptors and calcium mobilisation at human receptors.  However, this 
comment was based on examination of potencies vs. binding affinity and didn’t take 
into account maximal effects.  As shown in Table 5, chapter 3, most authors have found 
the relative activity of indomethacin to be 1.0.  The data presented in chapter 3 is the 
first demonstration that indomethacin can behave as a partial agonist and this casts 
doubt on this explanation.  Indomethacin clearly gives GEJ a stimulus with greater 
potency relative to GDand GD a stimulus resulting in greater activity: either could be 
considered to represent greater relative efficacy.  Hata’s molecular simulations have 
highlighted possible interactions between indomethacin and Lys209 in TMV 
(carboxylic acid charge stabilised H-bond interaction similar to the C1 carboxylate of 
prostanoid agonists) and Phe110 in TMIII (hydrophobic interaction with N-(p-
chlorobenzoyl); similar to or in place of the C11 carbonyl interaction with His106).  In 
other words, key interactions made by prostanoid agonists with Arg178 in EC2 and 
Glu268 in TMVI are absent and this may underpin its ability to transduce differently.  
Similarly, 13,14 dihydro 15 keto PGD2 and 15 deoxy '12,14 PGJ2  also lack the potential 
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for interaction with Arg178 since both lack C15 hydroxy groups and the possibility for 
stereochemical arrangement at this point. 
These data demonstrate that stimulus trafficking by the prostanoid CRTH2 receptor can 
occur when coupled either through GD or GEJ subunits of the same Gi/o class G-protein.  
The greatest determinant of prostanoid agonist sensitivity to coupling partner appears to 
be the oxygen functionality of the cyclopentyl head group.  Agonist sensitivity varied in 
the order: F series > D series > J series.  Signals transduced in response to each series 
appeared to be trafficked relative to the other series.  Three agonist molecules have been 
identified as the most sensitive markers of trafficking at this receptor: 13,14 dihydro 15 
keto PGD2, 15 deoxy '12,14 PGJ2 and indomethacin.  The usefulness of the chimeric 
GD16z49 G-protein has been further qualified such that validation of such strategies for 
generating convenient assays must include a range of physiologically relevant readouts 
in the terms-of-reference.  Lastly, receptor desensitisation may have affected assay data 
with its own pharmacological profile and this possibility will be explored further in the 
next chapter. 
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5.5  Figure caption list: 
Figure 1. Representative data showing prostaglandin D2 (PGD2) stimulated binding of 
[35S]-GTPJS binding in membranes derived from CHO K1 hCRTH2 cells of clones 5 
and 15, and from un-transfected CHO K1 cells.  Assay methodology was unoptimised; 
specific conditions are described in Results.  Data are mean of duplicate points 
generated in the same experiment. 
 
Figure 2. Prostaglandin D2 (PGD2) stimulated binding of [35S]-GTPJS binding in 
membranes derived from CHO K1 hCRTH2 cells of clone 15, in the presence of 
indicated concentrations of GDP.  Assay conditions: 5 Pg protein well-1, 125 Pg beads 
well-1, 0.3 nM [35S]-GTPJS, 3 hr incubation.  Data are mean of duplicate points 
generated in a single experiment. 
 
Figure 3.  [35S]-GTPJS accumulation in membranes derived from CHO K1 hCRTH2 
cells in response to prostaglandin D2 (PGD2), PGE2, PGF2D and indomethacin.  Assay 
conditions were optimised as described in Methods & Results.: 10 Pg protein well-1, 125 
Pg beads well-1, 1.2 nM [35S]-GTPJS, 30 PM GDP, 60 min incubation.  Data are mean ± 
sem of three independent experiments. 
 
Figure 4.  Antagonism of prostaglandin D2 (PGD2) stimulated [35S]-GTPJS 
accumulation by AH23848B in membranes derived from CHO K1 hCRTH2 cells.  
Panel A: Parallel rightward displacement of PGD2 E/[A] curves in the presence of 
increasing concentrations of AH23848B resulting in pKb estimate of 6.9 ± 0.1.  Panel B: 
Inhibition of response to application of PGD2 EC80 by increasing concentrations of 
AH23848B resulting in pIC50 estimate of 6.2 ± 0.07.  Data are mean ± sem of three 
independent experiments. 
 
Figure 5.  Antagonism of prostaglandin D2 (PGD2) stimulated [35S]-GTPJS 
accumulation by GW853481X in membranes derived from CHO K1 hCRTH2 cells 
showing parallel rightward displacement of E/[A] curves in the presence of increasing 
concentrations of antagonist.  pKb estimate: 7.5 ± 0.1.  Data are mean ± sem of three 
independent experiments. 
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Figure 6.  Inhibition of prostaglandin D2 (PGD2) stimulated [35S]-GTPJS accumulation 
by pertussis toxin in membranes derived from CHO K1 hCRTH2 cells.  Sham treatment 
reduced responses relative to untreated controls but data was not controlled for 
membrane or protein recovery.  Data are mean ± sem of three independent experiments. 
 
Figure 7.  SAR Shuffle diagram displaying agonist potency SAR in CHO K1 hCRTH2 
[35S]-GTPJS accumulation assay without PTX treatment and CHO GD16z49 hCRTH2 cell 
calcium assay with PTX treatment. 
 
Figure 8.  SAR Shuffle diagram displaying agonist potency SAR in CHO K1 hCRTH2 
[35S]-GTPJS accumulation assay and CHO K1 hCRTH2 cell calcium assay (without 
PTX treatment). 
 
Figure 9.  Comparative E/[A] curves for PGD2 & indomethacin in [35S]-GTPJS 
accumulation assays (assay A), and calcium mobilisation assays at CHO K1 hCRTH2 
cells (assay B) and CHO GD16z49 hCRTH2 cells treated with PTX (50 ng ml-1; assay C).  
Data has been scaled such that PGD2 Emax = 100 % in each assay.  Data are mean ± sem; 
PGD2 n = 10 - 12, indomethacin n = 3. 
 
 
 
 
 
 
 
 
 
 
 
 
5.6  Figures 
Follow on next page 
 171
Figure 1
0
50
100
150
200
250
300
9 8 7 6 5 4
-log [PGD2]
CC
PM
CHO K1 hCRTH2 clone 15
CHO K1 hCRTH2 clone 5
CHO K1 wild type
172
Figure 2
100 nM GDP
300 nM GDP
1 PM GDP
30 PM GDP
100 PM GDP
300 PM GDP
11 10 9 8 7 6 5
100
150
200
250
300
-log [PGD2]
CC
PM
173
Figure 3
11 10 9 8 7 6 5 4
PGD2
PGE2
PGF2D
Indomethacin
-log [compound]
150
200
250
300
350
400
450
CC
PM
174
Figure 4
10 9 8 7 6 5
-log [PGD2]
100
150
200
250
300
350
400
450
CC
PM
Untreated
Vehicle
10 PM
3 PM
1 PM
0.3 PM
0.1 PM
30 nM
9 8 7 6 5 4
150
200
250
300
350
400
450
-log [AH23848]
CC
PM
Vehicle
AH23848B
175
Figure 5
Untreated
Vehicle
10 PM
3 PM
1 PM
0.3 PM
0.1 PM
30 nM
10 9 8 7 6 5
100
150
200
250
300
350
400
450
-log [PGD2]
CC
PM
176
Figure 6
0
20
40
60
80
100
120
140
10 9 8 7 6 5
-log [PGD2]
CC
PM
Sham
PTX treated
177
CHO GD16z49 hCRTH2 + PTX - [Ca2+]iFigure 7
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Chapter 6: 
 
 
Receptor desensitisation & Gi/o / Gq synergy: impact on 
agonist stimulus trafficking at human prostanoid CRTH2 
receptors. 
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6.1  Summary: 
Agonist stimulus trafficking by calcium-coupled human prostanoid CRTH2 
receptors has been described in chapters 3 to 5.  During these studies it was noted 
that exposure of receptor-expressing cells to prostaglandin D2 (PGD2) desensitised 
the cells to subsequent exposure to prostanoid agonists.  In this chapter, the 
desensitisation phenomena have been investigated using a range of pharmacological 
techniques.  Uridine 5ƍ triphosphate (UTP) has been used as a non-prostanoid 
agonist with which to investigate cross-desensitisation events. 
PGD2 & UTP stimulated calcium mobilisation in cells expressing recombinant 
prostanoid hCRTH2 & endogenous purinergic P2Y2 receptors with and without  co-
expression of chimeric GD16z49 G-proteins.  Calcium fluxes were transient: 
maximum fluorescence (representing [Ca2+]i) occurred at 3 s (UTP) to 12 s (PGD2) 
post agonist addition; recovery to baseline was achieved by 10 mins post-addition.  
UTP responses were partially pertussis toxin (PTX) sensitive indicating coupling to 
Gi/o but also to another calcium coupled G-protein (presumably GDq). 
PGD2 responses in chimera-expressing cells were insensitive to the absence of 
calcium in the assay buffer but were reduced in non chimera-expressing cells (67 % 
Emax reduction; 0.7 log unit pEC50 reduction).  Paradoxically, the maximum effect 
elicited by UTP increased by 21 - 29 % in the absence of calcium while potency 
decreased by 0.6 log units.  Responses to both agonists were sensitive to the 
phospholipase CE inhibitor U71322 and the calcium-store depleting agent 
thapsigargin.  Taken together, these results suggest a combination of internal store 
release and plasma membrane calcium entry for both agonists. 
PGD2 produced rapid & long-lasting (> 120 min) desensitisation of hCRTH2 
receptors.  The desensitisation was biphasic manner: phase 1. inhibition of Emax and 
pEC50 within 1min; phase 2. further inhibition of Emax.  Maximal desensitisation 
occurred 30 min post-challenge.  Concentrations of PGD2 sub-threshold with respect 
to calcium mobilisation produced non-significant desensitisation at 30 min post 
exposure.  Application of PGD2 at concentrations either below EC15 or above EC100 
resulted in total inhibition of responses to re-application of the same concentration 
of agonist.  In the range EC16-EC99 inhibition followed a bell-shaped relationship 
suggesting the presence of two inhibition mechanisms.  Inhibition at low 
concentrations of PGD2 was unaffected by PTX suggesting a non Gi/o G-protein 
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mediated mechanism.  Desensitisation was unaffected by treatment with the PKA 
inhibitor H89, the PKA activator dibutyryl cyclic adenosine 5ƍ monophosphate, or 
the PKC inhibitor GF109203X, suggesting that these kinases have little role in 
response uncoupling. 
Synergising interactions between UTP and PGD2 were revealed in experiments 
where cells were exposed to both agonists.  Following UTP pre-treatment, PGD2 
curves became biphasic in both cell types, with the emergence of a response phase 
shifted to the left of the control curve location. However, Emax only increased in non 
chimera-expressing cells suggesting that the response-increasing properties of GDq 
stimulation can only be observed in this cell line.  This may indicate that synergy 
between GD16z49 & GEJi/o subunits could occur under normal conditions in chimera-
expressing cells.  Finally, following UTP pre-treatment, PGD2 elicited small 
response curves in PTX-treated non chimera-expressing cells indicating that 50ng 
ml-1 PTX for 18 hr does not abolish all Gi/o mediated coupling to CRTH2 receptors. 
Taken together then, these data suggest that the signalling cascade associated with 
hCRTH2 receptor activation to be rewritten as shown.  The potential for synergising 
interactions to occur exists in both hCRTH2-expressing cell lines but appears to be 
present without the need for additional non-prostanoid agonists in chimera 
expressing cells.  Thus, the stimulus trafficking observed may therefore reflect the 
interruption or lack of synergising interactions under PTX-treated or non-chimera-
expressing conditions.  
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6.2  Introduction: 
The scientific literature contains many examples of studies describing the coupling of 
prostanoid chemoattractant receptor homologous molecule of TH2 cell (CRTH2) 
receptors to cellular effector mechanisms via pertussis toxin sensitive Gi/o (refs. cited 
below) or, in the case of Sawyer, et al. (2002), promiscuous GD15 G-proteins.  
Biochemical readouts measured have included inhibition of cAMP accumulation and 
mobilisation of intracellular calcium ([Ca2+]i).  However, despite many of these papers 
demonstrating biphasic or complex concentration-effect (E/[A]) curves and / or transient 
alterations in the concentration of [Ca2+]i (Hirai, et al., 2001, 2002; Monneret, et al., 
2002, 2003; Sawyer, et al., 2002; Powell, 2003; Mimura, et al., 2005; Mathiesen, et al., 
2005)  indicative of regulatory mechanism activation, the literature contains surprisingly 
little comment concerning such processes.  Indeed, Hirai, et al. (2001), report the 
earliest homologous desensitisation data providing the first indication that prostanoid 
CRTH2 receptors are acutely regulated but fail to make any reference to this aspect of 
their data. 
Acute regulation of prostanoid CRTH2 receptor mediated signalling can therefore take 
place at the receptor or second messenger level, and of relevance to this thesis is the 
regulation of [Ca2+].  G-protein coupled receptor (GPCR) desensitisation mechanisms 
(Chuang, et al., 1996; Claing, et al., 2002; Pierce, et al., 2002; Reiter & Lefkowitz, 
2006) and mechanisms of [Ca2+]i regulation (Caride, et al., 2001; Papp, et al., 2003; 
Saris & Carafoli, 2005) have been extensively reviewed and the reader is directed to 
these papers for a more comprehensive treatment of the area.   
Rapid desensitisation of receptor function is often a result of kinase-mediated receptor 
phosphorylation at specific serine or threonine residues by cAMP-dependent protein 
kinase A (PKA), calcium and / or diacyl glycerol (DAG) dependent PKC, and G-protein 
receptor kinases (GRKs; Chuang, et al., 1996; Claing, et al., 2002; Pierce, et al., 2002; 
Maudsley, et al., 2005).  Activation of PKA and PKC occurs as a consequence of G-
protein mediated second messenger production and result in phosphorylation of 
multiple proteins including receptor molecules of classes unrelated to the activated 
receptor (heterologous desensitisation; Chuang, et al., 1996).  GRKs are a family of 
seven proteins which interact with activated receptors via membrane-associated and 
activated G-protein EJ subunits (GRKs 2 & 3).  This results in co-localisation of the 
kinase only with the activated and agonist-occupied receptor (homologous 
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desensitisation) by which it is allosterically activated.  GRKs 4, 5 & 6 make lesser 
contributions to desensitisation and are constitutively associated with the plasma 
membrane (Pitcher, et al., 1998; Reiter & Lefkowitz, 2006).  It is unclear whether 
GRKs activated by one receptor type can desensitise simultaneously activated receptor 
molecules of another type since this would have the potential to weaken the specificity 
of GRK mediated desensitisation.  PKA / C mediated phosphorylation of receptors 
results in immediate uncoupling of receptors from G-proteins though in certain cases 
can result in a switch in coupling preference between G-protein types, for example PKA 
induced switching of E2-adrenoceptors away from Gs to Gi mediated MAPK activation 
(Pierce, et al, 2002; Maudsley, et al., 2005; but see commentary by Hill & Baker, 2003: 
it is unclear whether this represents true switching from Gs to Gi, the unmasking of 
ongoing promiscuous coupling to Gi, or of coupling via Gs activation of the small G-
protein Rap1).  On the other hand, GRK mediated phosphorylation results in 
recruitment of E-arrestins which sterically block G-protein interactions with the receptor 
and in turn recruit a complex of proteins associated with arrestin and GPCR 
ubiquitination and subsequent clathrin-dependent endocytosis, at least for the majority 
of receptors (Reiter & Lefkowitz, 2006).  Almost all GPCRs are internalised in some 
way following phosphorylation and are either 1. dephosphorylated and recycled to the 
cell surface; or 2. degraded in lysosomes.  While residing in endosomes, E-arrestin 
linked GPCRs may take part in activation of further signalling cascades through the 
arrestin and GRK molecules themselves (Hall, et al., 1999; Lefkowitz, et al., 2006).  
Thus, E-arrestin can provide a scaffold for construction of several mitogen-activated 
protein kinase (MAPK) signalling complexes involving extracellular signal regulated 
kinase (ERK), c-Jun amino terminal kinase (JNK) and other c-Src related kinases, can 
stabilise inhibitor of nuclear factor kappa-B (INB), and activate PKB (aka AKT).  
Meanwhile, GRKs 5 & 6 promote, while GRKs 2 & 3 attenuate, E-arrestin activation of 
ERK, and GRK 2 inhibits AKT and may also inhibit MEK1.  Furthermore, additional 
regulatory complexity is produced by differential E-arrestin 1 / 2 affinity for receptors 
(Oakley, et al, 2000), regulation based on E-arrestin homo- and hetero-dimerisation 
(Milano, et al., 2006) and patterns of receptor phosphorylation dependent upon the 
expression and sub-cellular organisation of GRK proteins (Scott, et al., 2002).  Further 
control is achieved through cross-talk between the two kinase regulatory systems 
(Chuang, et al., 1996).  For example, PKC can associate with GRK2 resulting in 
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phosphorylation of the latter and an increase in affinity and Vmax towards the activated 
receptor substrate (Chuang, et al., 1995).  PKC activation can also stimulate 
transcription of GRK2, at least in T-lymphocytes (De Blasi, et al., 1995), while PKA 
may produce similar changes in GRK2 activity while also promoting E-arrestin mRNA 
transcription and protein synthesis (Parruti, et al., 1993).  Thus, this system has the 
potential to exert exquisite control of GPCR mediated signalling and co-ordination of 
cellular responses through non G-protein mediated mechanisms.   
GRKs and protein kinases are not the only mediators of acute receptor regulation.  
Other more poorly characterised systems involve receptor relocation to caveolae with 
subsequent internalisation (Smart, et al., 1999), and association of regulator of G-
protein signalling (RGS) proteins with receptors (Ross & Wilkie, 2000).  Caveolae are 
small invaginations of the plasma membrane which seem to serve as foci for co-location 
of several signalling molecules but the processes governing receptor recruitment are not 
understood.  RGS proteins are a diverse group whose members all contain a 130 - 
residue long RGS sequence and act as GTPase activating proteins (GAPs) for GPCRs.  
By accelerating GTPase activity, RGSs increase the speed with which signals are turned 
off, either when the stimulus is removed or during stimulation if the receptor is 
internalised or phosphorylated (Pierce, et al., 2002).  Finally, receptor expression may 
also be regulated though this is over a chronic time-frame. 
Regulation of [Ca2+]i is achieved via calcium-regulated sequestration into the 
endoplasmic reticulum (ER) and mitochondria, but also by extraction into the 
extracellular milieu across the plasma membrane (Saris & Carafoli, 2005, for review).  
The endoplasmic reticulum of non muscle cells contains a high concentration of calcium 
bound to its carrier proteins calreticulin, calsequestrin (in sarcoplasmic reticulum), 
endoplasmin and several other proteins, some of which function as protein-folding 
chaperone proteins (Papp, et al., 2003).   Calcium is pumped into the ER via the 
sarcoplasmic / endoplasmic reticulum Ca2+ ATPase (SERCA) protein (also known as a 
Type II Ca-ATPase in non muscle cells) which is regulated by Ca-calmodulin / PKA 
dependent phosphorylation of phospholambdan with which the pump associates 
(Wuytack, et al., 2002).  The pump has the capacity to reduce the cytoplasmic [Ca2+] to 
below 1 PM.  Spanning the dual membranes of mitochondria, another Ca-ATPase 
operates under conditions of high [Ca2+]i to exchange Ca
2+ for 2H+ (Saris & Carafoli, 
2005).  Data has also emerged suggesting the co-location of mitochondrial Ca-ATPase 
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molecules near to ER IP3 receptors creating the possibility that high local concentrations 
of [Ca2+]i sufficient to activate the pump may be produced (Rizzuto, et al., 1993).  
Plasma membranes express two calcium pumps: the Na+/Ca2+ exchanger and the plasma 
membrane Ca-ATPase (PMCA; Caride, et al., 2001).  The latter protein is homologous 
to SERCA proteins, contains 10 transmembrane spanning regions and is also regulated 
by Ca-calmodulin.  PMCAs are encoded by four genes (termed PMCA1-4) each of 
which has two splice sites, A and C.  Splices at the C-site result in the production of 
proteins with differing Ca-calmodulin regulation properties and are termed a, b and c.  
The Na+/Ca2+ exchanger is not driven by ATP hydrolysis but instead relies upon the 
energy of the gradient produced by the Na+ pump (Philipson & Nicoll, 2000).  Whether 
this protein mediates calcium efflux or uptake therefore depends upon the polarisation 
state of the cell.  The exchanger is a 9 transmembrane spanning molecule, also 
containing splice sites which allow for differential regulation by ions, phosphatidyl 
inositol (4,5) diphosphate (PIP2) and protein kinase A.  It is unclear whether only some 
or all of these mechanisms operate in CHO cells. 
As stated above, published data concerning the desensitisation of prostanoid hCRTH2 
receptors is lacking.  Mathiesen, et al. (2005), have demonstrated by means of a green 
fluorescent protein / recombinant luciferase (GFP-RLuc) bioluminescent resonance 
energy transfer (BRET) assay that hCRTH2 receptors can activate E-arrestin through a 
non-PTX sensitive pathway.  Mathiesen, et al., interpret this result as indicating direct 
E-arrestin activation which would mark a divergence from the general schemes outlined 
above.  More probable is a GRK-mediated E-arrestin recruitment with subsequent 
activation of intracellular effectors (Smith & Luttrell, 2006; Lefkowitz, et al., 2006).  
The amino acid sequences of human and murine CRTH2 receptors contain clusters of 
serine and threonine residues at the C-terminal end of the receptor (Abe, et al., 1999) 
consistent with the suggested requirements for long-lasting GRK/E-arrestin association 
with the receptor (Reiter & Lefkowitz, 2006) which is likely to prolong the persistence 
of this receptor in endosomes.   
The flip-side of stimulus down-regulation is, of course, stimulus activation and 
synergism.  Studies conducted in the present work examining the ability of UTP and 
PGD2 to cross desensitise (heterologous desensitisation) unexpectedly revealed 
synergistic interactions between Gi/o coupled prostanoid hCRTH2 receptors and Gq 
coupled purinergic P2Y2 receptors.  Synergism or cross-talk has been reviewed in 
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general terms by Selbie & Hill (1998) and Cordeaux & Hill (2002), and also in terms 
specifically relating to calcium signalling by Werry, et al. (2003); the examples cited 
below are taken from these references. Synergistic interactions can take place at a wide 
range of transduction levels and can arise from combination or sharing of receptors (e.g. 
GABAB1/2), receptor domains (e.g. N and G opioid receptors) or G-proteins (e.g. 
angiotensin AT1 and bradykinin B2 receptors), simple addition of the effects of two 
agonists activating the same second messengers (e.g. prostanoid CRTH2 and chemokine 
CCR3, 4, 5 or 7 receptors), the resultant of activation of two (or more) dissimilar 
pathways (e.g. activation of PLCE o Ca2+ o PYK2 o cSrc and PI3K o PIP3 o 
cSrc), or from the conditional amplification of agonist effects usually below detection 
limits were it not accompanied by a co-stimulatory agonist (numerous examples, e.g. 
purinergic P2Y2 and neuropeptide Y NPYY1 receptors).  A number of transduction 
events mediated by Gi/o G-proteins cannot be observed unless accompanied by Gq-
coupled receptor agonists.  These interactions frequently involve the convergence of 
GDq and GEJi/o at specific transduction proteins such as PKC and PLCE, or of GDs and 
GEJi/o, for example at adenylate cyclases II & IV.  However, other molecules may also 
be targets for the sensitising effects of one agonist on the effects of another: 
phosphatidyl inositol 4 kinase (PI4K) and PI(4)P 5 kinase to increase the substrate 
supply to PLC; I(1,3,4,5)P4 production to remodel the ER and increase sensitivity to 
IP3; calpain to cleave the C-terminal of PLCE and increase its activity; I(1,4,5)P3 
receptor sensitisation; priming and / or triggering of Ca2+ release from distinct sub-
compartments of the ER calcium store or from mitochondria; regulation of Ca2+-
ATPase or exchange proteins (see above).  The significance of these phenomena to the 
studies presented in this thesis is two-fold: firstly, any constitutive activation of a 
pathway with the potential to cross-talk with the coupling of prostanoid hCRTH2 
receptors could lead to the generation of pharmacology based on synergistic interactions 
(both stimulatory and regulatory) rather than on a direct linear link to G-protein 
activation; and secondly, if synergism can occur, then the coupling partners expressed 
in CHO GD16z49 hCRTH2 cells, which represent both Gi/o and a chimera based on a GDq 
class G-protein may synergise on a routine basis. 
The studies described in this chapter were conceived in order to shed light on 
mechanisms of recombinant prostanoid hCRTH2 receptor desensitisation by 
pharmacological means.  In the course of their execution evidence relating to synergistic 
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interactions between hCRTH2 receptors and endogenously expressed purinergic P2Y2 
receptors was gathered. The two data sets provide insights into the behaviour of this 
intriguing prostanoid receptor and provide more context to assist with interpretation of 
stimulus trafficking data. 
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6.3  Results: 
6.3.1  Experiments with CHO K1 & CHO Ga16z49  cells. 
Uridine triphosphate (UTP; 1.7 nM  100 PM) produced concentration-related increases 
in fluorescence in CHO K1 and CHO GD16z49 cells (pEC50, Emax [normalised FLIPR 
intensity units (NFIU)]; 6.3 ± 0.2, 235 ± 50, and 6.1 ± 0.1, 156 ± 2, respectively).  
Prostaglandin D2 (PGD2; (0.17 nM  10 PM)) was without effect in either cell line. 
 
6.3.2  UTP signal transduction in  CHO K1 hCRTH2 & CHO Ga16z49 hCRTH2  cells. 
 
6.3.2.1  Effect of extracellular calcium & of pertussis toxin on UTP & PGD2 
responses. 
UTP was an agonist in both hCRTH2-expressing cell lines (CHO K1 hCRTH2 cells 
pEC50 6.4 ± 0.1; CHO GD16z49 hCRTH2 cells pEC50 UTP 6.2 ± 0.1).  Overnight culture 
with pertussis toxin (PTX; 50 ng ml-1) diminished UTP Emax in both cell lines (CHO K1 
hCRTH2 cells 17 ± 3 % inhibition (P < 0.05); CHO GD16z49 hCRTH2 cells 23 ± 3 % 
inhibition (P < 0.05); Figure 1.) with no alteration of pEC50.  Removal of extracellular 
calcium (Ca2+x) from the assay system produced an 11  16 % decrease in basal 
fluorescence counts for which all data were corrected.  In CHO GD16z49 hCRTH2 cells 
removal of Ca2+x did not affect PGD2 Emax or pEC50  (Table 1; Figure 1).  However, in 
CHO K1 hCRTH2 cells removal of Ca
2+
x resulted in a 67 ± 6 % reduction in PGD2 Emax 
(P < 0.01), with a concomitant rightward pEC50 shift of 0.7 ± 0.3 log units (P = 0.05).  
In both hCRTH2 expressing cell lines the removal of Ca
2+
x resulted in an unexpected 
increase in UTP Emax (CHO K1 hCRTH2 cells 21 ± 4 % (P < 0.05); CHO GD16z49 
hCRTH2 cells 29 ± 14 % (NS)) with a decrease in potency of c. 0.6 log units (NS).   
Following PTX treatment, removal of Ca2+x resulted in similar increases in UTP Emax 
(CHO K1 hCRTH2 cells 19 ± 4 % (P < 0.05); CHO GD16z49 hCRTH2 cells 25 ± 17 % 
(NS)) and pEC50.  However, PGD2 responses in CHO GD16z49 hCRTH2 cells were no 
longer insensitive to Ca2+x: Emax was reduced by 35 ± 18 % (P < 0.05) with a non-
significant 0.2 log unit decrease in pEC50. 
 
6.3.2.2  Experiments with inhibitors of the calcium mobilisation pathway 
Data describing the effect of calcium mobilisation pathway inhibitors on basal and 
PGD2-stimulated fluorescence has been presented previously in chapter 4. 
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UTP (1.7 nM  100 PM) E/[A] curves were unaffected by pre-treatment with either 
vehicle, H-89 or ryanodine (Figures 2, 3 & 4).  U71322 treatment totally abolished 
agonist responses in  CHO GD16z49 hCRTH2 cells ± PTX and reduced the Emax in CHO 
K1 hCRTH2 cells (41 % inhibition [control 214 ± 34; U71322 treated 118 ± 28 NFIU; P 
< 0.01]).  Thapsigargin totally abolished fluorescence increases in response to UTP in 
both cell lines ± PTX (where applicable).  However, in the presence of thapsigargin, 
UTP produced small but reproducible concentration-related reductions in fluorescence 
in both cell types.  These were not abolished by PTX treatment.  Experiments using 
heparin and E-ARK 495-689 were not performed using UTP as agonist. 
 
6.3.3  Time course of UTP & PGD2 calcium response generation & recovery in 
hCRTH2 expressing  cells. 
Exposure of hCRTH2 expressing cells to PGD2 and UTP resulted in transient increases 
in fluorescence representing increased [Ca2+]i (Figure 5).  The time required to reach 
maximum fluorescence varied in the order PGD2 in CHO K1 hCRTH2 (c. 12 s) > PGD2 
in CHO GD16z49 hCRTH2 (c. 10 s) > UTP (both cell types equivalent; c. 3 s).  
Fluorescence decayed rapidly for both agonists in all settings and had declined by 
approximately 90  110 % of the peak level at 5 min post challenge depending upon the 
concentration of agonist applied (Figures 6 & 7).  Fluorescence decayed further and 
reached a new steady state level at 10 min post challenge.  Where GEJi/o coupling was 
intact, the new steady state level was above the original baseline level (NS); following 
PTX treatment the new steady state was not significantly different to the starting 
baseline.  Fluorescence was observed to fall below the starting baseline level at 5 min 
post challenge for both agonists in all settings and for vehicle in CHO K1 CRTH2 cells 
(Figure 8; vehicle was not tested in CHO GD16z49 hCRTH2 cells).  In all subsequent 
studies 2nd treatments were applied 11 min post 1st treatment. 
 
6.3.4  Characteristics of UTP & PGD2 response desensitisation  in  hCRTH2 expressing  
cells. 
6.3.4.1. Effect of a single PGD2 concentration on subsequent PGD2 dilution series 
challenge. 
In experiments where PGD2 E/[A] curves (2
nd treatment) were applied to CRTH2 
expressing cells pre-treated with a single concentration of PGD2 (1
st treatment), PGD2 
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produced a profound and long-lasting desensitisation of the cells to subsequent PGD2 
challenge (Figure 9).  In CHO GD16z49 hCRTH2 cells the desensitisation consisted of 
two phases: an acute phase between t = 0 and t = 60 s characterised by a reduction in 
both Emax and rightward shift of the PGD2 pEC50 (Figure 10; Emax sd  0  18 %);  a 
slower phase between t = 60 s and t = 10 min characterised by a further inhibition of 
Emax but with no further change in pEC50.  The time to peak inhibition decreased with 
increasing first treatment PGD2 concentration; inhibition of Emax but not of pEC50 began 
to reverse between t = 60 min and t = 120 min.  Concentrations of PGD2 below the 
threshold for stimulation of [Ca2+]i (5 nM PGD2) also produced non-significant 
reductions in Emax at t = 30min.  In the continued presence of first treatment PGD2, 
second treatment PGD2 E/[A] curves were shifted to the right of the calculated PGD2 
occupancy curve (calculations based on Kd estimated in chapter 4; Figure 11) with 
concomitant curve depression in a manner reminiscent of non-competitive antagonism.  
Pre-treatment of cells with PGD2 (0.17 nM  10 PM) produced concentration-related 
inhibition of PGD2 EC70 (at t = 11 min pIC50 7.1 ± 0.2, nH 1.5 ± 0.3, max effect 98 ± 3 
% inhibition; cf. time matched agonist control pEC50 7.4 ± 0.1, nH 1.2 ± 0.2; Figure 12).  
Pre-treatment of cells with the partial agonist 15 keto PGF2D also elicited concentration 
dependent inhibition of PGD2 (at t = 11 min pIC50 5.5 ± 0.1, nH 2.0 ± 1.3, max effect 85 
± 2 % inhibition; time matched agonist control pEC50 5.9 ± 0.2,  nH 2.9 ± 1.9, Emax 75 ± 
10 %).   
 
6.3.4.2. Effect of protein kinase inhibitors & activators on PGD2 induced 
desensitisation. 
Application of the protein kinase C inhibitor GF109203X (1 PM), the protein kinase A 
inhibitor H89 (1 PM), the protein kinase A activator dibutyryl cyclic adenosine 
monophosphate (dbcAMP, 1 PM), or combinations of GF109203X with either H89 or 
dbcAMP to hCRTH2 expressing cells produced effects on intracellular calcium 
indistinguishable from that of vehicle (0.25 % DMSO; Figure 13).  First treatment 
PGD2 E/[A] curve pEC50 was lower than previously observed (CHO K1 hCRTH2 6.9 ± 
0.03; CHO GD16z49 hCRTH2  7.1 ± 0.05; P < 0.05) and was unaffected by incubation 
with any of these agents (Figure 14).  The subsequent application of PGD2 ECx 
(nominal values of x = 0  100 in increments of 10, then five subsequent two-fold 
increases in concentration) to wells previously exposed to first treatment agonist 
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resulted in the generation of inhibition curves.  In vehicle-incubated cells to which 
PGD2 EC80 was applied on second treatment pIC50 was lower than the pEC50 values 
described above (CHO K1 hCRTH2 pIC50 6.8 ± 0.3; CHO GD16z49 hCRTH2 pIC50 6.7 ± 
0.3).  Second treatment inhibition curve pIC50 decreased with increasing ECx 
concentration (Figure 15).  In CHO GD16z49 hCRTH2 cells, pIC50 declined with 
increasing ECx to a limit at 2 x EC100 following which no further decrease was 
observed; pIC50 decreased at all ECx tested in CHO GD16z49 hCRTH2 cells however, the 
highest EC used was subsequently found to be EC100.  Emax was unaffected by the ECx 
applied (Figure 16).  Neither pIC50 nor Emax were sensitive to incubation with protein 
kinase inhibitors / activators. 
 
6.3.4.3. Effect of agonist dilution series application on subsequent challenge with 
dilution series of the same agonist. 
Experiments were conducted in which PGD2 or UTP E/[A] dilution series (2
nd 
treatment) were applied to hCRTH2 expressing cells pre-treated with dilution series of 
the same agonist, such that the same amount of agonist was added twice to each well.  
In such experiments reapplication of agonist was found to elicit a bell-shaped E/[A] 
curve for both PGD2 and UTP, in both cell lines, with and without PTX treatment 
(Figure 17 & Table 2).  The exception to this was PGD2 in CHO K1 hCRTH2 cells + 
PTX where responses were abolished by the toxin.  PGD2 2
nd treatment curves were 
observed to have an ascending phase right-shifted with respect to the control curve, 
while those to UTP were observed to be superimposable with the control curve to the 
point of inflection of the bell shaped curve.  Apart from the changes in maximum effect 
described above, removal of Ca2+x did not otherwise alter the relationship between 1
st 
and 2nd treatment agonist curves. 
 
6.3.4.4. Effect of agonist dilution series application on subsequent challenge with 
dilution series of a different agonist 
In similar experiments in which PGD2 and UTP E/[A] curves were generated in cells 
pre-treated with dilution series of the other agonist (i.e., PGD2 following UTP, and vice 
versa), a range of effects were observed (Figure 18 & Table 2).  Pre-treatment of CHO 
GD16z49 hCRTH2 cells with PGD2 produced an inhibition of UTP responses (P < 0.05) 
which was not observed in PTX treated cells.  However, in CHO K1 hCRTH2 cells, the 
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same treatment with PGD2 resulted in a small left-shift and increase in UTP Emax, 
irrespective of PTX treatment (NS).  Where the pre-treatment involved application of a 
UTP dilution series, PGD2 E/[A] curves became biphasic with a similar Emax in CHO 
Ga16z49 hCRTH2 cells but became biphasic with a markedly enhanced Emax in CHO K1 
hCRTH2 cells (P < 0.01).  In the absence of extracellular calcium, PGD2 curves 
following UTP 1st treatment were monophasic with similar Emax values to those 
obtained with calcium present; EC50 values were the same as the EC50 of the first phase 
in the biphasic curves.  Furthermore, PGD2 2
nd treatment resulted in the production of 
concentration-related increases in [Ca2+]i in PTX treated CHO K1 hCRTH2 cells 
previously exposed to a UTP dilution series.  
 
6.3.5  Data Tables 
Follow on next page. 
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Table 1.  PGD2 and UTP E/[A] curve parameters with and without pertussis toxin (PTX) treatment, and with and without calcium added to assay 
buffer.  Buffer did not contain EGTA.  Slope parameters were in the ranges: CHO GD16z49 hCRTH2:  PGD2 0.9 - 1.4, UTP 1.2 - 1.8; CHO K1 
hCRTH2:  PGD2 1.5 - 1.9, UTP 1.3 - 1.6.  NSE denotes no significant effect.  Data are mean ± sem; n=6 from three independent experiments 
except * n=5. 
 
  CHO GD16z49 hCRTH2 CHO K1 hCRTH2
  Emax pEC50 Emax pEC50
PTX treatment Calcium in buffer PGD2
 X 197 ± 2 7.5 ± 0.09 99 ± 3 7.5 ± 0.08 
  194 ± 5 7.5 ± 0.06 41 ± 2 6.9 ± 0.18 
X X 43 ± 1 6.5 ± 0.06 NSE - 
X  30 ± 2 6.1 ± 0.1* NSE - 
  UTP 
 X 235 ± 2 6.2 ± 0.04 226 ± 1 6.4 ± 0.05 
  296 ± 12 5.8 ± 0.02 268 ± 4 5.8 ± 0.02 
X X 180 ± 4 6.1 ± 0.03 187 ± 2 6.3 ± 0.02 
X  225 ± 8 5.5 ± 0.02 218 ± 4 5.7 ± 0.01 
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Table 2.  PGD2 & UTP E/[A] curve data (2
nd treatment) from application to hCRTH2 expressing cells pre-treated (1
st treatment) with dilution 
series of either the same agonist (same amount of agonist added twice to each well) or with the other agonist (an amount of both agonists added 
to each well).  Key: 1st T  1st treatment; 2nd T  2nd treatment; X  either E or I as defined in the column X=; NSE  no significant effect; NC  
no calcium in buffer.  Where no data in column Phase 2curves were monophasic.  Where X = I, curves were bell-shaped; where X = E curves 
consisted of two sigmoidal E/[A] curves, both with positive slope.  Data are mean ± sem; n=3 from three independent experiments. 
 CHO GD16z49 hCRTH2 CHO K1 hCRTH2
 Phase 1 Phase 2 Phase 1 Phase 2 
1st T 2nd T PTX Emax pEC50 Xmax pXC50 X= Emax pEC50 Xmax pXC50 X= 
PGD2 PGD2 W 57 ± 1 7.6 ± 0.18 18 ± 2 5.8 ± 0.09 I NSE - - - - 
" " X NSE - - - - NSE - - - - 
UTP UTP W 107 ± 4 6.6 ± 0.1 22 ± 3 4.9 ± 0.04 I 110 ± 4 6.6 ± 0.1 13 ± 4 4.9 ± 0.03 I 
" " X 83 ± 7 6.5 ± 0.02 15 ± 2 4.7 ± 0.07 I 73 ± 3 6.4 ± 0.03 7 ± 1 4.9 ± 0.06 I 
PGD2 UTP W 162 ± 6 6.7 ± 0.08 - - - 241 ± 5 6.5 ± 0.06 - - - 
" " X 183 ± 1 6.3 ± 0.03 - - - 211 ± 7 6.3 ± 0.07 - - - 
UTP PGD2 W 98 ± 13 7.7 ± 0.08 161 ± 3 6.1 ± 0.03 E 92 ± 12 7.7 ± 0.05 148 ± 1 6.4 ± 0.05 E 
" " X 28 ± 1 5.8 ± 0.08 - - - 14 ± 3 7.5 ± 0.15 - - - 
PGD2 PGD2 W (NC) 187 ± 5 7.8 ± 0.05 158 ± 5 6.1 ± 0.01 I 169 ± 4 8.3 ± 0.04 - - - 
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6.4  Discussion: 
In this chapter, I have employed a number of pharmacological techniques to shed light 
on the mechanisms of prostanoid hCRTH2 receptor mediated response normalisation 
and desensitisation in CHO cells.   UTP was selected as a comparative agonist because 
of the well-established and consistent expression of mainly GDq-coupled purinergic 
P2Y2 receptors on CHO cells (e.g. Dickenson et al., 1998), and because other agonists 
tested (acetyl choline, adrenergic receptor agonists noradrenaline & phenylephrine, and 
sphingosine 1 phosphate) failed to produce robust calcium signals in my hands.    
Earlier results I obtained (chapter 4) suggested that PGD2-stimulated elevations of 
intracellular calcium were independent of the presence of extracellular calcium.  In 
those studies (and the present ones) calcium sequestration with EGTA was not included 
so a lack of effect could have indicated the presence of sufficient residual calcium to 
allow normal transduction to proceed.  The observation made in this chapter of PGD2 & 
UTP response calcium-dependence was therefore unexpected.  Because of the manner 
of data normalisation, the 10 % decrease in basal fluorescence associated with calcium 
removal from the assay buffer could have led to an approximately 25 % increase in the 
apparent agonist Emax.  For this reason, data was corrected for the change in baseline.  
The conversion of PGD2 response calcium-insensitivity in CHO GD16z49 hCRTH2 cells 
to a state of calcium-sensitivity by incubation with PTX suggests that GEJi/o coupling is 
insensitive to Ca2+x.  However, this is at odds with the observation of calcium sensitivity 
in CHO K1 hCRTH2 cells without PTX treatment.  Assuming that this result is not an 
artefact of double-expression or antibiotic selection, these findings can only be 
reconciled by postulating some form of amplification associated with co-recruitment of 
GEJi/o and GD16z49 to response generation and further data in support of this notion is 
discussed below.  Thus, it now appears that PGD2 elicits both mobilisation of 
intracellular calcium and simultaneous calcium influx through membrane located 
calcium channels.  GEJ subunits are known to activate L-type calcium channels (Viard, 
et al., 2001) but these are not expressed on CHO cells (Yoshida, et al., 1992).  A 
number of other voltage-independent calcium channels are expressed on CHO cells 
including TRP1 (store-operated) calcium channels (Vaca & Sampieri, 2002) and non-
selective cation channels 1 & 2 (NSCC1 & 2; Kawanabe, et al., 2001).  A simple linear 
scheme linking receptor activation, store depletion and channel opening cannot 
adequately accommodate all of these data whereas NSCCs are known to be activated by 
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GPCRs via GDq and GD12/13 (Kawanabe, et al., 2003, 2004).  If NSCCs are involved in 
the calcium dependence of PGD2 responses in CHO K1 hCRTH2 cells and in chimera-
expressing cells following PTX treatment then their activation by Gi/o and G16z49 
subunits (or directly via E-arrestin) is implied and suggests that NSCCs are more 
promiscuous with respect to G-proteins than previously recognised.  Furthermore, in 
almost perfect juxtaposition with the PGD2 data is the UTP E/[A] curve right-shift with 
Emax elevation in the absence of calcium.  This implies that P2Y2 activation results in 
both calcium entry and ER release with the former occurring with higher agonist 
potency.  The influx of extracellular calcium appears to dampen ER calcium release via 
an unknown negative feedback mechanism.  Whilst UTP E/[A] curves were partially 
sensitive to PTX indicating mixed GDi/o and GDq coupling, the effect of calcium 
removal was unaltered by toxin treatment and therefore seems related to GDq coupling 
for this agonist.  Clearly, the net result of calcium influx across the plasma membrane 
(amplification or down-regulation of endoplasmic reticulum (ER) calcium release) 
depends on the panoply of molecular events accompanying receptor activation.  
Interestingly, these results are not consistent with the investigations made using various 
inhibitors of the transduction pathway.  For both hCRTH2 (chapter 4) and P2Y2 calcium 
mobilisation was found to be wholly inhibited by U71322 (PLCE inhibitor), 
thapsigargin (calcium store depleting agent) and, for hCRTH2 only, by heparin (IP3R 
inhibitor) suggesting that calcium was totally derived from the intracellular stores.  
However, in the presence of thapsigargin, both UTP and PGD2 elicited inhibitory E/[A] 
curves which may relate to stimulation of the postulated Ca2+x-activated negative 
feedback mechanism  possibly involving a calcium-pump.  To summarise: hCRTH2 & 
P2Y2 receptor activation both result in calcium entry across the plasma membrane in 
addition to release from the ER; calcium entry may involve NSCCs which may 
therefore display greater G-protein promiscuity than previously recognised; removal of 
extracellular calcium removes the postulated negative-feedback mechanism in ER 
calcium release for GDq coupled P2Y2 receptors, but decreases total calcium 
mobilisation for GEJi/o or GD16z49 coupled CRTH2 receptors, with no change in settings 
where CRTH2 is coupled through both GEJi/o and GD16z49 suggesting synergy between 
the latter two mechanisms. 
Before examining the ability of PGD2 and UTP to desensitise receptors to further 
agonist challenge, it was necessary to establish the time-course of agonist responses and 
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whether calcium fluxes returned to resting levels following agonist exposure.  UTP 
generated fluorescence changes reached a maximum much more rapidly than PGD2, 
presumably as a result of being both GDq and GEJi/o coupled with associated co-
operative activation of PLCE Indeed, PGD2 response maxima were also achieved in 
chimera-expressing cells more rapidly than in non chimera-expressing cells.  Calcium 
levels rapidly returned to near-resting levels indicating activation of calcium 
sequestration / removal mechanisms: new steady-state levels were attained by 10 mins 
post-agonist exposure.  The observation that the profile of calcium mobilisation and 
recovery was similar for both agonists in both cell types implies that the calcium pumps 
responsible for [Ca2+]i normalisation were similarly expressed and activated under the 
diverse conditions employed.  Fluorescence level recovery was more complete where 
Gi/o signalling was inhibited by PTX but the difference was minor.  Therefore, in 
subsequent experiments the 11min incubation used as standard post 1st addition was 
sufficient for [Ca2+]i recovery before addition of the 2
nd intervention. 
PGD2 produced potent, long-lasting desensitisation of hCRTH2 receptors to subsequent 
PGD2 challenge in both hCRTH2 expressing cell lines (homologous desensitisation).  In 
CHO GD16z49 hCRTH2 cells this was characterised by two phases.  The first (rapid) 
phase produced inhibition of both Emax and agonist pEC50.  The second (slow) phase 
resulted in further Emax inhibition but with no further change in agonist potency.  By 
analogy with the behaviour of antagonists at receptors, changes such as these are 
consistent with a combination of receptor removal (cf. receptor alkylation experiments) 
and response uncoupling (cf. non competitive antagonists).  The analogy cannot explain 
how the agonist response curves come to lie so far to the right of the occupancy curve 
(even allowing for the use of an agonist radioligand to determine binding) since a 
competitive antagonist has not been employed.  The notion that PGD2 itself, once it has 
elicited an agonist response, continues to occupy the receptors in the guise of a non-
activating compound (antagonist) seems unsatisfactory since at first glance a molecule 
cannot change its intrinsic efficacy.  However, if a temporally separated coupling of the 
receptor to another transduction pathway occurred then it is conceivable that the 
presence of the second coupling partner might confer an altered conformation on the 
receptors ligand binding site and therefore alter affinity and / or efficacy through time. 
Furthermore, if the ligand were to combine with more than one site of interaction and 
was agonist at only one of these sites which had lower affinity for the agonist and which 
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desensitised on activation, then the response curve might lie to the right of the observed 
occupancy curve and the apparent agonist intrinsic efficacy might alter.  Some support 
for this notion comes from the fact that if one calculates an apparent pA2 based on 
control curve EC15 responses, the value obtained (7.8 ± 0.2) is similar to the Kd (8.6 ± 
0.04) for this agonist and remains constant irrespective of the treated curve used. 
Indeed, other puzzling aspects of the pharmacology of this receptor might also be 
explained: the discrepant Bmax values obtained either by saturation binding or by 
extrapolation from radioligand / protein linearity data (chapters 4 and 7); discrepant 
antagonist affinity values (chapter 3); putative agonist activity at high concentrations in 
the antagonist molecule GW853481X (chapter 7); multiphasic [3H]-PGD2 displacement 
curves (chapter 7).  An alternative mechanism might involve allosteric modulation of 
the receptor by intracellular proteins recruited to it during the desensitisation process 
such as E-arrestin and G-protein coupled receptor kinases (GRKs; Reiter & Lefkowitz, 
2006, for review) however, such modulation has not been previously reported.  In the 
present studies, where inhibition curves were produced against varying PGD2 ECx 
concentrations, behaviour consistent with competitive interaction was not observed: 
IC50s tended toward a limiting value (CHO GD16z49 hCRTH2 6.2 ± 0.03; CHO K1 
hCRTH2 6.6 ± 0.1) at [PGD2] above EC100 in a manner reminiscent of an allosteric 
interaction.   
Where PGD2 EC70 was applied to cells 11min after E/[A] curve construction, the 
resulting IC50 lay 0.3 log units to the right of the EC50 for both the full agonist PGD2 
and the partial agonist 15 keto PGF2D.  This implies a causal relationship between 
calcium mobilisation and desensitisation.  However, concentrations of  PGD2 sub-
threshold with respect to calcium mobilisation still produced noticeable (though non-
significant) desensitisation at 30 min post-challenge.  Although it is possible that low 
PGD2 concentrations resulted in the mobilisation of calcium below the detection limit of 
the assay, this result seems to imply that desensitisation does not have an obligate 
requirement for calcium.  In other words, desensitisation appears not to be a 
consequence of IP3 generation, or of NSCC activation but could be related to cAMP 
inhibition or to E-arrestin recruitment (Mathiesen, et al., 2005; see below).  Because 
cAMP inhibition would be expected to reduce PKA activation, and therefore to reduce 
receptor phosphorylation, this mechanism seems an unlikely explanation.  Indeed, 
involvement of PKA and PKC have both been excluded by the failure of the compounds 
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H89, dibutyryl cAMP and GF109203X to affect PGD2-induced desensitisation.  Thus 
the most probable mechanisms for PGD2 stimulated hCRTH2 receptor desensitisation 
are E-arrestin and GRK recruitment.  Indeed, Gallant, et al. (2007) have now shown that 
when co-expressed in HEK293(T) cells along with various signalling molecules, 
CRTH2 recruits GRKs 2, 3 & 4 and is internalised via an arrestin 3  dynamin 
dependent pathway.  The data presented here suggests the presence of two 
desensitisation mechanisms which could relate to differential GRK recruitment, GRK-
mediated vs. direct arrestin recruitment, ortho- and allo- steric agonist site occupation, 
activation of an alternative G-protein mediated desensitisation pathway, or perhaps 
temporal and spatial segregation of coupling partners such as that described by Shenoy 
and Lefkowitz (2005) for the angiotensin ATII receptor mediated activation of ERK1/2.  
Interestingly, Gallant, et al., produced approximate EC50 values for receptor 
internalisation of 70  180 nM, shifted to the right of agonist mediated cAMP 
accumulation EC50 values.  However, the data I present here for functional 
desensitisation demonstrates approximately equivalent EC50 and IC50 values suggesting 
a difference between the coupling of desensitisation and internalisation.   As 
demonstrated by Mathiesen, et al. (2005), E-arrestin recruitment by hCRTH2 may 
display its own antagonist pharmacology and an examination of the desensitisation 
characteristics of the panel of agonists used in these studies will be presented in chapter 
7.  The lack of PKA / C involvement in desensitisation should have excluded the 
possibility of heterologous receptor desensitisation and this was generally observed to 
be the case (see below).  These findings are contrary to those of Gallant, et al., (2007) 
who observed that both PKA- and PKC-dependent phosphorylation of the receptor were 
required for internalisation.  Nonetheless, assuming that GRK activation is taking place, 
and that PKA / C activation is not occurring, even to a small extent, this result would 
imply that GRKs activated by one receptor molecule do not have the capacity to inhibit 
simultaneously-activated receptor molecules of another type lending further support to 
the specific relationship between GRK activation and receptor desensitisation 
propounded by Lefkowitz and others (Pierce, et al., 2002; Reiter & Lefkowitz, 2006).  
A further aspect of homologous hCRTH2 receptor desensitisation was revealed by 
experiments in which a PGD2 dilution series was applied to cells previously exposed to 
the same dilution series.  In these assays, it was observed that the magnitude of the 
inhibition was greater than the magnitude of the stimulation at low concentrations of 
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PGD2 such that responses were completely ablated.   This again implies a non-causal 
link between G-protein mediated sequelae of receptor activation and desensitisation.  
However, re-plotting the data as shown in Figure 20 suggests that two mechanisms may 
be in operation: a non PTX-sensitive desensitisation capable of completely inhibiting 
the response to low concentrations of PGD2, and a second mechanism which appears to 
become more efficacious as [PGD2] increases and which may be causally linked.  
Following PTX treatment, total inhibition was observed at all [PGD2] tested in chimera-
expressing cells suggesting that the mechanism in operation at low [PGD2] is non GDi/o-
protein dependent.  Since the effect of PTX is to reduce overall response magnitude, the 
failure to observe the second mechanism coming into play may simply reflect 
insufficient calcium mobilisation to trigger it.  One scenario might involve initial 
desensitisation through non G-protein activated GRKs 5 & 6 and possibly E-arrestin 
recruitment, while the second phase results from G-protein activated GRK recruitment. 
Homologous desensitisation was also observed with UTP at P2Y2 receptors but the 
process differed from hCRTH2 receptor desensitisation in several respects: 1.  No 
inhibition was observed until UTP EC30 was achieved.  2.  Above UTP EC30 inhibition 
proceeded in a monophasic sigmoidal fashion, reaching maximum inhibition only at 
EC100.  3.  PTX treatment did not alter P2Y2 desensitisation.  No information regarding 
the molecular identity of the desensitisation partners has been generated here but the 
similarity between the monophasic inhibition of UTP responses and the second phase of 
the biphasic PGD2 mediated desensitisation makes it tempting to speculate that these 
processes are similar.  Furthermore, the first phase of hCRTH2 receptor desensitisation 
is specific to this receptor and may be another indicator of non-G-protein mediated E-
arrestin recruitment.  Lastly, because the potency of the UTP desensitisation curve is 
right-shifted compared with the calcium mobilisation curve, a lack of signal 
amplification with respect to desensitisation is implied which is not typical of sequential 
activation of several steps in a cascade, each with a hyperbolic stimulus-effect 
relationship.  Therefore, desensitisation may occur proximal to receptor stimulation (for 
example, GEJ mediated GRK activation). 
Similar experiments designed to detect heterologous desensitisation between hCRTH2 
and P2Y2 receptors provided results critical to the interpretation of stimulus trafficking 
data presented in earlier chapters.  Firstly, activation of each receptor type resulted in 
increased potency of responses through the other receptor in both hCRTH2 receptor 
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expressing cell types irrespective of PTX treatment (with the sole exception of PGD2 
responses following UTP treatment in PTX-exposed CHO GD16z49 cells).  In CHO K1 
hCRTH2 cells, but not chimera-expressing cells, this was accompanied by elevations in 
agonist maximal effects and is a critical finding: PTX has been assumed to produce 100 
% Gi/o inhibition but the ability of PGD2 to elicit responses following UTP exposure in 
PTX treated cells clearly indicates that some calcium mobilisation activity remains 
which could be mediated by Gi/o and since no evidence in support of an alternative 
coupling pathway has been obtained, this seems the most likely scenario.  Secondly, the 
effect of P2Y2 activation on PGD2 E/[A] curves resulted in the latter becoming clearly 
biphasic (Figure 18).  In both hCRTH2 expressing cell lines, phase 1 of PGD2 responses 
had higher potency than PGD2 in non-UTP exposed cells; phase 2 was of lower potency 
and in CHO GD16z49 cells resulted in the production of a similar Emax to that obtained in 
non-UTP treated cells.  However, in CHO K1 hCRTH2 cells, Emax was enhanced by c. 
50 % representing the amplifying effect of simultaneous GDq/11 and GEJi/o activation.  In 
chimera-expressing cells the chimera and GEJi/o may therefore synergise to produce the 
overall response observed.  Since the GD16 backbone of the chimera belongs to the Gq/11 
family of G-proteins this seems probable and presumably takes place at the level of 
PLCE(Cordeaux & Hill, 2002; Werry, et al., 2003), though this is not proven and other 
mechanisms may be involved.  Taken together, then, these two pieces of data suggest 
that under the conditions employed in earlier chapters under which trafficked agonist 
responses were observed, synergising interactions could have been taking place, at least 
in chimera-expressing cells.  Interestingly, in the absence of extracellular calcium, 
PGD2 responses were still potentiated but in a monophasic fashion leading to 
considerably higher agonist potency.  This suggests that the synergising interaction 
leads to greater release of intracellular calcium and reveals again the presence of a 
calcium reducing mechanism triggered in the presence of extracellular calcium.  Finally, 
it is possible to extract some comparisons from figures 2, 3 and 4 in which a fixed 
concentration of indomethacin (3PM) has been used to pre-treat cells in which UTP 
E/[A] curves were subsequently produced.  Despite the methodological differences, 
similar effects on UTP potency & maximum effect have been produced suggesting that 
the effects seen are related to the receptor rather than specifically to the agonist used. 
Trafficked responses could therefore be reflections of altered synergy, which in itself is 
a form of stimulus trafficking, but may not have the simple relationship to G-protein 
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activation first assumed.  Indeed, in both hCRTH2 expressing cell lines, differences in 
relative activity could represent differing abilities to trigger synergising interactions.  
Two possibilities arise from this: 1. F series prostanoids are largely partial because as a 
class they cannot trigger synergism; and opposed to this 2. F series molecules are 
inactive in CHO K1 hCRTH2 cells precisely because they do rely on a synergistic 
interaction which is not available to them in these cells.  In chimera-expressing cells 
under normal conditions it seems very likely that synergism is occurring but what about 
in CHO K1 hCRTH2 cells and chimera-expressing cells following PTX treatment?  
Whilst the data do show that PTX inhibition of Gi/o is not total, the residual PGD2 
mediated calcium mobilisation in PTX treated CHO K1 hCRTH2 cells under 
synergising conditions is barely detectable.  Furthermore, in experiments where twice 
the density (4 x 105 well-1) of CHO GD16z49 hCRTH2 cells were plated out and treated 
with the same PTX concentration PGD2 E/[A] curves were identical to those produced 
under standard conditions suggesting that 50 ng ml-1 PTX for 18 hr produces a very 
high degree of blockade.  In chimera-expressing cells PTX treatment produces a 
profound reduction in Emax and rightward shift in potency indicative of interruption of 
the synergising interaction.  Synergistic interactions would require simultaneous Gi/o 
and GDq activation.  The data presented here suggest that this does not occur except in 
non-PTX treated chimera-expressing cells.  Finally, while there is no evidence of an 
unobserved GDq activation through an undetected or unknown transduction pathway, for 
example through endogenous release of arachidonic acid for which flurbiprofen has 
been included in the cell culture medium, or constitutive receptor activation in a Gq 
coupled pathway, no experiments specifically designed to look for it have been 
conducted.  Taken together, then, while synergising interactions have not been ruled out 
requiring their consideration as a possible contaminant of stimulus trafficking data, the 
likely impact is small and could possibly be related to certain specific molecules. 
In addition to altering the emphasis placed on stimulus trafficking data these data cast 
new light on other aspects of the data gathered during this project.  If GD16z49 and GEJi/o 
synergise under normal conditions in CHO GD16z49 hCRTH2 cells then this may 
explain the lack of sensitivity to extracellular calcium until PTX treatment effectively 
disrupts the synergising interaction.  The transduction cascade resulting from prostanoid 
hCRTH2 receptor activation presented in chapter 4 therefore needs some revision 
(Figure 21).  The larger number of [3H]-PGD2 binding sites detected in CHO GD16z49 
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hCRTH2 cell membranes may not reflect altered receptor or G-protein expression but 
rather may indicate altered G-protein or E-arrestin recruitment. Therefore the R:G 
stoichiometry relevant to response generation in PTX treated chimera-expressing cells is 
unknown.  Similarly, responses to E-series prostaglandins observed in chimera-
expressing host cells may have arisen through a synergising interaction between a 
poorly expressed population of Gi/o coupled EP receptors (EP3?) and the chimera.  
Finally, the method of GTPJS assay employed in chapter 5 did not utilise antibody 
capture techniques but it is now clearly vital to establish which G-proteins accumulated 
[35S]-GTPJS in response to PGD2. 
Synergistic interactions involving CRTH2 receptors have been postulated to account for 
the supramaximal effects of 15 deoxy '12,14 PGJ2 at the receptor in transfected L1.2 cell 
migration and calcium mobilisation assays (Sugimoto, et al., 2005) but to date no direct 
evidence has been gathered.  Indeed, biphasic E/[A] curves with amplified maximum 
effects have been observed for PGD2 in an eosinophil shape change assay (Böhm, et al., 
2004).  These authors also attributed PTX-insensitive calcium mobilisation to GDq/11 
activation though this may instead reflect GDz mediation (but see Chapter 4: GDz 
coupling in CHO cells is unlikely).  Mast cells, the likely physiological source of 
inflammatory-cell recruiting PGD2, also produce other agents which have the potential 
to synergise with CRTH2 receptor activation such as histamine, platelet activating factor 
(PAF),  thromboxane A2, leukotrienes B4, C4 & D4 and eotaxin, while T-cells (which 
also secrete PGD2 (Tanaka, et al., 2000)) produce cytokines such as IL-4 and IFNJ.  
Such interactions are likely to have physiological relevance in inflammatory cells 
expressing the receptor.  For example, in addition to expressing PLCJ-activating T-cell 
receptor (TCR)/CD3 complexes (Chan, et al., 1992; Pezzicoli & Baldari, 2005), T-cells 
also express PLCE-activating Gi/o coupled CCR3, 4, 5 and 7 chemokine receptors 
(Alexander et al., 2006; Abbas & Lichtman, 2003).  Co-activation of the latter receptors 
might reasonably be expected to contribute to whole cell IP3 and DAG levels in an 
additive fashion (ignoring the impact of factors such as compartmentalisation and 
signalling complex association).  However, as Werry, et al. (2003) point out, 
synergising interactions could theoretically arise at multiple points in the transduction 
cascades dependent upon the precise molecular species activated in each pathway.  Of 
greater potential interest, though, is the observation that TCR activates PLCJ through 
activation of an intermediary protein tyrosine kinase, Zap70, which phosphorylates 
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PLCJ at Y319 (Pezzicoli & Baldari, 2005).  PLCE also contains multiple targets for 
serine, threonine and tyrosine protein kinases and it has been noted previously that PKA 
or PKC mediated phosphorylation of PLC isoforms can variously lead to stimulation or 
inhibition depending upon the context (Werry, et al., 2003, for review).  Although the 
potential for this interaction has long been recognised (e.g. Selbie & Hill, 1998) there is 
a huge gap in the scientific literature concerning this point: can immune cell receptors 
trigger synergising interactions with chemokine / chemoattractant receptors through 
phosphorylation of key molecules at convergent points in their signalling cascades?  
Another aspect of cascade convergence also deserves mention: Phospholipases CE & 
CJ use the same substrate, phosphoinositide 4,5 biphosphate as well as the pro-
inflammatory phosphoinositide 3 kinase (PI3K) group of enzymes.  One can reasonably 
expect these enzymes to compete with each other for substrate, particularly under 
conditions where substrate is limiting.  The interaction at this level is likely to be 
complex: PI3KJ can be activated by GEJ subunits with apparently no preference for 
particular EJ complex combinations (Vanhaesenbroeck, et al., 2001) while PI3KG in T-
cells is activated downstream of TCR activation.  Indeed, Stubbs, et al. (2002), have 
noted that indomethacin & PGD2 can elicit activation of LY-294002-sensitive PI3K in 
[human?] eosinophils & basophils although this was in an apparently PTX-insensitive 
system.  Both PI3K activation, and Pyk2 activation arising from Ca2+ mobilisation can 
converge upon c-Src activation resulting in another level of cross-talk (reviewed in 
Selbie & Hill, 1998).  Once activated, these pathways are likely to compete for 
phosphoinositide lipids resulting in fine-tuning of the overall response (Figure 21).  
Recently, activation of PI3K enzymes (presumed to be PI3KG and therefore GEJ 
mediated) by CRTH2 has been demonstrated confirming the value of studying this area 
of transduction (Xue, et al., 2006). 
In the next chapter I will examine the desensitisation pharmacology of a series of 
prostanoid molecules, and expand on the characteristics of selected atypical 
compounds, before drawing my conclusions from this thesis. 
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6.5  Figure caption list: 
Figure 1. UTP and PGD2 E/[A] curves in CHO GD16z49 hCRTH2 and CHO K1 hCRTH2 
cells with and without calcium in the assay buffer following PTX treatment (where 
applicable).  Buffer did not contain EGTA.  Data are mean ± sem of three independent 
experiments. 
 
Figure 2.  Effect of inhibitors of cell signalling molecules on UTP E/[A] curves in CHO 
K1 hCRTH2 cells.  All inhibitors were added at 3PM final assay concentration in 0.25 
% DMSO vehicle.  Data are mean ± sd of three independent experiments. 
 
Figure 3.  Effect of inhibitors of cell signalling molecules on UTP E/[A] curves in CHO 
GD16z49 hCRTH2 cells.  All inhibitors were added at 3 PM final assay concentration in 
0.25 % DMSO vehicle.  Data are mean ± sd of three independent experiments. 
 
Figure 4.  Effect of inhibitors of cell signalling molecules on UTP E/[A] curves in CHO 
GD16z49 hCRTH2 cells treated with PTX.  All inhibitors were added at 3 PM final assay 
concentration in 0.25 % DMSO vehicle.  Data are mean ± sd of three independent 
experiments. 
 
Figure 5.  Representative calcium flux time courses in response to exposure of cells to 
10 PM PGD2 or 30 PM UTP (representing EC100 for each agonist) in CHO GD16z49 
hCRTH2 (blue lines) and CHO K1 hCRTH2 (black lines) cells. 
 
Figure 6.  Time course of PGD2 and UTP stimulated calcium transients in CHO GD16z49 
hCRTH2 cells with and without PTX treatment.  Agonist concentrations were as 
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indicated in figure legends.  Basal fluorescence at the start of the experiment was 
subtracted from all data.  Data are mean ± sem of six determinations from three 
independent experiments. 
 
Figure 7.  Time course of PGD2 and UTP stimulated calcium transients in CHO K1 
hCRTH2 cells with and without PTX treatment.  Agonist concentrations were as 
indicated in figure legends.  Basal fluorescence at the start of the experiment was 
subtracted from all data.  Data are mean ± sem of six determinations from three 
independent experiments. 
 
Figure 8.  Representative data showing effect of vehicle addition on fluorescence in 
CHO K1 hCRTH2 cells without PTX treatment.  Basal fluorescence at the start of the 
experiment was subtracted from all data.   
 
Figure 9.  Desensitising effect of fixed PGD2 ECx concentrations on subsequent PGD2 
E/[A] curve generation in CHO GD16z49 hCRTH2 cells without PTX treatment at 5 mins 
post exposure to 1st treatment (see Methods for details).  Data are mean ± sem of three 
independent experiments. 
 
Figure 10.  Desensitising effect of fixed PGD2 ECx concentrations on subsequent 
response to 10 PM PGD2 (top panel) and PGD2 E/[A] curve pEC50 (bottom panel) in 
CHO GD16z49 hCRTH2 cells without PTX treatment at varying times post exposure to 1st 
treatment (see Methods for details).  Data points absent from pEC50 data plot following 
10 PM PGD2 first treatment represent points where curve fitting could not be achieved 
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due to the small response sizes obtained.  Data are mean ± sem of three independent 
experiments. 
 
Figure 11.  Concentration / fractional occupancy curve calculated from saturation 
binding data presented in chapter 4 (using an average Kd for the two hCRTH2 
expressing cell lines of 2.5 nM) plotted with a concentration / fractional response curve 
for PGD2  based on control curve data in CHOGD16z49 hCRTH2 cells. 
 
Figure 12.  Activation and inhibition PGD2 E/[A] curves in CHO GD16z49 hCRTH2 cells.  
Activation curve (positive-going, resulting in an EC50) was prepared as normal.  
Inhibition curve (negative going resulting in an IC50) was prepared by adding PGD2 
EC70 to cells 11 min after PGD2 activation curve was added.  Data are mean ± sem of 
three independent experiments. 
 
Figure 13.  Effect of adding the PKA inhibitor H89, the PKA activator dibutyryl cyclic 
adenosine monophosphate (dbcAMP), the PKC inhibitor GF109203X (GF), vehicle 
(veh; 0.25 % DMSO) or combinations as indicated on basal fluorescence in CHO 
GD16z49 hCRTH2 and CHO K1 hCRTH2 cells.  Data are mean ± sem of three 
independent experiments. 
 
Figure 14.   Effect of adding the PKA inhibitor H89, the PKA activator dibutyryl cyclic 
adenosine monophosphate (dbcAMP), the PKC inhibitor GF109203X (GF), vehicle 
(veh; 0.25 % DMSO) or combinations as indicated on 1st treatment PGD2 E/[A] curves  
in CHO GD16z49 hCRTH2 and CHO K1 hCRTH2 cells.  Data are mean ± sem of three 
independent experiments. 
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 Figure 15.  Effect of adding the PKA inhibitor H89, the PKA activator dibutyryl cyclic 
adenosine monophosphate (dbcAMP), the PKC inhibitor GF109203X (GF), vehicle 
(veh; 0.25 % DMSO) or combinations as indicated on 2nd treatment PGD2 inhibition 
curve pIC50 in CHO GD16z49 hCRTH2 and CHO K1 hCRTH2 cells.  Data are mean ± 
sem of three independent experiments. 
 
Figure 16.  Effect of adding the PKA inhibitor H89, the PKA activator dibutyryl cyclic 
adenosine monophosphate (dbcAMP), the PKC inhibitor GF109203X (GF), vehicle 
(veh; 0.25 % DMSO) or combinations as indicated on 2nd treatment PGD2 inhibition 
curve Imax in CHO GD16z49 hCRTH2 and CHO K1 hCRTH2 cells.  Data are mean ± sem 
of three independent experiments. 
 
Figure 17.  Desensitisation of PGD2 and UTP stimulated calcium mobilisation in CHO 
GD16z49 hCRTH2 and CHO K1 hCRTH2 cells with and without PTX treatment.  Agonist 
dilution series (2nd treatment) were added to cells previously exposed to a dilution series 
of the same agonist (1st treatment) such that each well received the same concentration 
of agonist twice. Data are mean ± sem of three independent experiments. 
 
Figure 18.  Synergy between PGD2 and UTP stimulated calcium mobilisation in CHO 
GD16z49 hCRTH2 and CHO K1 hCRTH2 cells with and without PTX treatment.  Agonist 
dilution series (2nd treatment) were added to cells previously exposed to a dilution series 
of the other agonist (1st treatment) such that wells received concentrations of PGD2 
followed by UTP or vice versa. Data are mean ± sem of three independent experiments. 
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Figure 19.  PGD2 E/[A] curves (2
nd treatment) in CHO GD16z49 hCRTH2 and CHO K1 
hCRTH2 cells following UTP exposure (1
st treatment) in the absence of calcium in the 
assay buffer.  EGTA was not added.  Data are mean ± sem of three independent 
experiments. 
 
Figure 20.  Data presented in Figure 17. replotted as % inhibition (wrt. control curve 
calcium mobilisation) vs. PGD2 concentration for agonists undergoing homologous 
desensitisation in CHO GD16z49 hCRTH2 cells.  Data are mean ± sem of three 
independent experiments. 
 
Figure 21.  Schematic representation of signal transduction pathways in CHO GD16z49 
hCRTH2 cells based on data described here and in chapter 4.  Abbreviations: hCRTH2  
human chemoattractant receptor homologous molecule of Th2 cells; GD& GEJ alpha 
subunit and beta/gamma subunit complex of GTP-binding protein; PLCEJ  
phospholipase C E or J; PIP2  phosphatidyl inositol diphosphate; DAG  diacyl 
glycerol; IP3  inositol (1,4,5) triphosphate; IP3R  inositol (1,4,5) triphosphate 
receptor; ER  endoplasmic reticulum; MAPK  mitogen activated protein kinase; GRK 
 G-protein coupled receptor kinase; NSCC  non-specific cation channel; PKC  
protein kinase C; Ad cyc  adenylate cyclase.  Blue arrows indicate steps supported by 
evidence generated in this thesis; shaded arrows indicate steps supported by evidence 
presented in the literature; dashed arrows indicate postulated links.  Red and yellow 
highlighting indicates possible points of synergy in cascade. 
 
6.6  Figures 
Follow on next page. 
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Chapter 7: 
 
 
Prostanoid receptor agonists of human CRTH2 receptors: 
pharmacology of receptor desensitisation reveals atypical 
behaviour.  Can ligands induce receptor desensitisation 
without activation? 
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7.1  Summary: 
In chapter 6, the ability of agonists of hCRTH2 receptors to desensitise the receptor 
to subsequent agonist challenge was investigated.  In this chapter, these studies have 
been extended to examine the ability of a panel of diverse prostanoid molecules to 
elicit desensitisation. 
Molecules previously shown to be agonists at hCRTH2 receptors desensitised them 
against subsequent exposure to PGD2 EC80  resulting in pIC50 values that either 
correlated with their calcium-mobilisation pEC50 values (CHO GD16z49 hCRTH2 r2 = 
0.83) or were in loose agreement with them (CHO K1 hCRTH2 r2 = 0.35). 
Unexpectedly, a large group of molecules devoid of agonist activity in either the 
calcium mobilisation or [35S]-GTPJS accumulation assays also partially inhibited 
PGD2 EC80 responses in a concentration-related manner.  Typically maximum 
inhibition values for these latter molecules were in the range 20 – 50 % in chimera-
expressing cells and 40 – 70 % in non-chimeric cells.  The lower maximum 
inhibition values observed in chimeric cells may reflect lower functional inhibition 
of synergy-amplified PGD2 responses in this cell line. 
A group of partial agonists, antagonists, and ‘non-agonist inhibitors’ were profiled 
further using Schild analyses in calcium mobilisation, [35S]-GTPJS accumulation  
and [3H]-PGD2 radioligand displacement assays.  GTPJS assay agonist pEC50 and 
antagonist pA2 values were consistently higher than the corresponding values in 
calcium assays.  The results for each class of compounds are summarised as 
follows: 
Antagonists: In addition to the previously identified hCRTH2 antagonists 
AH23848B and GW853481X, the compound 13,14 dihydro 15 keto PGE2 was also 
found to be an antagonist of CRTH2 receptors (No agonism; pIC50 (Ca2+) 5.6, pA2 
(Ca2+) 5.2 & (GTPJS) 5.7; pIC50 (binding) 6.1).  The GTPJS assay antagonist profile 
was complex and indicated an interaction with two sites.  
Partial agonists: The compounds PGF2D, 15 R PGF2D and 13,14 dihydro 15 keto 
PGF2D were partial agonists at hCRTH2 receptors in both assay formats: agonist 
pEC50 and antagonist pA2 values were in agreement.  Binding pIC50 values also 
correlated except for 15 R PGF2D. 
Non-agonist inhibitors: 19 hydroxy prostaglandins A2, E2 & F2D were non-agonist 
inhibitors of PGD2 responses in calcium assays (CHO GD16z49 pIC50, Imax: 7.5, 21 %; 
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7.1, 35 %; 5.8, 32 %, respectively) but were devoid of effect in GTPJS assays.  
Calcium assay Schild analysis demonstrated c. 20 % depression of PGD2 E/[A] 
curve maxima at all concentrations with no dextral curve shift while binding assays 
also indicated an interaction with the receptor.  PGE2 was also a non-agonist 
inhibitor of PGD2 responses (pIC50 7.4-7.7) but with additional antagonist affinity 
for the receptor (Ca2+ pA2 4.9-5.2; GTPJS pKb 5.6). 
Non-agonist inhibitors may trigger receptor desensitisation via activation of a 
pathway independent of G-protein mediated agonism.  This may involve non-G-
protein dependent recruitment of GRKs 5 & 6, or E-arrestin activation.  These data 
may also point to possible heterologous desensitisation of CRTH2-mediated 
responses in chimera-expressing cells by activation of the postulated EP3 receptor in 
these cells.  Clearly, further investigation is needed to elucidate the precise 
pharmacological events underpinning these observations. 
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7.2  Introduction: 
Whilst the journal-based scientific literature contains relatively few papers describing 
antagonists of prostanoid CRTH2 receptors (Birkinshaw, et al., 2006; Armer, et al., 
2005; Sugimoto, et al., 2005), the patent literature contains many examples of such 
compounds (see Wei & Bacon, 2005, for review).  In at least one case, these molecules 
have demonstrated an ability to selectively antagonise one CRTH2 mediated response 
while leaving others unaffected (Mathiesen, et al., 2005) which may involve so-called 
permissive antagonism (Kenakin, 2005).  Similarly, as described in earlier chapters of 
this thesis, agonists possessing the ability to direct stimuli towards particular response 
pathways have also been observed at this receptor.  In the cases of PGD2 and 15 keto 
PGF2D, at least, this agonism was accompanied by receptor desensitisation, resulting in 
an inability of agonist-exposed receptors to respond to subsequent agonist challenge.  It 
therefore seemed reasonable to assay the panel of prostanoid molecules used in earlier 
chapters for desensitisation and / or antagonist activity in a calcium mobilisation assay 
measured against an EC80 response to PGD2 at hCRTH2 receptors expressed in CHO 
cells either with or without the chimeric GD16z49 G-protein. 
As expected, pre-treatment with agonist molecules resulted in concentration-related 
inhibition of PGD2 EC80 responses.  However, a range of non-agonist molecules also 
possessed inhibitory activity and in this chapter the behaviour of these molecules has 
been investigated using pharmacological methods.  Finally, a radioligand binding assay 
has been developed in order to shed light on the nature of the interaction of these 
molecules with the receptor. 
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7.3  Results: 
7.3.1  Calcium flux assay 
 
7.3.1.1  Inhibition of PGD2 EC80 by prostanoid molecules 
 
7.3.1.1.1  CHO GD16z49 cells without PTX treatment.   
The panel of prostanoid molecules screened for agonism in CHO GD16z49 hCRTH2 cells 
without PTX pre-treatment was  also screened for their ability to inhibit responses to an 
EC80 of PGD2 (D2EC80; Table 1; Figure 1).   PGD2 inhibited D2EC80 with a maximum 
inhibition (Imax) of 102 ± 0.3 %, pIC50 8.5 ± 0.07.  In contrast to the lack of agonism 
previously observed in 65 % of compounds, no inhibitory effect was only shown by 6 % 
of compounds.  Potent inhibitory effects were observed for prostanoid molecules of the 
A, E and Tx series (e.g. 11 dehydro TxB2, 19 (R) hydroxy PGA2, 19 (R) hydroxy PGE2 
& PGE2).  Inhibitory potency (pIC50) data correlated poorly with agonist potency 
(pEC50) data (Figure 2; correlation coefficient (r2) = 0.01).  For regression analysis, 
where compounds were inactive in the agonism (pEC50) data set, a value of 4.5 was 
assigned.  Therefore, the true r2 value is lower than 0.01.  However, when compounds 
devoid of agonism were removed from the data set, the correlation was greatly 
improved (r2 = 0.83).   Therefore compounds could be grouped into two sets: 1. 
Compounds whose pEC50 and pIC50 values correlated reasonably well, and 2. 
Compounds with divergent pEC50 and pIC50 values (highlighted in Table 1).  The rank 
order of inhibitory potency for the most active compounds (inhibitory potency, pIC50, 
relative inhibitory activity [RImax cf. PGD2 = 100]) was:  PGD2 (8.5) = 11 dehydro TxB2 
(8.3, 44) > '17 6 keto PGF1D (7.7, 14) > 19 R hydroxy PGA2 (7.5, 21) = PGE1 (7.4, 44) 
= PGE2 (7.4, 38) = PGE3 (7.3, 34) > 19 R hydroxy PGE2 (7.1, 35) > 19 R hydroxy 
PGF1D (6.9, 27) = 20 hydroxy PGE2 (6.8, 4) = 2,3 dinor 11E PGF2D (6.8, 18) = 15 R 19 
R hydroxy PGF2D (6.7, 23) = 13,14 dihydro PGE1  (6.7, 48) > 20 hydroxy PGF2D (6.6, 
14) = PGD3 (6.6, 73) = 13,14 dihydro 15 keto PGF2D (6.6, 27) = 15 deoxy PGD2 (6.5, 
94).  All non-agonist inhibitory compounds produced RImax values below 53 % cf. 
PGD2 except for 11 dehydro 2,3 dinor TxB2 (5.4, 86) and 15 R 19 R hydroxy PGE2 
(5.4, 93).  Conversely, all agonist inhibitory compounds produced RImax values above 
70 % cf. PGD2 except for PGF2D (5.6, 27). 
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7.3.1.1.2  CHO GD16z49 cells + PTX treatment.   
The same panel of molecules was screened for D2EC80 inhibition in CHO GD16z49 
hCRTH2 cells with PTX pre-treatment (Table 1; Figure 3).  Under these conditions, 
PGD2 inhibited D2EC80 with a maximum inhibition (Imax) of 91 ± 2 % and pIC50 7.9 ± 
0.3.  No inhibitory effect was shown by 26 % of compounds.  Inhibitory potency (pIC50) 
data correlated poorly with pEC50 data in the same cells (Figure 4; correlation 
coefficient (r2; excluding iloprost) = 0.19).  (As before, pXC50 = 4.5 was assigned to 
compounds devoid of agonism or inhibition so the true r2 is lower than 0.19).  Almost 
all of the compounds displaying potent inhibitory effects in the absence of PTX 
treatment only achieved a modest percentage inhibition of D2EC80 at the highest 
concentration tested (e.g. 11 dehydro TxB2, '17 6 keto PGF1D, 19 R hydroxy PGA2, 
PGE1, PGE2, PGE3 & 19 R hydroxy PGE2 and so on).  When the regression was 
repeated but only with compounds producing both pEC50 and pIC50 values, r2 = 0.58.  
Therefore compounds could be grouped into three sets:  
1. Compounds whose pEC50 and pIC50 values correlated reasonably well; 
2. Compounds with agonist activity but no inhibitory activity (i.e. possessing pEC50 but 
not pIC50 values); 
3. Compounds with inhibitory activity but no agonist activity (i.e. possessing pIC50 but 
not pEC50 values; highlighted in Table 1).   
A number of compounds appeared to enhance D2EC80 activity, however because the 
signal remaining after PTX treatment is so small, minor changes in response translate 
into large changes in percentage response; therefore, these small changes are unlikely to 
be biologically significant.  The rank order of inhibitory potency for the most active 
compounds (pIC50, RImax cf. PGD2 = 100) was: 15 R 15 methyl PGD2 (8.4, 76) > PGD2 
(7.9) > 13,14 dihydro 15 keto PGD2 (7.2, 46) > PGD3 (6.9, 105) = 15 deoxy PGD2 (6.8, 
115) = PGJ2 (6.7, 157) = 15 deoxy '12,14 PGJ2 (6.6, 69) > 9,10 dihydro 15 deoxy '12,14 
PGJ2 (6.2, 96) = 15 S 15 methyl PGD2 (6.0, 24) > '12 PGJ2 (5.9, 120) = 17 phenyl 
PGD2 (5.9, 120) = 15 keto PGF1D (5.9, 98) > 15 R PGF2D (5.6, 108). 
 
7.3.1.1.3  CHO K1 cells without PTX treatment.   
Finally, the panel of prostanoids was screened for D2EC80 inhibition in CHO K1 
hCRTH2 cells without PTX treatment (Table 1; Figure 5).  17 % of compounds were 
without inhibitory effect: these were often (but not always) the same molecules that 
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were without effect in CHO GD16z49 hCRTH2 cells without PTX treatment.  These data 
also did not correlate well with agonist pEC50 data generated in the same cell line (r2 = 
0.002; Figure 6).  Removal of non-agonist compounds from the data set resulted in an 
improved correlation but r2 was still low (0.35).  However, as with data generated in 
chimera-expressing cells without PTX treatment, compounds could be grouped into 
agonists with inhibitory activity and non-agonists with inhibitory activity (highlighted 
in Table 1).  The rank order of inhibitory potency for the most active compounds (pIC50, 
RImax cf. PGD2 = 100) was:  19 R hydroxy PGA2 (8.9, 52) > 11 dehydro TxB2 (8.7, 56) 
> 15 R 15 methyl PGD2 (8.4, 74) > PGD2 (8.0) > Iloprost (7.8, 79) =  PGE2 (7.7, 51) > 
PGA2 (7.2, 51) = 6 keto PGF1D (7.2, 53) = 20 hydroxy PGE2 (7.1, 89) = 13,14 dihydro 
PGF1D (7.0, 53) > 16,16 dimethyl PGD2 (6.8, 76) = 15 R 19 R hydroxy PGF1D (6.6, 48).  
Only 41 % of non-agonist inhibitory compounds produced RImax values below 55 % cf. 
PGD2; 36 % produced values above 70 %.  The greatest RImax value was observed for 
20 hydroxy PGE2 (89 ± 3).  However, as with chimera-expressing cells without PTX 
treatment, 70 % of agonist inhibitory compounds produced RImax values above 70 % cf. 
PGD2; 15 deoxy PGD2  produced an RImax value of 18 ± 3 %. 
Overall, twelve compounds were non-agonist inhibitors at hCRTH2 receptors in both 
CHO K1 and CHO GD16z49 cells (e.g. 11 dehydro TxB2, 13,14 dihydro 15 keto PGE1, 
19(R) hydroxy PGA2, PGA2 & PGE2).  However, a further group of twenty-seven 
diverse molecules were inhibitors only in the chimera-expressing cell line.  These 
molecules are listed in Figure 7.   
 
7.3.1.2  Analysis of competition  
Analysis of competition (Schild analysis) was performed on a group of thirteen 
molecules representing a spectrum of full and partial agonist, antagonist, and inhibitor 
activities (Table 2; Figures 8 & 9).  When added to cells, test compounds produced 
calcium mobilisation data in agreement with data reported in earlier chapters.  The 
exceptions to this were GW853481X, which when tested to 100 PM revealed weak 
partial agonist activity (vehicle was constant at 1 % DMSO), and PGD3, which was 
significantly more potent as an agonist than previously noted.  Because agonist 
exposure could produce an inhibition of subsequent agonist responses, it was possible to 
estimate an antagonist potency for agonist molecules.  Agonist and partial agonist pEC50 
values agreed well with pA2 estimates for most molecules; the values for GW853481X 
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did not agree: pEC50 was 1.4 (CHO K1) – 1.8 (CHO GD16z49) log units lower than pKb. 
The analyses revealed previously unrecognised antagonist activity in PGE2 and 13,14 
dihydro 15 keto PGE2, and inhibitor activity in 19 R hydroxy PGE2 and 19 R hydroxy 
PGA2.  The full agonists PGD3 and 17 phenyl PGD2 were not investigated any further. 
 
7.3.2  [35S]-guanosine triphosphate binding assay 
 
7.3.2.1  Single antagonist concentration pA2 determination 
The antagonist properties of a single concentration of the same set of molecules was 
profiled at hCRTH2 receptors in CHO K1 cells using [35S]-GTPJS binding (Table 3; 
Figure 10).  Indomethacin was a full agonist and could not be tested further.  
GW853481X was devoid of agonist effects to 10 PM and shifted the PGD2 E/[A] curve 
beyond the detectable range resulting in an affinity estimate of > 1 PM.  The affinity 
estimates and baseline elevations for 13,14 dihydro 15 keto PGF2D (pA2, baseline cf. 
PGD2 Emax: 5.6 ± 0.1; 49 ± 3 %), 15 R PGF2D (6.4 ± 0.1; 68 ± 4 %), PGF2D (5.8 ± 0.2; 
33 ± 0.7 %), 15 keto PGF2D (pA2 5.8 ± 0.2, 44 ± 2 %) and 15 keto PGF2D(pA2 6.1 ± 0.1, 
70 ± 2 %) were in agreement with their partial agonist activity previously observed in 
this system (Chapter 5).  The compounds PGE2 and 13,14 dihydro 15 keto PGE2 were 
devoid of agonist effects, as previously observed, but yielded pA2 estimates of 5.8 ± 0.2 
and 5.7 ± 0.06, respectively.  Finally, 19 R hydroxy prostaglandins A2, E2 & F2D were 
without effect.   
 
7.3.2.2  Analysis of competition 
Generally, the agonist potency of partial agonists (15 keto PGF2D, 15 keto PGF1D, 15 R 
PGF2D and 13,14 dihydro 15 keto PGF2D) was 0.5 log units lower in this assay than 
previously observed in this system (Table 3; Figure 11); PGF2Dwas inactive as an 
agonist; PGE2 demonstrated previously unobserved agonist properties (pEC50 5.1 ± 0.2, 
Emax 21 ± 3 %.  However, with the exception of 13,14 dihydro 15 keto PGF2Dwhen 
agonist molecules were tested for antagonist activity, antagonist potencies were 
commensurate with previously obtained agonist data (Table 3) and also agreed well 
with pA2 estimates generated from a single agonist concentration.  Where antagonist 
potencies were estimated, the values were 0.4-1.6 log units higher than the 
corresponding values generated in calcium mobilisation assays.  Complex antagonist 
 242
behaviour was shown by 13,14 dihydro 15 keto PGE2: no effect was observed up to 3 
PM; at 10 PM, responses to low concentrations of PGD2 were observed to shift right 
while high concentrations were unaffected, resulting in curve steepening; at 30 PM, 
curves were seen to be biphasic while at 100 PM curves were once again monophasic, 
right-shifted, and corresponded only to the first phase of the biphasic curve.  The 
affinity of 13,14 dihydro 15 keto PGE2 was therefore in the range: phase 1 - 5.5 to 5.0, 
phase 2 – 4.5 to 4.0.  Finally, 19 R hydroxy prostaglandins A2, E2 & F2D were without 
effect.  
 
7.3.3  [3H]-PGD2 filtration binding assay 
 
7.3.3.1  Method development  
In the following text, the data presented are in the order CHO K1 hCRTH2 membranes 
followed by CHO GD16z49 hCRTH2 membranes.  The relationship between membrane 
protein concentration and ligand binding (protein linearity) at 2.2 nM radioligand was 
found to be linear to 12.8 & 1.2 Pg well-1 membrane protein (Figure 12).  Estimates of 
BBmax derived from the protein linearity assay were 52 & 139 pmol mg .  Radioligand 
vehicle (15 % acetonitrile + 29 % methanol v v  in distilled water) inhibited 3.5 nM 
[ H]-PGD
-1
-1
3
2 binding in a concentration-dependent manner resulting in an IC50 of 3.3 % v 
v  (final assay volumes of vehicle mixture per volume of assay buffer; Figure 13).  
Assays were therefore designed to avoid vehicle effects but where this was not possible, 
i.e. saturation binding assays, data were corrected for vehicle effects.  Saturation 
binding data analysed by non-linear regression and linear Scatchard transformation are 
reported in Chapter 4.  Estimates of K
-1
d & Bmax were: 2.7 ± 2 nM, 3.6 ± 1.1 pmol mg ;  
2.3 ± 0.5 nM, 9.9 ± 2.9 pmol mg .  Association of radioligand with membranes was 
found to be essentially complete by 20 mins with some diminution of counts by 60 min 
(Figure 14); subsequent assays were performed using a 30 min equilibration time.  Total 
binding in wells at plate edges was c. 20 % lower than in other wells of the plate and 
were therefore not used. 
-1
-1
 
7.3.3.2  Prostanoid molecule competition binding  
Competition binding assays were performed using 2 nM radioligand concentration, and 
17 & 6 Pg well-1 membrane protein.  The amount of membrane used was based on the 
 243
BBmax estimates obtained by non-linear regression of saturation binding and was 
predicted to result in 17 & 15 % binding of radioligand to receptor in a 200 Pl reaction 
volume.  Recalculation based on the higher Bmax estimates indicates that 100 % ligand 
binding may occur at both membranes. 
Prostanoid molecules displaced [3H]-PGD2 from CHO K1 hCRTH2 membranes but the 
results were variable (Figure 15). Total binding at low concentrations of displacing 
agent (max binding) varied from row-to-row of the plate.  Data was therefore 
normalised to max binding in each row.  Within individual E/[A] curves, data was also 
variable creating the impression that curves were biphasic.  This was generally not a 
consistent finding for any given molecule and the relative contributions of the two 
phases varied from curve-to-curve.  Data was therefore analysed according to a single-
site model (Table 4).   
 
A comparison of the key data generated for the most extensively profiled compounds is 
shown in Table 4. 
 
7.3.4  Data Tables 
Follow on next page. 
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Table 1. Inhibition of Prostaglandin D2 (PGD2) EC80 by prostanoid molecules in CHO K1 hCRTH2 cells and CHO GD16z49 hCRTH2 cells with 
and without pertussis toxin (PTX) treatment.  Data for compounds which did not elicit agonist calcium mobilisation responses are underlined; an 
asterisk denotes compounds that produced agonist effects but no inhibition.  Data are mean ± sem of four independent assay occasions. 
 CHO GD16z49 hCRTH2 CHO K1 hCRTH2
 -PTX +PTX  
Compound pIC50 RImax pIC50 RImax pIC50 RImax
15 (R) 15 methyl PGD2 - - 8.4 ± 0.2 76 ± 20 8.4 ± 0.1 74 ± 0.4 
PGD2 8.5 ± 0.07 100 7.9 ± 0.3 100 8.0 ± 0.04 100 
15 (R) 15 methyl PGF2D - - - NSE - 44 ± 6 
15 deoxy PGD2 6.5 ± 0.06 94 ± 3 6.8 ± 0.06 115 ± 20 5.6 ± 0.04 18 ± 3 
PGJ2 6.2 ± 0.05 90 ± 5 6.7 ± 0.12 157 ± 2 6.3 ± 0.04 71 ± 6 
15 deoxy '12,14 PGJ2 6.0 ± 0.06 79 ± 6 6.6 ± 0.3 69 ± 9 6.3 ± 0.1 78 ± 3 
15 (S) 15 methyl PGD2 - - 6.0 ± 0.1 24 ± 11 5.9 ± 0.03 75 ± 1 
13,14 dihydro 15 keto PGD2 6.0 ± 0.05 101 ± 4 7.2 ± 0.4 46 ± 20 6.3 ± 0.1 73 ± 3 
'12 PGJ2 5.7 ± 0.06 86 ± 3 5.9 ± 0.1 120 ± 10 5.5 ± 0.3 68 ± 12 
9,10 dihydro 15 deoxy '12,14 PGJ2 5.8 ± 0.09 79 ± 5 6.2 ± 0.06 96 ± 20 5.9 ± 0.02 72 ± 1 
17 phenyl PGD2 5.7 ± 0.06 89 ± 8 5.9 ± 0.3 120 ± 15 5.6 ± 0.03 82 ± 3 
PGD3 6.6 ± 0.17 73 ± 15 6.9 ± 0.2 105 ± 13 - 16 ± 11 
15 keto PGF2D 5.6 ± 0.06 92 ± 8 - 94 ± 28 5.4 ± 0.1 65 ± 4 
PGD1 5.5 ± 0.06 89 ± 4 7.2 ± 1.5 106 ± 21 5.8 ± 0.1 64 ± 1 
15 (R) PGF2D 5.1 ± 0.03 91 ± 2 5.6 ± 0.01 108 ± 8 5.4 ± 0.1 64 ± 6 
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16,16 dimethyl PGD2 5.2 ± 0.04 84 ± 5 - 44 ± 21 6.8 ± 0.03 76 ± 3 
15 keto PGF1D - 47 ± 9 5.9 ± 0.1 98 ± 22 5.3 ± 0.02 64 ± 3
PGF2D 5.6 ± 0.1 27 ± 1 - -39 ± 11 - 48 ± 3 
Butaprost methyl ester - - - -18 ± 8 5.0 ± 0.04 82 ± 2
Latanoprost - - - 80 ± 2 - 36 ± 6 
Cloprostenol - - - -45 ± 3 5.2 ± 0.2 72 ± 7
Misoprostol - - - -59 ± 50 - -16 ± 8 
15 (S) 15 methyl PGF2D - - - 45 ± 7 4.9 ± 0.1 59 ± 2
13,14 dihydro 15 keto PGF2D 6.6 ± 0.5 27 ± 6 - 44 ± 12 - 48 ± 10 
11 deoxy 11 methylene PGD2 5.6 ± 0.1 32 ± 9 - 15 ± 6 - 33 ± 8 
PGF3D 5.5 ± 0.2 34 ± 5 - 67 ± 10 5.5 ± 0.1 65 ± 3
11 dehydro TxB2 8.3 ± 0.5 29 ± 3 - -24 ± 6 8.7 ± 0.1 56 ± 3
15 (R) 19 (R) hydroxy PGF2D 6.7 ± 0.2 23 ± 1 - NSE - NSE 
13,14 dihydro PGE1 6.7 ± 0.2 48 ± 5 - 30 ± 10 - 27 ± 4 
PGE3 7.3 ± 0.3 34 ± 4 - NSE - 20 ± 4 
20 hydroxy PGF2D 6.6 ± 0.2 14 ± 3 - 45 ± 14 - 19 ± 3 
13,14 dihydroxy 15 keto PGA2 5.7 ± 0.3 25 ± 4 - NSE - 20 ± 3 
6 keto PGF1D 5.6 ± 0.2 19 ± 1 - 35 ± 13 7.2 ± 0.03 53 ± 5
6 keto PGE1 6.2 ± 0.1 51 ± 9 - -28 ± 5 5.4 ± 0.04 68 ± 2
'17 6 keto PGF1D 7.7 ± 0.4 14 ± 3 - -33 ± 13 - 12 ± 2 
PGA2 6.3 ± 0.5 27 ± 6 - NSE 7.2 ± 0.1 51 ± 7
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15 (R) PGE2 5.8 ± 0.4 24 ± 6 - NSE - 28 ± 2 
PGF1D 5.5 ± 0.06 53 ± 15 - -27 ± 5 - 10 ± 2 
PGA1 5.9 ± 0.06 25 ± 3 - NSE 6.4 ± 0.1 45 ± 0.4
13,14 dihydro PGF1D - 21 ± 1 - 19 ± 2* 7.0 ± 0.03 53 ± 5
13,14 dihydro 15 keto PGE2 5.6 ± 0.1 21 ± 9 - 23 ± 6 5.6 ± 0.1 61 ± 0.4
13,14 dihydro 15 keto PGF1D 5.8 ± 0.4 26 ± 18 - 46 ± 12 - 29 ± 6 
PGE1 7.4 ± 0.2 44 ± 4 - -33 ± 4* - NSE 
15 keto PGE1 5.8 ± 0.4 28 ± 4 - 34 ± 9 - 17 ± 6 
19 (R) hydroxy PGF1D 6.9 ± 0.7 27 ± 9 - NSE - NSE 
PGD1 alcohol - NSE - NSE* - 19 ± 4 
15 (R) 15 methyl PGE2 5.3 ± 0.2 37 ± 6 - NSE - NSE 
PGI2 5.3 ± 0.3 15 ± 5 - - - - 
15 (R) 19 (R) hydroxy PGF1D - NSE - NSE 6.6 ± 0.7 48 ± 29
13,14 dihydro 15 keto PGE1 5.7 ± 0.2 23 ± 6 - NSE 6.2 ± 0.3 51 ± 3
13,14 dihydro 15 (R) PGE1 5.6 ± 0.1 32 ± 3 - 35 ± 12 - 17 ± 5 
11 dehydro 2,3 dinor TxB2 5.4 ± 0.3 86 ± 2 - 18 ± 4 - 25 ± 6 
19 (R) hydroxy PGA2 7.5 ± 0.5 21 ± 6 - NSE 8.9 ± 0.1 52 ± 6
TxB2 - NSE - 29 ± 8 - NSE 
15 (R) 19 (R) hydroxy PGE2 5.4 ± 0.3 93 ± 6 - -51 ± 18 - NSE 
PGK1 5.9 ± 0.4 26 ± 2 - NSE - 17 ± 8 
15 keto PGE2 5.4 ± 0.3 24 ± 3 - NSE - NSE 
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20 hydroxy PGE2 6.8 ± 0.4 40 ± 7 - -27 ± 6 7.1 ± 0.03 89 ± 3
15 (R) PGE1 5.6 ± 0.3 33 ± 8 - 36 ± 8 - 57 ± 4 
11E 13,14 dihydro 15 keto PGF2D - 15 ± 6 - 38 ± 4 - NSE 
19 (R) hydroxy PGF2D 5.8 ± 0.4 32 ± 8 - 14 ± 7 - 46 ± 5 
19 (R) hydroxy PGE2 7.1 ± 0.7 35 ± 8 - 29 ± 20 6.2 ± 0.03 85 ± 5
2,3 dinor 11E PGF2D 6.8 ± 0.3 18 ± 2 - NSE* - 15 ± 3 
PGK2 - NSE - 28 ± 6 - NSE 
PGI3 5.6 ± 0.2 22 ± 4 - -41 ± 2 6.2 ± 0.04 77 ± 5
PGE2 7.4 ± 0.3 38 ± 3 - 55 ± 23 7.7 ± 0.1 51 ± 6
19 (R) hydroxy PGE1 5.6 ± 0.1 30 ± 7 - NSE - NSE 
PGB2 - 34 ± 10 - 33 ± 7 - 48 ± 6 
11deoxyPGE1 - - - -61 ± 17* - NSE 
Cicaprost - - - NSE - NSE 
Sulprostone - - - 33 ± 16 - 25 ± 10 
BW245C - - - NSE - 17 ± 5 
Butaprost free acid - - - -28 ± 10 - NSE 
17 phenyl PGE2 - - - NSE 4.9 ± 0.04 71 ± 1
16,16 dimethyl PGE2 - - - -24 ± 2 5.0 ± 0.1 71 ± 7
Iloprost - - 10.2 ± 0.1 -30 ± 12 7.8 ± 0.02 79 ± 4
Indomethacin 5.6 ± 0.06 98 ± 6 5.6 ± 0.3 107 ± 18 5.7 ± 0.03 83 ± 2 
GW853481X 6.1 ± 0.2 72 ± 7 6.4 ± 0.3 106 ± 8 5.5 ± 0.04 77 ± 3
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Table 2.  Summary of calcium mobilisation competition analysis (Schild analysis) data in CHO GD16z49 hCRTH2 and CHO K1 hCRTH2 cells.  
Data are presented describing the effect of test compound (antagonist) on the cells (1st addition) and the subsequent effect of the test compounds 
on PGD2 E/[A] curves (2nd addition).  Data are mean ± sem of 3 independent experiments.  GW853481X was included as a positive control.  
Terms in table are: pEC50 – negative log concentration producing 50 % of a maximal effect determined by curve fitting; Emax – curve asymptote 
at maximal effect; Emaxp - depression of agonist E/[A] curve maximum effect; pKb – antagonist affinity determined by non-linear regression of Schild 
analysis data; pA2 - antagonist affinity estimate  from effect of a single antagonist concentration.* - no antagonist affinity estimate generated.  
E.g, addition of GW853481X to CHO GD16z49 hCRTH2 cells produced low potency agonism (pEC50 4.5 ± 0.1, Emax 5 ± 3 %); following 
incubation (11 min 37 ºC) the same cells were challenged with PGD2 E/[A] curves, each curve being generated in the presence of a fixed 
concentration of test compound; under these conditions, GW853481X antagonised PGD2 E/[A] curves resulting in a pKb estimate of 6.3 ± 0.16. 
 
Compound Addition CHO GD16z49 hCRTH2 CHO K1 hCRTH2
GW853481X 1st pEC50 4.5 ± 0.1; Emax 5 ± 3 % pEC50 4.6 ± 0.15; Emax 11 ± 4 % 
 2nd No inhibition of PGD2 Emax ; pKb 6.3 ± 0.16 No inhibition of PGD2 Emax ; pKb 6.0 ± 0.17 
Non-receptor mediated agonism? 
Indomethacin 1st - pEC50 6.4 ± 0.2; Emax 83 ± 12 % 
 2nd - PGD2 Emax depressed; pA2 6.1 ± 0.1 
Partial agonist 
PGD3 1st - pEC50 6.3 ± 0.2; Emax 117 ± 9 % 
 2nd - PGD2 Emax depressed; pA2 6.7 ± 0.1 
Full agonist 
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17 phenyl PGD2 1st - pEC50 6.2 ± 0.2; Emax 101 ± 6 % 
 2nd - PGD2 Emax depressed; pA2 6.0 ± 0.1 
Full agonist 
15 R 15 methyl PGF2D 1st - pEC50 5.7 ± 0.1; Emax 64 ± 9 % 
 2nd - PGD2 Emax depressed; pA2 5.7 ± 0.1 
Partial agonist 
15 R PGF2D 1st - pEC50 5.0 ± 0.2; Emax 66 ± 12 % 
 2nd - PGD2 Emax depressed; pA2 5.2 ± 0.1 
Partial agonist 
13,14 dihydro 15 keto PGF2D 1st pEC50 5.1 ± 0.2; Emax 40 ± 8 % pEC50 4.8 ± 0.2; Emax 40 ± 11 % 
 2nd PGD2 Emax depressed; pA2 5.0 ± 0.1 
Partial agonist 
PGD2 Emax depressed; pA2 5.2 ± 0.1 
Partial agonist 
PGF2D 1st pEC50 5.1 ± 0.1; Emax 40 ± 6 % pEC50 4.7 ± 0.2; Emax 51 ± 8 % 
 2nd PGD2 Emax depressed; pA2 5.0 ± 0.03 
Partial agonist 
PGD2 Emax depressed *. 
Partial agonist 
13,14 dihydro 15 keto PGE2 1st NSE NSE 
 2nd pA2 5.2 ± 0.2 
Antagonist 
pA2 5.2 ± 0.1 
Antagonist 
PGE2 1st 
 
NSE 
 
NSE 
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PGE2 (contd.) 2nd pA2 5.2 ± 0.2 
Antagonist 
pA2 4.9 ± 0.2 
Antagonist 
19 R hydroxy PGE2 1st NSE NSE 
 2 PGDnd 2 Emax 20 ± 5 % p @ 30 PM; no pEC50 shift PGD2 Emax 22 ± 7 % p @ 30 PM; no pEC50 shift 
  Inhibitor Inhibitor 
19 R hydroxy PGA2 1st NSE NSE 
 2nd PGD2 Emax 20 ± 8 % p all curves cf. control; 
no pEC50 shift. 
PGD2 Emax 26 ± 9 % p all curves cf. control; 
no pEC50 shift. 
  Inhibitor Inhibitor 
19 R hydroxy PGF2D 1st NSE NSE 
 2nd NSE NSE 
  Inactive Inactive 
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Table 3.  Summary of [35S]-GTPJS competition analysis (Schild analysis) data and single antagonist concentration shift (Single Conc) data in 
CHO GD16z49 hCRTH2 and CHO K1 hCRTH2 cells.  Data are presented for effect of test compound on basal activity (agonism) and the 
subsequent effect of the test compounds on PGD2 E/[A] curves (antagonism).  Data are mean ± sem of 3 independent experiments.  Terms in 
table are: pEC50 – negative log concentration producing 50 % of a maximal effect determined by curve fitting; Emax – curve asymptote at 
maximal effect; Emaxp - depression of agonist E/[A] curve maximum effect; pKb – antagonist affinity determined by non-linear regression of 
Schild analysis data; pA2 - antagonist affinity estimate derived from effect of a single antagonist concentration. 
 
 
Compound Property Single Conc. Schild analysis 
GW853481X Agonism NSE NSE 
 Antagonism pA2 > 6.0 pA2 7.6 ± 0.1; curve shift too great at concentrations 
used to test effects on PGD2 Emax
AH23848B Agonism - NSE 
 Antagonism - pKb 6.9 ± 0.2; PGD2 Emax no effect 
15 keto PGF1D Agonism Basal 44 ± 2 % pEC50 5.7 ± 0.1; Emax 35 ± 4 % 
 Antagonism pA2 5.8 ± 0.2 pA2 5.9 ± 0.1; PGD2 Emax p 
15 keto PGF2D Agonism Basal 70 ± 2 % pEC50 5.7 ± 0.1; Emax 57 ± 3 % 
 Antagonism pA2 6.1 ± 0.1 pA2 6.3 ± 0.1; PGD2 Emax p 
15 R PGF2D Agonism Basal 68 ± 4 % pEC50 6.0 ± 0.1; Emax 37 ± 5 % 
 Antagonism pA2 6.4 ± 0.1 pA2 6.2 ± 0.1; PGD2 Emax p 
 252 
13,14 dihydro 15 keto PGF2D Agonism Basal 49 ± 3 % pEC50 5.4 ± 0.2; Emax 47 ± 4 % 
 Antagonism pA2 5.6 ± 0.1 pA2 5.2 ± 0.1; PGD2 Emax no effect 
PGF2D Agonism Basal 33 ± 0.7 % pEC50 5.1 ± 0.2; Emax 21 ± 3 % 
 Antagonism pA2 5.8 ± 0.2 pA2 5.6 ± 0.1; PGD2 Emax non sig. p 
13,14 dihydro 15 keto PGE2 Agonism NSE NSE 
 Antagonism pA2 5.7 ± 0.08 Complex, biphasic; phase 1 5.5-5.0; phase 2 4.5-4.0 
PGE2 Agonism NSE NSE 
 Antagonism pA2 5.8 ± 0.2 pKb 5.6 ± 0.3; PGD2 Emax no effect 
19 R hydroxy PGE2 Agonism NSE NSE 
 Antagonism NSE NSE 
19 R hydroxy PGA2 Agonism NSE NSE 
 Antagonism NSE NSE 
19 R hydroxy PGF2D Agonism NSE NSE 
 Antagonism NSE NSE 
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Table 4.  Key data for selected prostanoid molecules generated in calcium mobilisation & [35S]-GTPJS accumulation (functional) assays, and in 
[3H]-PGD2 competition binding assays.   Terms are: pEC50 / pIC50 – negative log concentration producing 50 % of a maximal effect determined 
by curve fitting; Emax / Imax – curve asymptote at maximal effect, or if curve-fitting not possible, the maximum effect at the highest concentration 
tested; both cases E - agonism, I - inhibition, R - relative to PGD2 max effect;  AOC – analysis of competition by the method of Schild (C – 
competitive, NC – non-competitive, PA – partial agonist, Emaxp or n - depression or elevation of agonist maximum effect; NSt – no curve shift); 
pKb – antagonist affinity determined by non-linear regression of Schild analysis data; pA2 - antagonist affinity estimate derived from effect of a 
single antagonist concentration;* - no estimation of antagonist affinity generated.   
Assay type Calcium mobilisation [35S]-GTPJS accumulation [3H]-PGD2 
competition binding 
Biological system CHO GD16z49 hCRTH2 cells CHO K1 hCRTH2 cells CHO K1 hCRTH2 membranes 
 pEC50, 
REmax
pIC50, 
RImax
AOC pEC50, 
Emax
pIC50, 
RImax
AOC pEC50, 
Emax
pA2 AOC pIC50, Imax
Agonists 
PGD2 7.8, 1.0 8.5, 1.0 - 7.9, 1.0 8.0, 1.0 - 8.1, 1.0 - - 7.4, 0.92 
Indomethacin -, 0.58 5.6, 0.98 - 6.9, 0.84 5.7, 0.83 pA2 6.1, PA 6.4, 1.13 - - 7.5, 0.65 
Partial Agonists 
17 phenyl PGD2 6.2, 1.22 5.7, 0.89 - 5.9, 0.86 5.6, 082 pA2 6.0, PA 6.2, 1.11 - - 6.7, 0.87 
15 keto PGF2D 6.0, 0.73 5.6, 0.98 - 5.4, 0.58 5.4, 0.65 - 6.1, 0.62 6.1 pA2 6.3; PA 7.1, 0.92 
15 keto PGF1D 5.6, 0.28 -, 0.47 - -, 0.16 5.3, 0.63 - 6.2, 0.37 5.8 pA2 5.9, PA 6.7, 0.90 
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15 R PGF2D 5.5, 0.55 5.1, 0.92 - 5.5, 0.73 5.4, 0.64 pA2 5.2, PA 6.3, 0.54 6.4 pA2 6.2, PA 7.9, 0.89 
PGF2D -, 0.17 5.6, 0.27 pA2 5.0; PA -, 0.54 -, 0.48 pEC50 4.7, PA* 5.5, 0.48 5.8 pA2 5.6, PA 6.7, 0.88 
13,14 dihydro 15 keto PGF2D -, 0.12 6.6, 0.27 pA2 5.0; PA NSE -, 0.48 pA2 5.2; PA 6.0, 0.39 5.6 pA2 5.2, PA 6.1, 0.96 
Antagonists 
AH23848B NSE -, 0.24 pKb 5.6, C NSE 6.2, 1.0 pA2 5.5, C - - pKb 6.9, C 6.7, 0.79 
GW853481X NSE 6.1, 0.72 pKb 6.3, C NSE 5.5, 0.77 pKb 6.0, C - >6 pKb 7.6, NC 7.4, 0.90 
13,14 dihydro 15 keto PGE2 NSE 5.6, 0.21 pA2 5.2 NSE 5.6, 0.61 pA2 5.2 NSE 5.7 Complex 6.1, 0.78 
Calcium mobilisation inhibitors 
19 R hydroxy PGA2 NSE 7.5, 0.21 NSt; 20% Emax p NSE 8.9, 0.52 NSt; 26% Emax p NSE NSE NSE 7.1, 0.71 
19 R hydroxy PGE2 NSE 7.1, 0.35 NSt; 20% Emax p NSE 6.2, 0.85 NSt; 22% Emax p NSE NSE NSE 6.0, 0.78 
19 R hydroxy PGF2D NSE 5.8, 0.32 NSE NSE -, 0.46 NSE NSE NSE NSE No fit 
11 dehydro TxB2 NSE 8.3, 0.29 - NSE 8.7, 0.56 - NSE - - - 
PGE2 NSE 7.4, 0.38 pA2 4.9 NSE 7.7, 0.51 pA2 5.2 NSE 5.8 pKb 5.6, C 6.5, 0.88 
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7.4  Discussion: 
Agonist activation of hCRTH2 receptors results in desensitisation of the receptor, as 
described in Chapter 6.  Under these circumstances, the pIC50 of PGD2 EC80 inhibition 
approximates the agonist pEC50 for both full (PGD2) and partial (15 keto PGF2D) 
agonists.  Profiling of a range of prostanoid agonists confirmed that this was so for all 
molecules possessing agonist activity but also revealed inhibitory activity in non-
agonist molecules.  This was presumed to herald antagonist affinity for the receptor but 
analyses of antagonist competition (Schild analyses) demonstrated that non-agonist 
inhibitors did not shift PGD2 E/[A] curves.  Indeed, some compounds were inhibitors 
only in hCRTH2-expressing CHO GD16z49 cells or  CHO K1 cells (but not both) 
suggesting that they were not simple competitive antagonists at the receptor and that the 
observed inhibition was related to a cellular process.  Furthermore, whereas agonists 
typically elicited greater than 70 % maximum inhibition of PGD2 EC80 responses, non-
agonist molecules typically only produced less than 50 % inhibition, suggesting 
differences in the mechanism of inhibition.  Non-agonist compounds inhibiting PGD2-
stimulated calcium mobilisation in both cell types were devoid of antagonist activity in 
GTPJS assays ruling out other solely receptor-based modes of antagonism such as 
allosteric inhibition and underlining the need for a whole-cell system in order to observe 
these phenomena.  It seems unlikely that the highly polar prostanoid molecules would 
be able to cross the plasma membrane but even if they did, non-specific modes of 
inhibition such as Fluo-3 quenching & calcium inhibition, and non-receptor based 
modes of action such as PLCE inhibition, would lead to the same degree of inhibition in 
both cell types since calcium coupling has been shown to be the same in both cell types 
(but could easily be ruled out by testing for activity against a non-prostanoid receptor in 
the same cells such as purinergic P2Y2 receptors).   
A possible explanation for these observations is receptor-mediated stimulation of a 
process independent of the G-protein mediated agonist effects I have studied.  As 
suggested in Chapter 6, this may involve activation of GRK’s 5 & 6 or E-arrestin 
recruitment.  Data generated in chimera-expressing cells following PTX treatment were 
variable as a result of the small signal size and so it is not possible to discuss the relative 
contributions of GDi/o and GD16z49 systems to the observed phenomena.  However, the 
data do suggest that molecules have differential ability to inhibit hCRTH2 receptor 
mediated agonism in chimera- and non-chimera- expressing cells which may relate to 
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differential GRK expression or activation.  Indeed, as noted in Chapter 6, receptor 
desensitisation appears to involve a non-G-protein mediated process at low agonist 
concentrations and a G-protein-mediated process at higher concentrations related to the 
magnitude of calcium mobilisation responses; the partial inhibition by non-agonist 
molecules may relate to the first phase of inhibition.  Because the potential exists for at 
least three molecules to be involved in non-G-protein mediated inhibition (GRKs 5, 6 & 
E-arrestin) the differing degrees of inhibition observed may represent differential 
recruitment of these molecules or of G-protein recruited molecules. 
A much wider range of prostanoid molecule structures were capable of eliciting 
response inhibition than were capable of eliciting G-protein mediated agonism.  Whilst 
this clearly indicates that the structural requirements for triggering the inhibitory 
response are less stringent than those for stimulating ‘agonism’, the relationship of the 
pharmacophoric contact points for each response in 3-D space is unknown and cannot 
be deduced from these data.  The binding pocket could be identical with differing 
degrees of conformational change underlying the differential responses observed.  
Alternatively, different amino acid residues could be contacted by different molecules.  
Indeed, non G-protein responses could be mediated by binding to a completely distinct 
site either with or without allosteric interaction with the G-protein activating binding 
site.  Whilst saturation binding detected a single population of binding sites, 
competition binding curves were frequently bi- or multi- phasic but deficiencies in the 
binding method used casts doubt on the validity of this observation (see below).  
Nonetheless, the ability of other prostanoid molecules such as PGE2 and the stable 
thromboxane metabolite 11 dehydro TxB2 to inhibit PGD2-mediated receptor activation 
adds another level of complexity to the regulation of this receptor pathway in vivo and 
provides a means by which endogenous synthesis of the non-agonist PGE2 by CHO 
cells can lead to the observed inhibition of CRTH2 mediated responses in these cells 
(see Chapter 3).  Interestingly, 11 dehydro TxB2 has been the subject of an earlier paper 
describing full agonist properties of the molecule in human eosinophils and basophils 
(Böhm, et al., 2004), whereas in the present studies it was devoid of agonist effect but 
possessed inhibitory properties.  The system studied by Böhm involved non PTX-
sensitive calcium mobilisation by hCRTH2 receptors endogenously expressed in these 
granulocytes which the authors attribute to GDq/11 activation but which could 
conceivably involve GDz activation (but see Chapter 4: GDz coupling is unlikely in 
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CHO cells).  Therefore, this molecule may possess a dramatic ability to create trafficked 
agonist stimuli and should be investigated further.  
A larger number of molecules were able to inhibit PGD2 EC80 responses in chimera-
expressing cells than in CHO K1 cells.  This may relate to disruption of synergistic 
interactions between GD16z49 and GEJi/o mediated response pathways in these cells, as 
discussed in Chapter 6, though the mechanism by which this might take place is 
unclear.  Indeed, the non PTX-sensitive calcium mobilisation observed by Böhm, et al. 
(2004), may suggest that this receptor can couple to, and therefore synergise with, 
GDq/11 under normal physiological conditions.  It was also noted in Chapter 3 that a 
calcium-coupled EP prostanoid receptor may be expressed in these cells raising the 
possibility that agonism of this receptor might lead to inhibition of the hCRTH2 
response pathway (heterologous desensitisation).  Simple intervention with receptor 
antagonists for prostanoid EP1 (e.g. AstraZeneca’s ZD6416; Sarkar, et al., 2003) and 
EP3 (e.g. Merck’s L-798,106; Juteau, et al., 1999) receptors would shed light on this 
question.  However, it does seem likely that the lower maximal inhibitions observed in 
the chimera-expressing cell line are due to weaker functional inhibition of the GD16z49 / 
GEJi/o synergy-amplified agonist responses in this cell line. 
Agonist potencies and antagonist affinities were consistently higher in [35S]-GTPJS 
assays compared to the corresponding calcium mobilisation assays.  This had previously 
been noted for GW853481X and AH23848B in Chapter 4 and an attribution to 
pathway-dependent affinity was postulated.  In the light of the present data, however, it 
seems more probable that compound affinity has been influenced by assay 
methodology, perhaps because of the inclusion of saponin to facilitate passage of 
compounds into membrane vesicles.  However, 13,14 dihydro 15 keto PGE2, which has 
been characterised as an antagonist of hCRTH2 receptors, displayed complex behaviour 
in Schild analysis commensurate with an interaction at two sites. Further 
experimentation is required to determine if this is a real effect, and if so, what it 
signifies.  One possibility is that because the assay methodology was optimised for the 
detection of agonism, inverse agonist properties have been missed and this should also 
be investigated. 
The binding assay data generated here is a useful indicator of an interaction with the 
receptor but cannot be relied upon to provide quantitative information because of 
deficiencies in the method employed.  Following the detection of a profound vehicle 
 258
effect, [3H]-PGD2 saturation binding assays had to be restricted to a low concentration 
range.  This failed to achieve full saturation of the receptor and may have missed the 
lower agonist affinity receptor population observed by Sawyer, et al (2002), and  
predicted here by back-calculation from protein linearity data.  Accurate estimation of 
BBmax is therefore impossible under the conditions employed but is likely to be 
substantially larger than the values calculated from saturation data.  Allowing for a 50 
% error on the estimates calculated from the protein linearity data, there could be more 
than enough protein to completely bind all of the available radioligand, leading to 100 
% depletion and marked under-estimation of competing ligand affinity.  As suggested 
above, and also by Mathiesen, et al. (2005), multiple binding sites may exist on this 
receptor which would further obscure estimation of receptor expression and could 
complicate displacement curve generation through allosteric interaction.  Another 
possible explanation involves the impact of receptor occupation by two agonists with 
differing efficacy for the reciprocal interaction between receptor and G-protein (Costa, 
et al., 1992).  As noted in chapter 6, there are several aspects of the pharmacology of 
this receptor that would be consistent with the presence of two (or more) binding sites.  
One puzzling aspect of the binding data is the observation of high affinity for almost all 
compounds tested irrespective of their functional potencies.  While there is no a priori 
reason to expect a correlation, a trend often emerges, but that was not the case here.  
Initially taken to represent a methodological deficiency, this phenomenon may also be 
evident in the data presented by Sawyer et al., (2002) in which 13,14 dihydro 15 keto 
PGF2D is a high affinity displacer of [ H]-PGD3 2 (pKi 8.5) but a low potency agonist in a 
cAMP inhibition assay (pEC50 6.2).  Therefore the present data may indicate a true 
phenomenon but for the reasons given above, and the observed high variability of 
binding assay data, definitive data from a re-developed assay using either [ I]-PGD125 2 
or, preferably, an iodinated antagonist radioligand, should be generated.  Other 
improvements could include performing the reaction at 4 ºC, increasing the ligand 
concentration (cut with cold ligand if iodinated versions are employed), reducing the 
membrane concentration, increasing the reaction volume, re-dissolving the radioligand 
in a more benign vehicle, and reformatting the assay to use scintillation proximity assay 
(SPA) technology.  However, these considerations aside, it does appear that PGD2 is 
displaced from the receptor by non-agonist inhibitors (i.e. molecules devoid of agonist 
activity but which inhibit D2EC80 responses), that displacement curves may be bi- or 
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multi-phasic, and that the maximum displacement achieved may be partial in some 
cases.  The exact nature of the affinity, phases and kinetics of ligand interaction is one 
of the key questions remaining and is vital to a full understanding of the behaviour of 
this receptor. 
Overall, while non G-protein mediated, receptor-stimulated receptor desensitisation has 
not been proven, it remains an attractive explanation for the ability of non-‘agonist’ 
molecules to inhibit PGD2 EC80 responses in cell-based, but not membrane-based, 
systems.  Alternatively, these data may point to binding site or coupling pathway 
dependent signalling and molecules such as these provide another means by which this 
intriguing chemoattractant receptor can be regulated in physiological and pathological 
situations.  Finally, an exciting avenue of research has been opened and further 
experimentation is clearly warranted: greater definition of the nature of the interaction 
these molecules have with the receptor, and measurement or visualisation of changes in 
cell-surface receptor behaviour are obvious targets.  Whilst an antagonist of this 
receptor is unlikely to provide a ‘wonder-drug’, the arrival of CRTH2 in the family of 
GPCRs and an understanding of the pleiotropic response pathways this receptor 
stimulates may herald a re-definition of the term ‘polypharmacology’ and ultimately 
lead to the search for agents with selectivity at the stimulus trafficking level. 
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7.5  Figure caption list: 
Figure 1. Inhibition of PGD2 EC80 by prostanoid molecules in calcium mobilisation 
assay using CHO GD16z49 hCRTH2 cells.  Data are mean ± sem of three independent 
experiments. 
 
Figure 2.  Correlation plot of agonist and inhibitor potencies for prostanoid molecules in 
calcium mobilisation assays using CHO GD16z49 hCRTH2 cells.  Data are mean ± sem of 
three independent experiments.  Terms are: pEC50 – negative log of the agonist 
concentration required to elicit 50 % of the maximum effect to that agonist; pIC50 - 
negative log of the inhibitor concentration required to elicit 50 % of the maximum 
inhibition by that agonist; in both cases parameters determined by curve fitting.  Dashed 
line indicates perfect 1:1 correlation. 
 
Figure 3. Inhibition of PGD2 EC80 by prostanoid molecules in calcium mobilisation 
assay using CHO GD16z49 hCRTH2 cells following pertussis toxin (50 ng ml-1) 
treatment.  Data are mean ± sem of three independent experiments. 
 
Figure 4.  Correlation plot of agonist and inhibitor potencies for prostanoid molecules in 
calcium mobilisation assays using CHO GD16z49 hCRTH2 cells following pertussis toxin 
(50ng ml-1) treatment.  Data are mean ± sem of three independent experiments.  Terms 
are: pEC50 – negative log of the agonist concentration required to elicit 50 % of the 
maximum effect to that agonist; pIC50 - negative log of the inhibitor concentration 
required to elicit 50 % of the maximum inhibition by that compound; in both cases 
parameters determined by curve fitting.  Dashed line indicates perfect 1:1 correlation. 
 
Figure 5. Inhibition of PGD2 EC80 by prostanoid molecules in calcium mobilisation 
assay using CHO K1 hCRTH2 cells following pertussis toxin (50 ng ml-1) treatment.  
Data are mean ± sem of three independent experiments. 
 
Figure 6.  Correlation plot of agonist and inhibitor potencies for prostanoid molecules in 
calcium mobilisation assays using CHO K1 hCRTH2 cells following pertussis toxin (50 
ng ml-1) treatment.  Data are mean ± sem of three independent experiments.  Terms are: 
pEC50 – negative log of the agonist concentration required to elicit 50 % of the 
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maximum effect to that agonist; pIC50 - negative log of the inhibitor concentration 
required to elicit 50 % of the maximum inhibition by that compound; in both cases 
parameters determined by curve fitting.  Dashed line indicates perfect 1:1 correlation. 
 
Figure 7.  Venn diagram depicting the incidence of non-agonist inhibitory prostanoid 
molecules (i.e. Molecules possessing inhibitory activity but not possessing agonist 
activity) in CHO GD16z49 - (lower region) and CHO K1 - (upper region) hCRTH2 cells.  
Overlapping area shows molecules displaying this behaviour in both cell types. 
 
Figure 8.  Analysis of competition (Schild analysis) of representative compounds at 
hCRTH2 receptors expressed in CHO GD16z49 cells, and (inset) agonist activity of test 
compounds determined in the same assay, using a calcium mobilisation assay.  Upper 
two panels (PGF2D and 13,14 dihydro 15 keto PGF2D) are partial agonists; middle two 
panels (GW853481X and 13,14 dihydro 15 keto PGE2) are antagonists; lower two 
panels (19 R hydroxy PGA2 and PGE2) are inhibitors which do not possess agonist 
activity.  Data are mean ± sem of three independent experiments.  Key to symbols in all 
panels:  vehicle, ” 41 nM, » 100 nM, Í 400 nM, ̊ 1.1 PM, æ 3.3 PM, t 10 PM & 
u 30 PM compound. 
 
Figure 9.  Analysis of competition (Schild analysis) of representative compounds at 
hCRTH2 receptors expressed in CHO K1 cells, and (inset) agonist activity of test 
compounds determined in the same assay, using a calcium mobilisation assay.  Upper 
two panels (PGF2D and 13,14 dihydro 15 keto PGF2D) are partial agonists; middle two 
panels (GW853481X and 13,14 dihydro 15 keto PGE2) are antagonists; lower two 
panels (19 R hydroxy PGA2 and PGE2) are inhibitors which do not possess agonist 
activity.  Data are mean ± sem of three independent experiments.  Key to symbols in all 
panels:  vehicle, ” 41 nM, » 100 nM, Í 400 nM, ̊ 1.1 PM, æ 3.3 PM, t 10 PM & 
u 30 PM compound. 
 
Figure 10.  Effect of single concentration (10PM, except 19 R hydroxy PGA2 = 1 PM) 
of representative compounds on PGD2 E/[A] curves at hCRTH2 receptors expressed on 
CHO K1 cell membranes using a [35S]-GTPJS accumulation assay.  Upper two panels 
(PGF2D and 13,14 dihydro 15 keto PGF2D) are partial agonists; middle two panels 
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(GW853481X and 13,14 dihydro 15 keto PGE2) are antagonists; lower two panels (19 R 
hydroxy PGA2 and PGE2) are inhibitors which do not possess agonist activity.  Data are 
mean ± sem of four independent experiments; abscissa: -log [compound], ordinate:  
cpm. Key to symbols in all panels: » vehicle,  test molecule treated. 
 
Figure 11.  Analysis of competition (Schild analysis) of representative compounds at 
hCRTH2 receptors expressed on CHO K1 cell membranes using a [35S]-GTPJS 
accumulation assay.  Upper two panels (PGF2D and 13,14 dihydro 15 keto PGF2D) are 
partial agonists; middle two panels (GW853481X and 13,14 dihydro 15 keto PGE2) are 
antagonists; lower two panels (19 R hydroxy PGA2 and PGE2) are inhibitors which do 
not possess agonist activity.  Data are mean ± sem of four independent experiments; 
abscissa: -log [PGD2], ordinate:  cpm.  Key to symbols in all panels:  untreated, » 
vehicle, ” 300 nM, Í 1 PM,  ̊ 3 PM,  æ 10 PM, u 30 PM & t 100 PM compound. 
 
Figure 12.  Relationship between total binding and membrane protein (protein linearity) 
for membranes derived from CHO K1- (upper panel) and CHO GD16z49- (lower panel) 
hCRTH2 cells.  Membranes were incubated with 2.2 nM [3H]-PGD2 for 60 min at room 
temp.  Data are triplicate determinations from a single experimental occaision. 
 
Figure 13.  Effect of radioligand vehicle (15 % acetonitrile + 29 % methanol v v-1 in 
distilled water) on total binding of 3.5 nM [3H]-PGD2 to membranes derived from CHO 
K1 hCRTH2 cells.  Membranes were incubated with ligand for 60 min at room temp.  
Data are mean ± sem of triplicate determinations from a single experimental occasion. 
 
Figure 14.  Displacement of [3H]-PGD2 (2 nM) binding by prostanoid molecules at 
CHO K1 hCRTH2 membranes.  Reaction mixtures were incubated for 30 min at room 
temp. prior to rapid filtration onto a glass fibre filtermat and scintillation counting.  
Because of the high degree of row-to-row variability, data have been normalised to total 
binding in that row.  Data are mean ± sem of normalised data from three independent 
experiments. 
 
7.6  Figures 
Follow on next page. 
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Figure 2.
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Figure 3.
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Figure 4. CHO GD16z49 hCRTH2 + PTX
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Figure 5.
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Figure 6. CHO K1 hCRTH2
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Figure 7.
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Figure 8.
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Figure 9.
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Figure 10.
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Figure 12.
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Chapter8: Final Remarks 
In this thesis I have examined the relationship between five alternative expressions of 
efficacy by recombinant prostanoid hCRTH2 receptors expressed in CHO cells: 
1. GD16z49 + GEJi/o mediated calcium mobilisation in whole cells (dual coupling). 
2. GD16z49 mediated calcium mobilisation (whole cells). 
3. GEJi/o mediated calcium mobilisation (whole cells). 
4. GDi/o mediated [35S]-GTPJS accumulation in cell membranes. 
5. Non Gi/o mediated, non syntopic inhibition of receptor activation (whole cells). 
Where relevant, the involvement of GEJi/o subunits has been demonstrated, that of 
GD16z49 has been deduced, while that of GDi/o has been assumed based on the deductions 
made in the calcium assays.  GDz and GDq/11 are expressed in these cells but their 
involvement in hCRTH2 receptor signal transduction has been excluded.  Receptor : G-
protein stoichiometry has been shown to be non-equivalent in the cell lines studied but 
the exact extent of the disparity has been clouded by reliance on an agonist radioligand.  
A greater degree of equivalence was expected between GEJi/o (calcium) and GDi/o 
(GTPJS) assays through the use of the same cell line to provide the biological system in 
each case.  However this was not specifically demonstrated, and true equivalence is 
unlikely to have been achieved because of the rigours of the membrane preparation 
procedure.  Whilst these are important considerations of which one should be mindful in 
arriving at a balanced interpretation of the data, they do not invalidate the approaches 
taken. 
Agonist pharmacology in the dual-coupled setting may have been influenced by 
synergistic interaction of the chimeric GD and native GEJ subunits, possibly at the 
PLCE activation level.  While synergism between two distinct receptor types would 
invalidate these data, because the interaction here is via a single receptor type, 
alterations in agonist behaviour observed in moving to single-coupling settings can still 
be considered an expression of agonist-directed stimulus trafficking. 
Two GD-based readouts (GD16z49 mediated calcium mobilisation and Gi/o based GTPJS 
accumulation) provided similar agonist rank order data but with evidence of differences 
consistent with altered response coupling efficiency.  However, when GDcoupling data 
were compared with GEJ coupling data, marked alterations in agonist behaviour were 
observed including reversals of agonist potency rank orders, reversals of agonist relative 
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activity orders and examples of compounds reducing in potency while others increased 
in potency.  Data such as these are not consistent with ‘strength of stimulus’ based 
changes and are considered to be evidence of agonist-directed stimulus trafficking. 
Since the Gi/o observed in the GTPJS assay is assumed to be derived from the same 
heterotrimers as the GEJi/o observed in calcium mobilisation assay, then the occurrence 
of trafficked agonist stimuli might point to a novel integrated activation paradigm of 
GEJ subunits in which receptor / agonist-dependent and GTP hydrolysis-dependent 
conformation changes in GD subunits combine to provide a resultant activation of GEJ 
subunits.   
A surprising finding was that non-agonist molecules (as shown in calcium mobilisation 
and GTPJS accumulation assays) could partially inhibit PGD2 responses in a manner 
apparently not related to competitive antagonism.  Agonist molecules also inhibit 
responses to subsequent PGD2 exposure but this is related to receptor desensitisation.  
The mechanism by which non-agonist inhibitors exert their effect has not been 
elucidated but may relate to non-G-protein mediated GRK activation.  This 
phenomenon displayed its own pharmacophore suggesting an interaction at a different 
(but possibly overlapping) binding site.  Kinetic radioligand binding assays are needed 
in order to test for allosteric inhibition of PGD2 responses: the binding assay developed 
here is significantly flawed and an alternative assay should be developed.  However, 
these considerations aside, competition binding data may have revealed the presence of 
multiple radioligand interaction sites. 
Several areas present opportunities for further study: 
1. Radioligand binding assay redevelopment, possibly with an antagonist 
radioligand. 
2. Assessment of the molecular identities of the G-proteins giving rise to the [35S]-
GTPJS accumulation signal through antibody capture techniques. 
3. Investigation into the properties of 11 dehydro thromboxane B2 which may be a 
highly sensitive indicator of stimulus trafficking and which may be a highly 
potent non-agonist inhibitor of PGD2; and 
4. Investigation into the molecular processes underpinning agonist-induced 
receptor desensitisation. 
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The data I have presented demonstrate the critical dependence of agonist pharmacology 
on both G-protein coupling partner and assay methodology, and contribute to our 
current understanding of efficacy in relation to agonist stimulus trafficking.  
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